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Preface 
 
Tumor suppressor genes (TSGs) play critical roles in many biological processes, 
including cell cycle control, apoptosis, DNA repair, cell division and differentiation, 
tumor migration and metastasis, and reprogramming control of somatic cells. TSGs 
were named so because of their functional roles in original tumor growth control 
experiments.  
Early somatic cell fusion studies of malignant and nonmalignant cell provided the first 
evidence of a class of negatively acting TSGs, harbored on normal chromosomes that 
contrast to dominant-acting oncogenes, which play important roles in tumor 
suppression. The first TSG was isolated from retinoblastoma, although recent evidence 
has suggested that this gene is also a key regulator of normal developmental events, as 
addressed in this book. Other important TSGs, such as P53, P16 and PTEN, were 
subsequently identified based on “two-hit” hypothesis of TSGs as well. 
Underlying mechanisms of TSGs have been vigorously investigated over the past 30 
years. This book covers the aspects of most fascinating fields, from cell cycle control, 
signaling pathways, gene dosage effects and epigenetic control of gene expression, to 
current challenges and future directions in TSG studies. Since tumor suppression is now 
a huge research field and many novel TSGs have been identified from various human 
malignancies, it is almost impossible to cover all interesting areas in just one book. 
As a classic TSG, P53 is addressed in this book because of its risk on polymorphism 
and its critical role in apoptosis pathways. P16 and its family that regulate cell cycle 
and determine cell fate are introduced and reviewed in detail. Some of the chapters 
focus on the epigenetic control of TSG, notably P16, in lung, pituitary tumors and 
meningioma. TSG studies in other models, such as transgenic mouse and Drosophila, 
are also included in this book. Studies on PTEN and other classic TSGs are described 
in these chapters well. The regulation of an important cellular signaling, TGF-beta, in 
lung cancer is presented in this book, and readers can find information on other 
signaling controls of carcinogenesis in different chapters. Furthermore, expression and 
purification of the human 101F6 protein, encoded by a candidate TSG on the 
chromosome 3p21.3, is presented as a crystallization trial example. Finally, one chapter 
discusses a classic approach using cell fusion and chromosome transfer to identify 
novel TSGs in nasopharyngeal carcinoma. 
X Preface 
 
A wide range of basic, translational, and clinical researches is leading the quest to find 
promising new ways to use these genes to suppress cancer. An example of such trails 
in head and neck cancer is presented in this book. Although we are not there yet, 
ongoing research efforts on TSGs, coupled with advances in gene therapy and other 
techniques, have the potential to open new avenues in the treatment of human tumors. 
We hope that this book will be helpful to both researchers and clinicians.  
 
Yue Cheng, PhD 
The University of Hong Kong 
China 
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Tumor Suppressor Gene  
p16/INK4A/CDKN2A and Its Role  
in Cell Cycle Exit, Differentiation,  
and Determination of Cell Fate 
Payal Agarwal, Farruk Mohammad Lutful Kabir,  
Patricia DeInnocentes and Richard Curtis Bird 
College of Veterinary Medicine, Auburn University, Auburn, Al 
USA 
1. Introduction 
Tumor suppressor genes and oncogenes are important regulatory genes which encode 
proteins regulating transitions in and out of the cell cycle and which also have a role in the 
gateway to terminal differentiation (Tripathy & Benz, 1992). Defects in tumor suppressor 
genes and oncogenes result in uncontrolled cell division, which leads to cancer (Tripathy & 
Benz, 1992). Oncogenes are mutated proto-oncogenes that have a role in malignancy of tumors 
and most frequently regulate cell cycle re-entry. Gain-of-function mutations result in 
transformation of proto-oncogenes into dominant oncogenes. Tumor suppressor genes encode 
proteins that suppress cell growth and most frequently result in exit from the cell cycle. Loss-
of-function mutations in tumor suppressor genes result in tumor malignancy and can account 
for hereditary cancers. Every gene has two alleles present in the genome (with a few 
exceptions in the hemizygous regions of the sex chromosomes). For tumor suppressor genes to 
be inactivated either deletion of one allele and somatic mutation of the other allele is required 
resulting in a loss of heterozygosity (Swellam et al., 2004), or somatic deletion of both of the 
alleles is required resulting in a complete loss of homozygosity (Quelle et al., 1997). Tumor 
suppressor genes can also be inactivated by hypermethylation of the gene resulting in 
promoter suppression so that genes can not be transcribed further (Herman et al., 1997). 
Telomere shortening and tumor suppressor gene promoter hyper-methylation can be used as 
potential breast cancer biomarkers (Radpour et al., 2010). 
Regulation of cell proliferation and differentiation is important in due course of growth and 
development of an organism. Cell proliferation is not an infinitely continuous process as 
cells undergo a finite number of cumulative population doublings (CPDs) in culture before 
entering replicative senescence (RS) (Hayflick, 1965). Cell replication or growth is controlled 
by a complex network of signals that control the cell cycle, the orderly sequence of events 
that all cells pass through as they grow to approximately twice their size, copy their 
chromosomes, and divide into two new cells. The cell cycle consists of 4 phases; G1, S, G2, 
and M phase (Enoch & Nurse, 1991). DNA duplication takes place in S phase and 
cytokinesis in M phase. G1 and G2 are gap phases, which provide the time for cells to 
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ensure suitability of the external and internal environment and preparation for DNA 
duplication and division. Cell cycle progression from one phase to another is controlled 
principally by cell cycle proteins; cyclins, the cofactors of cyclin dependent kinases (CDKs), 
a family of serine/threonine kinases (Afshari & Barrett, 1993). Cyclins are the cell cycle 
proteins, which bind to CDKs and activate them to function and enhance cell cycle 
progression (Pines & Hunter, 1991). Cyclin/CDK complexes are specific for each phase 
transition. In complex eukaryotic cells there are approximately 20 CDK related proteins. 
Complex combination of all these different CDKs and cyclins in different phases of the cell 
cycle provide tightly regulated control of cell cycle progression (Satyanarayana & Kaldis, 
2009). Levels of CDKs in cells vary little throughout the cell cycle, but cyclins, in contrast are 
periodically synthesized and destroyed in a timely manner to regulate the CDK’s activity 
during cell cycle (Malumbres & Barbacid, 2009).  
Early G1 phase progression is facilitated by CDK4/6 binding with cyclin D family proteins. 
These complexes phosphorylate members of the retinoblastoma protein (Rb) family (Rb, 
p130, and p107) (Sherr & Roberts, 1999). Phosphorylation of Rb results in release of E2F 
protein, which otherwise binds to Rb. E2F is a transcription factor, which activates E2F 
responsive genes, which are required for further cell-cycle progression in S phase 
(Weinberg, 1995). CyclinE/CDK2 complexes complete Rb phosphorylation and promote 
further progression of the cell cycle through late G1 phase. These complexes further activate 
E2F-mediated transcription and passage through the restriction point to complete G1/S 
phase transition (Sherr & Roberts, 1999). At the onset of S phase, cyclin A is synthesized, 
forms a complex with CDK2 and phosphorylates proteins involved in DNA replication 
(Petersen et al., 1999).  
During replication of DNA in S phase of the cell cycle, CDC6 and Cdt1 are recruited to 
recognition complexes. These factors help in the recruitment of mini-chromosome 
maintenance (MCM) proteins to replication origins which are known as pre-replicative 
complexes (preRC). In early S phase, preRC recruits the functional replication complex 
including DNA polymerase and associated processivity factors such as proliferating cell 
nuclear antigen (PCNA). Subsequent cell cycle transition takes place through the activity of the 
CDK1/cyclinA complex initiating prophase of mitosis (Furuno et al., 1999). Finally, activation 
of CDK1/cyclin B complex activity completes entry into mitosis (Riabowol et al., 1989).  
Along with the cyclins and CDKs, other proteins such as the tumor suppressor genes, the 
retinoblastoma protein (Rb), p53 and transcription factors such as the E2F proteins, play 
important roles in regulating cell cycle progression. The cell cycle has two important check 
points that occur at the G1/S and G2/M phase transitions (Hartwell & Weinert, 1989). These 
check points control cell cycle progression during normal proliferation and during stress, 
DNA damage, and other types of cellular dysfunction. At these cell cycle check points, 
cellular CDKs can be inhibited by cyclin-dependent kinase inhibitors (CKIs); thus, inhibiting 
and regulating cell cycle progression (Morgan, 1997). Rb can remain active suppressing 
downstream transcription factors if cyclin/CDKs are suppressed and p53 can directly 
activate CKI gene expression (Udayakumar et al., 2010). 
All of the CKIs are proven tumor suppressor genes or suspected of having this potential. Two 
CKI families which play important roles in regulating cell division are; the INK4 family and 
the KIP/CIP family (Vidal & Koff, 2000). INK4 family inhibitors inhibit CDK4 and CDK6 in 
association with cyclin D, while KIPs inhibit CDK1, CDK2 and CDK4 associations with cyclin 
A, cyclin B, and cyclin E. The INK4 family consists of p16 (INK4A), p15 (INK4B), p18 (INK4C), 
and p19 (INK4D). The KIP family consists of p21 (CIP1), p27 (KIP1), and p57 (KIP2).  
Tumor Suppressor Gene p16/INK4A/CDKN2A  
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1.1 INK4A/CDKN2A/p16 
p16 is an important CKI and a tumor suppressor gene encoded on the 9p21 region of the 
human genome, chromosome number 4 in mouse, and chromosome 11 in dogs (Serrano  
et al., 1993; Kamb et al., 1994; Asamoto et al., 1998; Fosmire et al., 2007) at the 
INK4A/ARF/INK4B locus. This gene locus is a 35kb multigene region which encodes three 
distinct major tumor suppressor genes, p15, p14ARF, and p16 (Sherr & Weber, 2000). 
INK4A/ARF/INK4B gene locus is repressed in young and normal cells by polycomb 
proteins and histone H3 lysine27 (H3K27) trimethylation (Kotake et al., 2007; Kia et al., 2008; 
Agger et al., 2009) and is induced during aging or by hyperproliferative oncogenic stimuli or 
stress. The INK4A/ARF locus has been speculated to have a global anti-aging effect by 
favoring cell quiescence and limiting cell proliferation (Matheu et al., 2009).  
The classic role of p16/INK4A/CDKN2A is to check the cell cycle in early G1 phase and 
inhibit further transition of the cell cycle from G1 to S phase as a component of a multi-
protein regulatory complex. During G1 phase, CDK4 and CDK6 form complexes with cyclin 
D1 which in turn phosphorylate the Rb protein family resulting in additional 
phosporylation by cyclin E/CDK complexes. These inhibitory phosphorylations of Rb cause 
release of the E2F transcription factor from Rb/E2F complexes. Rb otherwise inhibits 
transcription factor E2F (Weinberg, 1995). E2F is a transcription factor which initiates 
transcription of genes required for S phase such as DNA polymerase, thymidine kinase, 
dihydrofolate reductase, replication origin binding protein HsOrc1 and MCM (Lukas et al., 
1996). Action of p16 inhibits binding of CDK4/6 with cyclin D1 which leaves Rb, and Rb-
related proteins like p107 and p103, un-phosphorylated and E2F bound and inactive 
(Serrano et al., 1993; Walkley & Orkin, 2006). INK4 proteins cause both inhibitory structural 
changes and block activating structural changes to bound CDKs. p16 binds next to the ATP 
binding site of the catalytic cleft, opposite to the cyclin binding site, which results in a 
structural change in the cyclin binding site (Russo et al., 1998). p16/INK4A targets CDK4 
and CDK6, rather than the cyclin subunit, and actually competes with cyclin D1 for CDK 
binding. Binding of p16 results in changes in conformation of CDK proteins so that they can 
no longer bind cyclin D1 (Russo et al., 1998). p16 distorts the kinase catalytic cleft, interferes 
with ATP binding, and thus may also deactivate pre-assembled CDK4/6-cyclin D1 
complexes blocking their function (Russo et al., 1998). Binding sites for p16 and cyclin D1 on 
CDK4 are overlapping in some cases and are present near the amino terminus where a 
majority of the mutations in CDK4 are found. Mutations in the p16 binding site result in 
diminished capability of p16 binding to CDK4 and also compromise the binding of cyclin 
D1 to CDK4, which can also lead to melanoma (Coleman et al., 1997; Tsao et al., 1998). Other 
than inhibiting the pRb/E2F pathway, the very recently reported function of p16 is to 
downregulate CDK1 expression by upregulating miR-410 and miR-650 (Chien et al., 2011). 
CDK1 is an indispensable kinase which is most important for cell cycle regulation during 
G2/M phase (Santamaria et al., 2007). The regulation of CDK1 by p16 is post-transcriptional. 
Thus, p16 is an important tumor suppressor gene which regulates gene expression at 
different levels by modifying functional equilibrium of transcription factors, and 
consequently of miRNAs, and also by binding to post-transcriptional regulators (hnRNP 
C1/C2 and hnRNP A2/B1) (Souza-Rodrigues et al., 2007). The role of p16 in cell growth can 
also be attributed by irreversible repression of the hTERT (human telomerase) gene by 
increasing the amount of histone H3, trimethylated on lysine 27 (H3K27), bound to the 
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hTERT promoter (Bazarov et al., 2010). hTERT encodes the catalytic subunit of telomerase; 
therefore, p16 induction results in repression of telomerase and thus telomere shortening. 
Another binding partner important for cell growth inhibition by p16 is GRIM-19 (Gene 
associated with Retinoid-IFN-induced Mortality-19). GRIM-19 is a tumor suppressor gene 
mutations of which have been found in primary human tumors. GRIM-19 and p16 
synergistically inhibit cell cycle progression via the E2F pathway (Sun et al., 2010). 
2. Gene location and mapping of the p16 gene 
The region of the human chromosome, 9p21 encompassing the INK4A gene locus, 
corresponds to regions of dog chromosome 11, mouse chromosome 4, and rat chromosome 
5. These regions have been demonstrated to be frequently mutated in various types of 
cancer (Ruas & Peters, 1998; Sharpless, 2005). The INK4A gene locus also alternatively 
named the CDKN2B/CDKN2A or INK4A/ARF/INK4B locus, encodes three members of 
the INK4 family of cyclin dependent kinase inhibitors (CKIs), including p15, p16, and the 
MDM2 ubiquitin ligase inhibitor p14ARF (Gil & Peters, 2006). p15 has its own reading 
frame and is physically distinct, but p14ARF and p16 share a common second and third 
exon but each has a different and unique first exon (Kim & Sharpless, 2006). It has been 
reported that tandem gene duplication and rearrangement occurred during the evolution 
of INK4A (p16) and INK4B (p15) that are located 30 kbp apart on the same chromosome 
(Fig.1) (Sharpless, 2005).  
The INK4A gene was initially discovered to have three exons. Subsequent evidence 
identified an additional exon between the INK4B and INK4A genes, designated as exon1β, 
that was alternatively spliced from INK4A exon 1 (Mao et al., 1995; Quelle et al., 1995; 
Stone et al., 1995a). This alternative exon 1β was transcribed from a promoter different from 
the p16INK4A first exon (exon 1α) and then spliced to the same second and third exons of 
INK4A to form a transcript, usually shorter than that encoding p16INK4A (Stone et al., 
1995b). The 1β transcript encodes a completely different protein from p16 because splicing 
of exon 1β to exon 2 allows translation from an alternative reading frame resulting in the 
different protein sequence (Fig. 2) (Quelle et al., 1995; Stone et al., 1995a).  
In most mammals this later protein is referred to as p14ARF (‘14’ indicates molecular weight 
of the protein and ARF for alternative reading frame). An ortholog of exon1β in mouse and 
rat is longer than those from other mammals resulting in a larger protein and is designated 
p19ARF (Quelle et al., 1995). Thus, these two alternative INK4A transcripts (p16 and 
p14ARF/p19ARF) share a large overlapping nucleotide sequence for the common exons 2 
and 3 but result in structurally unrelated proteins due to presence of unique alternative first 
exons. Both have become important candidates for the study of novel cancer mechanisms. 
In dogs, the p16 and p14ARF transcripts derived from INK4A locus have not been fully 
elucidated. There are no full-length mRNAs or expressed sequence tags (ESTs) available that 
would completely define these transcripts. In addition this region of the chromosome is 
extremely GC-rich making it difficult to clone and sequence and causing a gap in the 
CanFam 2.0 genome assembly (Lindblad-Toh et al., 2005). The biological functions of these 
two proteins are fairly well understood compared to their genomic structure. Several lines 
of evidence suggest that both p16 and p14ARF act as potent tumor suppressors apart from 
their roles as cell cycle regulators during the G1 to S phase transition and p53 mediated cell 
cycle arrest, respectively. 
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Fig. 1. Evolution of mammalian CKIs.  Schematic representation of gene duplication and the 
evolution of CKIs (p16INK4A, p15INK4B, p18INK4C and p19INK4D) from a single ancestor 
INK4 gene. The chromosomal localization of INK4 genes are widely conserved across 
mammals. During the course of evolution, INK4C and INK4D were integrated into different 
chromosomes while INK4A and INK4B remained located on the same chromosome. Here 
human chromosomes and corresponding INK4 genes are shown. 
 
 
Fig. 2. Alternative splicing of p16INK4A and p14ARF. Exon E1α is spliced to INK4A  
exons - E2 and E3 forming the p16 mature transcript whereas E1β is alternatively spliced to 
the same E2 and E3 exons generating the mature p14ARF transcript. The latter produces a 
different protein from p16 because translation occurs from an alternative reading frame.  
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Primary melanomas, osteosarcoma and mammary tumor cell lines from dogs have been 
shown to harbor frequent loss of p16 (Levine & Fleischli, 2000; Koenig et al., 2002; 
DeInnocentes et al., 2009). Opposing roles of p16 and p14ARF have also been documented, 
where p16 inactivation attenuates senescence and ageing while p14ARF inactivation induces 
senescence and aging in skeletal muscle of BubR1 mice (Baker et al., 2008). p16 and p14ARF 
contribute to reduced growth and survival of B lymphopoiesis and inhibit malignant 
transformation (Signer et al., 2008). This contrasting behavior could be due to a level of 
tissue-specific activity of these CKIs. 
2.1 Cellular location of p16  
The subcellular localization of p16 has been even more cryptic than its genetic behavior and 
expression. Most studies have supported the localization of this protein both in the nucleus 
and the cytoplasm. But there are some debates on its specific roles, being in both cellular 
fractions, and in the context of normal and tumor cell lines. It is generally assumed that p16 is 
transported to the nucleus and acts as a CKI to regulate the G1 phase cell cycle checkpoint. 
This phenomenon has been reported in normal cells where the protein was mainly found in 
the nucleus but not in the cytoplasm (Bartkova et al., 1996). However many tumor cell lines 
have been shown to harbor p16 in the cytoplasm as well as in the nucleus (Geradts et al., 2000; 
Nilsson & Landberg, 2006). Two major populations of p16 have been identified in subcellular 
fractions – one is unphosphorylated or basic in form and the other is phosphorylated or acidic 
in form and both are generally derived from post-translational modification. The 
phosphorylated form was found to be associated with CDK4 in normal human fibroblasts 
(Gump et al., 2003). It has been reported that the localization of the two forms of p16 in both 
cellular compartments mostly depends on cancer types. In breast cancer cell lines, both forms 
of p16 were observed in the cytoplasm while the phosphorylated form was predominant in the 
nucleus (Nilsson & Landberg, 2006). In addition, strong cytoplasmic expression of p16 was 
observed in many tumor cell lines including primary breast carcinoma associated with a 
malignant phenotype (Emig et al., 1998; Evangelou et al., 2004) suggesting that the protein 
might have specific roles for its cytoplasmic localization in certain malignancies. But so far 
there is no direct evidence for the function of this tumor suppressor in the cytoplasm. One 
possible mechanism is that p16 can bind to CDK4/6 in the nucleus and the complex is 
transported to the cytoplasm, inhibiting the association of CDK4/6 with cyclinD in the nucleus 
and thereby blocking the G1/S phase transition of the cell cycle. In normal cells and epithelial-
derived breast carcinoma, a novel substrate for CDK4/6 has been identified which is more 
prevalent in the cytoplasm than in the nucleus (Kwon et al., 1995). This might cause p16 
localization bound to CDK4/6 to the cytoplasm and thus prevent CDK4/6 from acting on the 
substrate cyclinD1. Another mechanism may be hinted that p16 is mutated in some tumors 
and resulting in the defective protein being localized in the cytoplasm. However, this 
speculation is not supported by the fact that p16 is expressed in both the nucleus and the 
cytoplasm in cell lines with wild-type p16 protein (Craig et al., 1998). Other studies have 
suggested that the cytoplasmic localization might represent a mechanism for p16 inactivation 
in various tumors (Evangelou et al., 2004; Nilsson & Landberg, 2006).  
2.2 Other INK4 family CKIs – p15, p18, p19 
There are two classes of CKIs that interact with cyclin-dependent kinases (CDKs) and 
reversibly block their enzymatic activities. The first group consists of p21, p27, and p57 and 
the second group is comprised of p16/INK4A, p15/INK4B, p18/INK4C and p19/INK4D. 
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The INK4 family CKIs (the second group) generally inhibit the assembly of CDKs by 
binding to CDK4 or CDK6 (Sherr & Roberts, 1995). Like p15/INK4B and p16/INK4A genes, 
p18/INK4C and p19/INK4D have been demonstrated to have evolved through tandem 
gene duplication and rearrangement during the course of evolution. Cross-species 
observations have suggested that a common vertebrate ancestor containing a single INK4 
gene that was duplicated and gave rise to the INK4B-INK4A and INK4C-INK4D gene 
clusters. After the divergence of mammals and other higher animals from lower vertebrates 
(~350 million years ago), further gene duplication and rearrangement resulted in the four 
different INK4 genes (Fig.1) (Gilley & Fried, 2001; Sharpless, 2005). It has been reported that 
p15 and p16 arose from a common ancestor or single gene locus placed on the same 
chromosome whereas, p18 and p19 mapped to different chromosomes in humans and other 
mammals (Guan et al., 1994; Hirai et al., 1995).  
Both p18 and p19 proteins share basic structural and biochemical properties with p15 and 
p16 proteins. All of them consist of repeated ankyrin motifs that play important roles in 
folding of proteins and in molecular interactions with other proteins such as CDK4/6 (Hirai 
et al., 1995). The p18 and p19 have not been studied as extensively as p16 and there is also 
some debate about their roles as independent tumor suppressors (Hirai et al., 1995). Unlike 
p16 and p15, which are deleted in a number of established tumor cell lines (both human and 
canine), the expression of p18 and p19 can be readily detected in many cell lines including 
many different primary tissues (Hirai et al., 1995). For example, both p18 and p19 are 
uniformly expressed in canine mammary tumor (CMT) cell lines and normal canine 
fibroblasts (NCF) (Bird et al., unpublished data). Although p15 and p16 differ significantly 
from each other as one is encoded by two exons and the other by three exons with 
alternative splicing of the first exon, respectively (Stone et al., 1995a), the two proteins are 
closely related in their structures and functions. Both have four ankyrin repeats, are 
involved in similar mechanisms of cell cycle regulation and in some instances may be 
interchangeable as tumor suppressors (Krimpenfort et al., 2007). 
Expression of p18 and p19, have been shown to predominate during early to mid-gestation in 
mouse development (Zindy et al., 1997) while expression of p15 has been found in later stages 
of gestation (Zindy et al., 1997). Circumstantially, it appears that different INK4 proteins are 
not functionally redundant as they appear to be expressed during different periods of 
development and may also be expressed in distinct tissue-specific profiles. Expression of p15 is 
down-regulated during human lymphocyte mitogenesis with a marked increase in Rb kinase 
activity providing a potential role for p15 in cell cycle arrest. p15 mediated growth suppression 
is induced by TGF mediated by SP1 and SP3 transcription factors (Li et al., 1995). p15 and p27 
levels were decreased during lymphocyte activation and appear important in maintaining cell 
quiescence (Lois et al., 1995). Although p15 acts as a tumor suppressor, the frequency of 
mutations and defects in p15 in tumor cells is lower than p16 (Stone et al., 1995a). 
Overexpression of p15 can induce cell cycle arrest in cancer cells (Thullberg et al., 2000), TGF-
mediated cell cycle arrest in human keratenocytes (HaCaT) (Hannon & Beach, 1994), and cell 
cycle arrest by the pyrido-pyrimidine derivative JTP-70902 in the human colon cancer cell line 
HT-29 (Yamaguchi et al., 2007). p18 inhibits the CDK-cyclin binding site by distorting the ATP 
binding site and by misaligning catalytic residues. p18 can also distort the cyclin-binding site 
of CDKs by reducing the size of the interface of bound cyclin (Jeffrey et al., 2000). A lack of 
mutations in p18 and p19 has been reported in tumor-derived cell lines and primary tumors, 
which were mutated for p16 and p15 expression, which shows distinct biological function of 
evolutionary related INK4 proteins (Zariwala & Xiong, 1996). 
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The INK4 and CIP cyclin dependent kinase inhibitor families have overlapping roles of cell 
cycle arrest in mouse embryo fibroblasts. Loss of both INK4 (p15, p16, and p18) and CIP 
(p21) promotes pRB inactivation, cell immortalization, and H-rasV12/c-myc-induced loss of 
contact inhibition. However, loss of both families of CKIs is still only weakly able to cause 
cell immortalization largely due to active apoptosis induction (Carbone et al., 2007). This 
data strongly supports the concept that both CKI inactivation and apoptosis failure are 
required to promote a neoplastic phenotype. 
2.3 Structure of p16 
p16 encodes four or five ankyrin repeats (Russo et al., 1998). Ankyrin repeats are 30 amino 
acid structural motifs that resemble the letter ‘L’ with a stem made of a pair of anti-parallel 
helices with a beta-hairpin region forming the base (Russo et al., 1998). The functional 
domain of p16 involved in interaction with CDK4/6, is located in the C-terminal half 
including the III and IV ankyrin repeats and the C-terminal flanking region accompanied by 
loops 2 and 3 (Fahham et al., 2010). p16 interacts with the N and C lobes of CDK6 and binds 
to one side of the catalytic cleft opposite to the cyclin binding site. CDK6 bound to p16 is 
inactive because it can not bind to cyclin and is not phosphorylated; thus, proliferation is 
suppressed (Russo et al., 1998). p16/INK4A also exerts transcriptional control over cyclin 
D1. Activating transcription factor-2 (ATF-2) and cAMP-responsive element-binding protein 
(CREB) induce the cyclinD1 expression by binding to cAMP-response element/activating 
transcription factor-2 (CRE/ATF-2) binding site at cyclinD1 promoter side, p16 represses the 
ATF-2 and CREB expression by 40-50%, thus inactivates cyclinD1 independent of its CDK4 
inactivating properties (D'Amico et al., 2004). 
2.4 p14ARF/p16gamma/p12 
As has been noted, the INK4A locus encodes two distinct p16 and p14ARF proteins. 
However, it has also been reported that besides these two proteins, this gene locus also 
encodes two additional proteins; p16gamma and p12 (Fig.3).  
p14ARF inhibits MDM2, which results in stabilization of the important tumor suppressor 
p53. p53 is a transcription factor, which activates expression of proteins required for cell-
cycle inhibition and apoptosis (Boehme & Blattner, 2009). One of the downstream regulatory 
protein activations mediated by p53 is p21 up-regulation which checks the cell cycle late in 
the G1/S phase transition. p53 also acts as a transcription repressor of other genes (Gomez-
Lazaro et al., 2004). p53 is more stable in mammary epithelial cells in comparison to 
fibroblasts in humans, which indicates the importance of p53 in mammary epithelial cell 
growth (Delmolino et al., 1993). Under normal conditions, p53 is rapidly degraded to keep 
its protein level low, mediated through the E3 ubiquitin ligase MDM2. Under conditions of 
stress or other dysfunction, p14ARF binds to MDM2, thus releasing and stabilizing p53 by 
blocking MDM2. Wild type p53-induced phosphatase 1 (Wip1/Ppm1d) stabilizes MDM2 
and downregulates p53, p38MAPK, and p16 expression (Lin et al., 2007; Yu et al., 2007). 
Disruption of Wip1 activates p53, p16, and p14ARF pathways, through p38MAPK signaling, 
and suppresses mouse embryo fibroblast transformation by oncogenes in vivo (Bulavin et al., 
2004). Another mechanism of p14ARF induction and p53 stabilization is stimulation of the 
DMP1 promoter by HER2/neu growth factor receptor overexpression (Mallakin et al., 2010). 
HER2/neu activates the DMP1 promoter through the phosphatidylinositol-3'-kinase-Akt-
NF-κB pathway, which in turn activates p14ARF transcription (Taneja et al., 2010). 
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p14ARF expression is not directly involved in the response to DNA damage although p53 
negatively regulates p14ARF expression and both of them have an inverse correlation with 
each other with respect to activity (Stott et al., 1998). Function of p14ARF is not limited to 
p53 as p14ARF also has other independent roles in cellular systems such as vascular 
regression in the developing eye (McKeller et al., 2002) and arrest of cell cycle in murine 
embryo fibroblasts in the absence of p53 (Weber et al., 2000). Loss of p14ARF, results in 
tumorigenesis by facilitating angiogenesis, which is independent of the p53 pathway 
(Ulanet & Hanahan, 2010). Other than MDM2, p14ARF also binds to E2F-1, MDMX, HIF1-, 
topoisomerase I, c-myc, and nucleophosmine (NPM) (Boehme & Blattner, 2009). p19ARF 
(the mouse homolog of human p14ARF) is able to induce cell cycle arrest in mammalian 
fibroblasts analogous to p16 (Quelle et al., 1995). 
 
 
Fig. 3. Transcription from the INK4A/ARF locus. Schematic representation of all the four 
different transcripts, transcribed from the common INK4A/ARF gene locus. p14ARF and 
p16/INK4A share exon 2 and exon 3, but differ in their first exons. p14ARF includes exon  
1β while p16 includes exon 1α. The stop codon for p14ARF reading frame is located in 
exon2. The stop codon for the p16/INK4A is located in exon 3. Another transcript 
transcribed from this locus is p16γ, which has an extra exon (exon2γ) along with all three 
exons of the p16/INK4A transcript. Exon2γ (197bp) is located in intron 2 between exon 2 
and exon 3. p16γ encodes a 18kDa protein. The smallest 12kDa protein encoded from 
INK4A locus is p12. p12 shares the first exon, exon1α with p16, but first exon of p12 
transcribes little longer in intron 1 to give an additional 274bp sequence. Stop codon for p12 
is located in the additional intron 1α sequence and introduces an earlier stop codon and 
encoding a 12kDa protein spite having a longer transcript than p16/INK4A. 
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E2F induces cell proliferation by activating S phase regulatory proteins but, according to 
one report, E2F can induce senescence in human diploid fibroblasts by inducing p14ARF 
expression, which is required for p53 stabilization (Dimri et al., 2000). Id1 encodes a helix-
loop-helix transcription factor that is overexpressed in high grade breast tumors and 
estrogen receptor-negative diseases (Gupta et al., 2007). Overexpression of Id1 or 
inactivation of the p14ARF-p53-p21 pathway can also revert senescence induced by ras 
signaling in mouse mammary carcinoma (Swarbrick et al., 2008). Other than facilitating 
the DNA-damage-induction response of p53, p14ARF also has a role in nucleotide 
excision repair. p14ARF induces expression of the damaged-DNA recognition protein 
xeroderma pigmentosum, complementation group C (XPC), by disrupting the interaction 
of E2F-4 and DRTF polypeptide 1(DP1). p14ARF also reduces the interaction of the E2F-4-
p130 repressor complex with the XPC promoter (Dominguez-Brauer et al., 2009). TGF- 
activity controls the expression of p14ARF during mouse embryonic development 
(Freeman-Anderson et al., 2009). 
Other than p16 and p14ARF transcription from the INK4A locus, there is one more 
alternative transcript that has been reported derived from this gene in human lymphoblastic 
leukemia which is termed as p16 gamma (p16)(Fig.3) (Lin et al., 2007). p16 has been 
demonstrated to be expressed at both transcriptional and translational levels confirming its 
functional potential (Lin et al., 2007). p16 shares the same exon 1, exon 2, and exon 3 as 
p16 but with a 197 bp insertion between exon 2 and 3 due to an alternative splicing event 
that extends exon 2 and concedes a stop codon. p16 is also an ankyrin-repeat protein and 
interacts with CDK4. p16 suppresses E2F activity and induces cell cycle arrest like 
p16/INK4A. It is not known what functionally distinguishes these 2 transcripts or their 
encoded proteins. 
There is an alternative splice variant of p16 present in human pancreas as well, known as 
p12 (Fig.3)(Robertson & Jones, 1999). p12 is a 12kd size protein, which is encoded from the 
same INK4/ARF locus. The p12 gene shares the p16 promoter, 5’UTR, ATG-start codon and 
exon 1, and uses the alternative splice donor site to splice to exon 2. The extra sequence 
encodes a premature stop codon that results in a smaller protein. p12 shares the first ankyrin 
repeat with p16 but is not predicted to bind to CDK4 or CDK6 based on crystal structure 
studies. p12 is reported to suppress cell growth but in a pRb-independent mechanism 
(Sharpless, 2005). When the effect of ectopic expression of all the three transcripts, p16, 
p14ARF, and p12 was compared, p16 had the most inhibitory effects on cell growth of the 
human lung cancer cell line A549 (Zhang et al., 2010b).  
3. The role of p16 
3.1 p16 as a tumor suppressor gene 
CKI p16 is an important tumor suppressor gene, defects in which are associated with cancer 
(Koh et al., 1995). p16 is functional as a growth suppressor gene as introduction of full 
length p16 cDNA caused marked growth suprression in p16-null human glioma cells (Arap 
et al., 1995), lung cancer in vitro and in vivo (Jin et al., 1995), carcinoma cell lines in vitro and 
in vivo (Spillare et al., 1996), esophageal cancer cells (Schrump et al., 1996), and human and 
canine breast cancer cells (Campbell et al., 2000; DeInnocentes et al., 2009). p16 defects are 
second in frequency only to those in p53 for human malignancies (Baylin et al., 1998). p53 
and p16 are thought to work via two independent pathways of growth suppression, but 
both of them are important in suppressing malignant transformation (Gruis et al., 1995). p16 
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gene deletions are associated with, and appear permissive for, late-stage, high-grade cancers 
such as; melanoma, bladder cancer, schistosomal bladder cancer, esophageal cancer, breast 
cancer, and glioblastoma (Gruis et al., 1995; Izumoto et al., 1995; Zhou et al., 1995; Swellam 
et al., 2004; DeInnocentes et al., 2009). Deletion of the 9p21 region encoding the p16-
INK4A/p14ARF/p15 tumor suppressor loci in humans results in tumor formation in a wide 
range of tissues (Kamb et al., 1994; Kleihues et al., 1994; Packenham et al., 1995). Loss of 
heterozygosity (Swellam et al., 2004), loss of homozygosity (Ranade et al., 1995; Quelle et al., 
1997), and hypermethylation of the promoter (Herman et al., 1997) in the 9p21 region are all 
important mechanisms which have been shown to result in loss of p16 expression and 
promote p16-related neoplasms. Hyper-methylation of the p16 promoter region appears to 
occur early in neoplastic transformation before development of tumorigenicity in rat 
respiratory epithelium (Yamada et al., 2010). Loss of p16 is associated with extended life 
span but is not sufficient for immortality (Loughran et al., 1996; Noble et al., 1996). 
Frequency of loss of p16 is high in pre-malignant lesions suggesting the importance of loss 
of p16 activity as an early event in cancer progression (Liggett & Sidransky, 1998) and 
evaluation of p16 expression could have value as an early prognostic indicator for 
predicting cancer recurrence (Bartoletti et al., 2007). Hypermethylation of CpG islands in the 
p16 promoter results in enhanced cell proliferation in human colorectal cancer and can 
activate DNA demethylation in the invasive region suppressing proliferation but enhancing 
tumor invasion (Jie et al., 2007). Additionally INK4A/ARF hypermethylation occurs 
frequently in mammary epithelial cells in high risk women with sporadic breast cancer 
(Bean et al., 2007; Jing et al., 2007; Sharma et al., 2007).  
K-cyclin (ORF72) is a human homolog of cyclinD1 in Kaposi’s sarcoma-associated 
herpesvirus (KSHV/HHV-8) which is oncogenic in immune suppressed individuals. p16 
inhibits the unphophorylated CDK6-K-cyclin complex and functional availaibility of  
K-cyclin for tumorogenesis is largely dependent upon the balance of expression of p16 and 
CDK6 (Yoshioka et al., 2010). This complex is resistant to CKI p21 and p27 and can 
phopshorylate both of them explaining the important role of p16 as a tumor suppressor 
gene in malignancies induced by KSHV and their resistance to multiple CKI activities.  
Mutations in the p16 encoding gene have also been reported in other cancer types such as 
glioblastomas, pancreatic adenocarcinomas, and melanoma-prone pedigrees. Allelic 
variants of p16 in melanoma-prone pedigrees have been found, which are deficient in 
interaction with CDK4 and CDK6. p16 allelic variants with decreased CDK interaction 
capability predisposes these individuals to increased risk of cancer which reinforces the 
important role of p16 as a tumor suppressor gene (Reymond & Brent, 1995). Mutations in 
CDK4 prevent p16 binding to CDK4 and have been identified for several noncontiguous 
amino acid sequences. This suggests there may be multiple binding sites for p16. Such 
mutated CDK4s have oncogenic potential and occur spontaneously in melanomas and other 
neoplasms (Ceha et al., 1998). 
Matrix metalloproteinases (MMPs) are the zinc-dependent endopeptidases, which are 
capable of degrading components of the extracellular matrix. The MMP family is composed 
of at least 20 enzymes. One of the MMP family enzymes is MMP-2, which has been reported 
to be strongly linked with various types of human cancers such as glioma (Uhm et al., 1996) 
and astrogliomas (Qin et al., 1998). p16 represses expression of MMP-2 and invasiveness of 
gliomas (Chintala et al., 1997) by blocking Sp1 to mediate gene transcription of MMP-2 
(Wang et al., 2006). Thus, p16 can inhibit the cyclin-CDK complex to suppress the cell cycle 
can also suppress tumor invasion through other cell regulatory functions.  
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Rab proteins are members of Ras-related small GTPase family. Rab27A is also linked with 
human genetic diseases (Seabra et al., 2002). Rab27A is associated with invasive and 
metastatic breast cancer, which is facilitated by down-regulation of p16 and up-regulation 
of cyclinD1 (Wang et al., 2008). Concomitant overexpression of p16 and p73 has oncogenic 
potential and affects the development and growth of breast carcinomas (Garcia et al., 
2004). 
Alteration of p15 and p16 expression and overexpression of TGF- are found frequently in 
schistomal bladder cancers and squamous cell carcinomas (Swellam et al., 2004). Loss of p16 
expression has prognostic value in predicting recurrence-free probability in patients affected 
by low-grade urothelial bladder cancer (Bartoletti et al., 2007). p16 has been reported to be 
inactive in human colorectal cancer but p16 expression is elevated by the demethylation of 
the p16 promoter in invasive cancer cells, as these cells cease proliferation at the invasive 
front (Jie et al., 2007).  
-catenin is the key downstream effector of Wnt signaling and is also a potent oncogene. -
catenin can also inhibit cell proliferation by activating the p14ARF-p53-p21 pathway during 
trans-differentiation of squamous cell differentiation associated with endometrial carcinoma 
(Saegusa et al., 2005). p16 is also induced along with loss of pRb expression in trans-
differentiation of endometrial carcinoma cells, mediated by -catenin and p21 (Saegusa et 
al., 2006). Deletion of p16 has been reported in high-grade B-cell non-Hodgkin’s lymphoma 
(Fosmire et al., 2007) along with increases in Rb phosphorylation at CDK4 phosphorylated 
sites. Inactivation of p16 has also been reported in high grade non-Hodgkin’s lymphoma 
and is less prevalent in low-grade tumors (Modiano et al., 2007). p16 inactivation is more 
frequent in blastoid mantle cell lymphoma (Dreyling et al., 1997). 
p16 forms a complex with HIF-1α, the transcription factor for the VEGF gene promoter, thus 
represses the transactivation of VEGF. p16 inhibits VEGF gene expression and inhibits 
cancer cell induced angiogenesis in breast cancer cells and the loss of p16 is a significant 
transition in neoplastic development (Zhang et al., 2010a).  
3.2 Role of p16 in cell quiescence 
p16 checks the cell cycle at the G1/S phase transition and thus has an important role in cell 
cycle exit and quiescence in a variety of cell systems. Growth suppression by p16 depends 
upon the presence of functional Rb. Growth in Rb null fibroblasts failed to be suppressed by 
p16 (Medema et al., 1995). Ectopic p16 expression prevents re-entry into the cell cycle (Lea et 
al., 2003) and p16 expression can induce a G0-like state in hematopoietic cells (Furukawa et 
al., 2000). p16 expression is up-regulated by exposure to cellular stressors such as oxidative 
stress, aging, UV exposure, ionizing radiation, chemotherapeutic agents, telomere 
dysfunction, and wound healing (Kim & Sharpless, 2006; Natarajan et al., 2006). In response 
to non-lethal UVC irradiation, only p16 positive cell lines can induce cell cycle delay in 
comparison to p16 null cell lines (Wang et al., 1996). p16 is induced by MAPK activation, in 
response to stimulation of the ERK/MAPK pathway through RAS/RAF signaling (Ohtani et 
al., 2001). RAS activation induces p16 expression through ERK mediated activation of 
Ets1/2 (Ohtani et al., 2001) and p14ARF through Jun-mediated activation of DMP1 
(Sreeramaneni et al., 2005). Histone acetyltransferases (HATs), such as p300/CBP are 
important transcriptional up-regulators. The GC-rich region in the p16 promoter is the 
putative binding site for transcription factor Sp1 (Gizard et al., 2005). p300 in-cooperation 
with Sp1 transcriptionally upregulates p16 expression and induces cell cycle arrest in HeLa 
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cells (Kivinen et al., 1999; Wang et al., 2008). Smooth muscle cells in mature arteries in rat 
have low rates of proliferation. Suppression of proliferation is dependent on the up-
regulated levels of p16 and p27, which makes these cells unable to activate cyclinD1 and 
cyclinE and their associated kinase activties (Izzard et al., 2002). 
p16 has also been associated with a variety of additional cell proliferation control proteins 
that either bind and suppress its function or compete for p16 targets. SEI-1/p34/TRIP-Br1 
protein induces CDK4-mediated Rb phosphorylation through physical binding, 
independent of p16 (Li et al., 2005). SEI-1 facilitates CDK4 function making it resistant to p16 
inhibition. ISOC2 protein binds and co-localizes with p16 inhibiting the function of p16 
(Huang et al., 2007). Other than ISOC2, p16 protein has also been found to bind to 
proliferating cell nuclear antigen (PCNA) and minichromosome maintenance protein 6 
(MCM6) (Souza-Rodrigues et al., 2007). The same authors have reported that p16 interacts 
with DNA polymeraseδ accessory protein PCNA, thus inhibiting the function of DNA 
polymerase. 
p16 is normally localized in the nucleus where it functions as an inhibitor of CDK/cyclin 
complexes but it has also been reported that p16 can be co-localized in the cytoplasm 
(Nilsson & Landberg, 2006) . Both cytoplasmic and nuclear p16 bind CDK6 and have a role 
in cell cycle arrest. Human melanocytes initiate differentiation by activation of the cAMP 
synthesis pathway. This results in increased association of p16 and p27 with CDK4 and 
CDK2, respectively, Rb phosphoryalation failure and decreased expression of E2F proteins 
with decreased DNA-binding activity (Haddad et al., 1999). Senescence induced by the 
cAMP pathway in these cells can be attributed to the complex formation of CKI/CDK 
complexes, which cause cell cycle exit (Haddad et al., 1999). 
It is known that p16 induces cell cycle arrest via Rb, but there is one more mechanism by 
which p16 can arrest cell cycle independent of Rb. IB is a specific inhibitor of NFB, 
which competes with p16 for binding to CDK4 and inhibits its activity (Li et al., 2003). This 
observation has led to speculation that IB could substitute for p16 in CDK4 inhibition in 
malignant cells. Other than that, in G1 phase, activity of CDKs is required for proper 
recruitment of mini-chromosome maintenance (MCM) protein to the origin recognition 
complex. p16 influences CDKs and thus influences prereplicative complex (preRC) at the 
MCM level resulting in arrest of cell cycle (Braden et al., 2006). 
c-myc is a transcription factor that plays an important role in cell proliferation. c-myc can 
induce cell cycle progression from G1 phase to S phase in quiescent cells (Eilers et al., 1991). 
Oncogenic activity of altered CDK4 is due to its inability to bind p16 and inhibiting its 
enzymic activity. The oncogenic activity of c-myc and the CDK4/cyclin D1 complex require 
each other to effectively transform cells. CDK4 requires Myc protein for proper function 
and, similary, Myc requires the CDK4 cyclinD complex kinase activity to effect tumor 
transformation. p16 inhibits the transcription regulatory activity of c-myc by blocking cyclin 
D1/CDK4 complex formation (Haas et al., 1997). 
Introduction of adenovirus expressing p16 in human cancer cell lines result in p16-mediated 
cytotoxicity and results in apoptosis (Kim et al., 2000). p16 expression and estrogen receptor 
(ER) gene expression are inversely related (Hui et al., 2000). p16 expressing adenovirus 
vector resulted in delay in tumor growth in a polyomavirus middle-T antigen model of 
murine breast carcinoma, in comparison with, p19, p27, p18, and p21 which were ineffective 
(Schreiber et al., 1999).  
 
Tumor Suppressor Genes 
 
14
In dogs, the p16 and p14ARF transcripts derived from INK4A locus have not been fully 
elucidated. There are no full-length mRNAs or expressed sequence tags (ESTs) available that 
would completely define these transcripts. In addition this region of the chromosome is 
extremely GC-rich making it difficult to clone and sequence and causing a gap in the 
CanFam 2.0 genome assembly (Lindblad-Toh et al., 2005). The biological functions of these 
two proteins are fairly well understood compared to their genomic structure. Several lines 
of evidence suggest that both p16 and p14ARF act as potent tumor suppressors apart from 
their roles as cell cycle regulators during the G1 to S phase transition and p53 mediated cell 
cycle arrest, respectively. 
3.3 Role of p16 in cell differentiation 
Other than senescence and quiescence, p16 also has a role in cell differentiation like other 
CKIs. Expression of p16 increases by several fold in terminally differentiated human adult 
brain tissue and p16 is thought to play role in human brain development (Lois et al., 1995). 
During differentiation of human embryonic teratocarcinoma cells (NT2) into post-mitotic 
neurons, expression of p16 and p15 protein levels become elevated (Lois et al., 1995). The 
role of p16 in melanocyte differentiation has also been investigated. Microphthalmia 
transcription factor (MITF) is able to induce cell cycle arrest prior to cell differentiation by 
activation of p16 protein (Loercher et al., 2005). 
A-type lamins are intermediate filaments which affect gene expression in differentiation and 
are thought to function through an Rb-dependent mechanism. Rb associates with a number 
of tissue specific transcription factors in an E2F-independent manner and induces 
differentiation in those tissues. Rb associates with MyoD and Mef2 in skeletal muscle cells 
(Sellers et al., 1998; Novitch et al., 1999), CBFA1 and Runx2 in osteocytes (Thomas et al., 
2001; Thomas et al., 2004), and C/EBP in adipocytes and during macrophage differentiation 
(Chen et al., 1996). pRb is essential for muscle and fat cell differentiation (Korenjak & Brehm, 
2005) and cellular senescence (Ohtani et al., 2001). Cells lacking A-type lamins do not arrest 
in the presence of p16 because destabilization of pRb (Nitta et al., 2006). This report suggests 
a dependence of p16-induced cell cycle arrest on Rb and posits a role for A-type lamins in 
Rb-dependent cell cycle arrest.  
Cyclin, CDKs, and CKIs have been associated with proliferation and differentiation in a 
variety of cell and tissue systems. CyclinD1, the principle cofactor of p16, targets CDK4/6 
and may participate in myoblast differentiation (Rao & Kohtz, 1995). Thus, p16 appears to 
play a key regulatory role in cell differentiation and senescence through management of cell 
cycle exit. CDK4/6 also regulates cell division at different stages of erythroid maturation 
(Malumbres et al., 2004). CDK4 knock-out mice lack postnatal homeostasis of pituitary 
somato/lactotrophs and pancreatic B cells (Jirawatnotai et al., 2004). CDK6 knock-out mice 
have mild defects in hematopoeitic cell differentiation. Double deficiency of CDK4/6 in 
embryos appears to have no effect on organogenesis and associated cell proliferation 
although they are lethal due to defects in the erythroid lineage (Malumbres et al., 2004). 
Thus, CDK4/6 are required for many specific tissue differentiation events along with cell 
cycle progression. For example CDK4 activity is required for pancreatic -cell proliferation 
and increased expression of p16, limits the regenerative capacity of -cells with aging 
(Krishnamurthy et al., 2006).  
Cell proliferation inhibits cell differentiation while, conversely, factors inducing cell cycle 
exit often lead to differentiation. Cell cycle regulatory proteins are multifunctional and can 
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also affect cell differentiation independent of their role in cell cycle. p21 deficient cells are 
defective in differentiation although differentiation can resume by transducing cells with 
p16 to compliment the mutation (Gius et al., 1999). Cyclin-CDK complexes can inhibit 
differentiation in a kinase-dependent manner. The cyclin D1-CDK4 complex can 
phosphorylate and inhibit DMP1 or Mef2c transcription factors that are essential for 
differentiation of skeletal muscle and pre-hypertrophic chondrocytes (Hirai & Sherr, 1996; 
Lazaro et al., 2002; Arnold et al., 2007). CDK2 and CDK4 can inhibit TGF- induced growth 
arrest by phosphorylating Smad3 (Matsuura et al., 2004). p16, as a direct inhibitor of cyclin 
D1 and CDK4 complexes may thus have an indirect role in cell differentiation. 
3.4 Role of p16 in cell senescence 
Cell senescence is a permanent cell resting phase and is related to cell aging (Smith & 
Pereira-Smith, 1996). Senescence can be either induced by DNA replication stress or by 
oncogene expression but is most often the result of replicative senescence. Accumulation of 
p16 is associated with replicative senescence. Increased p16 expression has been found in 
lymphocytes only a few cell doublings before replicative senescence (Chebel et al., 2007). 
Oncogene induced senescence is linked with elevated p16 and p14ARF expression (Serrano, 
1997; Markowski et al., 2010). Deletion of the INK4/ARF gene locus, in K-ras constitutively 
expressing mice, results in loss of senescence and invasive, metastasizing tumors (Bennecke 
et al., 2010). 
p16 expression has been shown to promote premature cell senescence (Zindy et al., 1997). 
Level of p16 expression increases as mouse embryonic fibroblasts reaches senescence (Zindy et 
al., 1997). Immortal fibroblast (NIH3T3) and tumor cell lines frequently lack p16 expression 
suggesting the removal of p16 as a potential pathway to bypass senescence and also points 
towards the importance of p16 as a tumor suppressor gene (Kamb et al., 1994; Nobori et al., 
1994; Zindy et al., 1997). T box proteins (Tbx2) and polycomb proteins (BMI1, Cbx7, Mel18) 
have been reported to be repressors of all three genes of the INK4 locus (p16, p14ARF, and 
p15) (Jacobs et al., 1999; Gil et al., 2004). Repression of the INK4B/INK4A/ARF locus is 
controlled by methylation of histone 3 at lysine 27, by binding of chromobox 7(CBX7) within 
the polycomb repressive complex 1 to ANRIL (antisense non-coding RNA of 
INK4B/INK4A/ARF locus) (Yap et al., 2010). Bmi-1 encodes the polycomb protein, which 
represses both p16 and p14ARF and is linked with regulation of the replicative life span of 
human fibroblasts (Itahana et al., 2003). BMI1 protein represses p16 expression by binding 
directly to the Bmi-1 response element (BRE), within the p16 promoter (Meng et al., 2010), and 
is dependent on the continued presence of EZH2-containing Polycomb-Repressive Complex 2 
(PRC2) complex (Bracken et al., 2007). Enhancer of zeste homolog 2 (EZH2) is a histone 
methyltransferase and a component of the polycomb group protein complex which represses 
INK4a/ARF gene expression in pancreatic islet beta cells (Chen et al., 2009).  
Under a stress and senescence stimulus EZH2 levels decrease coinciding with up-regulated 
p16. Coincidently PRC2 and PRC1 complexes, localized at the regulatory domain of p16, are 
lost when cells enter senescence which in turn results in decreased levels of histone H3K27 
trimethylation (H3K27me3) and increased levels of the histone demethylase Jmjd3 with the 
recruitment of the MLL1 protein (Agherbi et al., 2009). Polycomb proteins are recruited to 
the INK4/ARF locus through CDC6 and, upon senescence and with an increase in Jmjd3 
levels, MLL1 protein is recruited to the locus provoking dissociation of polycomb protein 
from the INK4/ARF locus. This leads to transcription and replication of the INK4/ARF locus 
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in early S phase prior to reaching senescence (Agherbi et al., 2009). CDC6 is an essential DNA 
replication regulator. CDC6 overexpression induces increased INK4/ARF tumor suppressor 
gene expression through epigenetic modification of chromatin at the INK4/ARF locus 
(Borlado & Mendez, 2008). COOH–terminal-binding protein (CtBP), a physiologically 
regulated co-repressor, has also been reported to have a significant role in p16 repression. 
Several of the pathways noted above repress p16 via CtBP-mediated repression as CtBP forms 
bridges between proteins having PxDLS amino acid motifs including several transcription 
factors and other proteins involved in transcription (Mroz et al., 2008). 
The levels of p27 and p16 proteins are significantly increased in contact-inhibited human 
fibroblasts while in contrast, levels were low in serum-deprived human fibroblasts but in 
both cases, even through the mechanisms of growth arrest are different, they both affect the 
same pathway involving CDK4, cyclin D1, and Rb (Dietrich et al., 1997). Maintenance of p16 
and p27 levels have also been shown to contribute to the low levels of proliferation in 
normal blood vessels (Izzard et al., 2002) and p16 mRNA and protein accumulate in human 
fibroblasts as they become senescent (Hara et al., 1996).  
4. Potential of p16 as a therapeutic or gene therapy target 
p16 is an important tumor suppressor gene, deletion of which causes various types of 
tumors making it an important potential target for cancer gene therapy. It has been reported 
that p16 positive oropharyngeal squamous cell carcinoma (OPSCC) patients respond more 
favorably to intensity-modulated radiotherapy treatment in comparison to similar p16 
negative tumors (Shoushtari et al., 2010). Infectious delivery of the whole p15/p16/p14ARF 
locus, in infectious bacterial artificial chromosomes, results in growth suppression in human 
glioma cells (Inoue et al., 2004). Induction of p16 using the DNA methyltransferase inhibitor 
zebularine combined with the histone deacetylation (HDAC) inhibitors depsipeptide led to 
inhibition of cell growth in lung tumor cell lines (Chen et al., 2010). Ectopic p16 introduction 
in cancer cells alone or with other tumor suppressor genes inhibits cell growth and induces 
apoptosis and senescence, while p16 gene silencing reduced the p53-mediated response to 
chemotherapeutic agents in cancers (Derenzini et al., 2009). Histone methyltransferase EZH2 
inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat together 
induce p16, p21, p27, and FBX032 and down-regulates cyclin E and HOXA9 levels, which 
induces apoptosis in cultured and primary human acute myeloid leukemia (AML) cell line 
cells (Fiskus et al., 2009). p16 along with the murine granulocyte-macrophage colony-
stimulating factor gene (AdGM-CSF) can induce effective anti-tumor immunity (Wang et al., 
2002). Exogenous expression of p16 and p53 induce apoptosis in lung carcinoma cells (Bai et 
al., 2000), leukemia cell line K562 (Rui & Su, 2002), non-small lung cancer (Wu et al., 2000), 
and pancreatic cancer (Ghaneh et al., 2001). p16 along with p27 inhibits angioplasty-induced 
neointimal hyperplasia and coronary artery occlusion (Tsui et al., 2001), inhibits 
proliferation in neointimal hyperplasia (McArthur et al., 2001), and a wide range of other 
tumor types (Patel et al., 2000). Ectopic expression of p16 by replication-competent 
adenovirus leads to potent anti-tumor effects in gastric cancer xenografts in nude mice (Ma 
et al., 2009) while p16 transfection along with cisplatin treatment increased senescence and 
growth inhibition in non-small cell lung cancer xenografts in mice (Fang et al., 2007). Ectopic 
p16 expression was able to induce growth arrest in pancreatic carcinoma JF305 cell lines (Ma 
et al., 2007), human laryngeal squamous cell carcinoma (Liu et al., 2003; Fu et al., 2004), and 
inhibit experimental lung metastasis in Balb/c nude mice (Kim et al., 2003), inhibit cell 
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growth in nasopharyngeal carcinoma (Lee et al., 2003), and a murine model of head and 
neck cancer (Rhee et al., 2003), human mesothelioma (Yang et al., 2003), and suppress tumor 
growth by glioblastoma cells in vivo and in vitro (Adachi et al., 2002). p16 transfection 
suppressed growth of Bcap-37 breast cancer cells (Bai et al., 2001), the human melanoma cell 
line WM-983A (Cheng et al., 1999), human lung adenocarcinomas (Fu et al., 1999), 
pancreatic cancer (Calbo et al., 2001), and inhibits cardiac hypertrophy in vitro and in vivo 
(Nozato et al., 2001). p16 also inhibited cell growth in a human ovarian cancer cell line 
(Wang et al., 1999), a human gastric cell line (Sun & Lu, 1997), and a small cell lung 
carcinoma (Sumitomo et al., 1999). All of these diverse examples demonstrate the potent and 
broadly efficient effects of exogenous p16 expression on cell proliferation in p16 negative 
cancer cells in vitro and in vivo and reflects the importance of p16 as regulatory factor and 
potential target for gene therapy and cancer therapeutics. 
5. Conclusions 
p16/INK4A/CDKN2A is an important tumor suppressor gene, which is required for the 
control of unregulated cell growth in many and perhaps most cell types. The INK4A locus is 
also unique in eukaryotes, where 3 and perhaps 4 transcripts are derived which have similar 
functions of suppressing cell growth but that work via very different pathways. Most 
surprising is the utilization of alternative open reading frames from a single gene complex 
mandating co-evolution of the unrelated protein sequences. Despite these constraints, 
mutation of p16 is second only to p53 in mutation frequency in a wide range of tumors. This 
strongly suggests that p16 may have real potential as an important new target for cancer 
gene therapy. p16 is not just an important cell cycle regulatory protein that helps suppress 
the cell growth and tumor formation, p16 also has a role in other cell cycle phases. p16 has 
been reported to play an important role in cell differentiation, cell quiescence, and cell 
senescence, which makes it not just a tumor suppressor protein but a cell regulatory protein 
that plays a critical role in regulating terminal differentiation and the aging process. There is 
a great need to investigate all the subtleties surrounding p16 function and to unravel all the 
pathways and binding partners of p16. p16 is a promising gene located within a complex 
gene locus with many roles in cell metabolism.  
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1. Introduction  
Phosphatase and tension homolog deleted on chromosome 10, PTEN, is a tumor suppressor gene 
that is responsible for controlling tumorigenesis in various organs (Li and Sun 1997, Steck et 
al. 1997, Li et al. 1997, Ali, Schriml and Dean 1999). Functionally, PTEN exhibits 
phospholipid phosphatase activity and negatively regulates the conversion of 
phosphatidylinositol 4, 5-diphosphate (PIP2) to PIP3 (Stambolic et al. 1998, Wu et al. 1998). 
PTEN ablation results in the accumulation of PIP3, which recruits AKT to the cell 
membrane, where PIP3-dependent protein kinase-1 (PDK1) and mammalian target of 
rapamycin (mTOR) complex 2 (mTORC2), also known as the Rictor-mTOR complex, 
activate and phosphorylate AKT at amino acid residues Thr308 and Ser473, respectively 
(Alessi et al. 1997, Sarbassov et al. 2004, Sarbassov et al. 2005). Consequently, activated AKT 
acts as a key effector and modulates a variety of downstream signal regulators. One AKT-
targeting protein is tuberous sclerosis complex 2 (TSC2) (Inoki et al. 2002, Manning et al. 
2002), which is a GTPase-activating protein that forms a complex with TSC1 to block a small 
GTPase Rheb at GDP-bound status, consequently resulting in mTORC1 (the Raptor-mTOR 
complex) inhibition. Thus, AKT-mediated TSC1-TSC2 inhibition results in mTORC1 
activation, which promotes cell growth and protein translation partly through 
phosphorylating S6 kinase (S6K) and the eIF-4E-binding protein 1 (4E-BP1) (Brunn et al. 
1997, Hara et al. 1997, Brown et al. 1995). Activated mTORC1 and S6K can also regulate 
PI3K-AKT signaling through a negative feedback mechanism [see Fig 1; reviewed in 
(Carracedo and Pandolfi 2008, Manning and Cantley 2007)]. In addition, activated AKT can 
target glycogen synthase kinase 3 (GSK3) (Cross et al. 1995), -catenin (Fang et al. 2007, He 
et al. 2007), double minute 2 (Mdm2) (Mayo and Donner 2001, Zhou et al. 2001b), p21 (Zhou 
et al. 2001a), p27 (Fujita et al. 2002), forkhead-related transcription factors (Brunet et al. 
1999), Bcl2-antagonist of cell death (Datta et al. 1997, Peso et al. 1997), and other genes, 
leading to cellular proliferation, anti-apoptosis, survival, and tumorigenesis [see Fig 1; 
(Cully et al. 2006, Kishimoto et al. 2003, Manning and Cantley 2007, Dunlop and Tee 2009)]. 
To model Pten-deficient malignancies, conditional Pten mutant alleles have been generated 
in mice. Using tissue-specific Cre-loxP-mediated Pten gene excision, the roles of Pten have 
been intensively studied across multiple organs in mice. We previously used an inducible 
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Cre under the control of a ubiquitous promoter, ROSA26 (R26), to examine the susceptibility 
of all tissues to Pten-deficient tumorigenesis in an adult mice strain referred to as R26-
Ptenfx/fx. We found that lymphomas accounted for the majority of Pten-deficient 
malignancies (Lu et al. 2007). However, the high incidence and short latency of lymphomas 
in the R26-Ptenfx/fx mice limited our analyses of the tumors arising from the epithelial tissues, 
the most common origin of human cancers. To address the susceptibility of epithelial tissues 
to Pten loss, we performed spatiotemporally controlled Pten excision by using a newly 
generated inducible Cre transgene driven by the keratin 8 (K8) promoter in a mouse strain 
referred to as K8-Ptenfx/fx. In this epithelial Pten-deficient mouse, multiple epithelial tumors 
arose, and they could be monitored at different time points after Pten was ablated. 
 
 
Fig. 1. Schematic illustration of PTEN/PI3K/AKT and their downstream effectors. 
2. Genetic tool for conditional genetic manipulation in the epithelial tissues  
To develop transgenic mice expressing inducible Cre (CreERT) in epithelial tissues, we 
generated and characterized the transgenic mouse line Tg(K18-EGFP, K8-CreERT), in which the 
visualized enhanced green fluorescence protein (EGFP) is driven by the K18 upstream 
regulatory elements and the CreERT fusion gene is driven by K8 (Fig 2). To evaluate the 
induced CreERT recombinase activity after tamoxifen (Tam) administration, Tg(K18-EGFP,K8-
CreERT) mice, hereafter abbreviated as K18-EG/K8-CE, were bred with ROSA26 Cre reporter 
(R26RLacZ/+) mice (Soriano 1999) to generate K18-EG/K8-CEtg/+;R26RLacZ/+ bigenic mice.  
We monitored K18 promoter-directed EGFP expression in the offspring of C57BL/6 females, 
which were bred with different lines of K18-EG/K8-CE males. We found that lines B, G, and 
H among eight transgenic lines exhibited strong and consistent EGFP signals in the tail, 
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footpads, and all internal organs lined by simple epithelium (data not shown). 
Subsequently, these three lines were selected to breed with R26RLacZ/+ mice to generate 
double-transgenic mice (referred to K18-EG/K8CEtg/+;R26RLacZ/+), which were evaluated by 
whole mount X-gal staining of inducible CreERT recombinase expression driven by the K8 
upstream sequence. At 5-6 weeks of age, Tam was intraperitoneally administered to K18-
EG/K8CEtg/+;R26RLacZ/+ bigenic and control (R26RLacZ/+) mice, after which we examined inducible 
Cre activity by assessing X-gal staining, which reflected LacZ expression at 10 days after Tam 
treatment. We found that similar LacZ expression patterns were observed among the B, G, and H 
lines on the R26RLacZ/+ background.  
2.1 Evaluation of inducible Cre activity of K18-EG/K8-CEtg/+; R26RLacZ/+ bigenic mice 
across multiple organs  
In the lower respiratory tract of bigenic mice, EGFP- and X-gal-positive staining was clearly 
observed in the trachea, bronchi, and bronchioles, but not in the alveoli (Fig 2BB’ and CC’). 
Histological sections of X-gal-stained tissues revealed that inducible Cre activity was mainly 
restricted in the pseudostratified epithelial cells of the terminal bronchiole (TB) (Fig 2C’) that 
expressed K8, which colocalized with EGFP fluorescence driven by the K18 upstream 
sequence (Fig 1B’), but Cre activity was not observed in the pneumocyte lining of the 
alveolar sac (AS) (Fig 2B and C). In the liver of bigenic mice, intense EGFP- and X-gal-
positive staining revealed the organization of bile ducts or gross portal tracts (Fig 2D and E). 
Intense EGFP- and X-gal-positive staining was also visualized in the gallbladder (GB, Fig 2D 
and E). Through histological analysis and immunofluorescence staining using an antibody 
against K8, we found that intense K8 and EGFP expression was detected in the intrahepatic 
bile duct (BD) compared with that in the surrounding hepatocytes (Fig 2D’). Intensely X-gal-
stained cells were mainly observed in the epithelial lining of the intrahepatic BD (Fig 2E’) 
and gallbladder (data not shown). Furthermore, bright EGFP-positive and intense X-gal-
positive signals could be easily visualized in the pancreas, but not in the adjacent spleen (Fig 
2F and G), of bigenic mice. Microscopically, pancreatic ducts (PDs) and exocrine acini 
expressed EGFP and K8 (Fig 2F’), which colocalized with X-gal staining (Fig 2G’).  
Along the gastrointestinal tract of bigenic mice, the hind-stomach and intestine also 
exhibited bright EGFP fluorescence (Fig 2H and J) and the intense blue X-gal staining 
indicative of LacZ expression (Fig 2I and K). Immunostaining using an antibody against K8, 
together with EGFP fluorescence, revealed that both K8 and EGFP expression appeared in 
the epithelial cells of the hind stomach (Fig 2H’) and small intestine (Fig 2J’). Tam-induced 
LacZ expression was detected in the lower portion of zymogenic and parietal cells in the 
glandular hind stomach (Fig 2I’) and in crypts of the small intestine (Fig 2K’).  
We further examined EGFP and induced LacZ expression in the reproductive tracts of 
bigenic mice (Fig 3). In the male reproductive tract, the seminal vesicles (SVs; Fig 3A and B) 
and epididymis (Fig 3E and F) exhibited intense EGFP expression and X-gal staining, 
whereas the testis exhibited neither LacZ nor EGFP expression (Fig 3E and F). In the 
prostate, the ventral prostate (VP) lobes and dorsolateral prostate (DLP) lobes exhibited 
strong LacZ and EGFP expression (Fig 3C and D) compared to that in the anterior prostate 
(AP) lobes (Fig 2A and B). Immunostaining of K8 was colocalized with EGFP fluorescence in 
the epithelial lining of the SV (Fig 3A’), the VP (Fig 3C’) and epididymis (Fig 3E’). In 
addition, the histological sections revealed X-gal-positive staining in the epithelia of 
corresponding organs (Fig 3B’, D’, and F’). Notably, patchy EGFP and X-gal signals partly 
overlapped with K8-expressing luminal cells of the AP (Fig 3A” and B’’), indicative of 
inefficient expression of EGFP and LacZ in the AP of bigenic mice.  
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Fig. 2. Evaluation of the visualization marker EGFP and inducible Cre activity of Tg(K18-
EGFP, K8-CreERT) mice. (A) Schematic illustration of the genetic tool, Tg(K18-EGFP,  
K8-CreERT) referred to K18-EG/K8-CE, which exhibits EGFP expression under the control  
of the K18 promoter and inducible Cre activity driven by the K8 promoter, which was 
evaluated by the Cre reporter allele, R26RlacZ, after tamoxifen (Tam) administration. (B-K) 
Visualization of EGFP and evaluation of Tam-induced Cre-loxP recombination activity in 
the dissected organs of K18-EG/K8-CEtg/+;R26RLacZ/+ mice treated with Tam for 10 days. (B) 
Whole-mount EGFP expression was visualized in the trachea, bronchus, and bronchiole of 
the K18-EG/K8-CEtg/+;R26RLacZ/+ lung. (B’) EGFP and immunofluorescent staining of K8 (red) 
revealed the colocalization of EGFP and K8 in the bronchiole columnar epithelium but not 
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in the AS. DAPI staining was used to indicate the nuclei. (C) The presence of LacZ 
expression was indicated by X-gal-stained epithelial tissues that had similar staining profiles 
as the EGFP-expressing tissue of the K18-EG/K8-CEtg/+;R26RLacZ/+ lung in (B). (C’) A 
histological section of the X-gal-stained lung was counterstained with Nuclear Fast Red to 
detect X-gal-stained epithelial cells. Insets in (B’) and (C’), high magnification of the 
epithelium of the terminal bronchiole (TB); (D) Intense EGFP expression was visualized as 
branching portal tracts in the K18-EG/K8CEtg/+;R26RLacZ/+ liver. GB, gallbladder; L, left liver 
lobe; M, medial liver lobe; (D’) EGFP and K8 expression was strongly detected in bile ducts 
(BDs) residing close to the portal vein (PV) and weakly detected in hepatocytes. CV, central 
vein; (E) Intense X-gal-positive blue patterns were similar to the EGFP expression patterns 
in the GB and branching portal tracts, but only patchy staining was observed in the liver 
parenchyma. (E’) Sections of whole-mount X-gal-stained liver exhibited strong blue staining 
in the BD. (F) and (G) Intense EGFP expression and the presence of LacZ were detected in 
the pancreas but not in the spleen (Spl). (F’) EGFP and K8 expression as positively detected 
in the exocrine acini and pancreatic ducts (PDs). (G’) Homogenous blue staining was 
histologically observed in the pancreatic acini and PDs. (H) and (I) Intense EGFP- and X-gal-
positive staining was observed in the hind-stomach (HS), but not in the forestomach (FS). 
(H’) and (I’) EGFP and LacZ expression were highly localized at the base of the glandular 
stomach. (J) and (J’) Epithelial cells of the small intestine (jejunum) exhibited a strong EGFP 
signal. (K) and (K’) Mosaic LacZ activity revealed by X-gal staining in the crypts and upper 
differentiated epithelium of the jejunum. Scale bar, 100 μm. 
In the reproductive tract of our bigenic females, EGFP was detected in the K8-expressing 
simple epithelium of the oviduct and uterus (Fig 3GG’ and II’). However, mosaic X-gal-
positive patterns were observed in the simple epithelium of the oviduct and uterine glands 
(Fig 3 H’ and J’). Unexpectedly, LacZ and EGFP expression was not detected either grossly 
(Fig 3 G and H) or microscopically (Fig 3G’ and H’) in the ovarian surface epithelium (OSE; 
data not shown), which was thought to be the K8/K18-expressing cell type. The lack of 
EGFP and inducible LacZ expression in the OSE of bigenic mice indicated that the cis-
regulatory elements within the K8-K18 intergenic sequence are unable to drive EGFP and 
CreERT expression in the OSE.  
2.2 Temporally controlled fate mapping to evaluate epithelial turnover in the 
mammary luminal epithelium and intestinal epithelium  
In the adult stage, epithelial cell turnover is required to ensure the long-term maintenance of 
epithelial tissue homeostasis, which may be dysregulated during tumorigenesis. The process 
for epithelial renewal through generating new cells, differentiation, and migration from 
their stem/progenitors and niche varies among different epithelial tissues (Blanpain, 
Horsley and Fuchs 2007). As our K18-EG/K8-CEtg/+;R26RLacZ/+ mice were administered Tam 
by intraperitoneal injection at 6 weeks of age, we could monitor LacZ expression in various 
epithelial organs at different time points to determine whether inducible Cre activity 
occurred in higher hierarchical K8-expressing stem/progenitors to continuously give rise to 
their descendants. If the inducible Cre activity occurred in the stem/progenitors, then 
permanent LacZ activity could be detected in their descendants during cell turnover. In 
contrast, if the Tam-induced LacZ-expressing cells are terminally differentiated cells, then 
the LacZ-positive cells may be replaced by newly generated cells in which the loxP-flanked 
stop cassette of the R26R allele is not excised, indicating that these cells arise from K8-
independent epithelial progenitors.  
 
Tumor Suppressor Genes 
 
40
 
Fig. 3. EGFP visualization and evaluation of Tam-induced Cre activity in the reproductive 
organs of K18-EG/K8-CEtg/+;R26RLacZ/+ mice treated with Tam for 10 days. (A) and (B) The 
seminal vesicle (SV) exhibits greater EGFP and LacZ expression than the anterior prostate 
(AP). (A’) and (B’) Histological sections revealed an intensive EGFP signal (green) 
coexpressed with K8- (red) and X-gal-stained LacZ-expressing epithelia. (A’’) and (B’’) 
Histological sections revealed a weak mosaic EGFP signal (green) coexpressed with K8 (red) 
and few X-gal-stained cells, indicative of poor inducible Cre activity in the AP. (C) and (D) 
Whole-mount EGFP and LacZ were present in the bladder and prostate [ventral prostate 
(VP) and dorsolateral prostate (DLP)]. (C’) and (D’) Sections revealed intense EGFP and K8 
coexpressing cells and X-gal-stained epithelia in the VP. (E) and (F) Intense EGFP- and X-
gal-positive staining was clearly detected in the epididymis but not in the testis. (E’) and (F’) 
Histological sections of the epididymis exhibited an intense EGFP signal (green) 
coexpressed with K8 and LacZ activity. (G-J) In the female reproductive tract, an intense 
EGFP signal was observed in the oviduct (OD) and uterus (U), whereas X-gal staining was 
more strongly detected in the uterus. (G’-J’) Sections exhibited EGFP and K8 coexpression in 
the epithelia of the oviduct (G’) and uterus (I’), whereas mosaic X-gal-stained epithelia were 
observed in the corresponding organs (H’) and (J’). Scale bar, 100 μm. 
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Fig. 4. Intestinal and mammary epithelial turnover monitored by LacZ activity in K18-
EG/K8-CEtg/+;R26RLacZ/+ mice. (A) Partial X-gal staining was detected in the intestines 
(jejunum) of the B line-derived K18-EG/K8-CEtg/+;R26RLacZ/+ mice in the absence of Tam 
administration (vehicle treatment) after 10 days. (B-D) After Tam administration for 10, 21, 
and 42 days, intense X-gal staining patterns were clearly detected in the K18-EG/K8-
CEtg/+;R26RLacZ/+ intestines. (A’-D’) Histological sections of the aforementioned samples were 
counterstained with Nuclear Fast Red, and they exhibited continuous X-gal-stained 
epithelial cells that emerged from the lower crypts to the upper absorptive cells in the K18-
EG/K8-CEtg/+;R26RLacZ/+ mice treated with Tam (B’-D’) for 10-42 days. Conversely, a few X-
gal-positive cells were detected in the intestines of vehicle-treated mice, indicating the leaky 
expression of LacZ. (E-H) Lower and (E’-H’) higher magnification of X-gal-stained fourth 
mammary fat pads revealed the presence of X-gal-stained branching ducts in K18-EG/K8-
CEtg/+;R26RLacZ/+ mammary glands after Tam treatment for 10, 21, and 42 days (FF’-HH’), 
whereas no X-gal-stained cells were detected in the absence of Tam (EE’). (E’’-H’’) 
Histological sections of the aforementioned mammary samples were counterstained with 
Nuclear Fast Red, and they exhibited X-gal-stained luminal epithelia (F’’-H’’) in a time-
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dependent manner in comparison to the staining in the vehicle control. (I) Timeline for the 
lineage tracing of a lactating mammary gland. The K18-EG/K8-CEtg/+;R26RLacZ/+ female was 
treated with Tam at 6 weeks of age and followed for 3 weeks to set up mating, and then the 
animal was analyzed at 1 week postparturition. (J-M) The dissected K18-EG/K8-
CEtg/+;R26RLacZ/+ mammary gland was visualized by EGFP expression (J-L) and LacZ activity 
(K-M) both grossly and histologically. (L) Lactating alveolar epithelia of mammary glands 
exhibited uniform EGFP expression and mosaic patchy LacZ expression. Nuclei were 
counterstained with DAPI. (M) Histology sections were counterstained with Nuclear Fast Red, 
and they exhibited a mosaic pattern of X-gal-stained epithelial cells in the lactating mammary 
gland. Scale bars of A-D, E-H, and E’-H’, 0.25 cm; Scale bars of E’’-H’’ and L-M, 100 μm. 
Complete epithelial turnover in the intestine requires approximately 5 days [for review, see 
(van der Flier and Clevers 2009)]. Conversely, the relatively slower turnover rate of mammary 
epithelial cells is regulated by the estrous cycle, and these cells undergo alveolar 
morphogenesis during pregnancy and lactation. Thus, we selectively monitored inducible 
LacZ activity in intestinal and mammary epithelia at 10, 21, and 42 days after Tam 
administration. In the absence of Tam administration (vehicle control), spotty X-gal signals 
were detected in the small intestine (Fig 4AA’), which indicated a leakage of inducible CreERT 
activity, resulting in rare but detectable levels of LacZ expression. After 10 days of Tam 
administration, X-gal-stained intestinal epithelia were detected in the cell lineage that emerged 
from the crypts, differentiated, and migrated upward to the villi (Fig 4BB’). This phenomenon 
was also observed after 21 and 42 days of induction (Fig 4CC’ and DD’), indicating that the K8-
expressing epithelia are composed of stem/progenitor cells that have the capability for long-
term intestinal maintenance. In contrast, the numbers of X-gal-stained ductal cells in 
mammary glands gradually reduced after Tam treatment for 21 and 42 days (Fig 4G-G’’and H-
H’’) compared to the number of X-gal-stained cells after 10 days of Tam treatment (Fig 4F). 
This observation suggests that the Tam-induced LacZ-expressing cells are replaced by newly 
generated cells from K8-independent epithelial origins, which give rise to LacZ-negative 
luminal cells that subsequently replace previous LacZ-positive cells to maintain mammary 
gland homeostasis. 
3. Characterization of Pten-deficient epithelial tumors  
3.1 The tumor latency, tumor spectrum, and tumor incidence of K18-EG/K8-CEtg/+; 
Ptenfx/fx mice 
Throughout intensive analyses of inducible Cre activity controlled by the K8 promoter in 
various epithelial tissues as shown in Section 2, we further monitored epithelial tumors 
arising from Pten-deficient epithelial tissues to clarify the susceptibility of different epithelia 
to Pten loss in multiple organs. Thus, we generated K18-EG/K8-CEtg/+;Ptenfx/+, K18-EG/K8-
CEtg/+;Ptenfx/fx (referred to K8-Ptenfx/+ and K8-Ptenfx/fx, respectively), and their littermate 
controls and induced Cre-loxP recombination using Tam to excise exon 5 of Pten as 
illustrated in Fig 5A. All mice were on a mixed B6/129/Balb/c background.  
Our results revealed that 92% of K8-Ptenfx/fx mice (23/25) and 26.3% of K8-Ptenfx/+ mice 
(5/19) developed various malignant tumors by 60 and 100 weeks after Tam treatment, 
respectively (Fig 5B). The cumulative cancer-free survival is presented in Fig 5B. The overall 
mean latency of Pten-deficient tumors was approximately 25 weeks. All tumors were 
primarily analyzed by gross appearance and H&E-stained histology. The malignant tumors 
that developed in K8-Ptenfx/fx and K8-Ptenfx/+ mice are summarized in Table 1.  
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We found that pancreatic ductal cancer (PDAC; 10 mice), cholangiocarcinoma (CC; 4 mice), 
hepatocellular carcinoma (HCC; 3 mice), and mammary gland tumors (MGTs; 7 females) 
accounted for the majority of the identified Pten-deficient malignancies (Fig 5C; Table 1), 
which are selectively described in Sections 3.2-3.4. Prostate cancer (two males) and 
precancerous lesions (prostate intraepithelial neoplasia) were also frequently found in K8-
Ptenfx/fx mice (data not shown). Other malignancies arising from the thyroid, lung, stomach, 
and uterus were occasionally identified in the K8-Ptenfx/fx mice (Table 1). In addition, 
multiple tumors arising from different organs were observed in K8-Ptenfx/fx mice (eight mice, 
32%; three males and five females; Table 1). Moreover, five different epithelial malignancies 
arising from the thyroid, lung, pancreas, intestine, and breast were found in five K8-Ptenfx/+ 
females. At present, no malignant tumors have been found in K8-Ptenfx/+ males, which may 
be due to the limited animal numbers (n=7); a higher number of K8-Ptenfx/+ males might be 
required for further confirmation.  
 
 
 
Fig. 5. Analysis of malignant tumors in the K8-Ptenfx/fx and K8-Ptenfx/+ mice. (A) Schematic 
illustration of the genetic tool, Tg(K18-EGFP, K8-CreERT), used to conditionally excise the 
Pten floxed allele after Tam administration. (B) Cancer-free survival of control, K8-Ptenfx/+, 
and K8-Ptenfx/fx mice. (C) Major epithelial malignancies (n>3) of K8-Ptenfx/fx mice. PDAC, 
pancreatic ductal cancer; CC, cholangiocarcinoma; HCC, hepatocellular carcinoma; MGT, 
mammary gland tumor.  
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*multiple tumors in 3 males and 5 females 
Table 1. Malignancies of the K8-Ptenfx/+ and K8-Ptenfx/fx mice. 
3.2 Pten-deficient pancreatic malignancies 
Among different tumor types, pancreatic malignancies developed approximately 12 weeks 
before other epithelial lesions, and pancreatic malignancies accounted for the majority of 
epithelial malignancies in Tam-treated K8-Ptenfx/fx mice (Fig 5C). Pancreata isolated from 
control mice (Fig. 6 A-C) and sick K8-Ptenfx/fx mice (Fig. 6 D-F, G-I, and J-L) were subjected to 
stereomicroscopy and histology. Grossly, the normal pancreas exhibited vasculature and a 
white appearance and was a soft organ connected to the caudal lobe of the liver, common 
bile duct, stomach, duodenum, and spleen (Fig. 6A). In the Pten-deficient pancreata, 
desmoplastic changes and cystic dilation could be identified (Fig. 6 D, G, and J). In addition, 
the higher EGFP intensity exhibited tubular or patchy patterns in the K8-Ptenfx/fx mutants 
(Fig. 6 E, H, and K; arrows) compared to the uniform GFP pattern of the control (Fig. 6B). 
Microscopically, interlobular ductal hyperplasia (Fig. 6F), acinar-to-ductal metaplasia (Fig. 
6I), and PDAC (Fig. 6L) were identified in some K8-Ptenfx/f mice. In our observations, PDAC 
progression in K8-Ptenfx/fx mice is an immediate life-threatening disease as like in humans. In 
general, our findings were consistent with an earlier report that characterized pancreatic 
ductal metaplasia and pancreatic cancer initiation in mice in which Pten was ablated by 
Pdx1-Cre starting from the developing pancreas specifically (Stanger et al. 2005). Our 
inducible Cre activity in the K8-expressing cells of the adult mouse pancreas likely includes 
pancreatic ducts and centroacinal cells in which Pten is excised, leading to PDAC. 
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Fig. 6. Pancreatic malignancy of the K8-Ptenfx/fx mice. Age-matched Tg(K18-EGFP, K8-CreER) 
pancreata were used as the control. Gross appearances and EGFP expression in control (A-
B) and K8-Ptenfx/fx pancreata (D-E, G-H, and J-K) were observed by stereomicroscopy. H&E-
stained histological sections of control pancreata revealed the exocrine acinar gland, 
pancreatic islet, interlobular duct, and blood vessel (C). Interlobular ductal hyperplasia (F), 
ductal metaplasia (I), and invasive pancreatic ductal adenocarcinoma (L) were histologically 
identified in the K8-Ptenfx/fx mice at 9-13 weeks after Tam treatment. Scale bar, 100 μm. 
3.3 Pten-deficient MGTs  
Previously, Li et al used a mammary-specific MMTV-Cre transgenic line to excise the loxP-
floxed Pten critical exon (exon 5) (Li et al. 2002). Some MMTV-Cre;Ptenfx/fx females develop 
MGTs as early as 2 months of age (Li et al. 2002). In our study, MGT was the most frequent 
(approximately 38.9%) malignancy in K8-Ptenfx/fx females (7/18 mice). Palpable MGTs were 
detected at 24-54 weeks (mean latency, 43 weeks) after Tam treatment (Fig 5C), and they 
were dissected and observed under a stereomicroscope. We found that EGFP-positive 
branches were clearly revealed in the control mammary gland, although the deeper 
mammary branches were shielded by thick adipose tissue (Fig 7A). In the K8-Ptenfx/fx 
mammary solid tumor, higher EGFP intensity was detected in a patchy pattern, which 
might represent a mass of hyperplastic epithelial cells (Fig 7B). Histologically, the 
representative Pten-deficient MGT was a solid epithelial mass with atypical glandular 
arrangement (Fig 7D) compared to the normal mammary ducts that were surrounded by 
adipose tissue (Fig 7C). To determine the effect of induced PTEN loss, we performed 
immunohistochemistry on the sections of the control and K8-Ptenfx/fx mammary tissues. Our 
results revealed that PTEN expression could be detected in various cells, including ductal 
luminal and basal epithelial cells, vascular endothelial cells, and stromal cells, within the 
control mammary gland (Fig 7E). In contrast, the loss of PTEN was specifically 
demonstrated in the epithelial tumor cells, but not in the neovascular endothelial cells and 
stromal cells, of K8-Ptenfx/fx MGTs (Fig 7F).  
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Fig. 7. Mammary tumors of the K8-Ptenfx/fx females. (A) Mammary fat pad with EGFP-
expressing ductal branches (inset) was obtained from a control female (42 weeks after Tam 
treatment); (B) MGT consisting of an EGFP-expressing tumor mass (inset) was obtained 
from a K8-Ptenfx/fx female (42 weeks after Tam treatment); (C) and (D) H&E-stained 
histological sections of control mammary tissue (C; 54 weeks after Tam treatment) and K8-
Ptenfx/fx MGT (D; 54 weeks after Tam treatment); (E) and (F) PTEN immunohistochemistry 
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revealed the induced loss of PTEN in a K8-Ptenfx/fx mammary epithelial tumor (F; 54 weeks 
after Tam treatment), whereas PTEN was expressed in various cell types within age-
matched control mammary tissue (arrows; E). Insets, high-power views of the PTEN levels 
in the control mammary duct (E) and mammary epithelial tumor (F); (G) and (H) 
Immunohistochemistry of p-Akt(Ser473) revealed cytoplasmic staining of p-Akt in tubular 
structures infiltrating within a stroma of a K8-Ptenfx/fx MGT (H; 35 weeks after Tam 
treatment) compared to a negatively stained mammary duct of an age-matched control 
mouse. Insets, high-power views of the p-Akt(Ser473) levels in the control mammary duct 
(G) and MGT (H). Scale bar (C-H), 100 μm. 
Then, we determined activation of AKT using antibody against phosphorylated AKT, p-
Akt(Ser473), and found that AKT phosphorylation appeared in the neoplastic epithelial cells 
of the K8-Ptenfx/fx MGT (Fig 7H), unlike the controls (Fig 7G).Thus, our data revealed that the 
mammary luminal epithelium was highly susceptible to Pten-deficient mammary 
tumorigenesis, although it might be replaced by a K8+-independent cell lineage as indicated 
by Cre reporter (LacZ) activity (Fig. 4E-H).  
3.4 Pten-deficient HCCs and intrahepatic CCs 
Liver-specific Pten ablation by albumin (Alb)-Cre has been reported to result in the 
development of steatohepatitis, metabolic disorders, and HCCs (Horie et al. 2004, Stiles et al. 
2004). According to two different reports, the latency of Pten-deficient hepatocellular 
carcinogenesis appears to be required for an extended time. Horie et al reported that Pten-
deficient HCCs developed in 66% of Alb-Cre;Ptenfx/fx animals at 74-78 weeks of age. Xu et al 
also found that the incidence of HCCs was 33% by 12-16 months of age (Xu et al. 2006). 
Interestingly, Xu et al reported that their Alb-Cre;Ptenfx/fx mice developed visible foci of CCs 
along with HCCs at late onset that were explained by the Alb-Cre mice exhibiting Cre 
activity in both hepatocytes and cholangiocytes (Xu et al. 2006). Moreover, early disease 
progression and higher penetrance of CCs were demonstrated when the Smad4 conditional 
allele was introduced into the Alb-Cre;Ptenfx/fx background (Xu et al. 2006).  
In our findings, low incidences of HCCs (3/25 mice) and CCs (4/25 mice) were identified 
in the Tam-treated K8-Ptenfx/fx mice at 9-54 (mean latency, 27 weeks) and 24-60 weeks 
(mean latency, 44 weeks), respectively (Fig 5C). Our observations indicated a longer 
period of disease progression for HCCs than for CCs after Pten loss was induced. 
However, the relative susceptibilities of hepatocytes and cholangiocytes to Pten-deficient 
tumorigenesis remain unclear because of the low incidence of both diseases. Moreover, 
the induced mosaic Cre recombination events in the hepatocytes compared to the uniform 
and intense reporter (LacZ) activity in the cholangiocytes of bile ducts as shown in Fig 2E 
should also be considered because differential induction of Cre activity may directly 
contribute to the differential pace of disease progression initiated in hepatocytes 
compared to that initiated in cholangiocytes. Nevertheless, we could identify both fatty 
accumulation in hepatocytes (Fig 8A) and dysplastic/hyperplastic cholangiocytes of the 
dilated bile ducts (Fig 8B) in the sections of K8-Ptenfx/fx livers at early time points (13 
weeks) after Tam treatment. These early events might directly or indirectly lead to HCC 
(Fig 8D) and CC, which could be identified by K19 expression (Fig 8F), in the Tam-treated 
K8-Ptenfx/fx mice at late onset. 
 
Tumor Suppressor Genes 
 
48
 
Fig. 8. Liver diseases of the K8-Ptenfx/fx mice. (A) Fatty changes of hepatocytes in a K8-Ptenfx/fx 
mouse at 13 weeks after Tam treatment; (B) Aberrant dilated bile ducts (arrows) of the 
portal tract in a K8-Ptenfx/fx mouse at 13 weeks after Tam treatment; (C) H&E-stained section 
and gross view (C’, inset) of a control liver at 60 weeks after Tam treatment; (D) H&E-
stained section and gross view (D’, inset) of a K8-Ptenfx/fx liver at 60 weeks after Tam 
treatment; (E) and (F) K19 expressed in the control bile ductal cells (E) and in the acinar 
pattern of a representative K8-Ptenfx/fx CC (31 weeks). Scale bar, 100 μm.  
4. Conclusion 
In this chapter, we demonstrated that the mouse K8-K18 intergenic sequence possesses the 
essential promoters and regulatory elements for controlling the bidirectional expression of 
CreERT and EGFP across multiple organs. Selectively ablating the tumor suppressor gene 
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Pten in the epithelial cells of multiple organs in this study provides an entry point to 
understand epithelial tissue susceptibility to Pten-deficient tumorigenesis. Our data reveal 
that the K8-expressing epithelia of the pancreatic ducts, prostate, and mammary glands are 
highly susceptible to Pten-deficient tumorigenesis. Hepatocytes and cholangiocytes of the 
liver also possibly undergo tumorigenesis after Pten loss, which may evoke a variety of 
downstream signaling circuits. All Pten-deficient malignancies described here are primary 
tumors that invade locally. Metastasis is rare in our current observation that requires further 
characterization. In the future, the same approach can possibly be used to establish clinically 
relevant mouse models to investigate adenocarcinoma initiation and progression by 
simultaneously creating additional genetic lesions in conjunction with the K8-Ptenfx/+ or K8-
Ptenfx/fx alleles; mice that carry multiple conditional alleles of cancer-related genes can be 
generated and characterized to understand tumor susceptibility, considering that cancer is a 
disease of multiple genetic events.  
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1. Introduction  
Loss of DNA or chromosomal deletion was frequently reported in different sporadic 
tumors, suggesting that those lost regions may contain putative tumor suppressor genes 
(TSGs). To map and isolate candidate genes from vast randomly lost areas, functional and 
complementary evidence is usually needed to define these areas to critical regions (CR). This 
is particularly important when one is dealing with sporadic cancers where clearly defined 
familial predisposition is present but high cancer risk families are not available for position 
cloning. A numerous studies have revealed extensive DNA deletions in nasopharyngeal 
carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). To identify candidate 
genes from these cancers, we used cell fusion and microcell-mediated chromosome transfer 
(MMCT) to introduce the whole chromosome or a chromosome fragment, into NPC and 
ESCC cell lines. Combined with other molecular approaches, we have successfully identified 
a number of novel TSGs on various human chromosomes.  
The nasopharynx is located behind the nasal cavity in the upper part of the pharynx (Fig. 1). 
NPC is a type of malignancy which arises from the epithelial cells in the nasopharynx. NPC 
is an unique cancer, which is commonly found in, Southeast Asia, North Africa, Middle 
East, and Arctic regions, but rare in most parts of the world (Jeyakumar et al 2006, Wei et al 
2005). The esophagus is a tube, which is about 25 cm long, for the food passage from mouth 
to stomach (Fig. 2). Esophageal cancer (EC) is classified into two major histologic subtypes: 
squamous cell carcinoma and adenocarcinoma (Daly et al 2000). Esophageal 
adenocarcinoma (EAC) arises from the cells of glands responsible for producing mucous in 
the esophageal wall. The majority of the cases (>80%) are ESCC in Hong Kong, while EAC 
shows a climbing incidence in Western countries. EC varies greatly in geographical 
distribution; high-risk areas include north-central China in Henan and Shanxi (Holmes et al 
2007, Qi et al 2005, Wu et al 2006).  
2. Chromosome transfer in tumor studies 
2.1 Somatic cell fusion and tumor suppression 
The theory for specific chromosomes contributing to tumor suppression was originally proven 
by somatic cell genetics (Harris et al 1969). In their study, Harris and colleagues fused the 
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mouse tumorigenic cells with non-tumorigenic cells to form a hybrid cell; some hybrid cells 
maintained the phenotypes of the parental cell lines and did not form tumors in the 
tumorigenicity assay. This suggests that non-tumorigenic cells contain genes, which are 
dominant and capable of suppressing the tumorigenic cell growth. The tumor suppression was 
further observed in human cell fusion experiments (Stanbridge, 1976 and 1992). The unstable 
tumorigenic hybrids showed loss of the selected chromosomes, resulting in the reemergence of 
its tumorigenicity properties. These findings suggested that some chromosomes may contain 
special regions, which can inhibit tumor formation, and thus provided the basis for further 
development of monochromosome transfer approaches to study the role of a particular 
chromosome in tumor development. These earlier experiments led to the hypothesis that the 
human genome might contain a group of genes suppressing tumor growth. 
 
 
Adapted from Cancer Research UK and American Society of Clinical Oncology  
Fig. 1. (A) Anatomy of human nasopharynx. (B) Location of nasopharyngeal carcinoma. 
 
 
Adapted from Cancer Research UK  
Fig. 2. Anatomy of human esophagus. 
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2.2 MMCT 
The microcell-mediated chromosome transfer (MMCT) technique is a functional approach to 
investigate the tumor suppressive role of a specific chromosome or chromosome fragment 
in recipient cells. By using this approach, a single human chromosome is transferred into 
cancer cell lines. Transfers of exogenous chromosomes are tested for their functional ability 
to complement existing defects present in cancer cells. In this approach, a microcell donor, 
which contains a human chromosome of interest, is used as a donor to transfer the selected 
chromosome into tumor cells. Microcells, presumably with one chromosome within a 
nuclear envelope and plasma membrane, are generated after disruption of the cytoskeleton 
of the donor cells. The microcells are then fused to a malignant cancer cell line to establish 
stable microcell hybrids (MCHs) (Anderson et al 1993, Fournier et al 1977a, Stanbridge 
1992). DNA genotyping and fluorescence in situ hybridization (FISH) are used for 
verification of a successful transfer. An in vivo nude mouse assay is then used to assess the 
tumorigenic potential of MCHs (Cheng et al 1998, Cheng et al 2000, Cheng et al 2002, Cheng 
et al 2003, Cheng et al 2004, Cheung et al 2009, Lung et al 2008a).  
2.3 Advantages of MMCT approach in TSG studies  
For the identification of TSGs contributing to the human cancers, initial efforts used the 
positional cloning of target regions defined by linkage analysis of pedigrees in hereditary 
cancer studies. The successful finding of the retinoblastoma gene, RB, is a good example 
(Friend et al 1986). However, the vast majority of the human cancers develop sporadically 
and involve numerous multiple gross deletions of chromosomal regions known as loss of 
heterozygosity (LOH). MMCT is a functional complementation approach useful for the 
identification of recessive-acting TSGs in sporadic cancers (Murakami 2002). Gene transfer 
approaches into human cancer cells may involve whole cell fusion, microcell fusion for 
intact or fragmented chromosomes, spheroplast fusion of yeast artificial chromosome 
(YAC), lipofection of bacteriophage P1, P1-derived artificial chromosome (PAC), bacterial 
artificial chromosome (BAC), or plasmids carrying the target genes, etc (Table 1) (Murakami 
2002).  
One of the advantages of the MMCT method is the transfer of a single copy of a 
chromosome allows strict control of dosage effect. If the transfer method is based on 
lipofection, it is impossible to control the copy number of DNA integrations into the 
genome. Compared to other commonly used artificial over-expression systems, the genes 
transferred by MMCT are expressed under the control of their endogenous promoters and 
enhancers and are regulated in their native environment. Thus, MMCT provides an ideal 
method for studying gene expression closely mimicking physiological levels and regulation 
controls under its native environment. Although the gene transfer by lipofection is 
convenient, the biological significance of functional studies of genes by the introduction of 
an expression vector should be carefully evaluated because the ectopic expression level of 
genes are not always equivalent to that found in the normal or tumor tissues, but are 
actually extraordinarily high in transfectants. An important issue to be addressed in the 
functional study of TSGs is whether the growth suppression resulting from exogenous gene 
over-expression by artificial procedures is a non-specific cytotoxic or cytostatic effect rather 
than a specific effect due to the expression of the gene itself.  
In the second step of the functional complementation cloning of TSGs, the in vivo 
tumorigenicity assay in the immunologically deficient mice is an indicator of the malignant 
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phenotype of cancer cells. The nude mouse tumorigenicity assay allows us to identify genes 
that fit the ultimate definition of a TSG, which requires functional evidence for the 
suppression of the malignant phenotype of cancer cells. The functional identification of 
TSGs in nude mouse assay can exclude the non-specific cytotoxic or cytostatic effects 
introduced by artificial gene expression. It also identifies a new category of molecules that 
are not cytotoxic in vitro, but are involved in the signaling cascades in different biological 
processes that hallmark cancer development such as the cell adhesion and sustained 
angiogenesis, inflammatory responses, evading immune destruction, and the tumor 
microenvironment. 
 
Vector Method Length of 
the insert
No of 
genes 
Promoter Position 
effect 
DNA 
copy 
number
References 
Cell Whole cell 
fusion 
3 Gb ~30,000 Endogenous - 2 (Murayama et 
al 1965) (Harris 
et al 1969) 
Chromosome Microcell 
fusion 
~ 150 Mb ~1,500 Endogenous - 1 (Fournier et al 
1977b) 
(Weissman et 
al 1987) 
(Koi et al 1989) 
Chromosomal 
fragment 
γ-Irradiation 
+ microcell 
fusion 
2-20 Mb 20-200 Endogenous - 1 (Dowdy et al 
1990, Koi et al 
1993), 
(Murakami 
 et al 1995) 
YAC Spheroplast 
fusion 
100-1600 
kb 
1-20 Endogenous + < - 1 (Pavan et al 
1990b) 
(Pachnis et al 
1990, Wada et 
al 1994), 
(Murakami et 
al 1998b) 
Fragmented 
YAC 
Homologous 
recombination 
+ 
Spheroplast 
fusion 
100-500 
kb 
1-10 Endogenous + / - 1 (Pavan et al 
1990a), 
(Murakami et 
al 1998a) 
P1, PAC, 
BAC 
Lipofection 80-200 kb <10 Endogenous + > - >1-10 (Todd et al 
1996) 
Plasmid Lipofection 
etc. 
<5 kb 
(cDNA) 
1 Artificial + >1-10 Numerous 
report 
Adapted from Murakami (2002).  
Table 1. Gene transfer methods into mammalian cells. 
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3. How to identify a TSG from a pool of genes? 
3.1 MMCT 
An intact single chromosome can be introduced into the recipient cell line using MMCT 
techniques. The establishment of mouse donor cells with a single copy of human 
chromosome is described previously (Fournier and Ruddle 1977a, Saxon et al 1985, 
Anderson and Stanbridge 1993). Figure 3 briefly outlines the procedures of MMCT. Donor 
cells were seeded on day 1 and incubated with 0.04 to 0.1 µg/ml colcemid for 48 to 56 hours 
to arrest cells in metaphase. Recipient cells were seeded on day 2 with the cell confluence 
reaching 80-90% the next day. Enucleation of the donor cells was achieved by centrifugation 
at 13,000 rpm for 65 to 70 min at 34C with 10 g/ml cytochalasin B (Sigma, MO, USA). The 
heterogeneous microcell mixture was then filtered through successive polycarbonate filters 
of 8/5/3 m pore sizes (Whatman, Middlesex, UK) to remove large microcells and other cell 
debris. Microcells were pelleted by centrifugation and resuspended thoroughly in 1 ml 
DMEM containing 50 g/ml phytohemagglutinin-p (PHA-P). The recipients were rinsed in 
PBS once and the microcell/PHA-P suspension was added to the recipient cells and 
incubated for 20-40 min. Microcells were fused to the recipient cell with 1-2 ml ice-cold PEG-
1000. The treated cells were rinsed with PBS four times and fed with medium. The selection 
medium [hypoxanthine, aminopterin, and thymidine (HAT) + G418] was added on day five. 
After about three-four weeks selection, only the recipient cells harboring the transferred 
chromosome containing the neomycin gene on the exogenously transferred chromosome 
survive; potential hybrids were picked and expanded for further analysis.  
 
 
Fig. 3. Schematic diagram of MMCT.  
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3.2 Confirmation of successful chromosome transfer  
The MCHs were subjected to DNA extraction and confirmation for the absence of mouse 
DNA contamination by DNA slot blot hybridization. Then the MCHs were subjected to 
microsatellite typing and fluorescence in situ hybridization (FISH). For microsatellite 
analysis, PCR products of microsatellite markers that amplified fragments with various 
numbers of repeat units are separated by gel or capillary electrophoresis. Microsatellite 
typing is a fast, simple, and reliable method to identify whether the donor allele has been 
transferred into the recipient cancer cell line. The high heterozygosity rate of microsatellite 
markers is used to demonstrate hybrid patterns in MCHs versus the recipient and donor 
cells to verify successful transfer of the donor human genetic materials into the human 
cancer cell line at the molecular level after MMCT.  
 
 
Fig. 4. DNA Slot blot analysis of chromosome 9 MCHs. The DNA of mouse A9 cells was 
used as a probe. The A9 and donor Neo 9 cells were used as positive controls for presence of 
mouse DNA, while the recipient cell line, HONE1 was used as a negative control for 
absence of mouse DNA. All MCHs was found to have no mouse DNA contamination. 
3.2.1 DNA slot blot hybridization  
The contamination of mouse DNA in MCHs was excluded by slot blot hybridization (Fig. 4). 
Five micrograms of genomic DNA of recipient cell lines, HONE1, microcell donor, MCHs, 
and A9 in 6X SSC (0.9 M NaCl and 90 mM Na Citrate, pH 7.4) were transferred onto a 
HybondTM N nylon membrane (Amersham Biosciences, Uppsala, Sweden) with a BIO-
DOT® SF slot blot apparatus (BioRad, CA, USA). The samples on the membrane were 
denatured for 10 min with a denaturing solution (1.5 M NaCl and 0.5 M NaOH) and then 
neutralized in 1 M NaCl and 0.5 M Tris-Cl, pH 7 for 5 min. The membrane was dried and 
cross-linked by UV on an UV transilluminator (Stratagene, CA, USA). A Gene ImagesTM 
AlkPhos DirectTM Labelling and Detection System (Amersham Biosciences, Uppsala, 
Sweden) was used according to manufacturer’s protocol. In brief, a total of 100 ng of A9 
DNA was denatured by heat for 5 min. The probe was labeled by covalently linking to 
alkaline phosphatase by incubating at 37C for 30 min with crosslinker solution and reaction 
buffer. The blot was prehybridized with 0.125 ml/cm2 hybridization buffer containing 12% 
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w/v urea, 0.5 M NaCl and 4% blocking reagent at 55C for at least 15 min. The labeled probe 
was added into hybridization buffer and hybridized to the membrane containing samples at 
55C overnight. The blot was then washed twice with 55C primary washing buffer (2 M Urea, 
0.1% w/v SDS, 50 mM Na phosphate pH 7, 150 mM NaCl, 1 mM MgCl2, 0.2% w/v blocking 
reagent) for 10 min with gentle agitation. The blot was then washed twice with secondary 
wash buffer (50 mM Tris-Cl, 100 mM NaCl, 2 mM MgCl2, pH 10) at room temperature for 5 
min. A chemiluminescent signal was generated by adding 40 μl/cm2 CDP-Star detection 
reagent (Amersham Biosciences, Uppsala, Sweden) and detected on X-ray film.  
3.2.2 Microsatellite typing  
Microsatellite typing was used in genomic analysis in this study (Fig. 5). The polymorphic 
markers, showing a high heterozygosity frequency, were used. PCR was performed to 
amplify genomic regions of particular markers. PCR reactions were carried out with 100 ng 
of DNA template, 1X PCR buffer, 2.5 mM MgCl2, 200 μM dNTP, 0.1 unit of AmpliTaq Gold 
DNA polymerase (Applied Biosystems, CA, USA), 0.3 μM of each fluorescence-labeled 
primer. PCR products were injected into semi-automated ABI PRISMTM 3100 Genetic 
Analyzer (Applied Biosystems, CA, USA) for capillary electrophoresis and analysis by 
Genotyper software. All markers were labeled with 6-FAM/VIC/NED fluorescence dye and 
have annealing temperatures of 55C.  
 
 
Fig. 5. PCR microsatellite typing of a representative donor, recipient, and hybrid cell line. 
The recipient HONE1, donor MCH556.15, and MCH HK11.13 cell lines were analyzed with 
the D11S1394 primers. The combined peak patterns of the hybrid cell line show successful 
transfer of chromosome 11 in recipient cells. 
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3.2.3 Whole chromosome painting FISH 
The confirmation of the presence of an extra copy of intact human chromosome in the 
hybrids was performed by whole chromosome painting FISH analysis. To obtain metaphase 
cells, logarithmic growth phase cells were treated with 0.05 g/ml colcemid for 4-6 hours. 
After harvesting the cells by centrifugation at 4000 rpm for 5 min, they were subjected to 
hypotonic treatment (0.075 M KCl) for no more than 25 min at 37C. Cells were fixed with 
methanol/acetic acid (3:1) overnight and then dropped onto glass slides. The whole 
chromosome paint (WCP) probes were used and they are a mixture of DNA sequences 
specific to a particular chromosome that are directly labeled with one of the Vysis™ 
fluorophores. The slides were denatured at 73C for 5 min [70% (v/v) formamide, 2 X SSC 
(pH7), 0.1 mM EDTA]. Slides were dehydrated for 1 min in 70%, 85%, and 100% ethanol 
successively. Probes were hybridized to the slides in LSI/WCP® hybridization buffer at 
37C in dark for overnight. The slide was washed at 73C in washing solution I (0.4 X SSC, 
0.3% NP40) for no more than 2 min, followed by washing with washing solution II ( 2 X 
SSC, 0.1% NP40), and counterstained with DAPI. Fluorescence signals were captured on an 
Olympus BX51 fluorescence microscope with the Spot software.  
3.3 In vivo nude mouse tumorigenicity assay and establishment of tumor segregants 
(TSs)  
After successful chromosome transfer, MCHs containing an exogenous chromosome were 
obtained and the tumorigenicity assay was then performed. The tumorigenicity of the each 
NPC/ESCC cell line was investigated by subcutaneous injection of 1 X 107 cells into 6-8 
week old female athymic BALB/c nu/nu mice. This assay has been repeatedly and 
successfully used for assessing the degree of tumor suppression in MCH populations 
(Goyette et al 1992, Saxon et al 1985, Weissman et al 1987). For each tested cell line, at least 
six sites were injected on three mice (two sites per animal). The animals were monitored 
regularly for tumor formation and palpable nodules were measured weekly using calipers. 
After a long period of incubation in the nude mice (>12 weeks), if notable tumors formed, 
they were surgically removed aseptically and then washed with PBS, followed by mincing 
the tissues as small as possible in a petri dish. The minced tissue was covered with 5 ml 
medium and left without any disturbance for at least three days. Medium was withdrawn 
and 10 ml of fresh medium was added. The cells were then harvested and were the 
TSs/revertants used in further analysis with their matched MCHs.  
3.4 TS analysis  
The TSs show a restoration of tumorigenicity in the tumorigenicity assay by elimination of 
critical regions (CRs) associated with tumor suppression (Cheng et al 2002, Cheung et al 
2009). Loss of donor genetic materials detected by microsatellite typing (see Section 3.2.2) 
was considered significant, when the intensity of the donor to recipient allele ratio in a TS 
versus its corresponding MCH parental cell line, was equal to or less than 0.8. The 
significance of these losses was simultaneously verified by bacterial artificial chromosome 
(BAC) FISH. Furthermore, the differential gene expression profiling between the tumor-
suppressive MCH cell lines versus their derived TSs and the highly tumorigenic recipient 
cell line was revealed by oligo microarray analysis. The BAC FISH and oligo microarray 
analyses will be discussed in detail. 
 
Identification of Tumor Suppressor Genes via Cell Fusion and Chromosomal Transfer 
 
61 
3.4.1 Bacterial artificial chromosome (BAC) FISH  
The BAC DNA probes were prepared by labeling the isolated BAC DNAs by nick translation. 
In brief, BAC clones were incubated in 5 ml LB medium containing 12.5 μg/ml 
chloramphenicol at 37C overnight. Bacterial cells were pelleted down and resuspended in 200 
μl of ice-cold alkaline lysis solution I. Four hundred microliters of freshly prepared alkaline 
lysis solution II were added, mixed by gentle inversion several times, and placed on ice for no 
more than 5 minutes. A total of 300 μl of ice-cold solution III was added, and the mixture was 
put on ice for 5 minutes, followed by centrifugation at maximum speed for five minutes at 4C. 
Supernatant was transferred into a fresh 1.5 ml tube containing 900 μl of isopropanol at room 
temperature and mixed by gentle inversion. The precipitated DNA was collected by 
centrifugation at maximum speed for five minutes at 4C; supernatant was discarded and the 
pellet was rinsed with 1 ml of 75% ethanol. The tube was centrifuged for 5 min at room 
temperature and ethanol was removed. The DNA pellet was air-dried and dissolved in 50 μl TE.  
 
 
Fig. 6. FISH analysis with BAC CTB-12N1 probe in recipient HONE1 cells, chromosome 11 
donor MCH556.15 cells, hybrid HK11.8 cells, and tumor revertant HK11.8-3TS cells. Thirty 
metaphases on average were observed for each cell line. Four copies of the BAC probe are 
observed in HONE1 cells, one in the donor cell line, 5 in the hybrid HK11.8 and 3 in the 
HK11.8-3TS. Arrows (   ) indicate BAC hybridization. 
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A total of 500 ng of BAC DNA was labeled with 10 μM SpectrumGreen/Orange TM-dUTP 
(Vysis, IL, USA), nick translation buffer (Vysis, IL, USA), 10 μl nick translation enzyme 
(Vysis, IL, USA) at 14C for 16 hours and stopped at 70C for 10 minutes. The probe was 
precipitated with 1 μg of COT-1 DNA (Invitrogen, CA, USA) and 2 μg salmon sperm DNA 
(Invitrogen, CA, USA), 4 μl water, 0.1 volume of 2 M sodium acetate, 2.5 volumes 100% 
ethanol and centrifuged at maximum speed for 30 min at 4C. The supernatant was 
removed. The pellet was air-dried and resuspended in 3 μl water and 7 μl LSI/WCP 
hybridization buffer. Procedures for the hybridization and detection were the same as that 
used for the whole chromosome painting FISH. Representative BAC FISH results are shown 
in Figure 6.  
3.4.2 Oligonucleotide microarray  
In order to investigate the differentially expressed genes of the tumor-suppressive MCHs 
versus their matched tumorigenic TSs, oligonucleotide microarray analysis was performed; 
a TSG is presumably up-regulated in MCHs and down-regulated in TSs (Robertson et al 
1997). Therefore, genes with that expression profile are potential TSGs in NPC. This method 
can also help to identify candidate genes that are downstream of the functional pathways. 
The 19K or 28K oligonucleotides were spotted on glass slides using a custom-built 
microarray spotter at the Genome Institute of Singapore. The incorporation of Cy3 and Cy5 
to cDNAs, competitive hybridizations, and processing of array images were performed as 
described (Lin et al 2004).  
In brief, a total of 20 μg of total RNA was mixed with 1 μg oligo dT and denatured at 65C 
for 5 min. Reverse transcription was done by using 1X first strand buffer, 4 μl of 0.1 M DTT, 
2 μl 20X low dT/aa-dUTP mix (1 M dATP, 1 M dGTP, 1 M dCTP, 200 mM dTTP, and 800 
mM amminoallyl dUTP), 100 unit of RNase OUT inhibitor (Invitrogen, CA, USA), and 400 
units of SuperScript II reverse transcriptase (Invitrogen, CA, USA) and incubated at 42C for 
60 min. Another 200 units of SuperScript II reverse transcriptase was added to the mixture 
and then it was incubated at 42C for 60 min. Five microliter of 500 mM EDTA (pH 8) and 10 
μl of 1M NaOH were added to the reaction mixture and incubated at 65C for 45 min, 
followed by adding 25 μl of 1 M Tris-Cl (pH 7.5) and 400 μl ddH2O and purified on a YM-30 
column (Millipore, MA, USA). One microliter of 500 mM NaHCO3 (pH 9) and fluorescent 
dye, Cy3 or Cy5 (GE Health Care Life Sciences, NJ, USA), were added to 9 μl of the cDNA 
for dye incorporation at room temperature for 1 hour.  
The chips, which contain synthesized 60-mers of 19K or 28K oligonucleotides, were 
prehybridized by using DIG Easy Hyb (Roche Diagnostics, Basel, Switzerland) at 42C for 
one hour. Four microliter of 4 M hydroxylamine (Sigma, MO, USA) was added to the 
labeled cDNA at room temperature for 15 min. Thirty-five microliter of 100 mM NaOAc (pH 
5.2) was added and mixed with the paired sample labeled with Cy3 and Cy5. The reaction 
mixtures were purified on YM-30 columns, containing 40 μg of herring sperm DNA 
(Invitrogen, CA, USA) and 22 μl DIG Easy Hyb were added, followed by denaturing at 65C 
for 5 min. The cDNA probe was hybridized onto slides and incubated in the MAUI 
hybridization chamber (BioMicro Systems, UT, USA) at 42C for 16 hours. After 
hybridization, slides were washed with 2X SSC + 0.1% SDS for 30 s, 1X SSC for 30 s and 0.2X 
SSC for 30 s and 0.05X SSC for 5 s. The slides were then scanned with GenePix 3100 
microarray scanner and analyzed by GenePix Pro 4.0 and 5.0 software (Axon Instruments, 
CA, USA). The results were uploaded to the database from Genome Institute of Singapore 
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(GIS MAdb, http://gismadb.gis.a-star.edu.sg). The hierarchical clustering was performed 
by CLUSTER program and the results were viewed by the TREE VIEW program (M. Eisen; 
http://rana.lbl.gov/EisenSoftware.htm). Stringency was set so that only data sets with 
expression ratios higher than 1.4 in hybrids/recipient cells and ratios less than 0.6 in 
hybrids/TSs for both duplicates were selected for further studies.  
3.5 Methylation study of candidate tumor suppressor genes  
Promoter hypermethylation is a major mechanism for silencing TSG expression. Promoter 
hypermethylation only occurs at cytosine (C), which is located on the 5’ end of guanine (G) 
of promoter CpG islands. Addition of a methyl group to cytosine by methyltransferase 
blocks the binding of the activator or inhibitor to the promoter sequence and consequently 
there is transcriptional silencing of the gene. By using 5-aza-2’-deoxycytidine, which can 
demethylate the methyl groups in the CpG islands, gene expression can be restored. Using 
this approach, methylation status of genes of interest may be elucidated. Besides using the 5-
aza-2‟-deoxycytidine, bisulfite genomic sequencing (BGS) and methylation-specific PCR 
(MSP) are other important methods used to analyze promoter hypermethylation. In the 
bisulfite treatment, the genomic DNAs are modified. All of the unmethylated cytosines are 
converted to uracils, while the methylated cytosines remain unchanged. By analyzing the 
promoter sequences and using sequence-specific primers, the promoter hypermethylation 
status can be determined. 
3.5.1 Bisulfite treatment  
Genomic DNA was treated with sodium metabisulfite to analyze the promoter 
hypermethylation status. Two micrograms of DNA were dissolved in 10 μl of water, 
followed by adding 1.1 μl of 3N NaOH and incubation at 37C for 15 min. Then 104 μl of 
urea/metabisulfite solution (6.24 M urea and 2 M sodium metabisulfite; Sigma, MO, USA), 6 
μl of 10 mM hydroquinone (Sigma, MO, USA) and 100 μl of mineral oil were added into the 
mixture and incubated at 55C for no more than 15 hours. The mixture was then purified by 
QIAquick PCR purification Kit (Qiagen, CA, USA) according to the manufacturer’s protocol 
and eluted with 200 μl elution buffer. The purified DNA was denatured in 23 μl of 3N 
NaOH at 37C for 15 min. The DNA was precipitated by adding 2 μl of tRNA (10 μg/μl; 
USB, OH, USA), 50 μl of 10 M ammonium acetate, and 500 μl of 100% ethanol, and stored at 
-20C for 30 min. The mixture was centrifuged at 12K rpm at 4C for 20 min; the supernatant 
was removed. The DNA pellet was washed with 500 μl of 70% ethanol and centrifuged at 
full speed at 4C for 20 min. The DNA pellet was air-dried and dissolved in 100 μl of 10 mM 
Tris-Cl (pH 8.5) solution. 
3.5.2 Bisulfite genomic sequencing (BGS) and methylation-specific PCR (MSP)  
BGS and MSP PCR reactions were carried out with 5 μl of bisulfite-treated DNA template, 
1X PCR buffer, 2.5 mM MgCl2, 200 μM dNTP, 0.1 unit of AmpliTaq Gold DNA polymerase 
(Applied Biosystems, CA, USA), 0.3 μM of primers. For the BGS, PCR products were then 
cloned into the TA cloning pMD18T Simple vector (TaKaRa Biotechnology, Dalian, China) 
and transformed into competent cells. Mini-preparation was performed to extract the 
plasmid DNA. For each examined cell line, five individual clones were checked to confirm 
the promoter hypermethylation status. The plasmids were then sequenced by using 
pMD18T7 forward and reverse sequencing primers and BigDye 3.1 terminator. Signals were 
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detected using an ABI PRISMTM 3100 Genetic Analyzer (Applied Biosystems, CA, USA). 
The bisulfite sequencing and MSP primers were designed by the MethPrimer 
(www.urogene.org/methprimer) guide (Li et al 2002).  
3.5.3 5-Aza-2’-deoxycytidine treatment  
The re-expression of the candidate genes silenced by promoter hypermethylation was 
investigated using a demethylation reagent. Cells were treated with 5 μM 5-aza-2’-
deoxycytidine (Sigma, MO, USA) for five days; freshly diluted drug was changed daily. 
After 5 days treatment, the cells were harvested for RNA extraction.  
3.6 Other functional assays we use to study the tumor suppressive phenotypes 
In order to examine the tumor suppressive phenotypes of NPC and EC cells expressing a 
candidate TSG, various functional assays were performed according to the major hallmarks 
of cancer (Hanahan et al 2011). Simple proliferation, cell cycle, colony formation, and soft 
agar assays are routinely performed to assess the inhibitory effects of the transgenes on cell 
growth ability in normal culture conditions, the change of cell cycle status, the ability of 
colony formation from a single cells, and the cell growth potential in an the anchorage-
independent environment. In addition, the migration, invasion, and angiogenic properties 
of the tumor suppressive transfectants were also examined. Some of those functional assays 
will be discussed in detail.  
3.6.1 Three-dimensional matrigel culture 
Matrigel contains a gelatinous protein mixture of extracellular matrix proteins such as 
laminin and collagen, which recapitulates the natural environment of tumor cells for better 
investigation of the functional impact of a candidate TSG. We aim to see whether there is 
any change in the numbers, sizes, and morphologies of colonies of transfectants with the 
transgenes versus the vector-alone, when grown in matrigel. In brief, matrigel basement 
membrane matrix (BD Biosciences, San Jose, CA, USA) was thawed on ice and 100 μl was 
coated as a bottom layer onto each well of a 24-well cluster plate. Subsequently, a total of 
5000 cells resuspended in 0.5 ml growth medium was seeded on top of this bottom matrigel 
layer. After 2 weeks, images were captured using an inverted light microscope (Nikon TMS, 
Ontario, Canada) at 20X magnification. 
3.6.2 Cell migration and invasion assays 
The cell migration and invasion abilities of cells were determined using a micropore 
chamber assay (BD Biosciences, San Jose, CA, USA). The chamber used for migration study 
consists of an 8 m pore size PET membrane at the bottom of the insert, while the chamber 
used for invasion study is a migration chamber coated with a thin layer of matrigel 
basement matrix. The migration and invasion abilities of each clone were determined by the 
number of cells passing through the membrane and the matrigel basement matrix, 
respectively. 
3.6.3 HUVEC tube formation assay 
The tube formation assay is an in vitro angiogenesis assay to assess the tube formation 
ability of vascular endothelial cells. Briefly, the Human Umbilical Vein Endothelial Cell 
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(HUVEC) was cultured in collagen pre-coated TC dishes. The conditioned medium of each 
cell line was collected by incubating the cells with DMEM/RPMI serum-free medium for 24 
hours. The 96-well plate pre-coated with 50 μl growth factor-reduced Matrigel (BD 
Bioscience, San Jose, CA, USA) per well was used. A total of 4 x 104 HUVEC cells 
resuspended in 100 μl conditioned media supplemented with 1% serum were seeded in each 
well. The HUVEC cells were then incubated at 37C for 6 hours to allow the formation of 
tube-like structures. The tubes formed were captured under microscopy and the total tube 
length formed by each sample was measured by Spot software (Diagnostic Instruments Inc, 
Sterling Heights, MI, USA). 
3.6.4 Matrigel plug angiogenesis study 
In vivo angiogenesis study was performed by matrigel plug angiogenesis analysis. A total of 
5 x 106 cells mixed with 50 μl DMEM and 250 μl ice-cold matrigel was injected into nude 
mice subcutaneously to allow gel plug formation. Each sample was injected into one flank of 
five female athymic nude mice. The matrigel mixed with the cells polymerizes to form a 
solid gel plug, which allows cell growth and blood vessel formation. After inoculation for 7 
days, the matrigel plug was excised, fixed with formalin, embedded in paraffin, sectioned, 
and mounted onto slides. The slides were stained with hematoxylin and eosin (H&E) for 
histological observation. The blood vessels formed were stained with monoclonal antibody. 
The slide was scanned and the signal was quantified by ImageScope v10 software (Aperio, 
Vista, CA, USA).  
3.6.5 Human angiogenesis antibody array 
The angiogenesis-related proteins excreted from the TSGs versus the vector-alone 
transfectants were detected by the human angiogenesis antibody array (RayBiotech, 
Norcross, GA, USA). The array included two membranes pre-coated with 43 angiogenesis 
cytokine antibodies. The conditioned media were obtained as described in Section 3.6.3. 
After blocking and complete washing, the membranes were hybridized with biotin-
conjugated antibody at room temperature for 2 hours, followed by hybridizing with HRP-
conjugated streptavidin at room temperature for 2 hours. The membranes were then washed 
again and hybridized with the detection buffer. The signals were exposed to a X-ray film 
and quantified by Quantity One® software (Biorad, Hercules, CA, USA). 
4. Examples of candidate TSGs studied via MMCT and other functional 
approaches 
The technique of microcell fusion to transfer single normal chromosomes was used as a 
functional assay for the TSG activity (Goyette et al 1992, Saxon et al 1986, Weissman et al 
1987). This has been particularly useful in confirming TSG functions associated with specific 
chromosomes, where the mapping location is suspected, but no candidate TSG has been 
cloned. In addition, by transferring chromosomes possessing interstitial deletions, it has 
been possible to map the location of TSGs more precisely (Dowdy et al 1991).  
The analysis of tumor biopsy specimens, xenografts, and derived cell lines have identified 
an extensive chromosomal alterations in human genome, including those derived from 
chromosomes 1, 3, 9, 11, 12, 13, 14, 16, and 17 (Huang et al 1989, Mitelman et al 1983), 
Consistent with Knudson’s “two-hit” theory, studies of chromosomal loss or deletion may 
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provide useful clues for identification of critical genes involved in inherited cancers. 
However, it should be appreciated that the limitations of deletion or loss studies in sporadic 
cases may miss critical regions for several reasons. First, the minimally deleted regions may 
be obscured when all of the genome shows some degree of LOH, which is common in many 
sporadic tumors. Second, vast evidence has shown that some TSGs, notably p16 are silenced 
or imprinted by epigenetic events such as methylation, irrespective of their LOH status in 
tumors. Third, LOH was studied in primary tumors with karyotypic complexity, gene 
dosage changes, and contamination by normal cells. Finally, although LOH is commonly 
detected in practically all types of human cancers, neither LOH nor CGH (comparative 
genomic hybridization) studies provide functional evidence. To map novel TSGs, functional 
and complementary approaches are needed for distinguishing a critical region from 
extensive randomly lost areas. Chromosome 3 was the first chromosome used for the 
functional studies of tumor suppression in NPC. In this study we used a series of intact and 
deleted copies of human chromosome 3 derived from normal cells, with discrete interstitial 
deletions in the p arm, for transfer into the tumorigenic NPC HONE1 cell line. By using the 
MMCT approach, we successfully transferred these chromosome 3 fragments into HONE1 
cells and localized a tumor suppressive region on this chromosome. Comparison of the 
tumorigenic potential of the MCHs containing these exogenous chromosome 3 fragments 
identified chromosome 3p21.3 as the first tumor suppressive region in NPC (Cheng et al 
1998). This area was subsequently confirmed to harbor several TSGs associated with the 
development of NPC and other common cancers (Lerman and Minna 2000, Lo et al 2001, 
Yau et al 2006, Hesson et al 2007). Using these functional approaches, we also investigated 
known and candidate TSGs in other chromosomes, including chromosomes 9, 11, 13, 14 and 
17. These chromosomes contain important TSGs, such as p16, RB and p53 and a number of 
newly-identified TSGs. However, we only introduce a few of examples of these studies in 
this chapter due to the space limitation. (Cheng et al, 2000, 2002, 2003 and 2004, Ko et al 2005 
and 2008, Lung et al  2008a and 2008b, Cheung et al 2009, Lo et al 2007 and 2010) 
4.1 Chromosome 3: ADAMTS9 
In a subsequent study, an intact and two truncated human chromosomes 3 obtained from 
the same panel of chromosome 3 donor cells, were transferred into the highly tumorigenic 
ESCC SLMT-1 cell line. Similarly, the ability of these transferred chromosomes to 
functionally complement defects in the ESCC cell line was assessed by examining the impact 
of this transfer on tumorigenic potential in nude mice. PCR-microsatellite and BAC FISH 
analyses were used to narrow down and identify the CR associated specifically with tumor 
suppression. A 1.61 Mb CR located between markers D3S1600 and D3S1285 was found to be 
necessary for the tumorigenic suppression of ESCC. These findings further suggest that the 
CR present in the exogenous chromosomes contains functional tumor suppressive elements. 
In the study, we identified a candidate TSG, ADAMTS9, and one non-coding RNA, 
ENST351926 mapping to 3p14.2, which are located in the chromosome 3 CR of ESCC. The 
expression of ADAMTS9 in tumor suppressive MCHs was confirmed by reverse 
transcription (RT)–PCR. The positive expression of the gene was observed in all tumor 
suppressive MCHs, but was not found in tumorigenic MCHs and TSs, strongly suggesting 
that ADAMTS9 plays an important role in tumor suppression. The pseudogene is located 
upstream of the ADAMTS9 promoter region and whether it can serve as a riboregulator or 
gene expression regulator remains to be determined (Lo et al 2007).  
 
Identification of Tumor Suppressor Genes via Cell Fusion and Chromosomal Transfer 
 
67 
4.1.1 ADAMTS9 (A disintegrin-like and metalloprotease with thrombospondin type 1 
motif 9) 
As described, using a functional genomic mapping approach, we identified a CR for tumor 
suppression at 3p14.2 and discovered the important role of A Disintegrin-like And 
Metalloprotease with ThromboSpondin type 1 motif 9 (ADAMTS9), a gene previously 
mapped to this region (Clark et al 2000) in ESCC (Holmes and Vaughan 2007). ADAMTS9 
encodes a member of a large family of 19 metalloproteases involved in maturation of 
precursor proteins, extracellular matrix remodeling, cell migration, and inhibition of 
angiogenesis (Apte 2004, Porter et al 2005). Although the related matrix metalloproteases 
and ADAM proteases have been clearly implicated in tumor progression and angiogenesis, 
the role of ADAMTS proteases in cancer is less clearly defined. ADAMTS1 was first 
identified as an anti-angiogenic molecule (Vazquez et al 1999), and shown to have anti-
tumor effects. Recently, methylation studies identified another family member ADAMTS18 
as crucial in several human cancers including NPC and ESCC (Jin et al 2007).  
As mentioned in the previous section, ADAMTS9 was identified as one of the differentially 
expressed genes in these non-tumorigenic MCHs and their matched TS cell lines in our 
previous study (Lo et al 2007). It was suggested that ADAMTS9 is associated with tumor 
suppression in human esophageal cancer. Promoter hypermethylation contributes to 
ADAMTS9 gene silencing in ESCC (Lo et al 2007, Lung et al 2008b). However, the functional 
impact of ADAMTS9 on cancer development had not been explored. In the follow-up study, 
we evaluated the hypothesized anti-angiogenic and tumor suppressive functions of 
ADAMTS9 in ESCC, by stringent tumorigenicity and matrigel plug angiogenesis assays (Lo 
et al 2010). ADAMTS9 activation suppressed tumor formation in nude mice. In vivo 
angiogenesis assays revealed a reduction in microvessel numbers in gel plugs injected with 
tumor-suppressive cell transfectants. Similarly, conditioned media from cell transfectants 
dramatically reduced the tube-forming capacity of HUVECs. By using the angiogenesis 
antibody array, we found that these activities were associated with a reduction in expression 
levels of the pro-angiogenic factors, MMP9 and VEGFA, which were consistently reduced in 
ADAMTS9 transfectants. Based on the deletion patterns of the ADAMTS9 transcripts in 
tumors and a TS derived from the tumorigenic transfectants, we speculate that the tumor-
suppressive activity of ADAMTS9 in ESCC was associated with the thrombospondin (TSP) 
domains in the C-terminal region of the gene. Taken together, our data strongly suggest that 
ADAMTS9 plays a critical role in the “angiogenic switch” and transforms in the ESCC cell 
lines from a pro-angiogenic to a non-angiogenic phenotype.  
4.2 Chromosome 9: ENG, DEC1 
The transfer of chromosome 9 containing an interstitial deletion at 9p21 (where the well-
known TSG, p16 is located) to NPC HONE1 cell line did not result in tumor suppression in 
the nude mouse assay, but p16 cDNA suppressed growth of HONE1 cells in vitro assay. It 
suggests that p16 gene plays an important role in this cancer (Cheng et al., 2000). The similar 
transfer of chromosome 9 into SLMT1 provided the first functional tumor suppressive 
evidence in ESCC (Yang et al 2005). The result suggested that gene(s) other than p16 on 
chromosome 9 is (are) important for ESCC tumorigenesis. The ESCC chromosome 9 MCHs 
exhibited a delayed latency period in tumor formation compared with that of the parental 
SLMT1 cells. The delay in tumor growth kinetics was hypothesized to be associated with the 
loss or inactivation of wild type alleles from the exogenous transferred donor chromosome 
9. Detailed microsatellite marker-PCR deletion mapping analysis of the tumor suppressive 
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chromosome 9 MCHs and their corresponding derived TSs delineated that the critical 
regions that may harbor candidate TSGs to a 2.4 Mb region at 9q33-q34 around D9S112. 
4.2.1 ENG (Endoglin) 
The MMCT-identified CR at 9q32-34 is a gene-rich region. ENG (Endoglin), mapping to 9q33-
q34.1, is a component of the transforming growth factor beta (TGF-β) receptor complex and 
is involved in tumor angiogenesis by modulating the biological effect of TGF-β. Significant 
down-regulation of ENG was detected at frequencies of 87.5% in 16 ESCC cell lines, 39.1% 
directly in 23 ESCC tumor specimens from Hong Kong, and 33.4% in 18 ESCC tumor 
specimens from the high-risk ESCC region of Henan, China. Both epigenetic methylation 
and allelic loss appear to contribute to ENG down-regulation in ESCC tumors. Subsequent 
functional studies with restoration of ENG in an ESCC cell line demonstrated that ENG 
plays a critical role in ESCC carcinogenesis. Colony formation efficiency was significantly 
reduced by over-expression of ENG. In addition, significantly smaller colonies of ENG stable 
transfectants were formed in Matrigel culture. Significant suppression of invasion efficiency 
and tumorigenicity were also observed, when comparing the ENG stable transfectants with 
the vector-alone transfectants. No report had yet verified the functional role of ENG in ESCC 
tumor cells. This study provides evidence supporting ENG, as a cell invasion and tumor-
suppressing gene in ESCC. ENG may be functionally involved in TGF-β signaling. Down-
regulation of ENG in esophageal cancer in this study may provoke cancer progression 
through blocking the tumor suppression of the TGF-β signaling cascade. For the functional 
impact of ENG in cell migration, ENG may suppress cancer cell motility by a TGF-β-
dependent mechanism involving activation of the type I TGF-β receptor and Smad1, as 
reported in the study of prostate cancer cells (Craft et al 2007). In endothelial cells, high 
endoglin expression stimulates the type I activin receptor-like kinases (ALK1) pathway and 
indirectly inhibits ALK5 signaling for endothelial cell proliferation and migration, thus 
promoting the state of angiogenesis. ENG may act differently in cancer cell versus 
endothelial cells. ENG may suppress cancer cell proliferation in the pre-malignant stage; 
meanwhile, its expression could promote angiogenesis facilitating the cancer progression in 
the late malignant stage. The mechanism of ENG in suppressing ECSC tumor requires 
further study (Wong et al 2008).  
4.2.2 DEC1 (Deleted in Esophageal Cancer 1) 
DEC1 (Deleted in Esophageal Cancer 1) is in the vicinity of the CR at 9q32-34 and is down-
regulated frequently in ESCC cell lines and tumor tissues (Leung et al 2008). The DEC1 
protein localizes to both the cytoplasm and nucleus. The vesicular pattern of DEC1 in the 
cytoplasm appears to localize at the Golgi and Golgi-endoplasmic reticulum intermediate 
compartment. DEC1 is clinically important as the tissue microarray (TMA) study suggested 
an association of DEC1 expression with lymph node metastasis, early onset ESCC, and 
familial status (Wong et al 2011b). DEC1 stably transfected clones provided functional 
evidence for cell growth inhibition in vitro and significant delay in tumor growth in vivo 
(Yang et al., 2005). DEC1 stable clones showed significantly fewer colony numbers as 
compared to the vector-alone control. Restoration of DEC1 expression also negatively 
affected anchorage-independent growth properties of an ESCC cell line (Leung et al 2008). 
Using cDNA microarray analysis to reveal the differential expression profiling between 
tumor suppressive DEC1 clones versus the vector-alone transfectant, DUSP6 (dual-specificity 
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phosphatase 6) was identified as one of the downstream targets of DEC1, as it is up-regulated 
in DEC1 stable transfectants, C4 and C9, compared to vector-alone stable transfectants. It is 
expected that in clinical specimens, the higher expression of DEC1 associates with higher 
expression of DUSP6. This association was observed in tumor tissues in younger aged ESCC 
patients group. This association was only significant in these two groups, which was limited 
by the number of available samples (only 26 normal counterpart tissues and 74 tumor 
tissues). Subsequent functional study of DUSP also indicated that DUSP6 plays a crucial 
role for ESCC carcinogenesis by inhibiting cell invasion and impairing the epithelial-
mesenchymal transition (EMT)-associated phenotype (Wong et al 2011a). 
4.3 Chromosome 13: THSD1  
Chromosome 13q deletions are frequent events in several human cancers, including ESCC 
(Hu et al 2000, Pack et al 1999), nasopharyngeal (Tsang et al 1999) and lung (Tamura et al 
1997) cancers. Molecular evidence of gross deletions which implicate the existence of TSGs 
came from numerous LOH and CGH studies. Our group has pioneered the identification of 
the TSGs on chromosome 13 by the functional complementation approach in both NPC and 
ESCC (Cheng et al 2004, Ko et al 2008). The transfer of intact chromosome 13 in HONE1 cells 
identified a critical region essential for the viability and growth of NPC MCHs at 
chromosome 13q12, but it was not RB gene (Cheng et al 2004). By the microsatellite deletion 
mapping, D13S893 at 13q12, a minimally deleted region of 0.7 Mb, was found to be non-
randomly eliminated in the six chromosome 13 MCHs bounded by markers D13S1287 and 
D13S260. The growth suppressive activity involved at least one novel growth control gene for 
NPC tumorigenesis. Our subsequent study employed the same MMCT technique in an ESCC 
model with the ESCC cell line, SLMT1. The transfer of an intact chromosome 13 into this 
highly tumorigenic recipient cell line conferred tumor suppressive activity, and identified 
critical regions at 13q12.3, 13q14.11, and 13q14.3. Of interest, a 0.373 Mb at the critical region 2 
(CR2), mapped to 13q12.3 and was co-localized to the same CR identified in the NPC model 
system in our chromosome 13 transfer study (Cheng et al 2004, Ko et al 2008). 
4.3.1 THSD1 (Thrombospondin type I domain-containing 1) 
The ESCC functional studies implicate the importance of chromosome 13q14 in tumor 
suppression; TS microsatellite-deletion mapping analysis localized two CRs (CR3 at 
D13S263 and CR4 at D13S133) at chromosomal region 13q14, which are frequently 
eliminated (Ko et al 2008). Differential gene expression profiles of a reference immortalized 
normal esophageal epithelial cell line, three tumor-suppressing MCHs, and their 
tumorigenic parental SLMT1 cell line were revealed by cDNA oligonucleotide microarray 
analysis. Nine 13q14 candidates genes, including RB1, were identified to show down-
regulation in SLMT-1 as compared to NE1, the immortalized normal esophageal epithelial 
cell line, and the MCHs. RB1 is a well-known TSG mapped to 13q14, but our Western blot 
analysis indicated that the active form of RB was not increased in the tumor suppressive 
MCHs (data not shown). The data suggested that novel candidate TSG(s) other than RB1 
should be involved in the observed tumor suppression. RT-PCR was performed for 
KIAA0853, ESD, CHC1L, PHF11, RFP2, FLJ11712, THSD1, and C13orf9. Real-time PCR results 
validated the frequent down-regulation of THSD1 and PHF11 in ESCC cell lines. THSD1 is 
located between FLJ11712 and C13orf9 within 13q14.3, but only specific loss of THSD1 
expression in all cancer cell lines was detected. Since THSD1 showed a more prominent loss 
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than that of PHF11, it was the first target chosen for further functional characterization. 
Epigenetic silencing and LOH were the mechanisms responsible, at least in part, for the loss 
of THSD1 expression in ESCC tumorigenesis. The wild type THSD1 transfection in SLMT1 
resulted in significant reduction of colony formation ability, providing evidence for a 
growth suppressive role of THSD1 in ESCC tumorigenesis.  
The function of THSD1 is unknown. It encodes a transmembrane molecule containing a 
thrombospondin type 1 repeat (TSR), which may be involved in cell adhesion and 
angiogenesis (de Fraipont et al 2001). Interestingly, analysis of the differential expression 
levels of this gene in previous microarray studies show that high THSD1 expression 
positively correlated with a better distant metastasis survival in breast cancer patients. This 
is consistent with its loss possibly being associated with metastatic tumor spread; studies are 
needed to evaluate its potential importance as a biomarker for esophageal carcinoma. 
Further functional studies on THSD1 are now underway to elucidate its tumor suppressive 
role. 
4.4 Chromosome 14: LTBP-2  
Chromosome 14 loss is commonly found in different cancers, including esophageal (Ihara et 
al 2002), renal (Yoshimoto et al 2007), lung (Weir et al 2007), and colon cancers (Mourra et al 
2007). In NPC extensive chromosome 14 allelic loss has been reported (Dodd et al 2006, Lo et 
al 2000, Lung et al 2001, Shao et al 2002). This suggests the importance of chromosome 14 in 
tumor development. In our earlier NPC study, chromosome 14q11.2-13.1 and 14q32.1 
regions were found to associate with tumor suppression. In those chromosome 14 MCHs, 
non-random eliminations of two CRs were consistently observed and associated with tumor 
growth in tumorigenicity assays (Cheng et al 2003). In a later study, a new panel of 
chromosome 14 MCHs with an intact exogenous chromosome 14 was established. The 
potent ability to suppress tumor growth in the in vivo tumorigenicity assay of all intact 
chromosome 14 MCHs suggests the ability of chromosome 14 to suppress tumor formation 
in HONE1 cells. This is consistent with chromosome 14 harboring candidate TSGs involved 
in NPC development (Cheung et al 2009).  
An intact chromosome 14 was also transferred into the ESCC SLMT1 cell line. The 
tumorigenic potential of microcell hybrids containing the transferred chromosome 14 
provided functional evidence that tumor-suppressive regions of chromosome 14 are 
essential for esophageal cancer. TSs emerging in nude mice during the tumorigenicity 
assay was analyzed by detailed PCR-microsatellite typing and dual-colour BAC FISH to 
identify critical non-randomly eliminated regions. A 680-kb CR mapped to 14q32.13 and 
an approximately 2.2-Mb CR mapped to 14q32.33 were delineated. (Ko et al 2005). 
Microarray differential gene expression profiling of tumor-suppressive chromosome 14 
MCH cell lines and their tumorigenic TSs identified LTBP-2 (latent transforming growth 
factor β binding protein 2) mapped to 14q24 as a candidate TSG important for ESCC (Chan 
et al 2011). 
4.4.1 LTBP-2 (Latent transforming growth factor β binding protein 2) 
The extracellular matrix (ECM) protein LTBP-2 (Latent transforming growth factor β binding 
protein 2) encodes a secretary protein that functions as a component of the ECM microfibrils 
and belongs to the LTBP/fibrillin family (Chan et al 2011). Unlike other members in LTBP 
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family, LTBP-2 does not form complexes with the small latent TGF-βs. Interestingly, in 
addition to the first reported tumor suppressor role in ESCC, LTBP-2 is related to congenital 
glaucoma and rheumatoid arthritis which are eye and bone diseases, respectively. LTBP-2 
expression at the mRNA and protein levels was down-regulated in both ESCC cell lines and 
primary tumors. One of the mechanisms responsible for the down-regulation of LTBP-2 is 
via promoter hypermethylation. Restoration of LTBP-2 in an ESCC cancer cell line resulted 
in tumor suppression in nude mouse assay, which is partially explained by the significant 
reduction of colony-forming ability on matrigel 3D culture and anchorage-independent 
growth in vitro. Further in vitro functional characterization of LTBP-2 demonstrated its 
inhibitory role in angiogenesis, migration, and invasion of cancer cells. An angiogenesis 
protein array analysis of conditioned medium from LTBP-2 stable clone revealed the change 
in expressions of different cytokines, including GM-CSF, RANTES, VEGF, uPAR, I-309, 
MMP-1, Angiopoietin-1, and MCP-1, which in turn induce a less favorable 
microenvironment for angiogenesis and tumor growth. ESCC is a deadly disease and 
patients are usually diagnosed at late stage. In many late stage tumors, the TGF-β signaling 
pathway is involved in the activation of EMT program, which is responsible for cancer cell 
traits promoting malignancy. In contrast, TGF-β is well-known to be anti-proliferative. 
Interestingly, an inverse correlation of high LTBP-2 and survival in advanced ESCC stage 
was detected by IHC staining of primary ESCC tissues. LTBP-2 may indirectly regulate TGF-
β by competing with LTBP-1 for fibrillin-1 binding site (Hirani et al 2007).  
5. Conclusions 
In this book chapter, we focus on using MMCT, as a functional approach to identify 
candidate TSGs. The monochromosome transfers of selected chromosomes into the NPC 
and ESCC cell lines, HONE1 and SLMT1, were performed to determine whether tumor 
suppressing activities for NPC and ESCC mapped to chromosomes 3, 9, 11, 13, 14 and 17, as 
described in our previous reports. While all these experiments have been performed in the 
two NPC and SLMT1 cell lines HONE1 and SLMT1, it should be appreciated there are a few 
of well-established and well-characterized NPC and ESCC cell lines available for this kind of 
study. Not surprisingly, identification of TSGs or regions in these cell lines was 
subsequently confirmed to be important in other NPC and ESCC cell lines as well as 
primary tumors. By using the MMCT approach, we successfully identified several CRs 
associated with tumor suppression in the HONE1/SLMT1 cell line systems. These candidate 
TSGs mapping to these regions were subsequently studied for their role in tumor 
suppression assays. We discovered that ADAMTS9 at 3p14.2, ENG and DEC1 at 9q33-q34, 
are genes mapped into CRs, and important for tumor suppression in ESCC. Gene expression 
profiling of the 19K and 28K oligonucleotide microarrays, including tumor-suppressive 
MCH and tumorigenic TS cell lines, was utilized to identify candidate genes (THSD1 and 
LTBP-2) within the critical tumor suppressive regions. It is clear now that many genes 
contribute to the development of these two important cancers.  
6. Acknowledgements 
We would like to acknowledge the financial support from the Research Grants Council and 
the University Research Council of the Hong Kong Special Administrative Region, People’s 
 
Tumor Suppressor Genes 
 
 
72
Republic of China. We would also like to acknowledge our local and international 
collaborators for their cell lines, clinical tissues, TSG constructs, reagents, technologies, and 
valuable advice. In particular, Eric Stanbridge’s contributions to the MMCT and Edison 
Liu’s supply of oligonucleotide arrays, were invaluable for these studies.  
7. References 
Anderson MJ and Stanbridge EJ (1993). Tumor suppressor genes studied by cell 
hybridization and chromosome transfer. Faseb J 7: 826-833. 
Apte SS (2004). A disintegrin-like and metalloprotease (reprolysin type) with 
thrombospondin type 1 motifs: the ADAMTS family. Int J Biochem Cell Biol 36: 981-
985. 
Chan SH, Yee Ko JM, Chan KW, Chan YP, Tao Q, Hyytiainen M, Keski-Oja J, Law S, 
Srivastava G, Tang J, Tsao SW, Chen H, Stanbridge EJ and Lung ML (2011). The 
ECM protein LTBP-2 is a suppressor of esophageal squamous cell carcinoma tumor 
formation but higher tumor expression associates with poor patient outcome. Int J 
Cancer 129: 565-573. 
Cheng Y, Poulos NE, Lung ML, Hampton G, Ou B, Lerman MI and Stanbridge EJ (1998). 
Functional evidence for a nasopharyngeal carcinoma tumor suppressor gene that 
maps at chromosome 3p21.3. Proc Natl Acad Sci U S A 95: 3042-3047. 
Cheng Y, Stanbridge EJ, Kong H, Bengtsson U, Lerman MI and Lung ML (2000). A 
functional investigation of tumor suppressor gene activities in a nasopharyngeal 
carcinoma cell line HONE1 using a monochromosome transfer approach. Genes 
Chromosomes Cancer 28: 82-91. 
Cheng Y, Chakrabarti R, Garcia-Barcelo M, Ha TJ, Srivatsan ES, Stanbridge EJ and Lung 
ML (2002). Mapping of nasopharyngeal carcinoma tumor-suppressive activity to 
a 1.8-megabase region of chromosome band 11q13. Genes Chromosomes Cancer 34: 
97-103. 
Cheng Y, Ko JM, Lung HL, Lo PH, Stanbridge EJ and Lung ML (2003). Monochromosome 
transfer provides functional evidence for growth-suppressive genes on 
chromosome 14 in nasopharyngeal carcinoma. Genes Chromosomes Cancer 37: 359-
368. 
Cheng Y, Lung HL, Wong PS, Hao DC, Man CS, Stanbridge EJ and Lung ML (2004). 
Chromosome 13q12 region critical for the viability and growth of nasopharyngeal 
carcinoma hybrids. Int J Cancer 109: 357-362. 
Cheung AK, Lung HL, Ko JM, Cheng Y, Stanbridge EJ, Zabarovsky ER, Nicholls JM, Chua D, 
Tsao SW, Guan XY and Lung ML (2009). Chromosome 14 transfer and functional 
studies identify a candidate tumor suppressor gene, mirror image polydactyly 1, in 
nasopharyngeal carcinoma. Proc Natl Acad Sci U S A 106: 14478-14483. 
Clark ME, Kelner GS, Turbeville LA, Boyer A, Arden KC and Maki RA (2000). ADAMTS9, a 
novel member of the ADAM-TS/ metallospondin gene family. Genomics 67: 343-
350. 
Craft CS, Romero D, Vary CP and Bergan RC (2007). Endoglin inhibits prostate cancer 
motility via activation of the ALK2-Smad1 pathway. Oncogene 26: 7240-7250. 
 
Identification of Tumor Suppressor Genes via Cell Fusion and Chromosomal Transfer 
 
73 
Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK and Fremgen AM 
(2000). Esophageal cancer: results of an American College of Surgeons Patient Care 
Evaluation Study. J Am Coll Surg 190: 562-572; discussion 572-563. 
de Fraipont F, Nicholson AC, Feige JJ and Van Meir EG (2001). Thrombospondins and 
tumor angiogenesis. Trends Mol Med 7: 401-407. 
Dodd LE, Sengupta S, Chen IH, den Boon JA, Cheng YJ, Westra W, Newton MA, Mittl BF, 
McShane L, Chen CJ, Ahlquist P and Hildesheim A (2006). Genes involved in DNA 
repair and nitrosamine metabolism and those located on chromosome 14q32 are 
dysregulated in nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 15: 
2216-2225. 
Dowdy SF, Scanlon DJ, Fasching CL, Casey G and Stanbridge EJ (1990). Irradiation 
microcell-mediated chromosome transfer (XMMCT): the generation of specific 
chromosomal arm deletions. Genes Chromosomes Cancer 2: 318-327. 
Dowdy SF, Fasching CL, Araujo D, Lai KM, Livanos E, Weissman BE and Stanbridge EJ 
(1991). Suppression of tumorigenicity in Wilms tumor by the p15.5-p14 region of 
chromosome 11. Science 254: 293-295. 
Fournier RE and Ruddle FH (1977a). Stable association of the human transgenome and host 
murine chromosomes demonstrated with trispecific microcell hybrids. Proc Natl 
Acad Sci U S A 74: 3937-3941. 
Fournier RE and Ruddle FH (1977b). Microcell-mediated transfer of murine chromosomes 
into mouse, Chinese hamster, and human somatic cells. Proc Natl Acad Sci U S A 74: 
319-323. 
Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM and Dryja TP 
(1986). A human DNA segment with properties of the gene that predisposes to 
retinoblastoma and osteosarcoma. Nature 323: 643-646. 
Goyette MC, Cho K, Fasching CL, Levy DB, Kinzler KW, Paraskeva C, Vogelstein B and 
Stanbridge EJ (1992). Progression of colorectal cancer is associated with multiple 
tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by 
correction of any single defect via chromosome transfer. Mol Cell Biol 12: 1387-1395. 
Hanahan D and Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell 144: 646-
674. 
Harris H, Miller OJ, Klein G, Worst P and Tachibana T (1969). Suppression of malignancy by 
cell fusion. Nature 223: 363-368. 
Hesson LB, Cooper WN and Latif F (2007). Evaluation of the 3p21.3 tumor-suppressor gene 
cluster. Oncogene 26:7283-7301 
Hirani R, Hanssen E and Gibson MA (2007). LTBP-2 specifically interacts with the amino-
terminal region of fibrillin-1 and competes with LTBP-1 for binding to this 
microfibrillar protein. Matrix Biol 26: 213-223. 
Holmes RS and Vaughan TL (2007). Epidemiology and pathogenesis of esophageal cancer. 
Semin Radiat Oncol 17: 2-9. 
Hu N, Roth MJ, Polymeropolous M, Tang ZZ, Emmert-Buck MR, Wang QH, Goldstein AM, 
Feng SS, Dawsey SM, Ding T, Zhuang ZP, Han XY, Ried T, Giffen C and Taylor PR 
(2000). Identification of novel regions of allelic loss from a genomewide scan of 
esophageal squamous-cell carcinoma in a high-risk Chinese population. Genes 
Chromosomes Cancer 27: 217-228. 
 
Tumor Suppressor Genes 
 
 
74
Huang DP, Ho JH, Chan WK, Lau WH and Lui M (1989). Cytogenetics of undifferentiated 
nasopharyngeal carcinoma xenografts from southern Chinese. Int J Cancer 43: 936-
939. 
Ihara Y, Kato Y, Bando T, Yamagishi F, Minamimura T, Sakamoto T, Tsukada K and Isobe M 
(2002). Allelic imbalance of 14q32 in esophageal carcinoma. Cancer Genet Cytogenet 
135: 177-181. 
Jeyakumar A, Brickman TM and Doerr T (2006). Review of nasopharyngeal carcinoma. Ear 
Nose Throat J 85: 168-170, 172-163, 184. 
Jin H, Wang X, Ying J, Wong AH, Li H, Lee KY, Srivastava G, Chan AT, Yeo W, Ma BB, Putti 
TC, Lung ML, Shen ZY, Xu LY, Langford C and Tao Q (2007). Epigenetic 
identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently 
silenced in esophageal, nasopharyngeal and multiple other carcinomas. Oncogene 
26: 7490-7498. 
Ko JM, Yau WL, Chan PL, Lung HL, Yang L, Lo PH, Tang JC, Srivastava G, Stanbridge EJ 
and Lung ML (2005). Functional evidence of decreased tumorigenicity associated 
with monochromosome transfer of chromosome 14 in esophageal cancer and the 
mapping of tumor-suppressive regions to 14q32. Genes Chromosomes Cancer 43: 284-
293. 
Ko JM, Chan PL, Yau WL, Chan HK, Chan KC, Yu ZY, Kwong FM, Miller LD, Liu ET, Yang 
LC, Lo PH, Stanbridge EJ, Tang JC, Srivastava G, Tsao SW, Law S and Lung ML 
(2008). Monochromosome transfer and microarray analysis identify a critical 
tumor-suppressive region mapping to chromosome 13q14 and THSD1 in 
esophageal carcinoma. Mol Cancer Res 6: 592-603. 
Koi M, Morita H, Yamada H, Satoh H, Barrett JC and Oshimura M (1989). Normal human 
chromosome 11 suppresses tumorigenicity of human cervical tumor cell line SiHa. 
Mol Carcinog 2: 12-21. 
Koi M, Johnson LA, Kalikin LM, Little PF, Nakamura Y and Feinberg AP (1993). Tumor cell 
growth arrest caused by subchromosomal transferable DNA fragments from 
chromosome 11. Science 260: 361-364. 
Lerman MI, Minna JD (2000). The 630-kb lung cancer homozygous deletion region on 
human chromosome 3p21.3: identification and evaluation of the resident candidate 
tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 
Tumor Suppressor Gene Consortium. Cancer Res. 60:6116-6133. 
Leung AC, Wong VC, Yang LC, Chan PL, Daigo Y, Nakamura Y, Qi RZ, Miller LD, Liu ET, 
Wang LD, Li JL, Law S, Tsao SW and Lung ML (2008). Frequent decreased 
expression of candidate tumor suppressor gene, DEC1, and its anchorage-
independent growth properties and impact on global gene expression in 
esophageal carcinoma. Int J Cancer 122: 587-594. 
Li LC and Dahiya R (2002). MethPrimer: designing primers for methylation PCRs. 
Bioinformatics 18: 1427-1431. 
Lin CY, Strom A, Vega VB, Kong SL, Yeo AL, Thomsen JS, Chan WC, Doray B, 
Bangarusamy DK, Ramasamy A, Vergara LA, Tang S, Chong A, Bajic VB, Miller 
LD, Gustafsson JA and Liu ET (2004). Discovery of estrogen receptor alpha target 
genes and response elements in breast tumor cells. Genome Biol 5: R66. 
 
Identification of Tumor Suppressor Genes via Cell Fusion and Chromosomal Transfer 
 
75 
Lo KW, Teo PM, Hui AB, To KF, Tsang YS, Chan SY, Mak KF, Lee JC and Huang DP (2000). 
High resolution allelotype of microdissected primary nasopharyngeal carcinoma. 
Cancer Res 60: 3348-3353. 
Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, Chow LS, Teo PM, Johnson PJ, Huang 
DP (2001). High frequency of promoter hypermethylation of RASSF1A in 
nasopharyngeal carcinoma. Cancer Res. 61:3877-3881. 
Lo PH, Leung AC, Kwok CY, Cheung WS, Ko JM, Yang LC, Law S, Wang LD, Li J, 
Stanbridge EJ, Srivastava G, Tang JC, Tsao SW and Lung ML (2007). Identification 
of a tumor suppressive critical region mapping to 3p14.2 in esophageal squamous 
cell carcinoma and studies of a candidate tumor suppressor gene, ADAMTS9. 
Oncogene 26: 148-157. 
Lo PH, Lung HL, Cheung AK, Apte SS, Chan KW, Kwong FM, Ko JM, Cheng Y, Law S, 
Srivastava G, Zabarovsky ER, Tsao SW, Tang JC, Stanbridge EJ and Lung ML 
(2010). Extracellular protease ADAMTS9 suppresses esophageal and 
nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis. Cancer Res 
70: 5567-5576. 
Lung HL, Lo CC, Wong CC, Cheung AK, Cheong KF, Wong N, Kwong FM, Chan KC, Law 
EW, Tsao SW, Chua D, Sham JS, Cheng Y, Stanbridge EJ, Robertson GP and Lung 
ML (2008a). Identification of tumor suppressive activity by irradiation microcell-
mediated chromosome transfer and involvement of alpha B-crystallin in 
nasopharyngeal carcinoma. Int J Cancer 122: 1288-1296. 
Lung HL, Lo PH, Xie D, Apte SS, Cheung AK, Cheng Y, Law EW, Chua D, Zeng YX, Tsao 
SW, Stanbridge EJ and Lung ML (2008b). Characterization of a novel 
epigenetically-silenced, growth-suppressive gene, ADAMTS9, and its association 
with lymph node metastases in nasopharyngeal carcinoma. Int J Cancer 123: 401-
408. 
Lung ML, Choi CV, Kong H, Yuen PW, Kwong D, Sham J and Wei WI (2001). Microsatellite 
allelotyping of chinese nasopharyngeal carcinomas. Anticancer Res 21: 3081-3084. 
Mitelman F, Mark-Vendel E, Mineur A, Giovanella B and Klein G (1983). A 3q+ marker 
chromosome in EBV-carrying nasopharyngeal carcinomas. Int J Cancer 32: 651-655. 
Mourra N, Zeitoun G, Buecher B, Finetti P, Lagarde A, Adelaide J, Birnbaum D, Thomas G 
and Olschwang S (2007). High frequency of chromosome 14 deletion in early-onset 
colon cancer. Dis Colon Rectum 50: 1881-1886. 
Murakami Y, Nobukuni T, Tamura K, Maruyama T, Sekiya T, Arai Y, Gomyou H, Tanigami 
A, Ohki M, Cabin D, Frischmeyer P, Hunt P and Reeves RH (1998a). Localization of 
tumor suppressor activity important in nonsmall cell lung carcinoma on 
chromosome 11q. Proc Natl Acad Sci U S A 95: 8153-8158. 
Murakami Y and Sekiya T (1998b). Accumulation of genetic alterations and their 
significance in each primary human cancer and cell line. Mutat Res 400: 421-437. 
Murakami Y (2002). Functional cloning of a tumor suppressor gene, TSLC1, in human non-
small cell lung cancer. Oncogene 21: 6936-6948. 
Murakami YS, Brothman AR, Leach RJ and White RL (1995). Suppression of malignant 
phenotype in a human prostate cancer cell line by fragments of normal 
chromosomal region 17q. Cancer Res 55: 3389-3394. 
 
Tumor Suppressor Genes 
 
 
76
Murayama F and Okada Y (1965). Effect of calcium on the cell fusion reaction caused by 
HVJ. Biken J 8: 103-105. 
Pachnis V, Pevny L, Rothstein R and Costantini F (1990). Transfer of a yeast artificial 
chromosome carrying human DNA from Saccharomyces cerevisiae into 
mammalian cells. Proc Natl Acad Sci U S A 87: 5109-5113. 
Pack SD, Karkera JD, Zhuang Z, Pak ED, Balan KV, Hwu P, Park WS, Pham T, Ault DO, 
Glaser M, Liotta L, Detera-Wadleigh SD and Wadleigh RG (1999). Molecular 
cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative 
genomic hybridization reveals a consistent pattern of chromosomal alterations. 
Genes Chromosomes Cancer 25: 160-168. 
Pavan WJ, Hieter P and Reeves RH (1990a). Generation of deletion derivatives by targeted 
transformation of human-derived yeast artificial chromosomes. Proc Natl Acad Sci 
U S A 87: 1300-1304. 
Pavan WJ, Hieter P and Reeves RH (1990b). Modification and transfer into an embryonal 
carcinoma cell line of a 360-kilobase human-derived yeast artificial chromosome. 
Mol Cell Biol 10: 4163-4169. 
Porter S, Clark IM, Kevorkian L and Edwards DR (2005). The ADAMTS metalloproteinases. 
Biochem J 386: 15-27. 
Qi Y, Chiu JF, Wang L, Kwong DL and He QY (2005). Comparative proteomic analysis of 
esophageal squamous cell carcinoma. Proteomics 5: 2960-2971. 
Robertson GP, Hufford A and Lugo TG (1997). A panel of transferable fragments of human 
chromosome 11q. Cytogenet Cell Genet 79: 53-59. 
Saxon PJ, Srivatsan ES, Leipzig GV, Sameshima JH and Stanbridge EJ (1985). Selective transfer 
of individual human chromosomes to recipient cells. Mol Cell Biol 5: 140-146. 
Saxon PJ, Srivatsan ES and Stanbridge EJ (1986). Introduction of human chromosome 11 via 
microcell transfer controls tumorigenic expression of HeLa cells. EMBO J 5: 3461-
3466. 
Shao J, Li Y, Wu Q, Liang X, Yu X, Huang L, Hou J, Huang X, Ernberg I, Hu LF and Zeng Y 
(2002). High frequency loss of heterozygosity on the long arms of chromosomes 13 
and 14 in nasopharyngeal carcinoma in Southern China. Chin Med J (Engl) 115: 571-
575. 
Stanbridge EJ (1976). Suppression of malignancy in human cells. Nature 260: 17-20. 
Stanbridge EJ (1992). Functional evidence for human tumour suppressor genes: 
chromosome and molecular genetic studies. Cancer Surv 12: 5-24. 
Tamura K, Zhang X, Murakami Y, Hirohashi S, Xu HJ, Hu SX, Benedict WF and Sekiya T 
(1997). Deletion of three distinct regions on chromosome 13q in human non-small-
cell lung cancer. Int J Cancer 74: 45-49. 
Todd MC, Xiang RH, Garcia DK, Kerbacher KE, Moore SL, Hensel CH, Liu P, Siciliano MJ, 
Kok K, van den Berg A, Veldhuis P, Buys CH, Killary AM and Naylor SL (1996). 
An 80 Kb P1 clone from chromosome 3p21.3 suppresses tumor growth in vivo. 
Oncogene 13: 2387-2396. 
Tsang YS, Lo KW, Leung SF, Choi PH, Fong Y, Lee JC and Huang DP (1999). Two distinct 
regions of deletion on chromosome 13q in primary nasopharyngeal carcinoma. Int J 
Cancer 83: 305-308. 
 
Identification of Tumor Suppressor Genes via Cell Fusion and Chromosomal Transfer 
 
77 
Vazquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M and Iruela-Arispe 
ML (1999). METH-1, a human ortholog of ADAMTS-1, and METH-2 are members 
of a new family of proteins with angio-inhibitory activity. J Biol Chem 274: 23349-
23357. 
Wada M, Ihara Y, Tatsuka M, Mitsui H, Kohno K, Kuwano M and Schlessinger D (1994). 
HPRT yeast artificial chromosome transfer into human cells by four methods and 
an involvement of homologous recombination. Biochem Biophys Res Commun 200: 
1693-1700. 
Wei WI and Sham JS (2005). Nasopharyngeal carcinoma. Lancet 365: 2041-2054. 
Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja 
A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, 
Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, 
Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis 
ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, 
Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, 
Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, 
Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, 
Wistuba, II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin 
MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES and Meyerson M 
(2007). Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 
893-898. 
Weissman BE, Saxon PJ, Pasquale SR, Jones GR, Geiser AG and Stanbridge EJ (1987). 
Introduction of a normal human chromosome 11 into a Wilms' tumor cell line 
controls its tumorigenic expression. Science 236: 175-180. 
Wong VC, Chan PL, Bernabeu C, Law S, Wang LD, Li JL, Tsao SW, Srivastava G and Lung 
ML (2008). Identification of an invasion and tumor-suppressing gene, Endoglin 
(ENG), silenced by both epigenetic inactivation and allelic loss in esophageal 
squamous cell carcinoma. Int J Cancer 123: 2816-2823. 
Wong VC, Chen H, Ko JM, Chan KW, Chan YP, Law S, Chua D, Kwong DL, Lung HL, 
Srivastava G, Tang JC, Tsao SW, Zabarovsky ER, Stanbridge EJ and Lung ML 
(2011a). Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell 
invasion and epithelial-mesenchymal transition (EMT)-associated phenotype. Int J 
Cancer. 
Wong VC, Ko JM, Qi RZ, Li PJ, Wang LD, Li JL, Chan YP, Chan KW, Stanbridge EJ and 
Lung ML (2011b). Abrogated expression of DEC1 during oesophageal squamous 
cell carcinoma progression is age- and family history-related and significantly 
associated with lymph node metastasis. Br J Cancer 104: 841-849. 
Wu X, Chen VW, Ruiz B, Andrews P, Su LJ and Correa P (2006). Incidence of esophageal 
and gastric carcinomas among American Asians/Pacific Islanders, whites, and 
blacks: subsite and histology differences. Cancer 106: 683-692. 
Yang L, Leung AC, Ko JM, Lo PH, Tang JC, Srivastava G, Oshimura M, Stanbridge EJ, Daigo 
Y, Nakamura Y, Tang CM, Lau KW, Law S and Lung ML (2005). Tumor 
suppressive role of a 2.4 Mb 9q33-q34 critical region and DEC1 in esophageal 
squamous cell carcinoma. Oncogene 24: 697-705. 
 
Tumor Suppressor Genes 
 
 
78
Yau WL, Lung HL, Zabarovsky ER, Lerman MI, Sham JS, Chua DT, Tsao SW, Stanbridge EJ, 
Lung ML (2006). Functional studies of the chromosome 3p21.3 candidate tumor 
suppressor gene BLU/ZMYND10 in nasopharyngeal carcinoma. Int J Cancer  
119:2821-2826. 
Yoshimoto T, Matsuura K, Karnan S, Tagawa H, Nakada C, Tanigawa M, Tsukamoto Y, 
Uchida T, Kashima K, Akizuki S, Takeuchi I, Sato F, Mimata H, Seto M and 
Moriyama M (2007). High-resolution analysis of DNA copy number alterations and 
gene expression in renal clear cell carcinoma. J Pathol 213: 392-401. 
4 
TP53 Gene Polymorphisms in Cancer Risk: 
The Modulating Effect of Ageing, Ethnicity 
and TP53 Somatic Abnormalities 
Evgeny V. Denisov1, Nadezhda V. Cherdyntseva1, Nicolay V. Litviakov1, 
Elena A. Malinovskaya1, Natalya N. Babyshkina1,  
Valentina A. Belyavskaya2 and Mikhail I. Voevoda3 
1Cancer Research Institute,  
Siberian Branch of Russian Academy of Medical Sciences, Tomsk, 
2Research Center of Virology and Biotechnology VECTOR, Koltsovo, 
3Institute of Internal Medicine,  
Siberian Branch of Russian Academy of Medical Sciences, Novosibirsk, 
Russian Federation 
1. Introduction 
The multi-talented “guardian of the genome” p53 is fundamental to preventing tumor 
development through the regulation of important cellular processes such as cell cycle arrest 
and senescence, DNA replication and repair, apoptosis, metabolism, antioxidant defense, 
and autophagy, among others. (Chumakov, 2007; Green and Kroemer, 2009; McCarthy, 
2011; Olovnikov et al., 2009; Vousden and Prives, 2009; Vousden and Ryan, 2009). p53 
protein is encoded by the TP53 gene (OMIM no. 191170), the structure of which is extremely 
variable in both healthy and diseased subjects, particularly in cancer, because of multiple 
germinal and somatic variations (Olivier et al., 2010; Whibley et al., 2009). Currently, 
approximately 85 polymorphisms and 27580 somatic mutations are known in the TP53 gene 
(Petitjean et al., 2007b). In addition, the TP53 gene, as a classic tumor suppressor, undergoes 
a loss of heterozygosity (LOH) and hypo- or hypermethylation (Brosh and Rotter, 2009; 
Sidhu et al., 2005; Soussi, 2007). From all polymorphisms found in the TP53 gene, three - 
rs1042522, rs17878362, and rs1625895 - are well studied in terms of functional 
characterization, distribution in human populations and association with cancer risk. 
During the last 15 years, the predisposing value of these TP53 polymorphic variants has 
been estimated in relation to many human cancers; however, the data are inconsistent.  
It is not surprising that cancer risk is a consequence of the interaction between constitutional 
genetics and environmental exposure. The combination of genetic background (gene-gene 
interactions) and environmental endo- and exogenous factors varies among individuals of 
different ethnical groups and might explain the distinct tumor susceptibility. Cancer is an 
extremely complicated phenotype and, together with the incomplete penetrance of the 
inherited tumor risk alleles, interaction with environmental risk factors could substantially 
alter hereditary susceptibility (Perez-Losada et al., 2011). Nutritional aspects, reproductive 
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factors, and alcohol, smoking, and radiation along with other exposures may considerably 
influence the genetic background via genotoxic effects or the activation/inhibition of major 
pathways and modify cancer susceptibility. This statement is especially true of TP53, the 
functionality of which has inducible character and depends on environmental exposure. 
Additionally, cancer arises as a result of the stepwise accumulation of genetic mutations, 
chromosomal aberrations and epigenetic alterations (Hanahan and Weinberg, 2011; 
Marshall, 1991). Thus, TP53 polymorphisms may define the sequence of mutational events, 
as previously demonstrated (Denisov et al., 2011; Hrstka et al., 2009; Litviakov et al., 2010; 
Whibley et al., 2009). Even more importantly, the manifestation of functional roles of TP53 
polymorphisms is tissue- and age-specific, meaning that their effect on p53-controlled 
processes may vary between cell types and age groups (Azzam et al., 2011; Bonafe et al., 
2004; Salvioli et al., 2005). Based on the above reasoning, a simultaneous account of TP53 
polymorphisms and their tissue- and age-specific effects, along with ethnicity-specific 
genetic background and environmental exposure, may reveal how TP53 germline variations 
modify cancer risk. In this review, we focus on the recent findings regarding TP53 
polymorphisms, rs1042522, rs17878362, and rs1625895, their functional role and association 
with cancer risk, their relationships with environmental exposure and somatic aberrations in 
tumors, as well as discuss some hypotheses explaining the present contradictions in the 
biological role of TP53 variations in cancer. 
2. Functional TP53 polymorphisms and cancer risk 
2.1 TP53 polymorphisms: The functional value 
The TP53 rs1042522 (Ex4+119C>G: C and G alleles) polymorphism displays substitution of 
C to G in codon 72 of exon 4 of the TP53 gene, changing the amino acid from proline (Pro) to 
arginine (Arg) in the proline-rich domain of p53 protein (Harris et al., 1986). p53 forms 
p53Pro and p52Arg are characterized by molecular differences in protein structure (Table 1); 
however, the data are contradictory and inconclusive (Naldi et al., 2010; Ozeki et al., 2011; 
Thomas et al., 1999). In addition, there is no final opinion concerning the influence of TP53 
rs1042522 polymorphism on the p53 mRNA level (Nikbahkt Dastjerdi, 2011; Ribeiro et al., 
1997; Siddique et al., 2005; Wang et al., 1999). Further, it is beyond any doubt that p53Pro 
and p53Arg differ in their capability to regulate p53-dependent cell processes (Table 1). 
Many thousands of years ago, precisely such p53 functional differentiation was the reason 
for dramatic changes in the proportion of rs1042522 alleles from equatorial areas to northern 
latitudes (Beckman et al., 1994; Sjalander et al., 1996). In particular, the rs1042522 C allele is 
the ancestral form with ~60-95% frequency in African populations, whereas the  
G allele arose some 30,000 to 50,000 years ago and increased in percentage as populations 
migrated farther north, where its allele frequency reached 75-85% (Hirshfield et al., 2010; 
Jeong et al., 2010). The most likely components of evolutionary selection pressure fixing 
TP53 alleles into these geographic regions are implantation and reproduction, as well as 
sunburn resistance (Hirshfield et al., 2010; Hu et al., 2011; Jeong et al., 2010), the antithetic 
regulation of which has been demonstrated for p53 rs1042522 protein forms (Table 1). 
Specifically, the rs1042522 G allele exhibits 2-fold higher transcriptional activity toward the 
LIF gene, which encodes a cytokine that is required for optimal implantation and 
reproduction, compared with the C allele (Feng et al., 2011; Jeong et al., 2010; Kang et al., 2009).  
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p53 protein forms 
Ref. rs1042522 rs17878362 rs1625895 
G C A1 A2 G A 
p53 protein 
structure 
Identical Altered 
topology of G-
quadruplexes 
in intron 3 
- - 
(Marcel et al., 2011; 
Naldi et al., 2010; 
Ozeki et al., 2011; 
Thomas et al., 1999) Different 
p53 mRNA level 
High Low 
High Low - - 
(Gemignani et al., 
2004; Nikbahkt 
Dastjerdi, 2011; 
Ribeiro et al., 1997; 
Siddique et al., 2005) 
Identical 
Capability to 
transactivation Low High - - - - (Frank et al., 2011; Thomas et al., 1999) 
cell cycle arrest Low High - - - - (Frank et al., 2011; Pim and Banks, 2004) 
senescence 
induction Low High - - - - 
(Frank et al., 2011; 
Salvioli et al., 2005) 
DNA repair Low High High Low High Low 
(Siddique and 
Sabapathy, 2006; 
Wu et al., 2002) 
genomic 
stability 
maintenance 
Low High - - High Low 
(Litviakov et al., 2010; 
Qiu et al., 2008; 
Schwartz et al., 2011; 
Siddique and 
Sabapathy, 2006) 
apoptosis 
activation 
in extrinsic 
pathway Low High 
High Low High Low 
(Bendesky et al., 
2007; Biros et al., 
2002; Bonafe et al., 
2002; Dumont et al., 
2003; Pim and 
Banks, 2004; 
Schneider-Stock et 
al., 2004b; Siddique 
and Sabapathy, 2006; 
Wu et al., 2002) 
in intrinsic 
pathway High Low 
suppression of 
transformed 
cell growth 
High Low - - - - (Thomas et al., 1999) 
survival in 
hypoxia High Low - - - - (Sansone et al., 2007; 
Vannini et al., 2008) induction of cell 
death in hypoxia Low High - - - - 
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cell-cell 
adhesion 
activation 
High Low - - - - (Jeong et al., 2010) 
reproduction High Low - - - - 
(Feng et al., 2011; 
Jeong et al., 2010; 
Kang et al., 2009; 
Kay et al., 2006) 
degradation 
mediated by 
E6 
oncoprotein High Low - - - - (Storey et al., 1998) 
MDM2 
ubiquitin 
ligase 
High Low 
- - - - (Dumont et al., 2003; Ozeki et al., 2011) Low High 
sunburn High Low - - - - 
(McGregor et al., 
2002; Pezeshki et al., 
2006) 
Table 1. Structural and functional characteristics of p53 proteins encoded by TP53 
(rs1042522, rs17878362 and rs1625895) polymorphisms. 
Moreover, the C allele was found to be increased in women with recurrent implantation 
failure and individuals undergoing in vitro fertilization (IVF), and is a risk factor for 
implantation failure after IVF (Kang et al., 2009; Kay et al., 2006). Interestingly, the 
frequency of the G allele has been positively correlated with low winter temperatures (Shi et 
al., 2009). In this respect, northern populations living in cold climates and having a high 
percentage of G alleles could be at an advantage due to a reduced risk of implantation 
failure (Feng et al., 2011; Hu et al., 2011). Additionally, it is critical to note that the 
geographic distribution of rs1042522 alleles is also linked with the capacity of p53 to 
regulate pigmentation and sunburn resistance through the activation of tyrosinase, the rate-
limiting enzyme for melanin synthesis, and by induction of transcription of the melanogenic 
cytokine pro-opiomelanocortin (Hirshfield et al., 2010; Khlgatian et al., 2002; Murase et al., 
2009). Accordingly, one may reasonably suppose that the p53-dependent stimulation of 
pigmentation could be a protective mechanism from UV light for light-skinned populations. 
Previously, a significant positive association between the G allele and susceptibility to 
sunburn was demonstrated (McGregor et al., 2002; Pezeshki et al., 2006), whereas the C 
allele was most prevalent in dark-skinned races originating from areas with high ambient 
UV levels (McGregor et al., 2002). 
It should not be forgotten that one of the main functions of TP53 is the maintenance of 
genomic stability through the removal of genetically aberrant cells and the suppression of 
tumor development. Different abilities concerning induction cell cycle arrest, DNA repair, 
and senescence, the activation of apoptosis and the suppression of transformed cell growth, 
and survival in hypoxia have been observed for the p53 protein encoded by alleles with 
TP53 rs1042522 polymorphism (Table 1). As compared to p53Arg, p53Pro protein (C allele) 
is the best transactivation molecule (Frank et al., 2011; Thomas et al., 1999) and displays a 
high capability to block the cell cycle (Frank et al., 2011; Pim and Banks, 2004), induce DNA 
repair (Siddique and Sabapathy, 2006), remove micronuclei (Siddique and Sabapathy, 2006) 
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and chromosome aberrations (Litviakov et al., 2010; Schwartz et al., 2011), and stimulate cell 
senescence (Frank et al., 2011; Salvioli et al., 2005) and cell death in hypoxic environments 
via activation/inhibition of p53-target genes such as p21, p53R2, p48, GADD45, PAI-1 and 
the hypoxia response genes. In contrast, p53Arg protein induces apoptosis markedly better 
and with faster kinetics than p53Pro but mainly through intrinsic pathways and a significant 
ability to activate the DR-4, NOXA, PUMA, PIG-3, and PERP genes, localize to the 
mitochondria and release cytochrome C into the cytosol (Dumont et al., 2003; Jeong et al., 
2010; Pim and Banks, 2004; Thomas et al., 1999; Zhu et al., 2010). However, the strongly 
pronounced apoptotic ability of p53Arg does not protect against the process of 
carcinogenesis (Zhu et al., 2010). Likewise, p53Arg is more efficient than p53Pro in the 
suppression of transformed cell growth by the E7 and EJ-ras oncogenes and survival in 
hypoxia (Thomas et al., 1999; Vannini et al., 2008). Curiously, tumors of the head and neck 
losing the C and bearing the G allele show a lack of co-expression of Fas/FasL and high 
expression of Bcl2 proteins, and, as a consequence, markedly reduced apoptosis (Schneider-
Stock et al., 2004b). Simply stated, p53Pro protein seems to be the best inductor of apoptosis 
in the extrinsic pathway. This also results from the fact that p53Pro, but not p53Arg, along 
with NF-kB, transactivates caspase 4/11, an important component of the extrinsic pathway 
in apoptosis induction (Azzam et al., 2011; Frank et al., 2011). Aside from the above-
mentioned data, it was recently established that the TP53 rs1042522 polymorphism impacts 
the apoptotic function of p53 in a tissue-specific manner. Specifically, p53Pro protein more 
effectively activates programmed cell death in thymus (Frank et al., 2011), whereas in the 
small intestine, apoptosis is significantly higher in G-expressing cells (Azzam et al., 2011; 
Zhu et al., 2010). Interestingly, in the spleen, there was no difference in the induction of 
apoptosis between rs1042522 variants (Azzam et al., 2011). Taken together, the tumor-
suppressing function of p53 is considerably modified by TP53 rs1042522 polymorphism, 
while the effect of p53 allelic variants on tumor growth, mainly manifested in apoptosis 
regulation, depends on the genetic and tissue-specific background.  
p53 is a multifaceted and multifunctional molecule with implications in a majority of cell 
processes. There is growing evidence that p53 is involved in regulation of the epithelial–
mesenchymal transition (EMT) and cell phenotype, as well as cell migration and invasion 
(Muller et al., 2011). Breast and lung cancers with p53 mutations exhibit stem cell-like 
transcriptional patterns and are depleted in terms of the activity of differentiation genes 
(Mizuno et al., 2010). Furthermore, a loss of p53 leads to decreased expression of microRNA 
miR-200c, stimulated expression of EMT and stemness markers, and the development of high 
tumor grades in a cohort of breast tumors (Chang et al., 2011). Interestingly, p53 mutants with 
gain of novel function enhanced the efficiency of the reprogramming process compared with 
p53 deficiency (Sarig et al., 2010). As recently published by Jeong et al. (Jeong et al., 2010), TP53 
rs1042522 polymorphism may modify cell-cell adhesion, particularly through the high 
capability of p53Arg protein to induce expression of the PERP gene (Table 1). Additionally, 
p53Arg possesses the best ability to activate CHMP4C, a member of the EMT family of genes. 
In comparison with TP53 rs1042522 polymorphism, rs17878362 and rs1625895 variations are 
poorly characterized in terms of structural and functional properties. However, the current 
data are sufficiently convincing of significant influence on p53 activity. The TP53 rs17878362 
polymorphism consists of a 16 bp duplication in intron 3 (PIN3: A1, non-duplicated allele 
and A2, duplicated allele). In a series of previous studies, it was demonstrated that the 
presence of the rs17878362 minor allele (A2) results in decreasing p53 mRNA levels, 
intensity of DNA repair and apoptosis processes (Table 1) (Gemignani et al., 2004; Wu et al., 
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2002). In addition, there is an opinion that TP53 rs17878362 polymorphism may alter the 
topology of G-quadruplexes in intron 3, regulating the alternative splicing of intron 2, thus 
modulating the patterns of expression of transcripts encoding either p53 or its N-terminally 
truncated isoform, Δ40p53 (Marcel et al., 2011). With respect to rs1625895 (IVS6+62A>G: A 
and G alleles), this polymorphism displays an A>G transversion and, according to literature 
data, is responsible for changes in the induction of DNA repair and apoptosis and the 
maintenance of genomic stability (Table 1) (Qiu et al., 2008; Wu et al., 2002). It should be 
pointed out that TP53 rs1625895 and rs17878362 polymorphisms are in perfect linkage 
disequilibrium with rs1042522 (Sjalander et al., 1995; Weston et al., 1997) and, most likely, 
these intronic variations control the alternative splicing and mRNA level of p53Arg and 
p53Pro proteins. Consequently, it would be logical to take into account the TP53 linkage 
disequilibrium box in disease pathogenesis studies. 
2.2 TP53 polymorphisms: The cancer predisposing value 
Owing to the importance of p53 in tumor suppression, TP53 rs1042522, rs17878362, and 
rs1625895 polymorphisms altering p53 functionality might affect cancer risk (Whibley et al., 
2009). The results of the consortium works and last meta-analyses, demonstrating the 
predisposing value of TP53 germline variations in different types of human cancer, are 
overviewed in Table 2. It should be immediately noticed that in a majority of cancers, the 
data are inconclusive, and further studies are needed to clarify the associations. In addition, 
there are certain annoying mistakes in some meta-analyses, which result in entirely 
noncredible data, and it would be valuable to provide a new, more accurate estimation of 
association of TP53 polymorphisms with cancer risk (Economopoulos and Sergentanis, 2010; 
Lu et al., 2011a; Lu et al., 2011b; Lu et al., 2011c; Sergentanis and Economopoulos, 2010a, 
2011). However, in spite of the present disagreements and methodological flaws, association 
tendencies for some cancer localizations are clear (Table 2). Simply stated, the rs1042522 C 
allele is associated with increased susceptibility to cancers, including of the lung (Dai et al., 
2009; Francisco et al., 2010; Li et al., 2009; Yan et al., 2009), head and neck (Francisco et al., 
2010), thyroid (Francisco et al., 2010), esophagus (Wang et al., 2010a; Zhao et al., 2010), 
pancreas (Liu et al., 2011), liver (Chen et al., 2011; Francisco et al., 2010), gallbladder (Liu et 
al., 2011), nasopharynx (Zhuo et al., 2009b), and cervix (Francisco et al., 2010; Klug et al., 
2009). No significant contribution of TP53 rs1042522 polymorphism to oral cancer has been 
reported (Zhuo et al., 2009c). A high heterogeneity of results was observed in breast (He et 
al., 2011; Hu et al., 2010b; Lu et al., 2011b; Ma et al., 2011; Peng et al., 2011; Sergentanis and 
Economopoulos, 2010b; The Breast Cancer Association Consortium, 2006; Zhang et al., 
2010b; Zhuo et al., 2009a), colon and rectum (Dahabreh et al., 2010; Economopoulos and 
Sergentanis, 2010; Economopoulos et al., 2010; Liu et al., 2011; Tang et al., 2010; Wang et al., 
2010b) cancers. Though still not quite clear, cancer of the ovary (Schildkraut et al., 2009; 
Zhang et al., 2008), endometrium (Francisco et al., 2010; Jiang et al., 2010b), stomach 
(Francisco et al., 2010; Gao et al., 2009; Liu et al., 2011), bladder (Jiang et al., 2010a; Li et al., 
2010), prostate (Zhang et al., 2010a; Zhang et al., 2011b; Zhu et al., 2011), and skin (Francisco 
et al., 2010; Jiang et al., 2011) appear to be affected. As for the rs17878362 polymorphism, a 
clear association of the A2 allele with a high risk of breast cancer (He et al., 2011; Hu et al., 
2010a; Hu et al., 2010b; Zhang et al., 2011a) and a lack of involvement in lung (Hu et al., 
2010a), ovary (Schildkraut et al., 2009), colon and rectum (Hu et al., 2010a) cancer 
susceptibility has been demonstrated. Interestingly, Peng et al. (Peng et al., 2011) did not 
show a dependence of breast cancer development on rs17878362 germline variation. For the 
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rs1625895 polymorphism, no association with breast (He et al., 2011; Hu et al., 2010b) or 
ovary (Schildkraut et al., 2009) cancers has been presented in the available literature.  
Cancer is a heterogeneous polygenic disorder with a well-established gene environment 
playing an important role in disease etiology (Hanahan and Weinberg, 2011; Perez-Losada et 
al., 2011). The significant heterogeneity of the associative value of TP53 polymorphisms, 
especially rs1042522 variation, among human cancers is most likely explained by specific p53 
inducible functionality essentially depending on ethnicity-related genetic background and 
environmental exposure, tissue and age specificity (Azzam et al., 2011; Chung et al., 2010; 
Donehower, 2006; Francisco et al., 2010; van Heemst et al., 2005). The complex of lifestyle 
endo- and exogenous factors of each ethnic group, the proportion of which increases with age, 
may dramatically modulate the contribution of TP53 polymorphisms to cancer risk through, 
for example, genotoxic effects and epigenetic modifications of the TP53 gene structure. 
Exogenous modifiable factors, such as alcohol, smoking and betel or areca quid chewing, and 
radiation and chemical poisoning, together with endogenous estrogen metabolites and other 
secreted chemicals, have been found to be involved in DNA damage and epigenetic alterations 
(De Bont and van Larebeke, 2004; Hsu et al., 2010; Seviour and Lin, 2010). In this case, TP53 
functionally different polymorphisms serving as background for origin of TP53 abnormalities, 
such as mutations and a loss of heterozygosity (LOH), promote neoplastic transformation by 
switching off p53-dependent control of genomic stability and further accumulation of genetic 
damage (Denisov et al., 2011). As a classic tumor suppressor, TP53 inactivation seems to 
underlie Knudson’s “two-hit” model supposing that two mutations or “hits” (point mutation 
and loss of allele, producing LOH) are required to inactivate genes and cause cancer or 
promote disease progression (Knudson, 1971); however, there are tumors that are exceptions 
to this rule (Donehower and Lozano, 2009; Thiagalingam et al., 2002). Nevertheless, the 
simultaneous presence of mutations and LOH in the TP53 gene is a widespread phenomenon 
in human cancer, suggesting that one inactivation is not sufficient to completely inactivate p53 
(Baker et al., 1990; Nigro et al., 1989).  
 
Cancers rs1042522 rs17878362 rs1625895 Ref. 
Breast  
no no - 
(Ma et al., 2011; Peng et 
al., 2011; The Breast 
Cancer Association 
Consortium, 2006; Zhuo 
et al., 2009a) 
C↓, Mediterraneans A2↑ no (Hu et al., 2010a; Hu et al., 2010b) 
G↑ - - 
(Lu et al., 2011b; 
Sergentanis and 
Economopoulos, 2010b; 
Zhang et al., 2010b) 
G↑, Indians A2↑ no (He et al., 2011) 
no A2↑ - (Zhang et al., 2011a) 
Lung, head and 
neck, thyroid C↑ no - 
(Dai et al., 2009; 
Francisco et al., 2010; 
Hu et al., 2010a; Li et al., 
2009; Truong et al., 2010; 
Yan et al., 2009) 
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Gynecologic 
Ovary no no no (Schildkraut et al., 2009) C↓ - - (Zhang et al., 2008) 
Cervix G↑* - - (Klug et al., 2009) C↓ - - (Francisco et al., 2010) 
Endometrium no - - (Jiang et al., 2010b) C↑ - - (Francisco et al., 2010) 
Digestive tract  
Oral cavity no - - (Zhuo et al., 2009c) 
Stomach 
C↑ - - (Francisco et al., 2010; Liu et al., 2011) 
C↑, diffuse type, 
Asians - - (Gao et al., 2009) C↓, intestinal type, 
Caucasians 
Esophagus, 
pancreas, 
liver, 
gallbladder 
C↑ - - 
(Chen et al., 2011; 
Francisco et al., 2010; Liu 
et al., 2011; Wang et al., 
2010a; Zhao et al., 2010) 
Colon and 
rectum 
no no - 
(Economopoulos and 
Sergentanis, 2010; Hu et 
al., 2010a; Tang et al., 
2010; Wang et al., 2010b) 
C↓, Caucasians 
(tendency)† - - 
(Economopoulos et al., 
2010) 
C↓* - - (Dahabreh et al., 2010) 
C↑ - - (Liu et al., 2011) 
Total group 
without oral 
cavity 
C↑, Asians - - (Liu et al., 2011) 
Bladder G↑, Caucasians - - (Li et al., 2010) G↓, Asians - - (Jiang et al., 2010a) 
Nasopharynx G↓, C↑ - - (Zhuo et al., 2009b) 
Prostate  
no - - (Zhu et al., 2011) 
G↑, Caucasians - - (Zhang et al., 2010a) 
C↓‡ - - (Zhang et al., 2011b) 
Skin  no - - (Jiang et al., 2011) C↓ - - (Francisco et al., 2010) 
↑allele increases cancer risk. ↓allele decreases cancer risk.  
*only in non-epidemiological studies and studies, where controls were not in Hardy–Weinberg 
equilibrium and polymorphism analysis was determined from tumor tissue. †in studies where controls 
did not deviate from the Hardy-Weinberg equilibrium. ‡in population-based control subjects. 
Table 2. The association of TP53 gene polymorphisms with human cancers (data from the 
consortium works and the last meta-analyses). 
TP53 Gene Polymorphisms in Cancer Risk: 
The Modulating Effect of Ageing, Ethnicity and TP53 Somatic Abnormalities 
 
87 
2.3 TP53 polymorphisms: The background for TP53 abnormalities 
TP53 gene mutations, represented by specific single monoallelic missense aberrations, are 
“universal” genetic abnormalities in human tumors, with a frequency varying from 10 to 
close to 100% (Brosh and Rotter, 2009; Olivier et al., 2010; Rivlin et al., 2011). TP53 mutants 
display a loss of transactivation capability via conformational changes in p53 protein 
structure, as well as gain-of-function effects through the activation of multidrug resistance 
genes (ABCB1, ABCC1, ABCG1, and MVP), growth factor receptor genes (EGFR, bFGF, and 
VEGF), oncogenes (с-Myc, с-Fos, and Ras) or via the inhibition of paralogs p63 and p73, 
which are responsible for the induction of apoptosis (Brosh and Rotter, 2009; Olivier et al., 
2010; Oren and Rotter, 2010). Due to tumor-promoting effects, TP53 mutations have been 
shown to contribute to poor prognosis and therapeutic effectiveness in a majority of cancers 
(Brosh and Rotter, 2009; Olivier et al., 2010; Petitjean et al., 2007a). Despite the high TP53 
mutability, there is data concerning the presence of alternative inactivation pathways 
through the methylation of CG repeats in the TP53 gene (Almeida et al., 2009; Amatya et al., 
2005; Kang et al., 2001; Sidhu et al., 2005). Although the promoter region of TP53 does not 
contain a classic CpG island, the methylation of one or two CG sites may result in significant 
inhibitory effects in gene expression (Sidhu et al., 2005). As for the LOH in the region of the 
TP53 gene (17p13.1) or allelic imbalance (AI) as currently, the abnormality is detected in a 
majority of tumors leading to cancer progression and poor prognosis (Ellsworth et al., 2005; 
Frohling and Dohner, 2008; Lee et al., 2006; Tsuda, 2009; Willman and Hromas, 2010).  
At present, it is not known which of these inactivation hits occurs first; however, the 
initial step by way of LOH is expected to create prerequisites for mutations in retained 
TP53 alleles through a significant increase in genomic instability caused by the dramatic 
reduction of p53 functionality. In contrast, point mutations and methylation do not 
always result in inactivation or alteration of the activity of the corresponding protein. 
Information concerning the simultaneous occurrence of LOH and mutations in the TP53 
gene is well represented in association with rs1042522 alleles (Table 3). However, it was 
quite recently shown that rs17878362 and rs1625895 germline variations are also 
associated with TP53 somatic abnormalities in tumor cells (Denisov et al., 2011; Marcel et 
al., 2009), although the data are not numerous enough and require further confirmation. 
Several studies reported that LOH more often occurs at the C allele than at the G allele in 
tumor cells of rs1042522 heterozygous cancer patients. This phenomenon is typical for 
cancers of the breast (Bonafe et al., 2003; Denisov et al., 2009; Denisov et al., 2011; 
Wegman et al., 2009), lung (Nelson et al., 2005; Papadakis et al., 2002), head and neck 
(Marin et al., 2000; Mitra et al., 2007), colon and rectum (Schneider-Stock et al., 2004a), 
renal pelvis, ureter and bladder (Furihata et al., 2002), oral cavity (Hsieh et al., 2005), 
vulva (Brooks et al., 2000; Marin et al., 2000), liver (Anzola et al., 2003), skin (Marin et al., 
2000; McGregor et al., 2002), esophagus (Kawaguchi et al., 2000), and cervix (Pegoraro et 
al., 2002). However, the early studies on renal, bladder and oral cancer models did  
not show any differences in the preference of LOH at the rs1042522 alleles (Oka et al.,  
1991; Tandle et al., 2001). An interesting situation is that two reports involving ovary 
cancer have demonstrated contradictory results concerning preferential loss of the 
rs1042522 alleles in tumor (Buller et al., 1997; Wang et al., 2004); however, in a study by 
Wang et al. (Wang et al., 2004), the differences did not reach statistical significance. In a 
majority of cancers with a loss of the C allele, TP53 gene mutations are significantly more 
frequent displayed in the retained G variant. Interestingly, persons with the GG and GC 
genotype in blood also have an increased frequency of TP53 somatic mutations (Table 3). 
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Cancers 
Preferential 
loss 
Preferential 
mutation Ref. 
G C G C
Breast  
yes no no no (Kyndi et al., 2006)
no yes - - (Bonafe et al., 2003) 
- - yes no (Langerod et al., 2002) 
no yes yes no (Wegman et al., 2009) 
no yes yes no (Denisov et al., 2009;  Denisov et al., 2011) 
Head and neck no yes yes no (Mitra et al., 2007)no yes yes no (Marin et al., 2000)
Renal pelvis, 
ureter and bladder 
no no - - (Oka et al., 1991)
no yes yes no (Furihata et al., 2002) 
Oral cavity no yes
† yes no (Hsieh et al., 2005)
no no - - (Tandle et al., 2001) 
Colon and rectum no yes yes no (Schneider-Stock et al., 2004a) - - yes no (Godai et al., 2009)
Stomach - - no no (Belyavskaya et al., 2006) 
Vulva no yes yes no (Brooks et al., 2000) no yes yes no (Marin et al., 2000) 
Skin 
no yes yes no
- - no yes (Almquist et al., 2011) 
no yes no no (McGregor et al., 2002) 
Liver (hepatitis C 
virus) no yes - - (Anzola et al., 2003) 
Esophagus (HPV) no yes - - (Kawaguchi et al., 2000) 
Cervix (HPV) no yes - - (Pegoraro et al., 2002) 
Ovary no yes no yes (Buller et al., 1997)
- advanced 
  cancer yes no no yes (Wang et al., 2004) 
Lung  
- non-small cell 
  cancer 
- - no yes 
(Hu et al., 2005; Mechanic et al., 
2005; Szymanowska et al., 
2006) 
- - yes no (Lind et al., 2007) 
no yes yes no (Nelson et al., 2005) 
- advanced 
  cancer no yes - - (Papadakis et al., 2002) 
Total group of 
human cancers at 
the background of 
radiation 
no yes - - [own unpublished data] 
†C allele is preferentially lost in oral squamous cell carcinomas associated with cigarette smoking and 
areca quid chewing, while the frequency of G allele loss is increased with alcohol drinking. 
Table 3. The preferential loss and mutation of TP53 rs1042522 alleles in human cancer. 
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Selective loss of the rs1042522 C allele and retention and mutation of the G variant seems to 
be a unique phenomenon, of which the molecular mechanism, point of origin and biological 
significance remain unclear. As opposed to hereditary cancer, the origin of which occurs in 
Knudson’s “two-hit” model, in sporadic tumors, the question of whether the mutation or 
LOH arises first is not resolved, likely due to the high variability of inactivation modes 
among target (tumor suppressor) genes in cancer development (Thiagalingam et al., 2002; 
Wilentz et al., 2001). Thus, one may suppose that the LOH and mutations arise in any alleles 
and in any order but not simultaneously in the two allelic variants because the chances of 
this “scenario” are very low. Accordingly, in TP53 rs1042522 heterozygous carriers, the 
following groups of cells are theoretically possible: with LOH at both the C and G alleles 
and mutations in both the C and G alleles (Fig. 1). It is most likely that any variations from 
monoallelic inactivation hits may provoke neoplastic transformation because a 50% 
reduction in TP53 gene dosage, protein expression and activity is sufficient to promote 
tumorigenesis (Donehower and Lozano, 2009); however, loss of the chromosome region 
underlying LOH is always more dramatic than point mutation. The selective advantage will 
be displayed for the two groups of cells lacking the C allele and having a mutation in the G 
variant because of the uncontrolled proliferation caused by the withdrawal of cell cycle 
checking and the high survival capacity in hypoxia and conditions of chemotherapy 
provoked by the preferential activation of hypoxia and multidrug resistance genes by 
p53Arg and inactivation of p73 protein, an important determinant of cellular sensitivity to 
anticancer agents (Bergamaschi et al., 2003; Sansone et al., 2007; Siddique and Sabapathy, 
2006; Vannini et al., 2008). The dramatically increased genomic instability in these cells will 
most likely result in the second inactivation hit by mutation of the retained G allele in one 
clone and loss of the C variant in the other. Thus, any of these variants will lead to formation 
of a cell clone lacking the C allele and having the mutated G variant, the presence of which 
has been reported in a majority of human cancers (see above). As opposed to single 
monoallelic inactivation sufficient for tumorigenesis, biallelic switching of p53 activity may 
accelerate tumors to invade and metastasize. Taken together, the “two-hit” model of TP53 
somatic abnormalities was suggested to explain the regular occurrence of loss of the 
rs1042522 C allele and mutation of the G variant in human tumors. 
The biological value of TP53 somatic abnormalities in the rs1042522 polymorphic region is 
well investigated in relation to tumor onset and progression. Nonetheless, there are difficulties 
in determining the specific interrelationship between certain rs1042522 inactivation hits and 
tumor development, perhaps due to tissue-specific manifestation of TP53 allelic variants 
(Azzam et al., 2011). In particular, the positive contribution of loss of the C allele to short 
disease-free and overall survival, as well as tumor spreading, has been established in breast 
and colorectal cancers (Bonafe et al., 2003; Schneider-Stock et al., 2004a). Interestingly, 
inactivation of the C allele, already having mutations, has been associated with short survival 
and a worse outcome in patients with lung, ovarian and colorectal neoplasias (Godai et al., 
2009; Nelson et al., 2005; Wang et al., 2004). In contrast, patients lacking the G variant in breast 
tumors possessed early tumor onset and more recurrence and short disease-free survival 
(Kyndi et al., 2006; Wegman et al., 2009). In addition, it should be pointed out that preferential 
loss of the C allele in human tumors may imply a protective effect of this variant regarding 
cancer development (Denisov et al., 2010; Denisov et al., 2011); however, the current 
disagreements between meta-analyses (Table 2) and studies reporting rs1042522 allelic loss in 
tumors (Table 3) allow us to consider this statement as not quite truthful. Likely, further 
studies are needed to clarify the above-mentioned hypothesis.  
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Fig. 1. The “two-hit” model of regular occurrence of TP53 somatic abnormalities depending 
on the TP53 rs1042522 polymorphism and environmental exposure. This model describes 
rs1042522-specific origin of TP53 somatic aberrations in cancer tumors. At the first stage, 
LOH (indicated as a loss of chromosome arm) and/or mutation (indicated as asterisk on the 
chromosome arm) arise in any rs1042522 allele and in any order resulting in neoplastic 
transformation. From all tumor clones, only two ones with loss of the C allele and mutation 
in the G variant will have selective advantage via high survival capacity in hypoxia and 
therapy conditions, low ability to DNA repair and apoptosis. The dramatically increased 
genomic instability (GIS) in these cells will cause second inactivation forming the 
predominant tumor clone with loss of the C allele and mutation in the retained G variant. It 
is most likely that complete inactivation of p53 will impart invasive and/or metastatic 
potential to these cells. 
In summary, the cancer predisposing effect of the TP53 rs1042522 polymorphism through 
environment-induced regular occurrence of TP53 somatic abnormalities has been reviewed 
in the present study. The “two-hit” model was suggested to explain the universal 
phenomenon for a majority of human tumors, consisting of a preferential loss of the C allele 
and mutation of the G variant. As reviewed herein, functional differentiation between 
rs1042522 allelic variants and its tissue specificity underlie selective pressure to maintain 
cells in which the C allele is lost and the G allele is mutated. Moreover, the inactivation of 
both the C and G allelic variants, resulting in a dramatic reduction in p53 functionality, may 
serve as an important background for tumorigenesis, as explained by the results of a study 
series on the association of TP53 abnormalities in the rs1042522 polymorphic region with 
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tumor onset and aggressiveness (Bonafe et al., 2003; Godai et al., 2009; Kyndi et al., 2006; 
Nelson et al., 2005; Schneider-Stock et al., 2004a; Wang et al., 2004; Wegman et al., 2009).  
2.4 TP53 polymorphisms: The cancer predisposing effect and aging 
p53 is emerging as an important player in the regulation of senescence and longevity with 
pronounced antagonistic pleiotropy (Campisi, 2005; Donehower, 2006; Vigneron and 
Vousden, 2010). By suppressing cancers early in life, p53 is clearly a longevity assurance 
gene. However, there is some evidence that p53 might accelerate aging and reduce longevity 
late in life (Donehower, 2006). Results have shown that the genotype distribution of TP53 
polymorphisms, mainly the rs1042522 germline variation, in both healthy persons and 
cancer patients, is also consistent with antagonistic pleiotropy. As early as 1999, Bonafe et al. 
(Bonafe et al., 1999) demonstrated a slightly increased percentage of rs1042522 C carriers 
among Italian centenarians. Later, this research team reported that the presence of only 
major genotypes for rs1042522, rs17878362, and rs1625895, absence of the GSTT1 deletion, 
and the simultaneous occurrence of the TP53 genotypes with minor alleles and the GSTT1 
deletion, were much more frequent in young subjects than in centenarians (Gaspari et al., 
2003). However, our data did not confirm this fact, likely due to the small study sample 
(Belyavskaya et al., 2005). Based on the observations, it is most likely that the reason for 
disagreement can be explained by the different genetic backgrounds modifying the age-
specific functionality of TP53 polymorphisms (Belyavskaya et al., 2005). With respect to 
cancer, an age-specific dependence of cancer risk has been reported for TP53 
polymorphisms (Cherdyntseva et al., 2010; Chung et al., 2010; Gervas et al., 2007; 
Perel'muter et al., 2008). In this aspect, it is of note that some contradictions in the above-
mentioned meta-analyses could be due to age-related effects of TP53 germline variations. 
For example, breast cancer is one of a few diseases for which TP53 rs1042522 polymorphism 
raises many questions (He et al., 2011; Hu et al., 2010b; Lu et al., 2011b; Ma et al., 2011; Peng 
et al., 2011; Sergentanis and Economopoulos, 2010b; The Breast Cancer Association 
Consortium, 2006; Zhang et al., 2010b; Zhuo et al., 2009a). According to our data, the C allele 
contributes to high breast cancer risk in the premenopausal period (Cherdyntseva et al., 
2011), whereas a combination of rs1042522, rs17878362, and rs1625895 major genotypes 
often occurs in postmenopausal BC (Perel'muter et al., 2008). Therefore, a more accurate 
meta-analysis that takes into account age specificity is required to clarify the associations 
between rs1042522 and breast cancer risk. Interestingly, an age-associated change in the 
TP53 genotype distribution was also observed for lung cancer: the elderly (60-79 yr) affected 
subjects were characterized by an increased frequency of TP53 major genotypes, whereas a 
high proportion of heterozygous genotype combinations was frequently detected in mature 
(40-59 yr) patients (Cherdyntseva et al., 2010; Gervas et al., 2007). These data not only agreed 
with recent meta-analyses (Dai et al., 2009; Francisco et al., 2010; Li et al., 2009; Yan et al., 
2009) but also suggest that age might be an important modifier of the association between 
TP53 rs1042522 polymorphism and lung cancer risk. With regard to rs17878362 and 
rs1625895 germline variations, the alteration in frequency of their genotypes is most likely 
linked to the regulation of TP53 gene dosage particularly that which results in an increase in 
expression of the rs1042522 G allele, as already mentioned previously. Curiously enough, a 
high percentage of rs1042522 GG genotype was displayed in elderly patients with both 
breast and lung cancer. It is possible that apoptosis preferentially activated by p53Arg 
protein can lead to tissue atrophy, organ degeneration and cancer-related aging phenotypes 
(Campisi, 2005; Rodier et al., 2007). Moreover, it is known that the effect of TP53 rs1042522 
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polymorphism becomes evident as the age of individuals increases (Bonafe et al., 2004; 
Salvioli et al., 2005). In particular, cells isolated from centenarians and sexagenarians, GG 
carriers, undergo oxidative stress-induced apoptosis to a higher extent than cells obtained 
from C carriers (Bonafe et al., 2004). Additionally, individuals that live a long time with the 
C allele display slower cell cycle kinetics and an increased propensity to undergo cell 
senescence than age-matched persons not expressing the C variant (Salvioli et al., 2005). 
These findings result from the preferential induction of p21, cyclin-dependent kinase 
inhibitor 1, and, likely, age-dependent activation of PAI-1, plasminogen activator inhibitor 1, 
by p53Pro protein (Salvioli et al., 2005; Testa et al., 2009).  
Notwithstanding the age-specific effect of TP53 polymorphisms on cancer risk, interesting 
findings concerning their influence on longevity have been provided by Van Heemst et al. 
(van Heemst et al., 2005). Elderly patients, carriers of the CC genotype, display a 41% 
increased survival despite a 2.54-fold high cancer mortality. Interestingly, some have 
suggested that the increased longevity of individuals with the CC genotype may be due to a 
generally increased robustness after a diagnosis of cancer or other life-threatening diseases, 
perhaps via an age-dependent capability of p53Pro to stimulate the expression of PAI-1 
(Bojesen and Nordestgaard, 2008; Orsted et al., 2007; Testa et al., 2009). 
p53 is a central node in the molecular network of safeguarding the integrity of the genome. 
p53 activation can immediately result in alterations in the expression of more than a 
thousand genes (Kannan et al., 2011). However, the fate of p53 is also under the rigorous 
control of other molecular players. Quite recently, based on the results of an association 
study and epistatic interaction analysis, the age- and estrogen receptor-specific interplay 
between TP53 and FGFR2 has been demonstrated in breast cancer (Cherdyntseva et al., 
2011). It was found that combinations of FGFR2 rs1219648 minor and TP53 rs1042522, 
rs17878362, and rs1625895 major genotypes were associated with a high risk of BC, 
particularly in the postmenopausal period. In contrast, combinations of the FGFR2 and TP53 
major genotypes had a protective effect against BC, especially in premenopausal women. Of 
note, all observations were ER-dependent. A possible explanation arises from evidence that 
FGFR2, upregulated by estrogens through the rs1219648 (G allele)-formed estrogen receptor 
site, may result in p53 inactivation via the induction of MDM2 ubiquitin ligase 
(Cherdyntseva et al., 2011). Importantly, the presence of the minor rs1219648 allele may lead 
to elevated FGFR2 expression in tumor cells by itself (Meyer et al., 2008). Another point of 
view is based on a molecular network consisting of the preferential activation of apoptosis 
and cancer-related aging phenotype by p53Arg protein and the further induction of FGFR2 
expression leading to the transactivation of cancer genes and increased proliferation. The 
above-mentioned reasoning allows us once again to conclude that the p53-associated 
cellular defense system that controls cancer suppression directly depends on age-related 
features of the human organism, and this phenomenon should be taken into account in 
future association studies.  
2.5 TP53 polymorphisms: The cancer predisposing effect and ethnicity 
The TP53 polymorphism distribution dramatically changes across the globe (Beckman et al., 
1994; Sjalander et al., 1996), indicating selective pressure to fix TP53 alleles in certain 
geographic areas. As noted in previous sections of this review, the functionally different p53 
polymorphic proteins have the advantage of depending on specific environmental 
conditions (Hirshfield et al., 2010; Hu et al., 2011; Jeong et al., 2010). In addition, 
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manifestation of the cancer predisposing effects of TP53 polymorphisms may also be altered 
between the different ethnic groups (Weston et al., 1997). In the literature, there is a 
significant amount of evidence that TP53 polymorphisms (rs1042522, rs17878362, and 
rs1625895) differently influence cancer risk depending on ethnic components. For instance, 
TP53 rs1042522 polymorphism has a protective value against breast cancer in inhabitants of 
the Mediterranean area (Hu et al., 2010b), but a predisposing effect in Indians (He et al., 
2011). In addition, Sergentanis and Economopoulos (Sergentanis and Economopoulos, 
2010b) showed an enhancement of the association between the C allele and cancer, both 
breast cancer and lung cancer, with increasing latitude. Similar ethnicity-specific 
contribution of TP53 rs1042522 germline variation is also typical for other human cancers 
(Table 2) (Economopoulos et al., 2010; Gao et al., 2009; Jiang et al., 2010a; Li et al., 2010; Liu 
et al., 2011; Zhang et al., 2010a). Interestingly enough, the allelic expression of human genes, 
like allele frequency, was found to differ between ethnic groups (Spielman et al., 2007). 
Siddique et al. showed that the expression of TP53 rs1042522 alleles is selectively regulated 
in different ethnic populations: healthy Asian heterozygote individuals preferentially 
express the C allele, whereas Caucasians express the G allele. Conversely, approximately 
75% of Chinese heterozygote patients with breast cancer predominantly express the G allele 
(Siddique et al., 2005). Although the potential reason for this phenomenon could be 
preferential loss of the C allele in breast tumors of heterozygous patients, as mentioned above, 
the data of Siddique et al. may indirectly confirm a predisposing role of the G allele in breast 
cancer development, as shown in some meta-analyses (He et al., 2011; Lu et al., 2011b; 
Sergentanis and Economopoulos, 2010b; Zhang et al., 2010b). In addition, our research team 
first showed the high risk potential of the G allele and trend toward the protective value of the 
C variant in relation to breast cancer development in Mongolian ethnic groups (Tuvans, 
Altaians, Khakases, and Buryats) living in the Siberia region of Russia (Pisareva et al., in press). 
It is of note that our earlier data demonstrated significantly lower breast cancer incidence in 
these ethnic groups in comparison with Caucasians living in the same region (Pisareva et al., 
2007). Moreover, it is known that Caucasians are approximately 2-fold more prone to breast 
cancer than Asians (Siddique et al., 2005). As evident from the above, there is a specific 
selective pressure against high breast cancer incidence in people of Asian ethnicity, and a 
possible explanation for this might be the functional impact of the TP53 rs1042522 
polymorphism, of which the C allele is overrepresented in these populations. As indicated 
previously, the TP53 rs1042522 polymorphism has a significant effect on the origin of TP53 
somatic abnormalities, especially mutations, and, thus, may predispose one to cancer. Race-
specific differences in the frequency of TP53 alterations have been shown between colorectal 
patients of Afro-American and Caucasian origin, with the prevalence of mutations in the 
former, which were rs1042522 CC carriers. Surprisingly, the African American CC genotype 
was associated with a high risk of lymph node metastasis and increased mortality (Katkoori et 
al., 2009). Although the above evidence is small in number and needs further approval, 
calculation of the ethnic component is essential to perform accurate and qualitatively correct 
association studies. 
In summary, a disparity between different ethnicities (races) in various cancer incidences 
and outcomes depends on genetic differences affecting the biology of malignancy. 
Moreover, recent evidence indicates ethnic differences in toxicity from certain anticancer 
treatments as well their effectiveness, which apparently contributes to survival (Mahdi et al., 
2011; Soo et al., 2011). This might be explained by the diversity in genotype variants, gene 
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expression levels and epigenetic alterations providing different race/ethnicity-specific 
functional pathways. p53 is a key player contributing to the defense against cancer and has 
been shown to be involved in tumor progression and the response to cytostatic drugs via the 
regulation of metabolism and repair of DNA damage induced by chemotherapy. Therefore, 
the analysis of TP53 rs1042522 polymorphism together with other deciding factors may help 
to understand racial differences in cancer aggressiveness and clinical outcomes, which could 
increase treatment efficacy. 
3. Conclusions 
p53 (TP53 gene) is a key tumor suppressor that balances the need for cell proliferation 
against the need for cancer suppression, thereby maintaining genomic integrity. 
Polymorphisms in the TP53 gene significantly modify p53 functionality, thereby affecting 
the mechanisms of cancer prevention. Despite the substantial progress in molecular genetics 
and the understanding of tumorigenesis mechanisms in recent years, the value of TP53 
polymorphisms is not entirely clear in relation to a predisposition to or protection from 
cancer risk. In the present review, we focused on available information concerning the 
functional role of TP53 polymorphisms and data from consortium works and the latest 
meta-analyses demonstrating their effect on cancer risk. We supposed that the 
disagreements and ambiguities in these studies are linked to the changeable nature of TP53 
polymorphism manifestation dependent on environmental exposure, mainly age features 
and ethnic components of the analyzed individuals. In our opinion, the possible variations 
of the impact of TP53 polymorphisms on cancer susceptibility, mainly for rs1042522, might 
be presented as a complex gene-environmental mechanism realized through a regular 
occurrence of TP53 somatic abnormalities and selective pressure against certain TP53 alleles.  
Overall, the environment-specific character of TP53 polymorphisms has been reviewed to 
demonstrate potential cancer risk-modifying factors, which should be taken into account to 
avoid unclear and ambiguous results in future association studies. 
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1. Introduction  
Genes which protect cells from malignant transformation were referred to as tumor 
suppressor genes (TSGs). Since the first description of TSG, Rb (retinoblastoma susceptibility 
gene), a myriad of genes have been identified as TSGs. These TSGs play critical roles in cell 
cycle control, apoptosis, DNA damage detection and repair, adhesion, metastasis, 
senescence, and carcinogen detoxification. Loss function of TSGs may cause uncontrolled 
cell growth and cancer. TSGs may be inactivated by different mechanisms during 
carcinogenesis. In addition to genetic changes, epigenetic aberration plays an important role 
in inactivation of TSGs. Epigenetics is described as heritable changes in gene expression that 
do not involve a change in the DNA sequence (Berger et al., 2009). DNA methylation and 
histone modification are two predominant epigenetic changes. More recently, non-coding 
RNAs were regarded as new epigenetic regulation tools. The purpose of this chapter is to 
describe the effects of epigenetic modification on TSGs.  
2. Epigenetic changes during carcinogenesis  
Initially, cancer was thought to be driven by a series of genetic changes. Epigenetics is now 
recognized as more important player in the initiation and progression of cancers 
(Rodríguez-Paredes & Esteller, 2011). DNA methylation at the cytosine residue of the CpG 
dinucleotides is one of the best-studied epigenetic changes (Bird, 2002; M.M. Suzuki & Bird, 
2008). In normal cells, CpG loci are methylated scatteringly across the genome. By contrast, 
short CpG-rich DNA regions, called ‘CpG islands’, are normally unmethylated. These ‘CpG 
islands’ are preferentially located in the promoter region of about 60% of human genes. 
Global DNA hypomethylation was the first epigenetic alteration found in human cancer 
(Feinberg & Vogelstein, 1983). Hypomethylation may lead to deleterious consequences, 
including genome instability, activation of transposable elements, or loss of genomic 
imprinting (Esteller, 2008). However, promoter-specific hypermethylation was regarded as 
the major epigenetic change of cancer, which is associated with TSGs silencing (Herman & 
Baylin, 2003). 
Histone modification is another kind of epigenetic changes. Histones are subject to a wide 
range of post-transcriptional modifications in their N-terminal tails, including acetylation, 
methylation, phosphorylation, ubiquitination, SUMOylation and ADP-ribosylation 
(Kouzarides, 2007; Campos & Reinberg, 2009). It has been proposed that distinct histone 
modifications form different 'histone codes' (Strahl & Allis, 2000). Generally, histone 
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acetylation is associated with transcriptional activation, while the role of histone 
methylation in gene expression relies on the specific residue and methylation state. One of 
the common hallmarks of human cancer is global loss of monoacetylation of lysine (K) 16 
and trimethylation of lysine 20 on histone H4 (H4K16ac and H4K20me3) along with 
hypomethylation in repetitive DNA sequences (Fraga et al., 2005). Conversely, loss of 
acetylation of H3K9 and H4K16 (H3K9ac and H4K16ac) as well as trimethylation of H3K4 
(H3K4me3) and gain of trimethylation of H3K27 (H3K27me3) and dimethylation of H3K9 
(H3K9me2) occur at the promoters of TSGs and contribute to tumorigenesis by silencing of 
these critical genes (Figure 1) (Esteller, 2007a). In brief, aberrant ‘epigenomes’ marked by 
global DNA hypomethylation, promoter-specific hypermethylation, and abnormal histone 
modifications are main epigenetic changes in cancer. Since silencing of TSGs caused by CpG 
island hypermethylation and repressive histone modification is the common epigenetic 
event in human cancers, the following discussion will focus on the epigenetic silencing of 
TSGs during tumorigenesis.  
 
 
Fig. 1. Mechanisms of TSGs silencing by epigenetic changes during carcinogenesis.  
In normal cells, promoter region is unmethylated and possesses active histone modifications 
(e.g., H3K4me and acetylation of H3 and H4). Transcription of TSGs was activated. In cancer 
cells, the promoter region is densely methylated, active histone modifications were lost and 
inactive histone modifications were induced (e.g., hypoacetylation of histones H3 and H4, 
loss of H3K4me3, and gain of H3K9me and H3K27me3). MBDPs bind to methylated DNA. 
HDACs and HMTs were recruited. Transcription of TSGs was inactivated.  
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3. DNA methylation of TSGs  
3.1 DNA methyltransferase  
DNA methylation is catalyzed by DNA methyltransferases (DNMTs), which add methyl 
groups to the cytosine of CpG dinucleotides. Three main DNMTs have been identified. 
DNMT1 maintains the existing methylation patterns following DNA replication, whereas 
DNMT3A and DNMT3B are responsible for de novo methylation patterns (Bird, 2002; M.M. 
Suzuki & Bird, 2008). Overexpresion of DNMTs has been observed in cancers, which 
contributes to CpG island hypermethylation of TSGs and concomitant silencing of gene 
expression (Robert et al., 2002; Nosho et al., 2009). Although DNMTs have been classified as 
maintenance or de novo methyltransferases, all three DNMTs participate in both de novo and 
maintenance methylation, and cooperate to silence TSGs in human cancer (Rhee et al., 2000; 
G.D. Kim et al., 2002; Rhee et al., 2002). More recently, three independent groups revealed 
that somatic mutations in DNMT3A occur in acute myeloid leukemia (AML), and lead to 
some gene expression and methylation changes (Shah & Licht, 2011). The other DNMTs, 
including DNMT3L and DNMT2, were reported recently. DNMT3L appears to be required 
for the methylation of imprinted genes in germ cells, and interacts with DNMT3a and 3b in 
de novo methyltransferase activity (Chen et al., 2005). But the biological function of DNMT2 
remains unclear, its strong binding to DNA suggests that it may mark specific sequences in 
the genome (Dong et al., 2001).  
3.2 Hypermethylation of TSGs in cancer  
Promoter region hypermethylation is accepted as the mechanism of inactivation of TSGs in 
human cancers. The initial finding of CpG island hypermethylation of Rb in human cancer 
(Greger et al., 1989) was followed by the discovery of other TSGs undergoing methylation-
associated inactivation, such as VHL (von Hippel-Lindau tumor suppressor), p16INK4a 
(cyclin-dependent kinase inhibitor 2A [CDKN2A]), BRCA1 (breast-cancer susceptibility  
gene 1), and hMLH1 (mutL homolog-1) (Esteller, 2002, 2008). These methylated TSGs are 
distributed in all cellular pathways relevant to tumor development, such as cell cycle 
regulation, DNA repair, apoptosis, transcriptional regulation, carcinogen-metabolism and 
drug resistance, angiogenesis, metastasis and cell-adherence (Esteller, 2002, 2008). 
Hypermethylation of TSGs occurs at any time during carcinogenesis, especially in the early 
stages of the neoplastic process, which may facilitate cells to obtain further genetic lesions 
(Feinberg et al., 2006). One example is hypermethylation of DNA repair gene MGMT  
(O6-methylguanine-DNA methyltransferase) in the early phase of tumorigenesis, which 
results in the accumulation of genetic mutations that arise from the defects in DNA repair 
(Esteller et al., 2001a; Kuester et al., 2009). In addition, silencing of TSGs by promoter 
hypermethylation also let neoplastic cells addict to a particular oncogenic pathway, such as 
loss of SFRP (secreted frizzled-related proteins) expression in early stage of colon cancer 
activating the Wnt pathway (Baylin & Ohm, 2006). Furthermore, hypermethylation-induced 
silencing of transcription factors, such as GATA-4 and GATA-5 in colorectal and gastric 
cancers (Akiyama et al., 2003) as well as in esophageal cancer (Guo et al., 2006a), can also 
lead to inactivation of their downstream targets. Importantly, the increasing atypia observed 
at the histologic level is associated with the increasing number of methylated CpG islands at 
gene promoter regions. Our previous study suggested that the accumulation of DNA 
methylation was happened during esophagus carcinogenesis (Guo et al., 2006b).  
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The patterns of aberrant methylation of TSGs may represent different tumor types (Costello 
et al., 2000; Paz et al., 2003). Hypermethytion of GSTP1 (glutathione S-transferase-) was 
found in 80–90% of prostate cancers but hardly in other tumor types (Lee et al., 1994; Esteller 
et al., 1998; Cairns et al., 2001). Another finding indicated that CDX2 (caudal related 
homeobox gene) methylation is a feature of squamous esophageal cancer (Guo et al., 2007). 
Tumor-type specific hypermethylation occurs not only in sporadic tumor but also in 
inherited cancer syndromes (Esteller et al., 2001b), where hypermethylation serves as the 
second hit in the Knudson's two-hit model for TSG inactivation (Grady et al., 2000). But 
some TSGs, such as BRCA2, hMSH2, hMSH3, hMSH6, p19INK4d, CHK1, CHK2, MTAP and 
NKX3.1, are rarely methylated in caner (Esteller, 2007b). The mechanism of tumor-type 
specific methylation remains unclear. Several hypotheses have been proposed to explain this 
phenomenon: (1) in certain tumor type hypermethylation might occur at particular genes 
which confer a selective clonal advantage; (2) there are common sequence motifs in the 
hypermethylated promoters of TSGs (Esteller, 2007b); (3) selective DNA methylation can be 
directed by other chromatin players, such as Polycomb proteins, pinpointing ‘methylable’ 
islands (Schlesinger et al., 2006; Esteller, 2007b).  
3.3 Mechanisms of TSGs silencing by DNA methylation  
It was proposed as one of the mechanisms that DNA methylation may directly block the 
specific binding sites of transcription factors (Comb & Goodman, 1990; Deng et al., 2001). 
Another more acceptable mechanism is that methyl-CpG-binding proteins (MBDPs) 
recognize m5CpG sequences and silence transcription. There are five well-known MBDPs 
which were regarded as important “translators” between DNA methylation and 
transcriptional silencing, including MeCP2, MBD1, MBD2, MBD3 and MBD4 (Lopez-Serra & 
Esteller, 2008). MBDPs bind to methylated DNA, and then histone modification enzymes 
were recruited to establish silenced chromatin model (Nan et al., 1998; Fuks et al., 2003).  
4. Regulation of TSGs by histone modifications  
Hypermethylation of TSGs in human cancer was extensively studied. But limited researches 
were performed on the regulation of gene expression by histone modifications. One of the 
main reasons is lacking rapid and comprehensive methods to analyze the histone 
modifications (Esteller, 2007a; Taby & Issa, 2010). Importantly, the effective histone 
modifications were discovered during the past decade, especially histone acetylation and 
methylation on TSGs regulation.  
4.1 Histone acetylation 
Histone acetylation occurs mainly at lysine residues of the H3 and H4, and makes RNA 
polymerase and transcription factors easier to access the promoter region. Therefore, in 
general, the acetylation of histone lysines is associated with euchromatin and transcriptional 
activation of gene expression, whereas the deacetylated residues are associated with 
heterochromatin and transcriptional gene silencing. Histone acetyltransferases (HATs) and 
deacetylases (HDACs) are, respectively, responsible for the addition and removal of acetyl 
groups from lysine residues. The precise balance between HATs and HDACs determines the 
status of histone acetylation (Ellis et al., 2009; Taby & Issa, 2010). In cancer cells, disruption 
of the balance between HATs and HDACs contributes to transcriptional inactivation of 
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TSGs. The typical example of gene silencing by this mechanism is the inactivation of cyclin-
dependent kinase inhibitor p21WAF1 by hypoacetylation in the absence of CpG-island 
hypermethylation (Richon et al., 2000). Interestingly, some TSGs with CpG island 
hypermethylation, can also be re-expressed through inhibition of SIRT1 (a class III HDAC), 
which increases H4K16 and H3K9 acetylation at promoters without affecting the 
hypermethylation status (Pruitt et al., 2006). Furthermore, in addition to regulation of TSGs 
at transcriptional level, HATs/HDACs influence the activity of TSGs by post-translational 
modifications (Glozak et al., 2005). For example, p53 is subjected to extensive acetylation 
mediated by HATs such as Tip60 (Sykes et al., 2006) and p300 (Gu & Roeder, 1997) and can 
be deacetylated by HDACs like SIRT1 (Yi & Luo, 2010). The aberrant histone acetylation of 
TSGs during carcinogenesis may result from the alteration in HATs/HDACs. Inactivation of 
HAT activity through gene mutation (e.g., missense mutations of p300) or viral oncoproteins 
(e.g., the inactivation of p300 by E1A and SV40) has been reported in both hematological 
and solid tumors, whereas misdirection of HAT activities as a result of chromosomal 
translocations (e.g., mixed lineage leukemia protein [MLL]-CBP [MLL-CBP]) has been 
implicated in the onset and progression of acute leukemia (Ellis et al., 2009). On the other 
hand, overexpression of HDACs in solid tumors (Song et al., 2005) and aberrant recruitment 
them to specific promoters through interaction with proto-oncogenes in leukemias (Ellis et 
al., 2009) have also been reported.  
4.2 Histone methylation  
Similar to histone acetylation, histone methylation is dynamically regulated by the opposing 
activities of histone methyltransferases (HMTs) and histone demethylases (HDMTs), such as 
KDM1/LSD1 and the Jumonji domain-containing protein (JMJD) family. Methylation takes 
place on both lysine and arginine residues, and has different degrees, known as mono-, di-, 
and tri-methylation. In most instances, methylation at H3K9, H3K27 and H3K20 is 
associated with transcriptional repression, whereas methylation of H3K4, H3K36 and 
H3K79 is associated with transcriptional activation (Ellis et al., 2009; Taby & Issa, 2010). The 
shifting of balance between HMTs and HDMTs in cancer also causes the silencing of TSGs. 
For instance, the H3K27me3-specific HMT EZH2 (enhancer of zeste homolog 2), catalytic 
subunit of PRC2 (Polycomb-repressive complex 2), is overexpressed in a broad range of 
hematopoietic and solid tumors, including prostate, breast, colon, skin and lung cancer 
(Tsang & Cheng, 2011). Mechanistically, the overabundance of EZH2 in cancer leads to 
transcriptional silencing of TSGs, such as RUNX3 and DAB2IP through trimethylation of 
H3H27 (Fujii et al., 2008; Min et al., 2010). Conversely, the H3K27me3 repressive mark is 
demethylated by UTX/JMJD3 proteins, which belongs to JMJD family (Agger et al., 2007). 
Loss-of-function mutations of UTX in human cancers suggest UTX as a tumor suppressor 
gene (Van Haaften et al., 2009). This mutation could increase H3K27me3 level, and inactive 
Rb (Herz et al., 2010; J.K. Wang et al., 2010). The altered expression profiles of other histone 
methylation-modifying enzymes or abnormal targeting of these enzymes also contribute to 
inactivation of TSGs, such as downregulation of BRCA1 in breast cancer cells caused by 
overexpression of PLU-1 (a member of JMJD family responsible for demethylation of H3K4) 
(Yamane et al., 2007). Finally, it is worth to be mentioned that the histone methylation-
modifying enzymes also directly target non-histone proteins (Lan & Shi, 2009). Similar to the 
case of acetylation, p53 activity can be regulated by methylation or demethylation through 
HMTs or HDMTs (Huang et al., 2007, 2010).  
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5. Regulation of TSGs by interplay between DNA methylation and histone 
modifications 
In addition to the independent effect, DNA methylation and histone modifications may 
interact with each other to reorganize chromatin structure and gene expression (Cedar & 
Bergman, 2009; Murr, 2010). Promoter region hypermethylation of TSGs is associated with 
histone modifications in cancer cells (e.g., hypoacetylation of histone H3 and H4, loss of 
H3K4me3, and gain of H3K9me and H3K27me3) (Esteller, 2008) (Figure 1). These 
connections might be carried out by the direct interaction of DNA methylation machinery 
and histone modification enzymes (Cedar & Bergman, 2009). However, the question of 
which epigenetic change is the initial event still remains controversial. Emerging evidence 
indicates that histone modifications may induce DNA methylation. For example, H3K9me2 
may be necessary for DNA methylation in some TSGs, such as p16INK4a (Bachman et al., 
2003). In this model, H3K9me2 can serve as a binding site for heterochromatin protein 1 
(HP1), and thus generating a local heterochromatin by interacting with DNMTs and HDACs 
(Smallwood et al., 2007). On the other hand, DNA methylation machinery may recruit 
histone modification enzymes as well. The dynamic epigenetic silencing of GSTP1 in 
prostate cancers is one of the good examples. It was reported that CpG island methylation of 
GSTP1 played a critical role in deacetylation of H3K9 and concomitant methylation of H3K9 
(Stirzaker et al., 2004). The link of DNA methylation and histone modifications might be 
mediated by MBDPs, which could recruit the HDACs and HMTs to the promoter 
methylated target genes (Nan et al., 1998; Fuks et al., 2003; Stirzaker et al., 2004). 
Furthermore, DNMTs themselves are associated with histone modification enzymes, such as 
HDACs (Fuks et al., 2000), and G9a (Estève et al., 2006).  
6. Regulation of epigenetic modification machinery by TSGs  
The roles of epigenetic modifications in regulation of TSGs expression are widely 
accepted. As transcription factors, some TSGs may be involved in regulation of the 
epigenetic modification machinery. p53, one of the most well-documented TSGs, has been 
reported to regulate histone modification. HATs, such as p300/CBP and TRRAP, are 
recruited to target gene depended on binding of p53 to promoter, and thus induces gene 
expression (Barlev et al., 2001; Vrba et al., 2008). At the same time, p53 may cause 
repression of a subset target genes, such as MAP4, AFP and Nanog through recruiting 
SIN3A-HDAC (Murphy et al., 1999; Lin et al., 2004; Nguyen et al., 2005). More recently, 
Zeng et al showed that p53 recruit both HDAC and PcG to ARF locus to repress its 
expression by a negative feedback manner during normal cell growth (Zeng et al., 2011). 
Similar example was reported in RB protein. RB-mediated transcriptional repression was 
induced through the association with a variety of chromatin modification and remodeling 
enzymes, including DNMTs, HDACs, HMTs (Luo et al., 1998; Robertson et al., 2000; 
Kotake et al., 2007) and Brg1/Brm (Dunaief et al., 1994; Strober et al., 1996). The other 
examples, such as maspin was also known to direct epigenetic regulation. Maspin was 
regarded as an endogenous inhibitor of HDAC1 (Li et al., 2006). It is noticeable that the 
interaction of TSGs and histone modification enzymes may produce different outcomes. 
TSGs and histone modification enzymes may regulate each other, which may be 
determined upon different cellar states. 
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7. Non-coding RNAs enter epigenetic world  
Non-coding RNAs (ncRNAs) are functional RNA molecules that do not code for proteins. 
Based on size, they are divided into different classes: long ncRNAs (lncRNAs), Piwi-
interacting RNAs (piRNAs), small interfering RNAs (siRNAs), microRNAs (miRNAs), etc 
(Brosnan & Voinnet, 2009). NcRNAs can regulate gene expression through a diversity of 
mechanisms. Recently, a handful of studies have implicated ncRNAs in a variety of disease 
states, especially in cancer. Many ncRNAs, such as miRNAs and lncRNAs could play the 
similar roles as TSGs, and also function as oncogens that in turn regulate the expressions of 
TSGs in transcriptional and post-transcriptional level.  
7.1 Interplay between MiRNAs and epigenetic machinery  
MiRNAs are small ncRNAs with 19~22nt, which regulate gene expression via translational 
inhibition or mRNA degradation in a sequence-specific manner. MiRNAs could function as 
TSGs or oncogenes in cancer. In the last few years, increasing evidence has indicated that a 
substantial number of miRNA genes with tumor suppression functions are associated with 
CpG islands and silenced by epigenetic alterations in cancers. Indeed, miR-127 was found to 
be embedded in a CpG island region and epigenetically silenced by both promoter 
hypermethylation and histone modifications in cancer cells, and could be reactivated 
following treatment with combination of DNA demethylating agent and HDAC inhibitor 
(Saito et al., 2006). miR-9-1 was also found to be hypermethylated and consequently down-
regulated in breast cancer (Lehmann et al., 2008) as well as the hypermethylation of clustered 
miR-34b and miR-34c in colon cancer (Toyota et al., 2008). Intriguingly, miRNAs are not only 
epigenetically regulated but also act as chromatin modifiers to regulate the gene expression 
(Valeri et al., 2009). Fabbri et al reported the first evidence that miR-29s (miR-29a, -29b, -29c) 
directly target DNMT3a and DNMT3b (Fabbri et al., 2007). After miR-29s treatment, the 
epigenetically silenced TSGs like p15INK4b and ESR1 were re-expressed comparably to use of 
DNMT inhibitors (Fabbri et al., 2007; Garzon et al., 2009). Similarly, HMTs are also targets of 
miRNAs. Studies have shown that miR-101 exerts its tumor suppressive properties by 
targeting the EZH2 (Varambally et al., 2008; Friedman et al., 2009).  
7.2 LncRNA: A new player in epigenetics  
LncRNAs are emerging as new players in human cancers with potential roles in both 
oncogenic and tumor suppressive pathways, and the most fascinating thing is that they 
could play crucial roles in epigenetic modifications. Notably, evidence has suggested that 
lncRNAs can mediate epigenetic changes by recruiting chromatin remodeling complexes to 
specific genomic loci (Mercer et al., 2009). For example, ANRIL, a antisense to the 
INK4n/ARF/INK4a promoter, interacts with PRC1 component CBX7 to repress the 
transcription of INK4n/ARF/INK4a locus (Yap et al., 2010). On the other hand, lncRNAs 
could function as TSGs and modulate the epigenetic machinery by interaction with other 
proteins. In response to DNA damage, ncRNAs transcribed from the 5′ regulatory region of 
CCND1, binds to and activate TLS, which inhibits CBP/p300 histone acetyltransferase 
activities leading to repression of CCND1 transcription (X. Wang et al., 2008).  
8. Screening candidate TSGs by epigenetic strategies  
TSGs are generally silenced by CpG island hypermethylation and repressive histone 
modifications. So, epigenetic signatures may be applied to screen tumor suppressor. It is 
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important to isolate epigenetically silenced genes in cancer. To this end, many procedures 
were reported. For example, by comparation of genes expression level before and after 5-
aza-2’-deoxycytidine (5-aza-CdR) treatment, Suzuki et al isolated hypermethylation silenced 
genes SFRPs in colonic cancer cell lines and further analyzed their tumor suppressor 
function (H. Suzuki et al., 2002). Similarly, Gery et al employed microarray analysis to 
identify genes reactivated in lung cancer after combined treatment with 5-aza-CdR and 
SAHA. In this screen, Per1 was identified as a candidate tumor suppressor in lung cancer, 
and DNA hypermethylation and histone H3 acetylation are potential mechanisms for 
silencing Per1 (Gery et al., 2007). For the promoter CpG island hypermathylation detection, 
anti-mC immunological techniques, HPLC-TLC, HPCE, ERMA, bisulphite sequencing, MSP, 
MSP-ISH and DNA methylation mircroarray were employed (Laird, 2003). ChIP, ChIP 
coupled with microarray hybridization (ChIP-chip), ChIP coupled with next-generation 
DNA sequencing (ChIP-seq), mass spectrometry (Rasoulpour et al., 2011) were used to 
determine the regional or global repressive histone modifications (deacetylation of specific 
H3 and H4 lysine or methylation of H4K9/27 even the combination). 
9. Clinical application  
Understanding of how epigenetic alterations contribute to TSGs regulation would facilitate 
its transformation and clinical application. Based on the characters of stability, variability 
and reversibility, epigenetic modifications have potentials as both cancer biomarkers for 
detection, prognosis, and therapy prediction, and drug targets for cancer therapy (Mulero-
Navarro & Esteller, 2008).  
9.1 Epigenetic biomarkers  
As described previously, each tumor type may be represented by a different methylation 
pattern. Promoter region Hypermethylation usually occurred in the early stage of 
carcinogenesis. Therefore it is possible to detect early lesions by examination of TSGs 
methylation. Previous study has shown that HIN-1 (high in normal-1) methylation is an 
early event of human esophageal cancer (Guo et al., 2008). TSGs methylation can also be the 
predictors of tumor prognosis. For example, methylation of the promoter region of p16INK4a, 
CDH13 (H-cadherin gene), RASSF1A (Ras association domain family 1 gene) and APC 
(adenomatous polyposis coli gene) in patients with stage I NSCLC treated with surgery is 
associated with increased risk of early recurrence (Brock et al., 2008). In addition, DNA 
methylation may serve as chemotherapy predictor. The representative methylation markers to 
predict drug-responsiveness are MGMT (Esteller et al., 2000), hMLH1 (Plumb et al., 2000), 
WRN (the Werner syndrome–associated gene) (Agrelo et al., 2006), IGFBP-3 (insulin-like 
growth factor–binding protein-3) (Ibanez et al., 2010), or BRCA1 (Veeck et al., 2010) (Table 1).  
9.2 Epigenetic agents  
Unlike genetic mutations, epigenetic silenced TSGs can be awakened by drugs. Many 
epigenetic drugs have been discovered to rescue the functions of TSGs by reversing aberrant 
epigenetic changes. US Food and Drug Administration (FDA) have approved four 
epigenetic drugs for cancer therapy. Two DNMT inhibitors, 5-aza-CR (vidaza) and 5-aza-
CdR (decitabine), were used in the treatment of myelodysplastic syndromes and leukemia, 
while two HDAC inhibitors, vorinostat (suberoylanilide hydroxamic acid [SAHA]) and 
romidepsin (FK-228), were applied in cutaneous T cell lymphoma (Rodríguez-Paredes & 
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Esteller, 2011). These drugs can be administrated in combination or independent manner. 
Despite promising results, epigenetic related therapy still remains challenge. Similar with 
epigenetic changes in TSGs, ncRNAs pattern in cancer may serve as diagnosis, prognosis 
and chemosensitivity marker and therapeutic target.  
 
Hypermethylated 
TSGs Gene Function 
Representative 
Cancer Type Ref. 
Potential Clinical 
Application 
GSTP1 Conjugation to glutathione Prostate cancer 
(Lee et al., 
1994)
Detection 
GATA-4/-5 Transcription factor 
esophageal 
cancer 
(Guo et al., 
2006a) 
APC Wnt signaling 
Colorectal 
cancer; breast 
cancer 
(Mulero-
Navarro & 
Esteller, 
2008) 
CDX2 
Homeobox
transcription 
factor 
Squamous 
esophageal 
cancer 
(Guo et al., 
2007) 
p16INK4a 
Cyclin-
dependent 
kinase inhibitor
Colorectal 
cancer 
(Esteller et 
al., 2001c) 
Prognosis 
SFRP1 Antagonists of Wnt signaling Breast cancer 
(Veeck et 
al., 2006) 
DAPK Pro-apoptotic NSCLC (Tang et al., 2000) 
EMP3 myelin-related gene
glioma and 
neuroblastoma
(Alaminos 
et al., 2005)
CDH1 E cadherin, cell adhesion NSCLC 
(D. S. Kim 
et al., 2007) 
CDH13 H cadherin, cell adhesion NSCLC 
(D. S. Kim 
et al., 2007) 
MGMT 
DNA repair of 
06–alkyl-
guanine 
gliomas (Esteller et al., 2000) 
Chemosensitivity 
hMLH1 DNA mismatch repair 
Ovarian and 
colon cancer 
(Plumb et 
al., 2000) 
BRCA1 DNA repair, transcription Breast cancers 
(Veeck et 
al., 2010)
WRN DNA repair Colorectal cancer 
(Agrelo et 
al., 2006) 
IGFBP-3 Growth-factor-binding protein NSCLC 
(Ibanez et 
al., 2010 
CDH1 (E cadherin), EMP3 (epithelial membrane protein 3), DAPK (death-associated protein kinase). 
Table 1. Representative epigenetic markers in cancer. 
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10. Conclusion 
Aberrant epigenetic changes play important roles in human carcinogenesis. Major 
epigenetic changes include DNA methylation, aberrant histone modification and alterations 
of noncoding RNA patterns. The expression of TSGs was regulated by epigenetic 
modification. Epigenetic silencing of TSGs by promoter region hypermethylation in 
combination with repressive histone modifications was recognized as a common feature of 
various human cancers. Undoubtedly, understanding of the inactivation of TSGs is of 
fundamental importance in exploration of the pathogenesis and progression of cancer, and 
thus facilitating to yield attractive cancer biomarkers and therapeutic targets. The pivotal 
roles of ncRNAs in the development of cancer have refreshed the complicated epigenetic 
network, which provides a possibility on developing ncRNAs mediated diagnostics, 
prognostics and therapeutics. It is possible, in the near future, to find novel cancer-specific 
biomarkers and gene-specific drugs with low cytotoxicity.  
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1. Introduction 
Since its discovery three decades ago, p53 has been one of the most intensively and 
extensively studied tumor suppressor gene, which is accounted more than fifty eight 
thousand papers have been published to date. The p53 tumor suppressor protein was 
initially identified as a cellular protein that interacts with a viral oncoprotein, simian virus 
40 (SV40) large T antigen. The p53 cDNA isolated from tumor cells (i.e. mutant p53) 
exhibited oncogenic activity and was therefore initially recognized as an oncogene (Lane & 
Crawford, 1979). Nevertheless, the identification of wild-type p53 gene and subsequent 
functional studies in the late 1980’s revealed its real action as a tumor suppressor gene 
(Finlay at al., 1989).  
p53 tumor suppressor plays a critical role in the cellular response to genotoxic stress as a 
major defense against cancer, by maintaining genome integrity to prevent cells from 
inappropriate growth and division. Mutation of the p53 gene is known as the most common 
genetic changes in the development of human cancers. p53 regulates a wide variety of target 
genes responsible for different cellular outcomes related to its function as a tumor 
suppressor such as cell cycle arrest, apoptotic cell death, senescence, or DNA repair, 
depending on the cell type and cellular stress. Given the fact that apoptosis is an evolutionary 
conserved process through which the organisms remove abnormal cells, and thus represents a 
fundamental roadblock to tumorigenesis (reviewed in Ichwan 2008), it is not surprising that 
the role in apoptosis has been the focus for most of the scientists working on p53 in cancer 
treatment research. Loss of p53-dependent apoptosis caused by p53 mutation is believed to be 
a critical step for carcinogenesis in majority of human malignancies including Head and Neck 
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Squamous Cell Carcinoma (HNSCC). (Gleich, 2000; Vousden, 2000). Indeed, targeting the p53 
pathway of apoptosis to restore the function of p53 gene lost or functionally inactivated in 
cancer cells has been pursued in recent years.  
HNSCC is the most frequently occurring malignant tumor with poor prognosis resulting in 
major morbidity and mortality. HNSCC is the eighth most common cancer worldwide 
(Wang et al., 2009; Jemal et al. 2008) and it is increasing in incidence because it is often 
poorly understood by society in general and frequently ignored in its early stages. The main 
treatment of HNSCC is either radiotherapy or radical surgery depend on the location and 
the size of the tumor, which is often combined with adjuvant chemotherapy. However, 
those conventional therapies in particular radiotherapy and chemotherapy, are non-selective 
and can cause damage to normal tissue. Modification of the approaches have improved cure 
rate in only approximately half of the patients (Ichwan & Ikeda, 2008; Thomas & Grandis, 
2009). Recently, dramatic improvements in our knowledge of the molecular and genetic 
basis of HNSCC combined with advances in technology have resulted in novel molecular 
therapies for the disease by targeting of specific molecule in cancer therapy to selectively 
destroys cancer cells including targeting the function of p53 tumor suppressor. This chapter 
attempts to discuss the current state and challenges of the p53-mediated apoptosis pathway 
as a target in HNSCC therapy.  
2. p53: Its structure and role in apoptosis 
The structure and sequence of the p53 corresponds to key features of the protein and are 
well conserved in all vertebrates (Hainaut & Hollstein, 2000). The human p53 gene is located 
on the short arm of chromosome 17 at 17p13.1 (Isobe et al, 1986; McBride et al, 1986). The 
p53 protein consists of four functional domains: N-terminal transactivation domain, central 
core (DNA-binding domain, DBD), tetramerization domain and C-terminal regulatory 
domain (Fig. 1A). The DBD displays sequence-specific activity in binding to the consensus 
motif whereas C-terminal domain binds DNA nonspecifically (Melero et al, 2011). For its 
role as transcription factor, before they interact and recognizing by recognizing consensus 
sequences (DNA binding sites) of its target genes, p53 proteins need to form tetramers (Xu 
et al, 2011; Melero et al, 2011). Therefore, the protein is organized in two stably folded 
domains, the tetramerization and DNA-binding domains that are linked and flanked by 
intrinsically disordered segments (Melero et al, 2011) (Fig. 1B). In addition to p53, there are 
two other members in the unique protein family named p63 and p73 (Irwin & Kaelin, 2001). 
Structurally and functionally, all of these three proteins are related to each other. However, 
p53 seems to be evolving in the higher organisms to prevent tumorigenesis. Compared with 
the other genes in p53 family, p53 structure is the simplest among them. 
p53 acts as a transcription factor and mediates its effect by modulating the expression of its 
downstream target genes (El-Deiry, 1998; Ko & Prives, 1996). A number of p53-target genes 
have been identified and their function in the p53-pathway has been established. In the most 
recent genome- wide analyses, of the p53 binding suggest that hundreds of genes may be 
up- or down- regulated by p53 (Smeenk et al., 2008).  
In normal conditions, the amount of p53 protein in the cell is maintained at very low levels, 
which is tightly controlled by its important negative regulator which also an upstream 
target, MDM2 (also known as HDM2) (Vousden and Lu, 2002). MDM2 and p53 regulate 
each other through an autoregulatory feedback loop. The MDM2 activity is also modulated 
by its structural homologue partner protein called MDMX (also known as MDM4, HDM4, 
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or HDMX). MDM2 forms a heterodimers with MDM2 through C-terminal RING domain 
interactions (Brown et al, 2009). The MDM2-MDMX complex ubiquitinates p53 and thus 
targets it for proteasome-mediated degradation. MDM2 also inactivates p53 by both 
repressing its transcriptional activity (Wiman, 2010; Brown et al, 2009; Vousden & Lane, 
2007). Likewise MDM2, MDMX also binds directly to p53 and inhibits its transcriptional 
activity, however it does not induce p53 degradation. (Bottger 1999 in Shangary 2008). 
Besides MDM2 and MDM4 complex, ARF tumor suppressor also play a crucial role in 
preventing p53 from MDM2-induced degradation and stabilizing p53 by interacting with 
MDM2 (Brown et al, 2009) (Fig. 2).  
 
 
Fig. 1. Schematic representation of: A. Structure of human p53. Note the mutation hotspot is 
located at DBD. B. Organization of p53 as tetramers.  
Upon cellular stresses such as DNA damage, oncogene activation, hypoxia, oxidative stress, 
mitotic spindle damage and ribonucleotide depletion, p53 is activated, the ability of MDM2 
to interact with the p53 expression is diminished, resulting in the stabilization of p53 
protein. On the other hand, MDM2 is degraded by ARF, causing release of p53 from the 
p53-MDM2 complex in the nucleus (Sherr, 2006). 
The release of p53 from MDM2-mediated inhibition leads to the stabilization of p53 protein 
and the activation of its transcription activity, as a consequence of which p53 modulates the 
expression of its downstream target genes involved in cell cycle arrest, DNA repair, 
senescence, apoptosis, and inhibition of angiogenesis/metastasis as the final outcomes, 
Several general factors that influence this decision include p53 expression levels, the type of 
stress signal, the cell type and the cellular context at the time of exposure to stress (reviewed 
by Haupt et al., 2003; Balint &Vousden, 2001) (Fig. 2). Nevertheless, the exact criteria and the 
clear mechanism(s) leading to the choice between these final outcomes still need to be 
further elucidated.  
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Fig. 2. Cell cycle control by p53. The p53 expression is tightly regulated by MDM2 in a 
negative feed-back loop manner, whereas MDM2 expression is modulated by MDMX and 
negatively controlled by ARF. Cellular stresses and/or oncogene activation, disrupts the 
MDM2-p53 interaction resulting in the stabilization of p53 protein thus modulating the 
activation of its downstream genes involved in various cellular responses. 
p53 triggers apoptosis when cells suffer severe, irreparable damage, whereas it causes cell-
cycle arrest when the damage is mild, thereby enabling the cell to fix the damage (Haupt et al., 
2003). Depending on the strength of DNA damage, p53 preferentially modulate transcription 
of either pro-arrest or pro-apoptotic target genes. Upon severe DNA damage, p53 activates 
expression of multiple target genes whose products execute apoptosis, although evidence 
indicates that p53 also induces apoptosis in a transcription-independent manner(Gottlieb & 
Oren, 1998). p53 serves as a regulator of the apoptotic process that can modulate key control 
points in both the extrinsic (consists of cell surface receptors such as Fas, KILLER) and intrinsic 
pathways (centers on the mitochondria such as Bax, PUMA, Noxa, p53AIP1, PERP, PIDD) 
(Fridman & Lowe, 2003). Therefore, p53 apoptotic target genes are enlisted according to their 
functions in death receptor pathways, mitochondrial machinery and others that play distinct 
roles in p53-mediated apoptosis (Fridman & Lowe, 2003). 
Numerous studies have demonstrated that the stabilization and activation of p53 protein is 
not only regulated by its interactions with other proteins but also highly governed via 
complex networks of posttranslational modifications including phosphorylation, 
ubiquitylation, acetylation, sumoylation, neddylation, ADP-ribosylation, and cytoplasmic 
sequestration (Vogelstein et al., 2000). The N- and C-terminal regions of p53 is identified 
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where most of these modifications taken place (Bai and Zhu, 2006). Phosphorylation and 
acetylation have been thought as the major modifications enhancing the transcription 
activating ability of p53 because these modifications generally result in p53 stabilization and 
accumulation in the nucleus, where p53 interacts with sequence-specific sites of its target 
genes (Xu, 2003; Appella et al., 2001). p53 is phosphorylated on a number of serine residues 
in the N- and C-terminal domains (Bode & Dong, 2003). Phosphorylation of Ser46 following 
severe DNA-damage has been shown to be critical for inducing p53-mediated apoptosis 
(Oda et al., 2000). Severe, irreparable DNA damage induces phosphorylation at Ser46, and 
Ser46 phosphorylated p53 selectively transactivates pro-apoptotic genes, including p53AIP1 
that is critical for p53-mediated apoptotic induction. Ser46 phosphorylation would change the 
affinity of p53 to its target gene promoters, shifting from pro-arrest genes to pro-apoptotic 
genes (reviewed in Ichwan & Ikeda, 2008) (Fig. 3). The most recent study using analysis of 
genome-wide binding profiles of phosphorylated p53 has demonstrated that the extent of 
Ser46 phosphorylation of p53 bound to DNA is higher than Ser15 phosphorylation in cells 
directed towards apoptosis and the amount of chromatin-associated p53 phosphorylated at 
Ser46 is higher on certain apoptosis related target genes (Smeenk et al., 2011).  
 
 
Fig. 3. Phosphorylation of p53 at either Ser15 or Ser46 residue is selectively induced depend 
on the degree of genotoxic stress (Adopted with modification from Ichwan & Ikeda, 2008). 
p53 is also posttranslationally modified through acetylation at Lys370, Lys372, Lys373, 
Lys381, and Lys382 by p300/CBP and at Lys320 by PCAF (p300/CBP-associated factor). 
Acetylation augments p53 DNA binding, and to stimulate p53-mediated transactivation of 
its downstream target genes through the recruitment of coactivators (Ozaki & Nakagawara, 
2011). Additionally, acetylation has been suggested to regulate the stability of p53 by 
inhibiting its ubiquitylation by MDM2. In vivo, acetylation at Lys320, Lys373, and Lys382 is 
induced by many genotoxic agents such as UV-or Ionizing radiation, hypoxia, oxidative 
stress, and even depletion of ribonucleotide pools (Bai & Zhu, 2006). p53 can also be 
deacetylated by HDAC1 (Histone Deacetylase-1) and SIRT1 (Silent mating type information 
regulation 2 homolog 1). Intrinsic deacetylase activity of human SIRT1 attenuates p53-
dependent cell cycle arrest and apoptosis through down-regulation of the p21WAF1 and 
Bax (Brown et al., 2009). 
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3. Dysfunctions of p53-mediated apoptotic pathway in HNSCC  
Dysfunction of p53 by mutation and/or attenuated expression of the wild-type p53 by 
oncogenic proteins account in majority of tumor development have been well documented 
in HNSCC. Loss of heterozygosity 17p and mutations of the p53 have been detected in 
approximately half of all primary and most of recurrent cases of HNSCC (Nemunaitis et al., 
2009; Gasco & Crook, 2003; Osman et al., 2002; Taylor et al., 1999). Studies of HNSCC and 
cell lines suggested that after mutation of one TP53 allele, the remaining wild-type allele is 
deleted and accordingly the mutant phenotype expressed (Nylander et al., 2000 as cited in 
Yin et al., 1999). Mutations in p53 gene consist of high proportion of missense mutations, 
which lead to expression of mutated protein at high levels (reviewed in Goldstein et al., 2011 
and Nylander et al., 2000). More than ninety percent of the mutations are found in “hot 
spots’’ DBD (Fig 1), which highlighted several residues, such as R175, R282, R273 and the 
mostly occurred, R248. In HNSCC the main part is found within exons 5–8, but the pattern 
has been shown to vary between countries and races (Nylander et al., 2000). These 
mutations involved either in making direct contacts with DNA or support the structure of 
DNA binding surface. The examples of mutant proteins categorized as “contact“ are R248 
and R273, while “structural“ are R175 and R282 (Joerger & Ferscht, 2010). Structural 
mutants cause deformation that created internal cavities or surface crevices in the protein 
scaffold, thus inducing conformational changes in the DNA binding surface (Olivier et al., 
2009). Intriguingly, it has also been suggested that instead of the p53 loss-of-function, 
there are also ‘‘gain-of-function’’ mutants with oncogenic properties; they possess 
dominant negative activity due to their abilities to prevent wild-type p53 from binding to 
the promoter of its target genes through formation of a heterotetramer complex (Fig. 4) 
(Ichwan & Ikeda, 2008). Unfortunately, such mutants are usually has a prolonged half-life 
(Nylander 2000; Prives & Hall, 1999) and may neutralize the apoptotic activity of 
exogenous wild-type p53. Defect in Ser46 phosphorylation is also responsible for the 
acquisition of p53 resistance to p53 gene transfer on HNSCC (Ichwan et al., 2006). 
Furthermore, specific polymorphic forms at codon 72 ‘‘gain-of-function’’ p53 mutants 
which encode polymorphic alleles encode either proline (72P) or arginine (72R) have been 
shown to exhibit significant differences in the biochemical properties of the p53 protein 
(Murphy, 2006). In HNSCC cells, mutant p53 proteins with 72R are commonly found than 
72P (Marin et al., 2000; Brooks et al., 2000). The mutants that harbors 72R allele have also 
been shown to physically interact with a member of p53 family, p73 and repress its 
apoptotic activity in cancer cells (Marin et al., 2000).  
Accumulating evidences have shown that roughly half of all HNSCC cases still retain 
normal (wild-type) p53, supporting the idea that HNSCC is not characterized by a single 
molecular change. In this circumstance, the expression of the wild-type p53 may be 
inactivated by amplification or overexpression of oncogenic protein including MDM2, 
MDMX and HPV-E6 (Fig. 4).  
Amplified expression of either MDM2 and MDMX, in which both are known as p53 
inhibitors would severely degrade the protein, resulting in apoptotic blockade. Indeed, 
MDM2 is overexpressed in a variety of human cancers in HNSCC and has become a 
prognostic marker (Valentin-Vega et al., 2007; Huang et al., 2001; Ganly et al., 2000; 
Matsumura et al., 1996). The G-allele single nucleotide polymorphism at 309 of MDM2 
(MDM2 SNP309G) has been shown to be associated with significantly higher levels of the 
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MDM2 expression (reviewed in Vasquez et al., 2008). MDM2 overexpression also induces 
centrosome hyperamplification and chromosome in cultured HNSCC cells (Caroll et al., 
1999). The scenario may become worse when MDMX are excessively co-expressed as 
reported in a study in which majority of tumors with amplified MDM2 were also positive 
for MDMX (Valentin-Vega et al., 2007). Since MDMX potentiates MDM2, overexpression of 
MDMX may accelerate the p53 degradation and subsequently result in abrogation of p53-
mediated apoptotic pathway. 
 
 
Fig. 4. The pro-apoptotic function of p53 is abrogated in HNSCC by mutation and/or 
oncogenic proteins MDM2, MDMX, HPV-E6. 
HPV-E6 is an oncoprotein encoded by human papillomavirus (HPV), a double-stranded 
DNA virus that commonly associated with a diverse of human neoplasms such as warts 
(benign papilloma) as well as malignancy at cervical, vulvar, vaginal, anal, penile, and 
more recently HNSCC (Chung et al., 2009). More than 100 types of HPV have been 
identified but the most commonly detected HPV in HNSCC is HPV-16, which has been 
showed in 90–95% of all HPV positive HNSCC cases, followed by HPV-18, HPV-33, and 
HPV-33 (reviewed in Perez-Ordonez et al., 2006). The viral genome also encodes another 
two oncogenic proteins E5 and E7. However the key players involved in tumorigenesis 
are attributed to E6 and E7. The oncogenic potential of E6 and E7 are due to their ability to 
induce degradation of the tumor suppressors p53 and pRB respectively (Werness et al., 
1990; Dyson et al., 1989). The HPV-E6 binds to and targets p53 for inactivation and 
degradation by forming a complex with an E3 ubiquitin ligase, E6-associated protein 
(E6AP)(Chung et al., 2009). 
4. Restoration of p53-mediated apoptosis in HNSCC: The challenges and 
strategies to overcome 
Conventional treatment of HNSCC to destroy cancer cells by combination of radiotherapy 
and chemotherapy is often non-selective because it also destroys normal cells. Moreover, 
some cancer cells may acquire resistance to chemotherapy (i.e. doxorubicin, cisplatin, etc) 
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and radiation due to the expression some forms of mutant p53 that enhanced tumorigenic 
potential (Thomas & Grandis, 2009). For the past few years, several novel anticancer 
therapeutic strategies for restoration of the p53 pathway have been developed such as 
gene therapy, DNA vaccine, small-molecule inhibitors, antisense molecules, and tumor 
vaccines (Bayon et al., 2011). In particular, gene therapy, which represents the use of 
genetic material for therapeutic purposes, has been regarded as a promising therapeutic 
approach (Vattemi & Claudio, 2009). Several strategies have been developed for HNSCC 
gene therapy including targeting the function of p53 tumor suppressor gene. Indeed, 
HNSCC has become the focus of p53-targeted gene therapy and an ideal model for testing 
the efficacy of gene therapy strategies in a localized area with minimal systemic exposure 
to the agent (Thomas & Grandis, 2009). The replacement of the mutated gene with wild-
type p53 gene transfer (mostly using recombinant adenovirus Ad-p53) has been explored 
as a popular approach, either as a single anticancer agent or combined with other agents. 
Various studies have reported that wild-type p53 gene transfer efficiently induces 
apoptosis in most of cancer cells including HNSCC (reviewed in Ichwan & Ikeda, 2008). 
Clinically, this approach is usually carried out through local injection of recombinant Ad-
p53 into tumors. Several “brand names” of the recombinant adenoviruses have been 
introduced (Table 1). China became the first country to approve the use of Ad-p53 as a 
gene therapy agent (Gendicine) for HNSCC treatment. (Pearson at al., 2004). However, the 
clinical efficacy relies on the bystander effect in the tumor since not all cells will be 
injected (Brown et al., 2009), thus it may require multiple rounds of treatment. Moreover, 
some HNSCC cells are found to be resistant to Ad-p53 gene transfer (Ichwan et al., 2006). 
Although mechanisms underlying the p53 resistance have not been fully understood, it 
has been reported that certain dominant negative mutant p53 proteins expressed in p53-
resistant tumors may interfere the action of exogenous wild-type p53 and inhibition of the 
mutant p53 protein using mutant specific small interfering RNA (siRNA) simultaneously 
restored the p53-mediated apoptosis in p53-resistant HNSCC cells (Ichwan et al., 2006). 
Defect in phosphorylation of p53 protein at Ser46, which is critical for p53-mediated 
apoptosis, also plays a role for the acquisition of the resistance to p53 gene transfer in 
HNSCC cells and this resistance can be overcome by introducing p53S46D mutant that 
mimicks Ser46 phosphorylation (Ichwan et al., 2006). In regard to the potential use of 
recombinant adenoviruses in HNSCC treatment, specific oncolytic adenoviruses have 
been designed on the idea that the virus only replicate in cancer cells that lack p53 
function. Examples of these oncolytic viruses are ONYX-015, currently under Phase III 
development in the United States (Vattemi & Claudio, 2006) and H101 that have been 
commercially approved in China (Crompton & Kirn, 2007).  
Reactivating mutant p53 has been considered as an alternative strategy to treat HNSCC 
carrying mutated p53. Several small molecules have been discovered (Table 1) and all of 
them are still under early stage of preclinical trial. So far, the are only two reports 
regarding the utilization of these molecules to induce p53-dependent apoptosis on 
HNSCC cells. PRIMA-1 and CP-31398 work by protecting p53 mutants from unfolding 
(Roh et al., 2011). and induce the expression of p53-dependent pro-apoptotic mediators 
PUMA, Noxa, and Bax thus restoring p53-dependent transcription (Wang et al., 2007; Ho 
& Li, 2005). WR1065 has been proven as a radioprotector in a Phase III randomized trial 
(Brizel et al., 2002).  
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Table 1. Agents that targeting p53-mediated apoptosis. 
Different strategies are applied to restore p53-dependent apoptosis in the HNSCC cells 
that retain wild-type p53 but are not active because of the expression of negative 
regulatory proteins MDM2, MDMX and HPV-E6. Therefore, diminishing the expression of 
those p53 inhibitors would be the ultimate choice. To this end, siRNA and specific small 
molecule inhibitors have been shown to be feasible. Previous studies have shown that 
siRNA delivery into HPV-E6 positive cancer cells induces rapid apoptosis and restore p53 
response (Jiang & Milner 2002; Butz et al., 2003). On the other hand, introduction of 
siRNA did not induce apoptosis but markedly sensitized the different HPV-E6 expressing 
cells to the chemotherapy drugs (Koivusalo et al., 2005). siRNA treatment also seems 
effective to silence MDM2 and MDMX overexpression in some cancer cell lines (Lane et 
al., 2010; Brown et al., 2009; Zhang et al. 2005). Despite these promising achievements, the 
delivery of siRNA into the tumor of a patient is an important burden since siRNA is prone 
to degradation. To accomplish this, antisense oligonucleotide carried in an adenoviral 
vector could be used instead of siRNA; nonetheless, the clinical efficacy still needs to be 
confirmed. Recent advancements in research on the p53 pathway has been lead to the 
discovery of several non-genotoxic small compounds to activate the p53 response (Table 
1) that targeting p53-MDM2 complex. Nutlin3 is the first molecule known to mimic p53 
binding by interacting with the hydrophobic pocket of MDM2, discovered by a 
combination of high-throughput screening and computer modeling (Vassilev et al., 2004). 
 
Tumor Suppressor Genes 
 
138 
Subsequently, another MDM2 inhibitor MI-219 was discovered (Shangary et al., 2008). 
Both have been shown to disrupt p53-MDM2 interaction through binding to MDM2 
thereby reactivate p53-dependent apoptosis and are currently under Phase I clinical trial. 
RITA works by binding to p53 thus protecting it from interacting to MDM2 and was 
shown more effective in inducing apoptosis than the Nutlin3 (Issaeva et al., 2004). 
HL198C stabilize p53 by inhibiting MDM2 ubiquitin ligase activity (Atwal et al., 2007). 
Despite their early-stage (most are still in the preclinical trial) of development, the 
utilization of above-mentioned molecules may emerge as an attractive approach in the 
p53-based cancer therapy for HNSCC. 
5. Conclusion 
Dramatic advances in gaining knowledge of the p53 pathway have shift paradigms in 
cancer therapy. The ability of p53 tumor suppressor gene to induce apoptosis has been 
targeted as a novel therapeutic strategy for the patients with HNSCC in which aberrant 
function of p53 is a common event. Several molecular approaches including wild-type p53 
gene transfer and non-genotoxic molecules that capable to reactivate the p53-mediated 
apoptosis pathways in HNSCC have been established. Regardless a number of successful 
clinical trials, most of the attempts are still in preclinical stage and yet also facing a 
number of obstacles. Likewise other malignancies, HNSCC is caused by multiple genetic 
changes therefore p53 novel mechanisms for p53-induced apoptosis will remain 
challenging. Further intense efforts are still required to achieve a more efficient therapy of 
HNSCC in the future. 
6. Acknowledgment 
We thank Dr. Teng Ma from Section Molecular Craniofacial Embryology, Tokyo Medical 
and Dental University and Ms. Zafirah Liyana from Kulliyyah of Pharmacy International 
Islamic University Malaysia for providing literature retrieval. We also thank Ms. Wastuti 
Hidayati Suriyah from Kulliyyah of Pharmacy International Islamic University Malaysia for 
her kind technical assistance. This work was supported in part by the Research Endowment 
Fund, International Islamic University Malaysia, Grant No EDW-B 110210499 and EDW-B 
0905277. 
7. References 
Atwal, G. S., Bond, G. L., Metsuyanim, S., Papa, M., Friedman, E., Distelman-Menachem, T., 
Ben Asher, E., Lancet, D., Ross, D. A., Sninsky, J., White, T. J., Levine, A. J., & 
Yarden, R. (2007). Haplotype Structure and selection of The MDM2 Oncogene in 
Humans. Proceedings of National Academy of Sciences U.S.A., 104, pp 4524–4529, 
ISSN 0027-8424 
Bakalkin G, et al. (1995). p53 Binds Single-Stranded DNA Ends Through the C-Terminal 
Domain and Internal DNA Segments Via The Middle Domain. Nucleic Acids 
Research, 23, pp 362–369, ISSN 0305-1048 
Therapeutic Targeting of p53-Mediated Apoptosis Pathway  
in Head and Neck Squamous Cell Carcinomas: Current Progress and Challenges 
 
139 
Balint, E. E. & Vousden, K. H. (2001). Activation and Activities of the p53 Tumour 
Suppressor Protein. British Journal of Cancer, 85, pp 1813-1823, ISSN 0007-0920 
Bargonetti, J., Manfredi, J. J., Chen, X., Marshak, D. R. & Prives, C. (1993). A Proteolytic 
Fragment from the Central Region of p53 has Marked Sequence-Specific DNA-
Binding Activity when Generated from Wild Type but not from Oncogenic Mutant 
p53 Protein. Genes and Development, 7, pp 2565–2574, ISSN 0890-9369 
Bayon, R & Wenig, B. L. Targeted Molecular Therapy in Head and Neck Squamous Cell 
Carcinoma. Downloaded on March 29, 2011, 
http://emedicine.medscape.com/article/854971-overview 
Bode, A. M., & Dong, Z. (2004). Post-translational Modification of p53 in Tumorigenesis. 
Nature Reviews Cancer, 4, pp 793-805, ISSN 1474-175X 
Bottger, V., Bottger, A. & Garcia-Echeverria, C., et al. (1999). Comparative Study of the p53 – 
Mdm2 and p53-MDMX Interfaces. Oncogene, 18, pp 189–199, ISSN 0950-9232 
Brizel, D. M., Wasserman, T. H., Strnad, V., Rudat, V., Monnier, A., Eschwege, F., Zhang, J., 
Russell, L., Oster, W., & Sauer, R. (2000). Phase III randomized trial of amifostine as 
a radioprotector in head and neck cancer. Journal of Clinical Oncology, 18, pp 3339-
3345, ISSN 0732-183X 
Brooks, L. A., Tidy, J. A., Gusterson, B., Hiller, L., O'Nions, J., Gasco, M., Marin, M. C., 
Farrell, P. J., Kaelin, W. G. Jr., Crook, T. (2000). Preferential Retention of Codon 72 
Arginine p53 in Squamous Cell Carcinomas of The Vulva Occurs in Cancers 
Positive and Negative For Human Papillomavirus. Cancer Research, 15, pp 6875-
6877, ISSN 0008-5472 
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R. & Lane, D. P. (2009). Awakening Guardian 
Angels: Drugging the p53 Pathway. Nature Reviews Cancer, 9, pp 862-873, ISSN 
1474-175X 
Butz, K., Ristriani, T., Hengstermann, A., Denk, C., Scheffner, M., & Hoppe-Seyler, F. (2003). 
siRNA Targeting of The Viral E6 Oncogene Efficiently Kills Human 
Papillomavirus-Positive Cancer Cells. Oncogene, 22, pp 5938–5945, ISSN 0950-9232 
Carroll, P. E., Okuda, M., Horn, H. F., Biddinger, P., Stambrook, P. J., Gleich, L. L., Li, Y. Q., 
Tarapore, P. & Fukasawa, K. (1999). Centrosome Hyperamplifcation in Human 
Cancer: Chromosome Instability Induced by p53 Mutation and/or MDM2 
Overexpression. Oncogene ,18, pp 1935-1944, ISSN 0950-9232 
Christine, H., Chung & Gillison, M. L. (2009). Human Papillomavirus in Head and Neck 
Cancer: Its Role in Pathogenesis and Clinical Implications. Clinical Cancer Research, 
15, pp 6758-6762, ISSN 1078-0432 
Crompton, A. M. & Kirn, D. H. (2007). From ONYX-015 to Armed Vaccinia Viruses: the 
education and evolution of oncolytic virus development. Current Cancer Drug 
Targets, 7 pp 133-139, ISSN 1568-0096 
Dyson, N., Howley, P. M., Munger, K. & Harlow, E. (1989). The Human Papilloma Virus- 16 
E7 Oncoprotein is able to Bind to the Retinoblastoma Gene Product. Science, 243, pp 
934-937, ISSN 0036-8075 
El-Deiry, W. S. (1998). Regulation of p53 Downstream Genes. Seminars in Cancer Biology, 8, 
pp 345-357, ISSN 1044-579X 
Finlay, C. A., Hinds, P. W. & Levine, A. J. (1989). The p53 Proto-oncogene can Act as a 
Suppressor of Transformation. Cell, 57, pp 1083-1093, ISSN 0092-8674 
 
Tumor Suppressor Genes 
 
140 
Fridman, J. S., & Lowe, S. W. (2003). Control of Apoptosis by p53. Oncogene, 22, pp 9030-
9040, ISSN 0950-9232  
Ganly, I., Soutar, D. S., Brown, R. & Kaye, S. B. (2000). p53 Alterations in Recurrent 
Squamous Cell Cancer of the Head and Neck Refractory to Radiotherapy. British 
Journal of Cancer, 82, pp 392–398, ISSN 0007-0920 
Gasco, M. & Crook, T. (2003). The p53 Network in Head and Neck Cancer. Oral Oncology, 39, 
pp 222-231, ISSN 1368-8375 
Gleich, L. L. (2000). Gene Therapy For Head and Neck Cancer. Laryngoscope, 110, pp 708-726, 
ISSN 0023-852X 
Goldstein, I., Marcel, V., Olivier, M., Oren, M., Rotter, V. & Hainaut, P. (2011). Review: 
Understanding Wild- Type and Mutant p53 Activities in Human Cancer: New 
Landmarks on The Way to Targeted Therapies. Cancer Gene Therapy, 18, pp 2-11, 
ISSN 0929-1903 
Gottlieb, T. M. & Oren, M. (1998). p53 and Apoptosis. Seminars in Cancer Biology, 8, pp 359-
368, ISSN 1044-579X 
Hainaut, P., & Hollstein, M. (2000). p53 and Human Cancer: The First Ten Thousand 
Mutations. Advances in Cancer Research, 77, pp 81-137, ISSN 0065-230X 
Harwood, C. A., Yulug, I. G., Vousden, K. H., Allday, M. J., Gusterson, B., Ikawa, S., Hinds, 
P. W., Crook, T., & Kaelin, W. G. Jr. (2000). A Common Polymorphism Acts as an 
Intragenic Modifier of Mutant p53 Behaviour. Nature Genetics, 25, pp 47-54, ISSN 
1061-4036  
Haupt S., Berger, M., Goldberg, Z. & Haupt, Y. (2003). Apoptosis – The p53 Network. Journal 
of Cell Science, 116, pp 4077-4085, ISSN 0021-9533 
Ho, C. K., & Li, G. (2005). Mutant p53 Melanoma Cell Lines Respond Differently to CP-
31398-induced Apoptosis. British Journal of Dermatology, 153, pp 900-910, ISSN 0007-
0963 
Huang, J. S., Ho, T. J., Chiang, C. P., Kok, S. H., Kuo, Y. S. & Kuo, M. Y. (2001). MDM2 
Expression in Areca quid Chewing-Associated Oral Squamous Cell Carcinomas in 
Taiwan. Journal of Oral Pathology and Medicine, 30, pp 53-58, ISSN 0904-2512 
Ichwan, S. J. A. & Ikeda, M. A. (2008). Defect in Ser46 Phosphorylation of p53 Protein: A 
Resistance Mechanism against p53 Gene Transfer in Oral Squamous Cell 
Carcinoma Cells. Journal of Oral Biosciences, 50, pp 98-106, ISSN 1349-0079 
 Ichwan, S. J., Yamada, S., Sumrejkanchanakij, P., Ibrahim-Auerkari, E, Eto, K., & Ikeda, M. 
A. (2006). Defect in Serine 46 Phosphorylation of p53 Contributes to Acquisition of 
p53 Resistance in Oral Squamous Cell Carcinoma Cells. Oncogene, 25, pp 1216-1224, 
ISSN 0950-9232 
Irwin, M. S., & Kaelin W.G. (2001). p53 Family Update: p73 and p63 Develop Their Own 
Identities. Cell Growth and Differentiation, 12, pp 337-349, ISSN 1044-9523 
Irwin, M. S., & Kaelin W.G. (2001). p53 family update: p73 and p63 Develop Their Own 
Identities. Cell Growth and Differentiation, 12, pp 337-349. 
Isobe, M., Emanuel, B. S., Givol, D., Oren, M., & Croce, C. M. (1986). Localization of Gene 
for Human p53 Tumour Antigen to Band 17p13. Nature, 320 pp 84–85, ISSN 0028-
0836 
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. & Thun, M. J. (2008). Cancer 
Statistics. CA: A Cancer Journal for Clinicians, 58, pp 71–96, ISSN 0007-9235 
Therapeutic Targeting of p53-Mediated Apoptosis Pathway  
in Head and Neck Squamous Cell Carcinomas: Current Progress and Challenges 
 
141 
Jiang, M. & Milner, J. (2002). Selective Silencing of Viral Gene Expression in HPV-Positive 
Human Cervical Carcinoma Cells Treated With siRNA, a Primer of RNA 
Interference. Oncogene, 21, pp 6041–6048, ISSN 0950-9232 
Joerger, A. C., & Fersht, A. R. (2010). The Tumor Suppressor p53: From Structures to 
Drug Discovery. Cold Spring Harbor Perspective in Biology, 2, pp a000919, ISSN 
1943-0264 
Ko, L. J., Prives, C. (1996). p53: Puzzle and Paradigm. Genes and Development, 10, pp 1054-
1072, ISSN 0890-9369 
Koivusalo, R., Krausz, E., Helenius, H., & Hietanen, S. (2005). Chemotherapy compounds in 
cervical cancer cells primed by reconstitution of p53 function after short interfering 
RNA mediated degradation of human papillomavirus 18 E6 mRNA. Opposite 
Effect of siRNA in Combination With Different Drugs. Molecular Pharmacology, 68, 
pp 372–382, ISSN 0026-895X 
Lane, D. P. & Crawford, L. V. (1979). T-Antigen is Bound to a Host Protein in SV40-
Transformed Cells. Nature, 278, pp 261-263, ISSN 0028-0836 
Lane, D. P., Cheok, C. F., & Lain, S. (2010). p53-based Cancer Therapy. Cold Spring Harbor 
Perspectives in Biology, 2, pp a001222. 
Marin, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O'Nions, J., Tidy, J. A., James, N., 
McGregor, J. M., Harwood, C. A., Yulug, I. G., Vousden, K. H., Allday, M. J., 
Gusterson, B., Ikawa, S., Hinds, P. W., Crook, T., Kaelin, W. G. Jr. (2000). A 
Common Polymorphism Acts As an Intragenic Modifier of Mutant p53 Behaviour. 
Nature Genetics, 25, pp 47-54, ISSN 1061-4036 
Matsumura, T., Yoshihama, Y., Kimura, T., Shintani, S. & Alcade, R. E. (1996). p53 and 
MDM2 Expression in Oral Squamous Cell Carcinoma. Oncology, 53, pp 308–312, 
ISSN 0890-9091  
McBride, O. W., Merry, D., & Givol, D. (1986). The Gene for Human p53 Cellular Tumor 
Antigen is Located on Chromosome 17 Short Arm (17p13). Proceedings of National 
Academy of Sciences U.S.A., 83, pp 130–134, ISSN 0027-8424 
Melero, R., Rajagopalan, S., Lázaro, M., Joerger, A. C., Brandt, T., Veprintsev, D. T., Lasso, 
G., Gilc, D., Scheres S. H. W., Carazo, J. M., Fersht, A. R. & Valle, M. (2011). Electron 
Microscopy Studies on the Quaternary Structure of p53 Reveal Different Binding 
Modes for p53 Tetramers in Complex with DNA. Proceedings of National Academy of 
Sciences U.S.A., 108, pp 557–562, ISSN 0027-8424 
Murphy, M. E. (2006). Polymorphic Variants in The p53 Pathway. Cell Death and 
Differentiation, 13, pp 916-920, ISSN 1350-9047 
Nemunaitis, J., & Nemunaitisv J. (2011). Head and neck cancer: response to p53-based 
therapeutics. Head and Neck, 33, pp 131-134.  
Nemunaitis, J., Clayman, G., Agarwal, S. S. Hrushesky, W., Wells, J. R., Moore, C., Hamm, J., 
Yoo, G., Baselga, J., Murphy, B. A., Menander, K. A., Licato, L. L., Chada, S., 
Gibbons, R. D., Olivier, M., Hainaut, P., Roth, J. A., Sobol, R. E., & Goodwin, W. J. 
(2009). Squamous Cell Carcinoma of the Head and Neck Biomarkers Predict p53 
Gene Therapy Efficacy in Recurrent. Clinical Cancer Research, 15, pp 7719-7725, ISSN 
1078-0432 
 
Tumor Suppressor Genes 
 
142 
Nylander, K., Dabelsteen, E. & Hall, P. A. (2000). The p53 Molecule and Its Prognostic Role 
in Squamous Cell Carcinomas of The Head and Neck. Journal of Oral Pathology and 
Medicine, 29, pp 413–425, ISSN 0904-2512 
Oda, K., Arakawa, H., Tanaka, T., Matsuda, K., Tanikawa, C., Mori, T., Nishimori, H., 
Tamai, K., Tokino, T., Nakamura, Y., & Taya, Y. (2000). p53AIP1., a Potential 
Mediator of p53-Dependent Apoptosis., and its Regulation by Ser-46-
Phosphorylated p53. Cell, 102, pp 849-862, ISSN 0092-8674 
Olivier, M., Hollstein, M. & Hainaut, P. (2009). TP53 Mutations in Human Cancers: Origins, 
Consequences, and Clinical Use. Cold Spring Harbor Perspective in Biology, 2, pp 
a001008, ISSN 1943-0264 
Osman, I., Sherman, E., Singh, B., Venkatraman, E., Zelefsky, M., Bosl, G., Scher, H., Shah, J., 
Shaha, A., Kraus, D., Cordon-Cardo, C., Pfister, D.G. (2002). Alteration of p53 
Pathway in Squamous Cell Carcinoma of the Head and Neck: Impact of Treatment 
Outcome in Patients Treated with Larynx Preservation Intent. Journal of Clinical 
Oncology, 20, pp 2980–2987, ISSN 0732-183X 
Pearson, S., Jia, H., & Kandachi, K. (2004). China Approves First Gene Therapy. Nature 
Biotechnology, 22, pp 3 – 4, ISSN 1087-0156  
Perez-Ordonez, B., Beauchemin, M., & Jordan, R. C. K. (2006). Molecular Biology of 
Squamous Cell Carcinoma of the Head and Neck. Journal Clinical of Pathology, 59, 
pp 445–453, ISSN 0021-9746 
Prives, C. & Hall, P. A. (1999). The p53 Pathway. The Journal of Pathology, 187, pp 112–126, 
ISSN 1096-9896 
Roh J. L., Kang, S. K., Minn, I., Califano, J. A., Sidransky, D. & Koch, W. M. (2011). p53-
Reactivating small Molecules Induce Apoptosis and Enhance Chemotherapeutic 
Cytotoxicity in Head and Neck Squamous Cell Carcinoma. Oral Oncology, 47 pp 8-
15, ISSN 1368-8375  
Shangary, S. & Wang, S. (2008). Targeting the MDM2-p53 Interaction for Cancer Therapy. 
Clinical Cancer Research, 14, pp 5318–5324, ISSN 1078-0432  
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., 
Ding, K., Wang, G., Chen, J., Bernard, D., Zhang, J., Lu, Y., Gu, Q., Shah, R. B., 
Pienta, K. J., Ling, X., Kang, S., Guo, M., Sun, Y., Yang, D., & Wang, S. (2008). 
Temporal Activation of p53 By a Specific MDM2 Inhibitor is Selectively Toxic to 
Tumors and Leads to Complete Tumor Growth Inhibition. Proceedings of National 
Academy of Sciences U.S.A., 105, pp 3933–3938, ISSN 0027-8424 
Sherr, C. J. (2006). Divorcing ARF and p53: An Unsettled Case. Nature Reviews Cancer, 6, pp 
663-673, ISSN 1474-175X 
Smeenk, L., Heeringen, S. J., Koeppel, M., Gilbert, B. & Janssen-Megens, E., et al. (2011) Role 
of p53 Serine 46 in p53 Target Gene Regulation. PLoS ONE , 6, pp e17574, ISSN 
1932-6203 
Smeenk, L., van Heeringen, S. J., Koeppel, M., van Driel, M. A., Bartels, S. J. J., Akkers, R. C., 
Denissov, S., Stunnenberg, H. G., Lohrum, M. (2008). Characterization of Genome-
wide p53-binding sites Upon Stress Response. Nucleic Acids Research, 36, pp 3639–
3654, ISSN 0305-1048 
Therapeutic Targeting of p53-Mediated Apoptosis Pathway  
in Head and Neck Squamous Cell Carcinomas: Current Progress and Challenges 
 
143 
Smeenk, L., van Heeringen, S. J., Koeppel, M., van Driel, M. A., Bartels, S. J. J., Akkers, R. C., 
Denissov, S., Stunnenberg, H. G., & Lohrum, M. (2008). Characterization of 
Genome-Wide p53-Binding Sites Upon Stress Response. Nucleic Acids Research, 36, 
pp 3639–3654, ISSN 0305-1048 
Taylor, D., Koch, W. M., Zahurak, M., Shah, K., Sidransky, D. & Westra, W. H. (1999). 
Immunohistochemical Detection of the p53 Protein Accumulation in Head and 
Neck Cancer: Correlation with p53 Gene Alterations. Human Pathology, 30, pp 1221–
1225, ISSN 0046-8177 
Thomas, S. M. & Grandis, J. R. (2009). The Current State of Head and Neck Cancer Gene 
Therapy. Human Gene Therapy, 20, pp 1565–1575, ISSN 1043-0342  
Valentin-Vega, Y. A., Barboza, J. A., Chau, G. P., El-Naggar, A. K. & Lozano, G. (2007). High 
Levels of the p53 Inhibitor MDM4 in Head and Neck Squamous Carcinomas. 
Human Pathology, 38, pp 1553-1562, ISSN 0046-8177 
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., 
Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., & Liu, E. A. (2004). In Vivo 
Activation of The P53 Pathway by Small-Molecule Antagonists of MDM2. Science, 
303, 844–848, ISSN 0036-8075 
Vattemi, E., & Claudio, P. P. (2006). Adenoviral gene therapy in head and neck cancer. Drug 
News and Perspectives, 19, pp 329-337. ISSN: 0214-0934 
Vattemi, E., & Claudio, P. P. (2009). The Feasibility of Gene Therapy in The Treatment of 
Head and Neck Cancer. Head and Neck Oncology, 1, pp 3. ISSN: 1758-3284 
Vazquez, A., Bond E. E., Levine, A. J., & Bond, G. L. (2008). The Genetics of the p53 
Pathway, Apoptosis and Cancer Therapy. Nature Reviews Drug Discovery, 7, pp 979-
987, ISSN 1474-1776 
Vousden, K. H. & Lane, D. P. (2007). p53 in Health and Disease. Nature Reviews Molecular 
Cell Biology, 8, pp 275–283, ISSN 1471-0072 
Vousden, K. H. & Lu, X. (2002). Live or Let Die: The Cell’s Response to p53. Nature Reviews 
Cancer, 2, pp 594–604, ISSN 1474-175X 
Vousden, K. H. (2000). p53: Death Star. Cell, 103, pp 691-694, ISSN 0092-8674 
Wang, F., Arun, P., Friedman, J., Chen, Z. & Van Waes, C. (2009). Current and Potential 
Inflammation Targeted Therapies in Head and Neck Cancer. Current Opinion in 
Pharmacology, 9, pp 389–395, ISSN 1471-4892 
Wang, T., Lee, K., Rehman, A., & Daoud, S. S. (2007). PRIMA-1 Induces Apoptosis by 
Inhibiting JNK Signaling But Promoting the Activation of Bax. Biochemical and 
Biophysical Research Communications, 352, pp 203–212, ISSN 0006-291X 
Werness, B. A., Levine A. J. & Howley, P. M. (1990). Association of Human Papillomavirus 
Types 16 and 18 E6 Proteins with p53. Science, 248, pp 76-79, ISSN 0036-8075 
Wiman, K. G. (2010). Pharmacological Reactivation of Mutant p53: From Protein Structure to 
the Cancer Patient. Oncogene, 29, pp 4245–4252, ISSN 0950-9232 
Xu, J., Reumers, J., Couceiro, J. R., Smet, F. D., Gallardo R., Rudyak, S., Cornelis, A., 
Rozenski, J., Zwolinska, A., Marine, J. C., Lambrechts, D., Suh, Y. A., Rousseau, F. 
& Schymkowitz, J. (2011). Gain of Function of Mutant p53 by Coaggregation with 
Multiple Tumor Suppressors. Nature Chemical Biology, 7, pp 285–295, ISSN 1552-
4450 
 
Tumor Suppressor Genes 
 
144 
Yin, X. Y., Smith, M. L., Whiteside, T. L., Johnson, J. T., Heberman, R. B. & Locker, J. (1993). 
Abnormalities in the p53 Gene in Tumors and Cell Lines of Human Squamous Cell 
Carcinomas of the Head and Neck. International Journal of Cancer, 54, pp 322–327, 
ISSN 0020-7136 
Zhang, R., Wang, H., & Agrawal, S. (2005). Novel Antisense Anti-MDM2 Mixed-Backbone 
Oligonucleotides: Proof of Principle, In Vitro and In Vivo Activities, and 
Mechanisms. Current Cancer Drug Targets, 5, pp 43–49, ISSN 1568-0096 
7 
Signaling Mechanisms of Transforming  
Growth Factor-β (TGF-β) in Cancer: 
TGF-β Induces Apoptosis in Lung Cells  
by a Smad-Dependent Mechanism 
Mi Jung Lim, Tiffany Lin and Sonia B. Jakowlew 
National Cancer Institute, Cancer Training Branch, 
Bethesda, Maryland,  
USA 
1. Introduction 
1.1 TGF-β ligands, receptors and smads 
Transforming Growth Factor-beta (TGF-β), a cytokine that is expressed in a variety of 
normal tissues, including the lung (Bartram & Spear, 2004; Jakowlew et al., 1995, 1998; 
Kang et al., 2000; Montuenga et al., 1998), exerts diverse effects on a wide variety of 
cellular processes, including proliferation, differentiation, and apoptosis (Elliot & Blobe, 
2005; Massagué, 1998). More than sixty different TGF-β family members have been 
identified in various oraganisms, with at least 29 of these proteins being encoded in 
humans. Among the many proteins in the TGF-β superfamily are four TGF-β ligands, five 
activins, eight bone morphogenetic proteins (BMP), and 15 growth and differentiation 
factors (GDF). Three TGF-β isoforms have been identified in humans, including TGF-β1, 
TGF-β2, and TGF-β3, with each being a homodimeric polypeptide with a molecular 
weight of 25-kDa. All three TGF-β isoforms are initially synthesized as 55-kDa pro-
proteins that consist of an amino-terminal pro-region and a carboxy-terminal mature 
region (Gentry et al., 1988). The pro-region facilitates necessary dimerization of the pro-
proteins for future activity. TGF-β is secreted in a latent, inactive form in which the 12.5-
kDa carboxyl-terminal 112 amino acid-long mature form is non-covalently associated with 
the 80-kDa Latency-Associated Peptide (LAP) amino-terminal remainder (Barcellos-Hoff, 
1996; Barcellos-Hoff & Ewan, 2000). The LAP forms a complex with the 12.5-kDa TGF-β to 
keep it inactive (Arndjelovic et al., 2003; Stander et al., 1999). This complex is referred to 
as the small latent TGF-β complex. The small latent TGF-β complex may associate with 
members of the latent TGF-β-binding protein (LTBP) family to form the large latent TGF-β 
complex (Öklü & Hesketh, 2000). The liberation of TGF-β from the latent complexes is 
referred to as activation (Annes et al., 2003). The precise steps that are involved in 
liberation of the bioactive dimer are not completely understood, but may involve cleavage 
of the LTBP or LAP or both (Hyytiäinen et al., 2004).  
Active TGF-β exerts its effects with specific high affinity receptors. In mammals, five TGF-β 
superfamily type I receptors and seven type II receptors have been identified (Derynck et al., 
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2001; Massagué, 2000). The TGF-β type I and type II receptors are structurally related 
transmembrane glycoproteins that consist of an extracellular N-terminal ligand-binding 
domain with more than ten cysteine residues that regulate the dimeric structure, a 
transmembrane region, and a C-terminal serine/threonine kinase domain. The type I 
receptors, but not type II receptors, have a highly conserved region that is rich in glycine 
and serine residues, referred to as the GS domain, in the juxtamembrane domain next to the 
N-terminus of the kinase domain. The GS domain is a target for the type II receptor kinase, 
and upon its phosphorylation on specific serine and threonine residues, the type I receptor 
becomes activated (Heldin et al., 1997; Massagué, 2000). Being downstream of the type II 
receptor, the type I receptor plays an important role in determining the specifity of 
intracellular signals. The type I and II receptors exist as homodimers at the cell surface in the 
absence of ligands, but have an inherent heteromeric affinity for each other. Only select 
combinations of type I and II receptors act as ligand-binding signaling complexes. The 
molecular basis of the selectivity of the type I-type II receptor interactions remains poorly 
understood, but the structural complement at the interface may help define the selectivity of 
the receptor combinations. Most of the TGF-β ligands bind with high affinity to the type I 
receptor, also known as activin receptor-like kinase (ALK), or to the type II receptor, while 
others bind efficiently only to heteromeric receptor combinations.  
The intracellular signal transduction triggered by the kinase activity of TGF-β involves the 
phosphorylation of Smad family proteins and in turn, complex changes in the 
transcriptional regulation of various response genes. The Smad family proteins include 
Smad 1, 2, 3, 4, 5, 7, and 8. The Smads are divided into three subclasses depending on their 
structure and function: the receptor-regulated Smads (R-Smads), common-mediator Smad 
(Co-Smad), and inhibitory Smads (I-Smads). In general, the R-Smads, Smads 2 and 3, 
function downstream of the TGF-β ligands, while Smads 1, 5, and 8 are downstream of 
members of the BMP and GDF subfamilies of ligands. Smads 1, 2, 3, 5, and 8 are direct 
substrates for the TGF-β type I receptor kinase, whereas Co-Smad, Smad 4, participates in 
Smad complex formation. Smads 6 and 7, the I-Smads, interfere with TGF-β-induced Smad-
dependent signal transduction (Park, 2005; Whitman, 1997). Activation of cell surface 
receptors by ligands leads to phosphorylation of the R-Smads at two serine residues in a 
SSXS motif at their extreme C-termini. This phosphorylation allows the R-Smads to form 
both homomeric and heteromeric complexes with Smad4 that accumulate in the nucleus. 
There, they are directly involved in transcriptional regulation of target genes in cooperation 
with other transcription factors. 
Signaling by TGF-β is mediated by a ligand-induced heteromeric complex of two types of 
transmembrane serine/threonine kinase receptors designated as TGF-β type I receptor 
(TGF-β RI) and type II receptor (TGF-β RII). Initial ligand binding to constitutively active 
TGF-β RII is followed by recruitment of TGF-β RI into the heteromeric complex. Subsequent 
phosphorylation of TGF-β RI at its GS-domain and activation is mediated by TGF-β RII and 
leads to activation of TGF-β RI. Upon this activating phosphorylation, TGF-β RI 
phosphorylates the receptor-activated Smad proteins (R-Smads), Smad2 and Smad3, which 
form a heteromeric complex with the co-Smad, Smad4, and enter the nucleus. In the 
nucleus, the Smad complex associates with other transcription factors for transcriptional 
activation of specific target genes (Massagué and Wotton, 2000; ten Dijke et al., 2000; Wrana 
and Attisano, 2000). 
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1.2 Tumor suppressor activity of TGF-β 
TGF-β was originally called one of the most potent polypeptide growth inhibitors isolated 
from natural sources (Moses et al., 1985; Tucker et al., 1984). When it was demonstrated that 
TGF-β could act as an autocrine negative growth regulator in the several different epithelial 
cell lines, it was hypothesized that TGF-β may act as an inhibitor of tumor progression, a 
tumor suppressor (Artega et al., 1990; Glick et al., 1989). The identification and 
characterization of the intermediates in the TGF-β signaling pathway, comprised of the 
genes and proteins for the TGF-β receptors and Smads, has increased our understanding of 
the role of TGF-β as a tumor suppressor. The involvement of the TGF-β signaling pathway 
in tumor suppression is shown by mutations in the genes that encode the TGF-β receptors 
and Smad proteins in human tumors. 
The gene for TGF-β RII is frequently mutated in colon carcinoma cells from patients with 
hereditary non-polyposis colorectal cancer that also show microsatellite instability, as well 
as in gastric cancers and gliomas (Chung et al., 1996; Izumoto et al., 1997; Markowitz et al., 
1995). A specific region of adenine nucleotides in the coding region of TGF-β RII is prone to 
mutation in these patients from germline defects in their capacity for DNA mismatch repair. 
The nucleotide deletions or additions result in a shortened version of TGF-β RII that cannot 
participate in signaling transduction (Lu et al., 1996). However, the TGF-β RII gene is not 
mutated in other types of carcinoma with microsatellite instability, including breast, liver, 
pancreatic, and endometrial carcinoma (Abe et al., 1996; Kawate et al., 1999; Vincent et al., 
1996), while, a somatic frameshift mutation in the polyadenine tract of the TGF-β RII gene 
does occur in some endometrial cancer patients (Parekh et al., 2002). Missense and 
inactivating mutations in TGF-β RII have also been detected in colon cancers that do not 
exhibit microsatellite instability (Grady et al., 1999). Expression of TGF-β RII can be 
decreased in some cases of carcinoma, including head and neck squamous carcinoma, breast 
carcinoma, and laryngeal carcinoma (Eisma et al., 1996; Franchi et al., 2001; Gobbi et al., 
1999). Re-expression of TGF-β RII in carcinoma cells that have either lost expression of TGF-
β RII or show reduced TGF-β RII expression can inhibit the ability to become malignant.  
Although less common than in TGF-β RII, mutations in TGF-β RI also occur in patients with 
a variety of cancers, including ovarian cancers, metastatic breast cancers, T-cell lymphomas, 
and head and neck cancer metastases (Chen et al., 1998, 2001; Goggins, 1998; Schiemann et 
al., 1999). Patients with ovarian cancer show a high frequency of mutations of TGF-β RI 
(Chen et al., 2001), while expression of TGF-β RI is transcriptionally repressed by DNA 
methylation in cells from patients with gastric cancer (Kang et al., 1999). Over-expression of 
TGF-β RI in colon carcinoma cells with low levels of TGF-β RI also inhibits tumor 
progression as with TGF-β RII (Wang et al., 1996). Mutations in TGF-β RI do not appear to 
be associated with TGF-β RII mutations; such mutations suggest that these TGF-β receptors 
may function as tumor suppressors. 
Decreased TGF-β receptor expression or availability of TGF-β receptors at the cell surface 
may allow tumor cells to escape the growth inhibitory function of TGF-β (Kim et al., 2000). 
Expression of the TGF-β receptors in tumor cells may also be reduced by altered levels or 
activities of transcription factors that are required for expression of TGF-β RII, such as the 
Ets transcription factor. Hypermethylation of CpG islands in the promoters of TGF-β RI and 
TGF-β RII or mutations in the TGF-β RII promoter that interfere with transcription factor 
binding may also result in transcriptional silencing (Amoroso, et al., 1998). Decreased TGF-β 
RII function results in resistance to the growth inhibitory activity of TGF-β, but other TGF-β 
responses may not be affected in a similar fashion because they may require different levels 
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of signaling (Chen et al., 1993; Fafeur et al., 1993). The tumor suppressor role of TGF-β RII 
has been demonstrated by expressing wildtype TGF-β RII in cancer cells that lack a 
functional TGF-β RII allele (Sun et al., 1994; Wang et al., 1995) or by over-expressing TGF-β 
RII in vitro (Turco et al., 1999). Enhanced expression of TGF-β RII seems to confer growth 
inhibition, to suppress anchorage independent growth, and to significantly reduce tumor 
formation in experimental mice compared with parental cells. Over-expression of TGF-β RI 
or TGF-β RII in transgenic mice also shows enhanced tumor suppressor activity (Cui et al., 
1996; Minn et al., 2005), while expression of dominant-negative forms of TGF-β RII increases 
tumor formation (Böttinger et al., 1997; Go et al., 1999).  
Some of the genes for Smad proteins that function as mediators of TGF-β signal 
transduction also have mutations and deletions that occur in human carcinomas. Mutations 
in the genes encoding Smad2 and Smad3 are relatively rare and seem to occur only in a 
limited number of lung and colon carcinomas for Smad2 (Riggens et al., 1996; Uchida et al., 
1996), and gastric cancer for Smad3 (Han et al., 2004). In contrast, mutational inactivation of 
Smad4 (DPC4) is prominent in pancreatic carcer (Hahn et al., 1996). Mutations of Smad4 can 
be detected in human colorectal cancer, especially in those patients with late stage, 
metastatic disease (Maitra et al., 2000). This suggests that Smad4 may play a central role in 
TGF-β-mediated tumor suppression. Inactivation of the genes encoding Smad2 and Smad4 
occurs by several means, including deletion of entire chromosome segments, small 
deletions, and frameshift, nonsense, or missense mutations (Massagué & Wotton, 2000; 
Massagué et al., 2000). Mutations in Smad4 are detected principally in pancreatic 
carcinomas, and in colon carcinomas, and in other types of carcinomas, although with less 
frequency. Inactivation of both alleles of Smad4 and haploinsufficiency of the Smad4 locus 
may contribute to the progression of pancreatic and gastric cancers (Luttges et al., 2000; Xu 
et al., 2000). The existence of Smad4 mutations in several juvenile polyposis families further 
supports the suggestion that Smad4 is a tumor suppressor (Howe, 1998). Inactivating 
mutations in Smad4 are also observed in conjunction with mutations in TGF-β RI and TGF-β 
RII (Grady et al., 1999). This suggests that Smad4 also has tumor suppressor activities that 
are not related to TGF-β signaling. Alterations of Smad signaling, and of phosphorylation of 
Smad2 in particular, are associated with poor prognosis in human breast carcinomas, colon 
carcinomas, and head and neck squamous cell carcinomas (Xie et al., 2002, 2003a, 2000b). 
Loss of Smad3 expression in gastric cancer tissues and cell lines increases susceptibility to 
tumorigenesis (Han et al., 2004). Introduction of Smad3 into human gastric cancer cells that 
do not express Smad3 restores responsiveness to TGF-β. In addition, loss of Smad4 
expression and/or activity may increase the Ras signaling pathway to result in tumor 
progression (Iglesias et al., 2004). A protein-based strategy has been used to rapidly identify 
the most common alterations in the TGF-β signaling pathway by combining measurements 
of the levels and the state of activation of Smad signaling intermediates with DNA-based 
diagnostic assays (Yan et al., 2000). A mechanism for TGF-β resistance has been identified in 
TGF-β refractory squamous cell carcinoma cell lines using this protein-based strategy. 
1.3 TGF-β and apoptosis 
Another mechanism by which the tumor suppressor activity of TGF-β is mediated is 
through the process of programmed cell death or apoptosis. Unlike the molecular 
mechanisms by which TGF-β participates in cell proliferation and differentiation that have 
been well described, the mechanisms by which TGF-β exerts its apoptotic effects are only 
poorly understood in comparison. TGF-β-dependent apoptosis is important in the 
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elimination of damaged or abnormal cells from many normal tissues (Schuster and 
Krieglstein, 2002). For example, TGF-β is implicated to play a role in controlling liver size, 
and intravenous injection of TGF-β induces apoptosis in normal and regressing liver 
(Schulte-Hermann et al., 1993). Hepatic over-expression of TGF-β in transgenic mice causes 
apoptosis, as does treatment of primary hepatocytes with TGF-β. The apoptotic fate of cells 
after they are treated with TGF-β1 is often determined by cellular context and experimental 
conditions. For example, TGF-β acts as a death stimulus inducing apoptotic death in fetal 
hepatocytes and podocytes (Herrera et al., 2001; Schiffer et al., 2001), whereas it elicits pro-
survival activity to protect macrophages against apoptosis (Chin et al., 1999; Schlapbach et 
al., 2000). A regulated balance of cell division and apoptosis is required for normal 
morphogenesis, and alterations in these processes can lead to neoplastic transformation. Cell 
cycle progression and the onset of apoptosis have been connected in DNA-damaged cells 
through the analysis of the activation of the apoptotic cascade in p21Cip1-deficient HCT116 
colorectal cancer cells (Le et al., 2005; Pardali et al., 2005). DNA damage induces a similar 
level of p53 activation and proapoptotic Bcl-2 family member PUMA induction in p21Cip1-
deficient cells compared to wildtype isogenic counterparts. However, only p21Cip1-deficient 
cells show extensive cytochrome C release, mitochondrial membrane depolarization, and 
caspase activation. When ectopically expressed in p21Cip1-deficient cells, p21Cip1, p27Kip1, and 
p16Ink4a are all similarly effective at causing cell cycle arrest and inhibiting DNA damage-
induced apoptotic events. Application of TGF-β stimulates apoptosis in various epithelial 
cells. Preliminary findings show that TGF-β induces apoptosis through the regulation of the 
expression of various pro- and anti-apoptotic molecules, including p53, Bad, Bax, Bik, Bcl-2, 
and Bcl-XL (Motyl et al., 1998; Saltzman et al., 1998; Sanchez-Capelo, 2005; Teramoto et al., 
1998). TGF-β-induced apoptosis can also be mediated by caspases (Brown et al., 1998; Chen 
and Chang, 1997; Choi et al., 1998; Saltzman et al., 1998). The mitochondrial septin-like 
protein, Apoptosis-Related Protein in the TGF-β Signaling Pathway (ARTS), enhances cell 
death induced by TGF-β through activation of caspase 3 (Larisch et al., 2000). In addition, 
TGF-β-induced apoptosis is associated with the generation of reactive oxygen species 
(Albright et al., 2003). Antioxidants can block the TGF-β-induced apoptotic process. 
Resistance to apoptosis is one of the characteristics of cancer cells during progressive 
tumorigenesis. Apoptosis of human prostate cancer cells that is induced by TGF-β or over-
expression of Smad7 is caused by a specific activation of the p38 MAP kinase pathway that 
may occur in a TGF-β-activated kinase 1 (TAK1) and mitogen-activated protein kinase 
kinase 3 (MKK3)-dependent manner (Edlund et al., 2003). Members of the Mixed Lineage 
Kinase 3 (MLK3) family also mediate TGF-β-induced apoptosis in hepatoma cells (Kim et 
al., 2004). There is also strong evidence that the stress- and cytokine-inducible Growth 
Arrest and DNA Damage (GADD) inducible gene 45 protein (Mita et al., 2002; Takekawa & 
Saito, 1998; Takekawa et al., 2002; Yoo et al., 2003) and GADD153 protein (Park et al., 1992), 
also known as CCAAT/enhancer-binding Homologous Protein (CHOP) (Ron & Habener, 
1992), CCAAT/Enhancer-Binding Protein-zeta (C/EBP-ζ) (Hanson, 1998), and DNA 
Damage Inducible Transcript-3 (DDIT3) (Fornace et al., 1989), function in the p38 Mitogen-
Activated Protein Kinase (MAPK) pathway and induce apoptosis (Corazarri et al., 2003). It 
has also been shown that Smad-dependent expression of GADD45b is responsible for the 
delayed activation of p38 MAP kinase by TGF-β1 in pancreatic carcinoma cells (Takekawa et 
al., 2002). Activation of GADD45b by the TGF-β receptor/Smad signaling pathway also 
mediates the induction of proteoglycan biglycan expression by TGF-β, also with the 
involvement of mitogen activated protein kinase kinase 6 (MKK6) and p38 MAP kinase 
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(Mita et al., 2005). The p38 MAP kinase and p160/Rho/ROCK pathways have a role in TGF-
β-mediated Smad-dependent growth inhibition of breast cancer cells (Kamaraju & Roberts, 
2005). Smad3 contributes in a non-redundant manner to the induction of apoptosis in the 
mammary gland, but is dispensible for TGF-β effects on proliferation and differentiation in 
this tissue. TGF-β-induced p160/Rho/ROCK activation is also involved in the inhibition of 
Cdc25A, with resulting cell cycle arrest. TGF-β also regulates radiation-induced apoptosis 
and this is reduced in TGF-β1 null mice along with decreased p53 phosphorylation. TGF-β 
regulates biglycan gene expression through p38 MAP kinase signaling downstream of the 
Smads that also requires the small GTPase Rac1 (Groth et al., 2005). However, TGF-β-
Receptor activated p38 MAP kinase also mediates Smad-independent responses in breast 
cancer cells (Yu et al., 2002). Non-Smad signal transducers that are under the control of TGF-
β provide quantitative regulation of the signaling pathway, and serve as nodes for cross-talk 
with other signaling pathways, such as Notch, tyrosine kinase, G-protein-coupled receptor 
kinases, and cytokine receptors (Moustakas & Heldin, 2005). One of the characteristics of 
cancer cells during progressive tumorigenesis is resistance to apoptosis (Hanahan & 
Weinberg, 2000). Increasing the sensitivity of tumor cells to anticancer therapy is tightly 
correlated with the induction of apoptosis by anticancer drugs. Thus, it would be promising 
for disease treatment, including lung cancer, to activate TGF-β-mediated apoptosis by 
modulating the function of TGF-β in specific normal and tumor cell types. 
1.4 TGF-β and lung 
There is accumulating evidence that TGF-β may have a role in lung cancer and in lung 
disease. For example, elevated levels of TGF-β1 have been shown in plasma and lung 
tumors of patients with advanced lung cancer, and the prognosis of lung cancer patients 
who showed positive TGF-β1 was poorer than that of patients who were negative for this 
growth factor (Kong et al., 1996; Takanami et al., 1997). Lung cancer patients who responded 
to radiation therapy showed a decrease in circulating TGF-β levels compared to patients 
with no response or stable disease (Vujaskovic and Groen, 2000). One potential function of 
TGF-β in lungs and airways is regulation of epithelial cell survival through apoptosis. TGF-
β1 treatment of lung bronchial BEAS-2B cells increased apoptosis in cells exhibiting 
overexpression of Smad2 or Smad 3 (Yanagisawa et al., 1998). TGF-β1 treatment also 
enhanced Fas-induced apoptosis of alveolar and airway epithelial cells, and Fas-mediated 
apoptosis of alveolar epithelial cells was reported to be associated with increased expression 
of TGF-β1 (Hagimoto et al., 2002; Hagimoto et al., 1997).  
Besides TGF-β1, interleukin (IL)-6 is a multifunctional cytokine that is produced by a variety 
of cells during infection, trauma, and immunological challenge (Kishimoto et al., 1995). IL-6 
has been shown to mediate many inflammatory processes in the lung (Taga, 1997), and its 
dysregulated release has been implicated in the pathogenesis of a variety of respiratory 
conditions, including interstitial lung diseases (Berger, 2002; Bhatia & Moochhala, 2004; 
Shahar et al., 1996). IL-6 has been reported to have different effects on apoptosis of 
fibroblasts from normal and fibrotic lungs, with fibrotic lung cells showing enhanced 
resistance to apoptosis (Moodley et al., 2003) and to induce an increase in expression and 
activity of cathepsin, a cysteine protease that plays a major role in lysosomal bulk 
proteolysis, protein processing, matrix degradation, and tissue remodeling in the lung, in 
A549 lung cells (Gerber et al., 2001). Earlier reports have examined cross-talk between TGF-
β and IL-6 in epithelial cells, with TGF-β playing a role in the negative regulation of IL-6 
signaling in intestinal epithelial cells (Walia et al., 2003), as well as activating IL-6 expression in 
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prostate cancer cells (Park et al., 2003). In addition, bronchial epithelial 16 cells that are 
undergoing apoptosis have been shown to produce significantly more TGF-β, but less IL-6, 
than non-apoptotic cells (Hodge et al., 2002). This suggests that increased production of TGF-β 
and decreased expression of IL-6 by lung epithelial cells may contribute to the inhibition of 
proliferation, squamous metaplasia, and reduction of inflammation in lung injury.  
Lung cancer is the most lethal type of lung injury/cancer for both men and women. In the 
United States, in 2007, the most recent year for which statistics are currently available, lung 
cancer accounted for more deaths than breast, prostate and colon cancer combined, 
according to the U.S. Cancer Statistics Working Group. In that year, 109,643 men and 93,893 
women were diagnosed with lung cancer, and 88,329 men and 70,354 women died from 
lung cancer. The National Cancer Institute estimates there were 222,520 new cases of lung 
cancer and 157,300 deaths from lung cancer in 2010. Currently, 85% of lung cancer patients 
die within 5 years of diagnosis. This reflects the urgent need for improved therapies. 
Targeting signal transduction pathways that affect therapeutic resistance is one approach to 
improve patient outcomes. In normal cells, signaling is tightly regulated and begins with the 
transduction of signals through growth factor receptors or integrins to intracellular kinase 
enzymes, culminating in the regulation of cellular processes. Precise regulation of processes 
like cell division and apoptosis is required for normal morphogenesis, and alterations in 
these processes can lead to cancer. Increasing the sensitivity of tumor cells to anticancer 
therapy is tightly correlated with induction of apoptosis by anticancer drugs. Thus, it would 
be promising for disease treatment, including lung cancer, to activate TGF-β-mediated 
apoptosis by modulating the function of TGF-β in specific normal and tumor cells. 
We reported earlier that apoptosis is significantly decreased in the bronchio-alvelolar 
epithelium of mice that are heterozygous for TGF-β1 (Tang et al., 1998). This is consistent 
with a role for endogenous TGF-β1 in regulating apoptosis in lung. Here, we examined the 
ability of immortalized normal lung alveolar type II epithelial C10 cells to respond to TGF-
β1 and the functionality of the TGF-β1 signal transduction pathway in these cells. Our 
findings show that TGF-β1-mediated signaling induces apoptosis in C10 cells by a Smad-
dependent mechanism that requires activation of p38 MAPK and inhibition of the AKT 
pathway induced by IL-6. Furthermore, the GADD family members GADD45b and 
GADD153 are mediators of p38 MAPK activation in the process of TGF-β1-mediated 
apoptosis. 
2. Materials and methods 
2.1 Cell culture and reagents 
Previously established non-tumorigenic C10 cells derived from normal mouse lung 
epithelium were obtained from Dr. A. Malkinson (University of Colorado, Denver, CO). 
Cells were cultured in CMRL-1066 medium (Invitrogen, San Diego, CA) containing 10% 
heat-inactivated fetal bovine serum (FBS). Gadd153-deficient and wildtype cells were grown 
in DMEM with 10% non-heat inactivated FBS (Zinszner et al., 1998). Cells were treated with 
5 ng/ml recombinant human TGF-β1 obtained from R&D Systems (Minneapolis, MN) in a 
vehicle of 4 mM HCl containing 1 ng/ml BSA or vehicle alone. Antibodies against phospho-
specific and total p38 MAPK, ERK, JNK and AKT were from Cell Signaling Technologies 
(Beverly, MA). Antibodies against SMAD7 and GADD153 were from Santa Cruz 
Biotechnology (Santa Cruz, CA) and anti-hemagglutinin antibodies were from Covance 
(Berkeley, CA). The MAPK inhibitor SB203580 was from Calbiochem (San Diego, CA). 
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2.2 Plasmid constructs 
The hamster Gadd153 promoter fragments have been described previously (Luethy et al., 
1990). The 5’-deletion constructs of the hamster Gadd153 promoter containing fragments -778 
to +21, -225 to +21 and -36 to +21 were used to generate a Luciferase assay system in the pGL3-
basic vector (Promega, Madison, WI). The 5’-deletion constructs (-165 to +21 and -105 to +21) 
of the hamster Gadd153 promoter were generated by PCR using the 5’-primers 
(GGATATCGTCAGTGCCAGCGTGCCG and GGATATCGTCAGTGCCAGCGTGCCG, 
respectively) and the 3’-primer (ggaagcttgtgtgagactcaggctactg) and subcloned into the  
pGL3-basic vector. The mouse Gadd153- expressing plasmid was made by RT-PCR 
amplification using the 5’-primer (CGAAGCTTCCAGAAGGAAGTGCATC) and the 3’-primer 
(CGGGATCCGGAGAGACAGACAGG). All constructs were verified by DNA sequencing. 
2.3 Transient transfection and Luciferase assays 
C10 cells were transfected with 1-2 μg/well of DNAs and 1 ng/well of Renilla Luciferase 
reporter plasmid pRLTK (Promega) to normalize transfection efficiencies using 
Lipofectamine 2000 (Invitrogen). After 18-24 hours, cells were treated with TGF-β1 or 
vehicle. After 18 hours, cells were lysed and Luciferase activity was measured using a dual-
luciferase reporter assay system (Promega). All assays were performed in duplicate.  
2.4 Generation of stable cell lines 
C10 cells were transfected with HA-tagged Gadd45b, antisense Gadd45b, Gadd153 or 
Smad7 expression plasmids. Twenty-four hours after transfection, and every 4 days 
thereafter, the medium was replaced with fresh selection medium containing neomycin 
G418 (Invitrogen) at 800-µg/ml for 2 weeks. Neomycin-resistant clones were then 
individually transferred and expanded. After two additional passages in selection medium, 
independent clones were cultured in standard medium. As a mock control, the pcDNA3 
empty vector was used to transfect C10 cells and selected in the presence of neomycin. 
2.5 Western blot analysis 
C10 cells were stimulated in the presence or absence of TGF-β1. Freshly collected cells were 
homogenized in lysis buffer containing 0.05 mM Tris-HCl pH 7.4, 0.25% Na-deoxycholate, 
150 mM NaCl and 1 mM EDTA with protease inhibitors. Equal amounts of cell lysates were 
heated at 70oC for 10 minutes in sample loading buffer, separated by electrophoresis and 
transferred to membrane filters. Membranes were blocked with 5% nonfat dry milk in TBST 
buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.05% Tween 20 for 1 hour at 
room temperature, washed in TBST and incubated with various primary antibodies 
overnight at 4oC. Membranes were then incubated with horseradish peroxidase-conjugated 
secondary antibody for 1 hour at room temperature, washed in TBST buffer and proteins 
were visualized by enhanced chemiluminescence according to the manufacturer’s directions 
(Pierce, Rockford IL). 
2.6 Detection of apoptosis 
For DNA fragmentation assays, the Apoptotic DNA Ladder kit (Roche Applied Sciences, 
Indianapolis, IN) was used according to the manufacturer’s directions. Apoptosis was also 
quantitated by a Cell Death Detection ELISA assay (Roche Applied Sciences). All data points 
for the Cell Death Detection ELISA assay were determined in triplicate. 
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2.7 Semi-quantitative and real-time reverse transcription-polymerase chain reaction 
amplification 
Total RNA was isolated from C10 cells using Trizol reagent according to the manufacturer’s 
directions (Invitrogen). Reverse transcription (RT) was performed, followed by 
amplification by polymerase chain reaction (PCR) with oligonucleotide primers including 
Gadd45b 5'-primer (gggggattttgcaatcttct) and 3'-primer (cggtgaggcgatcctga), Gadd153  
5’-primer (ccagtcagagttctatggc) and 3’-primer (catgcttggtgcaggctgac) and glucose 6-
phosphate dehydrogenase (G6PD) 5’-primer (actgcagttccgagacgtgg) and 3’-primer 
(cagaagaggcagagtatagatggtg). As an internal control, mRNA for glucose-6-phosphate 
dehydrogenase (G6pd) was also amplified. Relative quantification of the mRNA levels of 
the target genes was determined using the DDCT method (Schmittgen et al., 2008). Results 
were expressed as N-fold difference in treated relative to untreated sample. All assays were 
performed twice in duplicate in independent PCR amplification reactions.  
2.8 Interleukin-6 immunoassay 
The levels of IL-6 in the supernatant of cultured cells were quantitated using a mouse 
Quantikine system (R&D Systems). Each measurement was performed in triplicate and an 
average value was recorded as pg/ml. 
2.9 Statistics 
Results were expressed as means ± standard error (S.E.) and the differences between means 
of treated and control groups were analyzed using the Student’s t test for paired data. A 
value of p < 0.05 was considered to be significant. 
3. Results 
3.1 TGF-β1 mediates apoptosis in mouse lung C10 cells 
Mouse lung C10 cells are a stable cell line originally derived from a Balb/c mouse lung 
explant with characteristics of alveolar type II pneumocytes (Smith et al., 1984). These 
normal cells are not transformed, are non-tumorigenic, and contain only wildtype K-ras 
alleles (Malkinson et al., 1997). Here, we examined the responsiveness of TGF-β1 in C10 
cells. TGF-β1 addition to C10 cells transiently transfected with Smad2 (ARE)- or Smad3 
((SBE)4)-dependent constructs augmented the transcriptional activity of these constructs by 
11-fold and 1.6-fold, respectively (Figure 1A), indicating that C10 cells respond to TGF-β1 
and Smad signaling is functional. Dramatic morphological changes characteristic of 
apoptosis, including large vacuoles, cell shrinkage and cytoplasmic blebbing were observed 
at 48 hours after TGF-β1 addition (Fig. 1B). Treatment with TGF-β1 also induced a 150- to 
200-bp internucleosomal DNA cleavage that produced a DNA fragmentation laddering 
pattern by 48 hours, and that was also detected by ELISA assay (Figure 1C and 1D). 
3.2 TGF-β1 activates p38 MAPK 
The MAPK signaling pathway, including p38 MAPK, extracellular signal-regulated kinase 
(ERK), and c-Jun N-terminal kinase (JNK), has been implicated in many physiological and 
pathological processes, including apoptosis (Javelaude & Mauviel, 2005; Zavadil & 
Böttinger, 2005). To study the possible role of the MAPK pathway in TGF-β1-mediated 
apoptosis in lung cells, C10 cells were treated with exogenous TGF-β1, and activation of p38 
MAPK, ERK1/ERK2, and JNK was then also examined using antibodies specific for total 
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and phosphorylated forms of each protein kinase. As shown in Figure 2A, there was a 
dramatic activation of p38 MAPK that occurred by 48 hours and the timing of activation of 
p38 MAPK by TGF-β1 coincided with induction of apoptosis by TGF-β1 (Figure 1). 
Activation of ERK1/ERK2 showed complex patterns of reduction and induction that were 
only modest. No activation of JNK by TGF-β1 was detected (data not shown). 
 
 
Fig. 1. TGF-β1 induces apoptosis in mouse lung C10 cells. 
A, Effect of TGF-β1 on basal ARE-Luc and (SBE)4-Luc transcription in C10 cells. C10 cells 
were transiently transfected with Smad2(ARE)-Luc, Smad3((SBE)4)-Luc or 3TP-Lux 
Luciferase reporters and cultured in vehicle (open bars) or TGF-β1 (filled bars) for 18-h. 
Luciferase activity was normalized to Renilla Luciferase values. The pGL3-basic empty 
vector control is shown. The results shown are the means standard error (S.E.) of two 
independent experiments performed in triplicate. B, Morphology of C10 cells by phase 
contrast microscopy at 24- and 48 hours after addition of TGF-β1. Magnification: 200X. The 
apoptotic response was determined by examining the DNA fragmentation pattern by C, gel 
electrophoresis and D, Cell Death Detection ELISA assay at various times after treatment 
with TGF-β1. **, p < 0.001 versus control. 
Because of the dramatic activation of p38 MAPK and induction of apoptosis by TGF-β1 in 
C10 cells, we chose to examine the role of p38 MAPK in this delayed apoptosis with MAPK 
SB203580, a potent inhibitor of p38 MAPK. Treatment of C10 cells with SB203580 strongly 
inhibited TGF-β1-induced apoptosis at 48 hours as determined by DNA fragmentation 
(Figure 2B). Inhibition of TGF-β1-induced apoptosis by SB203580 by 66% at 48 hours was 
also detected by ELISA assay (Figure 2C). Treatment of C10 cells with SB203580 also 
abrogated the morphological changes characteristic of apoptosis that were observed after 48 
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hours (Figure 2D). Our findings suggest that p38 MAPK activation by TGF-β1 is involved in 
TGF-β1-mediated apoptosis in C10 cells. 
 
 
Fig. 2. Activation of p38 MAPK by TGF-β1 results in apoptosis in C10 cells. 
A, Time course of phosphorylation of endogenous p38 MAP and ERK kinases after 
stimulation by TGF-β1. Total cell lysates were prepared from untreated or TGF-β1-treated 
cells and used for immunoblotting. Phosphorylated (P) and non-phosphorylated forms of 
p38 MAPK and ERK are indicated in the upper and lower panels, respectively. B-D, Cells 
were treated with TGF-β1 or vehicle alone in the presence or absence of 10 µM SB203580. 
The apoptotic response of C10 cells was determined by examining the DNA fragmentation 
pattern by B, gel electrophoresis and C, ELISA assay. The results shown are the means S.E. 
of two independent experiments performed in triplicate. *, p < 0.001 versus control. D, 
Morphology of C10 cells by phase contrast microscopy at 48 hours after treatment with 
TGF-β1 and SB203580. Magnification: 200X. 
3.3 TGF-β1 increases Gadd45b mRNA 
Since induction of apoptosis by TGF-β1 and activation of p38 MAPK occurred at a late time 
after addition of TGF-β1 in C10 cells, we considered the possiblity that additional protein 
mediators may be needed to activate p38 MAPK in response to TGF-β1. Previous studies 
have suggested the stress- and cytokine-inducible GADD45 family proteins (GADD45a, 
GADD45b, and GADD45g) function as specific activators of MEKK4, a MAPK kinase 
upstream in the p38 MAPK pathway (Mita et al., 2002), and induce apoptosis (Takekawa & 
Saito, 1998). To test the possible involvement of GADD family proteins in TGF-β1-mediated 
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apoptosis in C10 cells, we first examined expression of Gadd mRNA transcripts following 
treatment with TGF-β1 in these cells. Semi-quantitative and real-time RT-PCR amplification of 
RNA showed that Gadd45b mRNA was rapidly and significantly increased 8- and 11-fold by 
30 minutes and 1 hour, respectively, after treatment with TGF-β1, before decreasing (Figure 3A 
and B). Expression of transcripts for Gadd45a or Gadd45g was detected in C10 cells by RT-
PCR only after extended amplification at much lower levels (data not shown). These results 
suggest that GADD45b may play a role in TGF-β1-mediated apoptosis in C10 cells. 
 
 
Fig. 3. TGF-β1 increases expression of Gadd45b mRNA in C10 cells. 
Time course of expression of Gadd45 mRNA transcripts after stimulation by TGF-β1 using 
A, semi-quantitative and B, quantitative real-time RT-PCR amplification. Total RNA was 
prepared, reverse-transcribed and equal amounts of first-strand cDNA were amplified by 
PCR with Gadd45a-, Gadd45b- and Gadd45g -specific primers. G6pd, glucose-6-phosphate 
dehydrogenase. B, Relative expression of the Gadd45b gene in C10 cells treated with TGF-
β1. The results shown are the means S.E. of two independent experiments performed in 
duplicate. *, p < 0.001 versus control. 
3.4 GADD45b enhances the timing and sensitivity of TGF-β1-mediated apoptosis 
Having demonstrated that p38 MAPK is activated and expression of Gadd45b mRNA is 
increased coordinately with the induction of apoptosis by TGF-β1 in C10 cells, we next 
investigated whether overexpression of GADD45b could affect activation of p38 MAPK and 
lead to apoptosis. To test this, C10 cells were stably transfected with a hemagglutinin  
(HA)-tagged Gadd45b expression plasmid or empty vector used as control. In 
GADD45b-expressing cells (G-45b), p38 MAPK was activated in the absence of TGF-β1 
treatment, while TGF-β-induced activation of p38 MAPK occurred in control cells (Figure 4A). 
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Fig. 4. Overexpression of GADD45b activates p38 MAPK and increases the sensitivity of C10 
cells to TGF-β1-mediated apoptosis. 
A, C10 cells were stably transfected with either an empty vector (Control) or a 
hemaggluttinin (HA)-tagged Gadd45b expression vector (G-45b). Total cell lysates prepared 
from the cells untreated or treated with TGF-β1 for 48 hours were analyzed by 
immunoblotting. Phosphorylated (P) and non-phosphorylated forms of p38 MAPK are 
shown in the upper and middle panels, respectively. Expression of HA-tagged GADD45b 
and actin is shown in the middle and lower panels, respectively. B, Sense Gadd45b 
transcripts in C10 cells stably transfected with either an empty vector (Control) or an 
antisense Gadd45b expression vector (AS-G-45b) were subjected to RT-PCR analysis. 
Following a 1 hour incubation of the cells in the presence or absence of TGF-β1, total RNA 
was prepared and subjected to RT-PCR amplification using primers specific to the sense 
Gadd45b transcript. G6pd, glucose-6-phosphate dehydrogenase. C, Phosphorylation of 
endogenous p38 MAPK in total cell lysates prepared from C10 cells stably transfected with 
either an empty vector (Control) or an antisense Gadd45b expression vector (AS-G-45b) and 
untreated or treated with TGF-β1 for 24- and 48 hours, was analyzed by immunoblotting. 
Phosphorylated (P) and non-phosphorylated forms of p38 MAPK are shown in the upper 
and lower panels, respectively. D, C10 cells stably transfected with either an empty vector 
(Control), a Gadd45b expression vector (G-45b) or an antisense Gadd45b expression vector 
(AS-G-45b) were treated with vehicle (open bars) or TGF-β1 for 24- (gray bars) and 48 hours 
(dark bars). DNA fragmentation was detected by ELISA assay. *, p < 0.01 versus control.  
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To confirm the effect of GADD45b on activation of p38 MAPK, C10 cells were stably 
transfected with antisense Gadd45b cDNA (AS-G-45b) to block expression of the 
endogenous Gadd45b gene. Antisense Gadd45b suppressed endogenous Gadd45b mRNA 
expression induced by TGF-β1 (Fig 4B), and p38 MAPK activity was substantially reduced 
48 hours after treatment with TGF-β1 in AS-G-45b cells compared to control cells (Figure 
4C). These results suggest that endogenous GADD45b has a role in p38 MAPK activation. 
Next, to test whether GADD45b plays a role as a mediator of apoptosis induced by TGF-β1, 
we examined the ability of these cells to undergo apoptosis with or without TGF-β1. 
Apoptosis increased by ~50% in G-45b cells compared to control cells in the absence of  
TGF-β1, and overexpression of GADD45b increased the appearance of apoptosis in C10 cells 
by 24 hours (Figure 4D). However, apoptosis induced by TGF-β1 decreased in AS-G-45b 
cells compared to control cells 48 hours after TGF-β1 addition (Figure 4D). This result 
suggests that expression of endogenous GADD45b is necessary for TGF-β-mediated p38 
MAPK activation and apoptosis 
3.5 TGF-β1 increases GADD153 mRNA 
Because TGF-β1-mediated apoptosis in C10 cells involves increased expression of 
Gadd45b mRNA only after 0.5- and 1 hour, it is possible that additional proteins may be 
involved in TGF-β1-mediated apoptosis in these cells. Besides GADD45b, 
GADD153/CAATT enhancer binding protein homologous protein (CHOP), another 
member of the GADD family, has been implicated in processes that initiate apoptosis 
(Corazzari et al., 2003; Maytin et al., 2001; Murphy et al., 2001). We investigated whether 
GADD153 has a role in TGF-β-mediated apoptosis in C10 cells. Semi-quantitative and 
real-time RT-PCR amplification showed that Gadd153 mRNA had a gradual, but 
sustained, increase after TGF-β1 addition (Figure 5A), and by 3 hours, there was a 1.5-fold 
increase in expression of Gadd153 mRNA that increased significantly to 11- and 9-fold by 
24- and 48 hours, respectively (Figure 5B). 
We next used actinomycin D and cyclohexamide to investigate whether TGF-β1-induced 
Gadd153 mRNA expression is transcriptionally regulated and requires prior de novo 
protein synthesis or not. The addition of actinomycin D, an inhibitor of transcription, 
inhibited TGF-β1-induced Gadd153 mRNA expression (Figure 5C), indicating that up-
regulation of Gadd153 expression is transcriptionally dependent. To address whether the 
induction of Gadd153 mRNA expression by TGF-β1 requires de novo protein synthesis, the 
effect of the protein synthesis inhibitor cyclohexamide was examined. Addition of 
cyclohexamide by itself caused an increase in Gadd153 mRNA levels (Figure 5C). The level 
of Gadd153 mRNA expression was not significantly changed by addition of cyclohexamide 
and TGF-β1 together compared to cyclohexamide alone. This suggests that although 
Gadd153 mRNA is regulated by TGF-β1 in C10 cells, the induction of GADD153 by TGF-β1 
depends on prior de novo protein synthesis events. The increase in Gadd153 mRNA level in 
the presence of cyclohexamide could be explained by an increase in mRNA stability or loss 
of transcriptional repressors by cyclohexamide. 
3.6 GADD153 expression increases with overexpression of GADD45b 
Since expression of Gadd45b mRNA is induced early by TGF-β1 in C10 cells, while induction 
of Gadd153 mRNA occurs more gradually and maximizes at a later time compared to 
Gadd45b mRNA, we examined whether GADD45b could affect the expression of GADD153. 
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To test this, we used C10 cells that we had previously stably transfected with a (HA)-tagged 
sense or antisense Gadd45b expression plasmid. The basal level of GADD153 protein  
in GADD45b-expressing cells (G-45b) increased in the absence of TGF-β1, and treatment of 
these cells with TGF-β1 showed further increased expression of GADD153 protein after 24 
hours (Figure 6A). However, antisense Gadd45b (AS-G-45b) significantly suppressed 
endogenous GADD153 protein expression in the absence of TGF-β1 in AS-G-45b cells. 
 
 
Fig. 5. TGF-β1 increases expression of Gadd153 mRNA in C10 cells. 
Time course of expression of Gadd153 mRNA transcripts after stimulation by TGF-β1 using 
A, semi-quantitative and B, real-time RT-PCR amplification. Total RNA was prepared, 
reverse-transcribed and equal amounts of the first-strand cDNA were subjected to PCR 
amplification with specific primers for Gadd153 or glucose-6-phosphate dehydrogenase 
(G6pd). The results shown are the means S.E. of two independent experiments performed in 
duplicate. *, p<0.005, **, p < 0.001 versus control. C, C10 cells were treated with actinomycin 
(Act D; 1 μg/ml) or cycloheximide (CHX; 5 μg/ml) 1 hour before TGF-β1 addition, and 
incubated for 24 hours with or without TGF-β1. Total RNA was prepared and subjected to 
real-time RT-PCR using a primer specific for the Gadd153 transcript. The results shown are 
the means S.E. of three independent experiments performed in duplicate.  
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Expression of GADD153 protein was induced by TGF-β1 in C10 cells stably transfected with 
antisense Gadd45b cDNA, but at levels that were markedly reduced compared to control 
C10 cells. These results suggest that GADD45b is capable of inducing Gadd153 expression in 
response to TGF-β1 in C10 cells through a direct or indirect route. The ability of TGF-β1 to 
stimulate GADD153 expression in AS-G-45b cells could be explained by a residual level of 
Gadd45b that may be sufficient to stimulate a level of GADD153 expression, or alternatively, 
both Gadd45b-dependent and Gadd45b-independent mechanisms may exist for stimulating 
GADD153 expression in C10 cells. 
To confirm that endogenous GADD45b has an effect on TGF-β1-induced expression of 
GADD153, we used a hamster Gadd153 promoter Luciferase reporter construct. 
Cotransfection of Gadd45b plasmid showed that increasing amounts of Gadd45b using 0.1-, 
0.5- and 1-μg of Gadd45b cDNA, augmented transcriptional activity of Gadd153-Luc, with 
maximal induction occurring using 0.5-μg (Figure 6B). As a control, cotransfection of 
Gadd45b plasmid had no effect on the transcriptional activity of the TGF-β1-responsive 
p3TP-Lux reporter. These results suggest that GADD45b is involved in transactivation of the 
Gadd153 promoter. 
Having shown that GADD45b increases the activity of the Gadd153 promoter, we next set 
out to determine the minimum region of the Gadd153 promoter that was required for 
induction of Gadd45b. To accomplish this, we utilized a hamster Gadd153 promoter 
construct (pGadd153-778-+21-Luc) and a series of deletion constructs (pGadd153-225-+21-
Luc, pGadd153-165-+21-Luc, pGadd153-105-+21-Luc and pGadd153-36-+21-Luc). Addition 
of 0.5-μg of Gadd45b cDNA augmented transcriptional activity of pGadd153-778-+21-Luc 3-
fold (Figure 6C). Deletion of the Gadd153 promoter up to position –225 still conferred 
induction by GADD45b. However, deletion of additional nucleotides from –165 to –36 of the 
Gadd153 promoter resulted in reduced ability of GADD45b to induce the Gadd153 
promoter. In addition, cotransfection of Gadd45b with p3TP-Lux showed a minimal effect 
similar to that of pGadd153-36-+21-Luc, indicating specificity of the effect of GADD45b on 
GADD153. This suggests the existence of a sequence that is responsive to the effects of 
GADD45b in region –778 to -225 of the Gadd153 promoter. 
3.7 Overexpression of GADD153 activates p38 MAPK and induces apoptosis in the 
absence of TGF-β1 
To address the role of GADD153 inTGF-β1-mediated apoptosis in lung cells, we next 
investigated whether overexpression of GADD153 could activate p38 MAPK and lead to 
apoptosis in the absence of TGF-β1 in C10 cells. To test this, C10 cells were stably transfected 
with a Gadd153 expression vector or empty vector. Figure 7A shows increased expression of 
GADD153 protein in C10 cells stably transfected with Gadd153 expression plasmid (G-153-1 
and G-153-2), but not in control cells. While TGF-β1 treatment induced p38 MAPK 
activation in control cells, p38 MAPK in GADD153-expressing cells (G-153-1, G-153-2) was 
activated even in the absence of TGF-β1 (Figure 7B). In GADD153-expressing cells, 
apoptosis in the absence of TGF-β1 exceeded that in control cells that had been treated with 
TGF-β1, and sensitivity to TGF-β1-induced apoptosis was increased (Figure 7C and D). To 
further explore the involvement of p38 MAPK activation in GADD153-expressing cells, we 
used the potent inhibitor of p38 MAPK, SB203580. Treatment of GADD153-expressing cells 
with SB203580 strongly inhibited TGF-β1-induced apoptosis at 48 hours (Figure 7D). Our 
results suggest that the induction of GADD153 by TGF-β1 is part of the TGF-β1-mediated 
apoptotic pathway, and is upstream of p38 MAPK in this pathway. 
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Fig. 6. Effect of GADD45b on transactivation of GADD153. 
A, C10 cells stably transfected with either an empty vector (Control), a sense Gadd45b 
expression vector (G-45b) or an antisense Gadd45b expression vector (AS-G-45b) were treated 
with TGF-β1 or vehicle for 24 hours, and total cell lysates were analyzed by immunoblotting 
using GADD153-specific antibodies. Immunoblotting with actin antibodies is shown in the 
lower panel. B, C10 cells were transiently cotransfected with 0.5-μg Gadd153 (–778-+21)-Luc of 
the hamster Gadd153 promoter or 3TP-Luc plasmid as a negative control with increasing 
amounts of the Gadd45b expression plasmid. Cells were harvested 30 hours after transfection 
and assessed for Luciferase activity. The results shown are the means S.E. of three independent 
experiments performed. *, p < 0.05; **, p < 0.01 versus control. C, C10 cells were transiently 
cotransfected with 0.5-μg of Gadd45b expression plasmid and 0.5-μg of deletion mutants of 
the hamster Gadd153 promoter, including pGadd153 (-778-+21)-Luc, pGadd153 (-225-+21)-
Luc, pGadd153 (-165-+21)-Luc, pGadd153 (-105-+21)-Luc and pGadd153 (-36-+21)-Luc (filled 
bars) along with p3TP-Lux (open bar). Luciferase activity was measured. The results shown 
are the means S.E. of two independent experiments performed in triplicate. 
3.8 GADD153 expression and TGF-β1-mediated apoptosis is blocked by Smad7 
It has previously been reported that GADD45b is activated by TGF-β1 in a Smad-dependent 
manner (Takekawa et al., 2002; Yoo et al., 2003). Our results showed that GADD153 
induction occurs through GADD45b, which in turn, activates p38 MAPK, and leads to 
apoptosis in the presence of TGF-β1 in C10 cells. These findings evoked the possibility that 
TGF-β1-mediated apoptosis in C10 cells may be mediated by the Smad pathway. To 
determine whether the Smad pathway was required for TGF-β-mediated signaling of 
apoptosis, we asked whether overexpression of Smad7, an inhibitory Smad, would inhibit 
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this effect in C10 cells. In the Smad7-overexpressing cells detected by Smad7 antibody, 
expression of GADD153 protein was below the level of detection, and TGF-β1 addition did 
not result in induction of GADD153 protein as it did in control cells (Figure 8A). The basal 
level of apoptosis and the sensitivity to TGF-β1-mediated apoptosis was significantly 
reduced in C10 cells that overexpressed Smad7 (Figure 8B). The morphological changes 
described earlier did not occur in Smad7-overexpressing C10 cells treated with TGF-β1 
(Figure 8C). This indicates that TGF-β1-mediated apoptosis is Smad-dependent and requires 
induction of GADD153. To confirm that induction of GADD153 is important in determining 
sensitivity of C10 cells to TGF-β1-mediated apoptosis, we tested the ability of GADD153 to 
affect apoptosis in C10 cells that overexpressed Smad7. Transient restoration of GADD153 in 
C10 cells expressing Smad7 significantly augmented apoptosis in the absence of TGF-β1 and 
the level of apoptosis was not significantly affected by TGF-β1 treatment (Figure 8D). This 
suggests that the induction of GADD153 expression is a necessary and sufficient step for the 
induction of apoptosis in C10 cells that overexpress Smad7. 
Sensitivity of C10 cells to TGF-β1-mediated apoptosis, we tested the ability of GADD153 to 
affect apoptosis in C10 cells that overexpressed Smad7. Transient restoration of GADD153 in 
C10 cells expressing Smad7 significantly augmented apoptosis in the absence of TGF-β1 and 
the level of apoptosis was not significantly affected by TGF-β1 treatment (Figure 8D). This 
suggests that the induction of GADD153 expression is a necessary and sufficient step for the 
induction of apoptosis in C10 cells that overexpress Smad7. 
3.9 TGF-β1 regulates IL-6 production through a Smad2-dependent pathway 
Since overexpression of Smad7 not only blocked the basal apoptosis, but also resulted in a 
significant decrease in TGF-β1-mediated apoptosis compared to vector transfected control 
cells, it may be that TGF-β1 inhibits cell survival signaling pathways as well as activates 
apoptosis signaling pathways in C10 cells in a Smad-dependent manner. Among the 
cytokines that have been shown to participate in cellular survival, IL-6 can activate the 
phosphotidyl inositol-3 kinase (PI3K)/AKT survival pathway (Sierra, 2005). In addition, IL-
6 modulates TGF-β1-induced apoptosis via the PI3K/AKT pathway (Chen et al., 1999). To 
investigate possible crosstalk between TGF-β1 and IL-6, we examined IL-6 production by 
C10 cells that stably overexpress Smad7. Basal production of IL-6 was found to be 5-fold 
higher in Smad7-overexpressing C10 cells compared to control cells (Figure 9A), and IL-6 
production increased by accumulation in Smad7-overexpressing C10 cells after addition of 
TGF-β1. In contrast, no significant change in IL-6 production occurred in control C10 cells 
after treatment with TGF-β1. This result suggests that inhibition of the Smad signaling 
pathway by Smad7 leads to increased production of IL-6 in C10 cells. 
To investigate whether serine/threonine kinase AKT, a downstream target of PI3K, is 
involved, we also examined activation of AKT in C10 cells overexpressing Smad7. Figure 9B 
shows phosphorylation, and thus activation, of AKT in Smad7-overexpressing C10 cells. 
Activation of AKT was maintained at the basal level for up to 24 hours after treatment with 
TGF-β1 in C10 cells that overexpress Smad7, while activation of AKT was not detected in 
control C10 cells. To address the effect of IL-6 on TGF-β1-induced apoptosis, C10 cells were 
treated with either TGF-β1 or increasing amounts of IL-6. TGF-β1 induced apoptosis, while 
addition of IL-6 increased the ability of C10 cells to survive without TGF-β1 (Figure 9C). The 
ability of IL-6 to promote cell survival in C10 cells was detected using an IL-6 concentration 
as low as 1-ng/ml, maximized these effects using 10-ng/ml IL-6 and sustained these effects 
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using 50- and 100-ng/ml IL-6. Next, to investigate whether IL-6 affects apoptosis induced by 
TGF-β1, C10 cells were treated with TGF-β1 and IL-6 in combination using concentrations of 
10-, 50- or 100-ng/ml of IL-6. In the presence of TGF-β1, no treatments with IL-6 protected 
C10 cells from apoptosis induced by TGF-β1 (Figure 9D). These findings suggest that IL-6 
promotes cell survival in the absence of TGF-β1 in C10 cells, but does not inhibit apoptosis 
induced by TGF-β1, and also suggest that the apoptotic pathway may be predominant over 
IL-6-mediated survival in these cells. 
 
 
 
Fig. 7. Overexpression of GADD153 activates p38 MAPK and increases TGF-β1-mediated 
apoptosis in C10 cells. 
A, C10 cells were stably transfected with either an empty vector (Control) or a Gadd153 
expression vector (G-153-1 and G-153-2). Total cell lysates were isolated and 
immunoblotting was performed using GADD153-specific antibodies. Immunoblotting with 
actin antibodies is shown in the lower panel. B, Phosphorylation of endogenous p38 MAPK 
in total cell lysates prepared from C10 cells stably transfected with either an empty vector 
(Control) or a Gadd153 expression vector (G-153-1 and G-153-2) and treated with TGF-β1 or 
vehicle for 24- and 48 hours was analyzed by immunoblotting. Phosphorylated (P) and non-
phosphorylated forms of p38 MAPK are indicated in the upper and lower panels, 
respectively. C, C10 cells stably transfected with either an empty vector (Control) or a 
Gadd153 expression vector (G-153-1) were treated with vehicle (open bars) or with TGF-β1 
for 24- (gray bars) and 48 hours (dark bars). DNA fragmentation was detected by ELISA 
assay. *, p < 0.01; **, p < 0.001 versus control. D, C10 cells stably transfected with either an 
empty vector (Control) or a Gadd153 expression vector (G-153-1) were treated with vehicle 
(open bars), TGF-β1 (gray bars), 10 μM SB203580 (dark bars) or TGF-β1 and SB203580 in 
combination (lined bars) for 48 hours. DNA fragmentation was detected by ELISA assay. 
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Fig. 8. Overexpression of Smad7 blocks GADD153 expression and TGF-β1-mediated 
apoptosis. 
A, C10 cells were stably transfected with either an empty vector (Control) or a Flag-tagged 
Smad7 expression vector (Smad7) and treated with TGF-β1 for 24- and 48 hours. Total cell 
lysates were isolated and immunoblotting was performed using Smad7 and GADD153 
antibodies. Immunoblotting with actin antibodies is shown in the lower panel. B, C10 cells 
stably transfected with either an empty vector (Control) or a Smad7 expression vector 
(Smad7) were treated with vehicle (open bars) or with TGF-β1 for 24- (gray bars) and 48 
hours (dark bars). DNA fragmentation was detected by ELISA assay. *, p < 0.05, **, p, < 0.01 
versus control. C, Morphology of C10 cells stably transfected with either an empty vector 
(Control) or a Smad7 expression vector (Smad7) by phase contrast microscopy at 48 hours 
after treatment with or without TGF-β1. D, C10 cells stably transfected with a Smad7 
expression vector were transiently transfected with either an empty vector (Vector) or 
Gadd153 cDNA expression vector (Gadd153) and cultured with vehicle (open bars) or TGF-
β1 (filled bars) for 48 hours. DNA fragmentation was detected by ELISA assay. 
 ** p < 0.01 versus control. 
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Fig. 9. Overexpression of Smad7 increases IL-6 production in the presence or absence of 
TGF-β1. 
C10 cells were stably transfected with either an empty vector (Control) or a Flag-tagged 
Smad7 expression vector (Smad7). A, The cells were treated with TGF-β1 for the indicated 
times. Conditioned media were isolated and the level of IL-6 protein production was 
detected using a Quantikine assay as described in Materials and Methods. The results 
shown are the means S.E. of two independent experiments performed in triplicate. B, 
Time course of phosphorylation of endogenous AKT after stimulation by TGF-β1. Total 
cell lysates were prepared from untreated or TGF-β1-treated cells and used for 
immunoblotting. Phosphorylated (P) and non-phosphorylated total forms of AKT are 
indicated in the upper and lower panels, respectively. C,D, C10 cells were treated with 
vehicle (open bars) or TGF-β1 (filled bars) or IL-6 (1-, 10-, 50- or 100-ng/ml) (stippled 
bars) in C, or a combination of TGF-β1 and IL-6 (10-, 50- or 100-ng/ml) (stippled bars) in 
D, for 48 hours as indicated. DNA fragmentation was detected by ELISA assay at 48 hours 
after treatments. 
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Fig. 10. Production of IL-6 in embryo fibroblasts derived from Smad2- and Smad3-deficient 
mice and their wildtype littermates. 
Embryo fibroblasts from A, Smad2 null, B, Smad2 wildtype, C, Smad3 null and D, Smad3 
wildtype mice were cultured with vehicle (open bars) or TGF-β1 (filled bars) for 24- and 48 
hours. Conditioned media were isolated and the level of secreted IL-6 protein in pg/ml was 
detected using a Quantikine assay as described in Materials and Methods. The results 
shown are the means S.E. of two independent experiments performed in duplicate.  
*, p < 0.01, **, p < 0.001 versus control. 
Finally, to determine which Smad affects expression of IL-6, we examined the secretion of 
IL-6 in embryo fibroblasts from Smad2- and Smad3-deficient mice and their wildtype 
littermates. Treatment of Smad2 null mouse embryo fibroblasts (MEFs) with TGF-β1 
demonstrated that production of IL-6 was enhanced by TGF-β1 7-fold by 24 hours that 
increased to 15-fold by 48 hours, while no change was detected in the amount of IL-6 that 
was produced from wildtype MEFs (Figure 10B). In contrast, no change in IL-6 production 
was detected in Smad3 null and wildtype MEFs after treatment with TGF-β1 for up to 48 
hours. This suggests that TGF-β1 regulates IL-6 production via Smad2, but not via Smad3, in 
C10 cells. 
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4. Discussion 
The present study was undertaken to investigate the potential effect of TGF-β1 on apoptosis 
in immortalized normal mouse lung C10 cells. We reasoned that it would be easier to 
understand the mechanism of TGF-β1-mediated apoptosis in normal epithelial cells in 
which the TGF-β1 signaling pathway was functional than in tumor cells in which the TGF-
β1 pathway may not be functional. Addition of TGF-β1 to C10 cells activated the p38 MAPK 
pathway, and the p38 MAPK inhibitor SB203580 significantly reduced the TGF-β1-mediated 
apoptotic response. These findings suggest that activation of p38 MAPK is involved in TGF-
β1-mediated apoptosis in C10 cells. It has been reported that stress-activated protein kinases 
like p38 MAPK can mediate pro-apoptotic signals from TGF-β Receptors in multiple cell 
types, including lung cells (Undevia et al., 2004). Interestingly, although ERK1/ERK2 and 
JNK activation is associated with TGF-β Receptor-mediated apoptosis in some cell types, 
addition of TGF-β1 to C10 cells had only a marginal effect on activation of ERK and no effect 
on JNK. Thus, ERK and JNK do not appear to play essential roles in TGF-β1-mediated 
apoptosis in these lung cells. 
TGF-β1-mediated apoptosis in C10 cells has revealed an unexpected degree of complexity. 
TGF-β1-mediated apoptosis in C10 cells is dependent on signaling through Smads and p38 
MAPK. The delayed kinetics of p38 MAPK activation in TGF-β1-mediated apoptosis in C10 
cells suggest that one or more additional components may be involved in this process. 
Earlier reports have provided strong evidence that GADD45b is a critical upstream 
component in the apoptotic pathway of TGF-β1 in human pancreatic carcinoma cells and 
mouse hepatocytes (Takekawa et al., 2004; Yoo et al., 2003). A recent report outlined a role 
for Smad3 and Smad4 in activating Gadd45b through its third intron to facillitate G2 
progression following addition of TGF-β1 (Major & Jones, 2004). We examined the expression 
of Gadd45b mRNA in response to TGF-β1 in C10 cells. As in earlier reports, TGF-β1 induces 
expression of GADD45b in C10 cells. Overexpression of GADD45b accelerates the 
appearance of apoptosis in C10 cells by at least 24 hours, and down-regulation of GADD45b 
expression with an antisense construct inhibits TGF-β-mediated apoptosis. These results 
suggest that GADD45b participates in TGF-β1-mediated apoptosis in C10 cells. 
The participation of GADD45b in TGF-β1-mediated apoptosis in C10 cells does not rule out 
the possible involvement of other factors that may cooperate with GADD45b in TGF-β1-
mediated apoptosis. The time interval between the initial induction of Gadd45b mRNA 
expression by TGF-β1 stimulation and the appearance of apoptosis suggest that other factors 
may be involved. We explored the possible involvement of other GADD family members, 
including GADD5a and GADD45g. However, transcripts for Gadd45a or Gadd45g in the 
absence or presence of TGF-β1 were detected only at very low levels in C10 cells. Earlier 
reports showed that the stress-inducible transcription factor GADD153/CHOP induced 
apoptosis in mammalian cells through p38 MAPK-dependent and –independent 
mechanisms (Corazzari et al., 2003; Maytin et al., 2001; Murphy et al., 2001). GADD153 has 
been implicated in apoptosis, and cells isolated from Gadd153 null mice have been shown to 
be resistant to apoptosis-inducing regimes (Zinszner et al., 1998). In our study, Gadd153 
mRNA had a gradual and sustained increase in Gadd153 mRNA after treatment with TGF-
β1 that reached a maximum at 24- to 48 hours. The timing of Gadd153 mRNA induction is 
consistent with the appearance of TGF-β1-mediated apoptosis in C10 cells. Addition of 
actinomycin D and cyclohexamide showed that up-regulation of GADD153 expression is 
dependent on transcription and requires de novo protein synthesis. This suggests that 
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although Gadd153 mRNA is regulated by TGF-β1 in C10 cells, the induction of GADD153 
by TGF-β1 depends on prior protein synthesis events. 
Our results demonstrate that expression of GADD153 protein is induced in C10 cells stably 
transfected with Gadd45b cDNA, while it is markedly reduced in antisense Gadd45b-
expressing cells compared to control C10 cells untreated or treated with TGF-β1. 
Cotransfection of Gadd45b plasmid with Gadd153-Luc showed that increasing amounts of 
Gadd45b cDNA augmented transcriptional activity of Gadd153-Luc. These results suggest 
that GADD45b has a role in transactivation of GADD153 expression in response to TGF-β1 
in C10 cells in a direct or indirect manner. This is the first report of regulation of GADD153 
by GADD45b. Our findings also show that the induction of GADD153 is sufficient to 
activate p38 MAPK and to trigger apoptosis in the absence of TGF-β1 in C10 cells. 
In this study, we also demonstrated that GADD153 induction by TGF-β1 and TGF-β1-
mediated apoptosis was completely inhibited in C10 cells when Smad signaling was blocked 
by Smad7. Transient restoration of GADD153 in C10 cells overexpressing Smad7 
significantly augmented apoptosis in the absence of TGF-β1, and the level of apoptosis was 
not affected by TGF-β1 treatment. Our results suggest that GADD153 is a determining factor 
in TGF-β1-mediated apoptosis in C10 cells and induction of GADD153 may be useful to 
potentiate apoptosis in cells in which the TGF-β1 signaling pathway is not functional or only 
minimally functional, which is often the case in tumor cells. 
In addition to the p38 MAPK regulated apoptosis pathway, we also identified crosstalk 
between TGF-β1 and IL-6 in C10 cells. In C10 cells that overexpress Smad7, the basal level of 
IL-6 production was higher than in control cells and activation of AKT occurred without 
TGF-β1. Addition of IL-6 alone resulted in increased survival, and IL-6 in combination with 
TGF-β1 failed to block apoptosis induced by TGF-β1. The slow kinetics of delayed onset of 
TGF-β1-induced apoptosis may be attributed to the activation of the PI3K/AKT cell survival 
pathway during the early stage of TGF-β treatment (Yu et al., 2002). Activation of the AKT 
pathway by TGF-β1 has been shown to be mediated by a p38 MAPK-mediated mechanism 
(Horowitz et al., 2004). Activation of AKT in response to TGF-β1 addition does not appear to 
play an important role in normal C10 cells, indicating that this pathway probably does not 
participate in delaying the onset of apoptosis. However, if events occur which lead to the 
overexpression of Smad7, and thus decreased Smad-dependent TGF-β1 signaling, the 
activation of AKT may play a more prominent role. It has been reported that overexpression 
of Smad7 induced tumorigeniciy in human colon carcinoma cells by blocking TGF-β-
induced growth inhibition and apoptosis (Halder et al., 2005). It appears that the TGF-
β1/p38 MAPK-mediated apoptosis pathway in which GADD45b and GADD153 participate 
as intermediates, plays a more prominent role than the IL-6/AKT pathway does in C10 cells 
as outlined in Figure 11. Although our scenario depicts direct activation of GADD153 by 
GADD45b, this may or may not occur. Other factors may be involved. In addition, the 
survival pathway may be a less frequently used pathway in normal C10 cells compared to 
the apoptosis pathway. The predominance of these pathways may also change in tumor 
cells. Future studies will be needed to examine he role of these alternative pathways and 
crosstalk signaling that may be involved or abrogated in tumor cells. 
TGF-β1 induces GADD45b expression in a Smad-dependent manner. GADD45b then 
activates GADD153, which, in turn, activates p38 MAPK. Activated p38 MAPK results in 
apoptosis. This may be the predominant pathway in C10 cells. Alternatively, TGF-β may 
down-regulate IL-6 production through Smad2-dependent signaling. Elevated IL-6 may be 
able to induce activation of AKT to block or reduce apoptosis and increase cell survival. If 
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Smad signaling is blocked by Smad7 or reduced by another agent or phenomenon, it may be 
sufficient to confer a pro-survival/apoptosis-resistant phenotype to C10 cells. 
 
 
Fig. 11. A possible mechanism of TGF-β1-mediated apoptosis in mouse lung epithelial C10 
cells. 
5. Conclusion 
Resistance to apoptosis has been shown to be one of the characteristics of cancer cells during 
progressive tumorigenesis (Hanahan & Weinberg, 2000). Thus, it would be promising for 
the treatment of cancer, to activate TGF-β1-mediated apoptosis by modulating the function 
of TGF-β1 in specific tumor cell types. Our study has shown that in lung C10 cells that 
overexpress GADD153, both the basal level and sensitivity to apoptosis are increased, 
suggesting that the induction of GADD153 is an important step in the sensitivity of these 
lung cells to apoptosis. Future studies will need to be performed to evaluate whether 
increased levels of GADD153 can be stimulated effectively to increase TGF-β-mediated 
apoptosis in lung tumor cells in which this does not occur or occurs less frequently, and 
thus, bring about their destruction, and an effective therapy that can be used in the 
treatment of lung cancer. 
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1. Introduction 
In the course of the 20th century the fruit fly Drosophila melanogaster became one of the most 
studied metazoans and, as all other members of this family, flies can be afflicted by various 
forms of neoplasia. Pioneering studies in the field of Drosophila, mouse somatic cells and 
human genetics revealed about 40 years ago that cancer development may develop from 
loss of function in regulatory genes controlling cell growth and differentiation (Gateff and 
Schneiderman 1969, Gateff 1974, Harris et al. 1969, Knudson 1971). The discovery of 
mutations causing neoplasia during Drosophila development (Gateff 1978) has revealed that 
cell polarity is significantly affected in the tumor cells. Application of molecular biology for 
the study of genes controlling Drosophila development led to the isolation and 
characterization of the first tumor suppressor gene (TSG), the lethal (2) giant larvae (lgl) 
(Mechler, McGinnis and Gehring 1985) and consequently placed Drosophila at the center of 
cancer research. lgl encodes a cytosolic protein with two WD40 motifs, involved in protein-
protein interactions (Wodarz 2000). Lgl can bind to non-muscle myosin II and to the 
cytoskeleton matrix, along the baso-lateral portion of the plasma membrane in epithelial 
cells to affect cell polarization (Jakobs et al. 1996, Strand et al. 1994a, Strand, Raska and 
Mechler 1994b). In addition, Lgl can be a critical factor in the process of steroid-induced cell 
death during metamorphosis, a process which happens to be independent from the cell 
polarity function (Farkas and Mechler 2000). Similar to lgl, mutations in discs large-1 (dlg) 
and scribble (scrib) TSGs can cause tissue overgrowth phenotypes, as homozygous mutations 
in these genes lead to neoplastic transformation, thereby leading to imaginal disc 
overgrowth and brain tumors. In these tumors the overproliferating epithelial cells become 
rounded, rather than polygonal, lose their ability to terminally differentiate and fail to 
organize an epithelial monolayer (Bilder 2004). dlg, scrib and lgl mutants fail to pupariate 
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and have a prolonged larval life during which they grow enormously in size and become 
“giant”, bloated and transparent (Papagiannouli 2003). Further analysis revealed defects 
in apical-basal polarity, followed by loss of epithelial structure; therefore, all three TSGs 
are classified also as “cell polarity genes” (Wodarz 2000, Woods et al. 1996, Bilder and 
Perrimon 2000, Li et al. 2001). Dlg is a protein of the MAGUK (membrane - associated 
guanylate kinases) family, which consists of a class of scaffolding proteins that recruit 
signaling molecules into localized multimolecular complexes. Dlg localizes at the 
cytoplasmic side of septate junctions between adjacent epithelial cells, as well as in 
neuromuscular junctions. It contains 3 PDZ domains involved in protein-protein 
interactions with membrane or cytoskeletal proteins, an SH3 domain and a GUK domain. 
The Scrib protein is also a septate junctional protein of the LAP family (Bryant and Huwe 
2000), containing four PDZ domains and leucine-rich repeats (LRRs) (Bilder 2001, Wodarz 
2000, Mathew et al. 2002) thought to be involved in Ras signaling (Humbert, Russell and 
Richardson 2003).  
The Dlg, Scrib and Lgl proteins are highly conserved in sequence among different species 
and growing evidence suggests that they are functionally conserved to a large degree since 
the vertebrate homologues can rescue the polarity defects and tumorous overgrowth of the 
respective Drosophila mutants (Thomas et al. 1997b, Grifoni et al. 2004, Dow et al. 2003). 
There are four well characterized mammalian Dlg members: Dlg1 (hDlg/SAP97), Dlg2 
(PSD-93/Chapsyn-110), Dlg3 (NE-Dlg/SAP102) and Dlg4 (PSD-95/SAP90). All display the 
characteristic MAGUK structural domains of the Drosophila homologue, are involved in 
polarity establishment and are dysregulated in several cancer lines. There are also two Lgl 
(Lgl1/Hugl1 and Lgl2/Hugl2) mammalian homologues and only one single Scrib 
homologue in higher vertebrates. The human Scrib (hScrib) gene shows high homology to 
the Drosophila Scrib and colocalizes with Dlg family members (Humbert et al. 2003). 
Similarly, loss or alterations in expression of dlg, scrib and lgl in humans are correlated with 
more invasive and aggressive tumors (Humbert et al. 2003, Gardiol et al. 2006, Brumby and 
Richardson 2003, Nakagawa et al. 2004). 
2. Tumor suppressors as multitasking proteins 
Over the last decades, further work revealed that junction complexes are not just static 
barriers, limiting the diffusion of proteins along of the cortical cell domains, but have a 
broader function. As polarity scaffolds are nowadays considered as dynamic organizing 
centers of site-specific protein targeting or exclusion from adjacent domains that provide 
guiding cues for signaling molecules and targeted membrane insertion (Lecuit and 
Wieschaus 2002), studying these classical tumor suppressors in other tissue contexts has 
gained new interest (Papagiannouli and Mechler 2010). Recent advances in the diverse 
functions of dlg, scrib and lgl have defined them as key players in numerous tissues contents 
and malignancies at different time points throughout development; furthermore, they have 
revealed their multitasking role in: 1) junction and cytoskeleton establishment, epithelial cell 
and planar cell polarity, 2) asymmetric neuroblast division, formation of synapses and 
neuromuscular junctions, nervous system and brain development including memory 
(Moreau et al. 2010, Chen et al. 2008) and olfaction (Ganguly, Mackay and Anholt 2003, Mao 
et al. 2008), 3) testis, ovaries and other organ development, 4) cancer initiation, progression 
and metastasis and 5) mechanism of cooperation with various signaling pathways in 
different tissue contexts (Ras, SWH, Dpp, JNK, Wg, Egfr etc) (Figure 1). These new and 
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unexpected findings show that Dlg, Scrib and Lgl are dynamic cytoskeletal components 
which affect epithelial cell structure, polarity and growth behavior by directing the 
trafficking of proteins to proper plasma membrane surfaces of the cell and by organizing 
and stabilizing supramolecular adhesion and signaling complexes through their action as 
scaffolding adaptor molecules (Woods et al. 1996, Bilder, Li and Perrimon 2000, Harris and 
Lim 2001, Goode and Perrimon 1997, Lee et al. 2003, Gorczyca et al. 2007, Mahoney et al. 
2006, Thomas et al. 2000, Chen and Featherstone 2005, Bilder 2001, Humbert et al. 2003).  
2.1 Tumor suppressors in polarity establishment and functional cooperation with 
other polarity and signaling complexes 
Epithelial cells are polarized, with apical and baso-lateral domains. These domains are 
characterized by different components: outer-membrane, trans-membrane and inner- 
membrane proteins. A belt of adherens junctions (AJs) forming the zonula adherens (ZA) 
separates the apical domain of the cell membrane from its baso-lateral domain. The ZA 
complex consists of E-cadherin (E-cad), α-catenin, and Armadillo (the Drosophila β-catenin), 
and serves as a contact interface between neighboring cells and the cytoskeleton. Apically 
located components include the “Par-complex” consisting of Bazooka/Par3 (multi-PDZ 
containing protein), Drosophila atypical protein kinase C (aPKC), and DmPAR6 (a single-
PDZ containing protein) and the “Crumbs-complex” consisting of Crumbs (a trans-
membrane protein) and Stardust (a MAGUK protein). The septate junctions are situated in a 
region underneath the ZA, serve as a barrier, limiting the diffusion of membrane proteins 
and separate the apical from the basal components. In septate junctions the “Dlg-complex” 
includes Dlg, Scrib, and Camguk (Cask or Lin2, a MAGUK protein) (Mathew et al. 2002, 
Humbert et al. 2003), whereas the Lgl protein accumulates at the baso-lateral cortical matrix. 
In vertebrates the septate junctions are replaced by tight junctions, which are apical rather 
than basal to the adherens junctions and are composed of two integral membrane proteins, 
the Occludins and Claudins, and the proteins of the MAGUK family ZO-1, ZO-2 and ZO-3. 
In the Drosophila embryonic epidermis, mutations in dlg, scrib or lgl cause leakage of the 
apical protein Crumbs (Bilder et al. 2000, Bilder and Perrimon 2000). crumbs overexpression 
induces expansion of the apical domain and affects the formation of AJs (Wodarz et al. 1995, 
Grawe et al. 1996), similar to the scrib mutant phenotype (Bilder and Perrimon 2000), 
suggesting that laterally located tumor suppressor proteins regulate apical membrane 
polarity. Genetic analysis revealed antagonistic interactions between the apical Crumbs- and 
the lateral Dlg-complex, as crumbs and stardust mutants are rescued by mutations in dlg, scrib 
or lgl (Bilder, Schober and Perrimon 2003, Tanentzapf and Tepass 2003). Crumbs has one 
cytoplasmic motif that links it to the spectrin and actin cytoskeleton and one that interacts 
with polarity-regulatory factors such as Par6 and Stardust (Bulgakova and Knust 2009). The 
Par-complex plays a critical role in this antagonistic interaction (Humbert, Dow and Russell 
2006), as it restricts the Crumbs-complex apically, and the Par- and Crumbs- complexes act 
together to exclude the Dlg-complex from the apical membrane (Humbert et al. 2006, Bilder 
et al. 2003, Tanentzapf and Tepass 2003). This spatial segregation is facilitated by a 
biochemical interaction between the Scrib and Par complexes through Lgl (Hutterer et al. 
2004, Plant et al. 2003, Yamanaka et al. 2003, Betschinger, Mechtler and Knoblich 2003, 
Langevin et al. 2005). Moreover, in the Drosophila ectoderm, phosphorylation of aPKC is 
required for Lgl to establish the lateral domain and to prevent apical Lgl recruitment (Wirtz-
Peitz and Knoblich 2006, Hutterer et al. 2004).  
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In Xenopus, Lgl2 and aPKC act antagonistically to mutually regulate their localization and 
the establishment of apical-basal polarity in blastomeres (Chalmers et al. 2005). In Mardin-
Darby Canine kidney (MDCK) epithelial cells, studies of overexpression and RNAi-induced 
loss of function revealed that Lgl facilitates the establishment of apical-basal polarity 
through actively suppressing the formation of the Par-complex formation at the basal 
domain (Humbert et al. 2006, Yamanaka et al. 2003, Yamanaka et al. 2006). In zebrafish, Lgl2 
mutants show an epithelial-to-mesenchymal transition in basal epidermal cells, with loss of 
hemidesmosome formation and an increase in migratory behavior (Sonawane et al. 2005). At 
the same time, Lgl2 positively regulates hemidesmosome formation by mediating Integrin 
alpha 6 (Itga6)-targeting and maintaining its localization, while E-cad negatively regulates 
Itga6 targeting (Sonawane et al. 2009). Localization of aPKC in the basal epidermis is 
tightly correlated with Itga6 localization and hemidesmosome formation (Sonawane et al. 
2009). The role of Lgl and the Par-complex was also analyzed in the polarity establishment 
of the early C. elegans embryo, where they maintain two cortical domains which are 
sufficient to partition cell fate determinants in the C. elegans embryo, by a mechanism of 
“mutual exclusion” (Hoege et al. 2010). Lgl1 interacts with Par-2 in the posterior of the 
embryo, but Lgl1 can also compensate the function of Par-2 and restrict the anterior 
localization of the Par-complex, through a mechanism that involves Lgl phosphorylation 
(Hoege et al. 2010) and a negative regulation of non-muscle myosin-II at the posterior cortex 
(Beatty, Morton and Kemphues 2010) 
Of particular interest are studies that relate the adenomatous polyposis coli (APC) tumour 
suppressor to the mammalian Dlg homologues. Dlg1 was isolated in a yeast-two-hybrid 
screen and was found to directly interact with APC (Humbert et al. 2003, Ishidate et al. 
2000). Dlg3 also binds APC, thereby showing that this interaction is probably a common 
feature of Dlg family members. In the migrating astrocytes, vertebrate Dlg1 binds APC at 
the leading edge of migrating cells (Etienne-Manneville et al. 2005). In particular, activation 
of the Par6-PKC complex by Cdc42, at the leading edge of migrating cells, promotes the 
localized association of APC with microtubule plus ends and the assembly of Dlg-
containing puncta in the plasma membrane. Scrib also binds APC (Takizawa et al. 2006). As 
Dlg and Scrib can bind the Wnt signaling component APC, one could hypothesize that loss 
of Scrib or Dlg could interfere with the normal regulation of the APC--catenin complex, 
thereby leading to pro-migratory effects, if -catenin is stabilized and allowed to move to 
the nucleus (Humbert et al. 2006).  
In addition, Dlg, Scrib and Lgl play an important role in dorsal closure (DC), during which, the 
migration of the lateral epidermal leading edge (LE) cells closes the hole of the Drosophila 
dorsal epidermis. Loss of lgl results in defective DC (Manfruelli et al. 1996, Arquier et al. 2001) 
and loss of scrib together with one allele of dlg also results in incomplete DC (Bilder et al. 2000). 
Recent studies have shown that during DC the LE cells undergo a mesenchymal-to-epithelial-
like transition, during which integrin-mediated localization of the PAK serine/threonine 
kinase recruits Scrib in septate junction formation, required for epithelial plasticity (Bahri et al. 
2010). Wound healing is very similar to the DC in Drosophila and Scrib is here again a critical 
player in the polarization of migrating cells. During wound healing in the astrocytes, Scrib 
controls Cdc42 through its association with the exchange factor PIX (Osmani et al. 2006). By 
regulating Cdc42 activity, Scrib acts upstream of Dlg1 and is involved in the same molecular 
pathway controlling cell orientation. Cdc42 controls two distinct signaling pathways, 
promoting: 1) Rac- and PAK-dependent protrusion formation and 2) centrosome and Golgi 
reorientation through APC clustering and Dlg1 localization at the LE (Osmani et al. 2006). 
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The role of Dlg, Scrib and Lgl has also been studied in other tissue - specific epithelia. Dlg-1 
and Scrib are widely distributed throughout the eye in embryonic and postnatal 
development and overlap with E-cad and ZO-1 in portions of the cornea and retinal 
pigment epithelium; in contrast, little, if any, overlap with adhesion proteins is observed in 
the neural retina (Nguyen, Rivera and Griep 2005). Dlg1 was shown to be required for the 
development of lens epithelium in a cell autonomous manner as Dlg1 ablation leads to cell 
structure alterations and disposition of adhesion and cytoskeletal factors such as -catenin 
(Rivera et al. 2009). In the intestinal epithelium, Scrib regulates the integrity and plasticity of 
the epithelial barrier and TJ formation, by binding to the scaffolding protein ZO-1, 
independently of Lgl1 and Dlg1. The observation that Scrib is downregulated during 
intestinal inflammation provides the missing link to tumor development during chronic 
intestinal inflammation (Ivanov et al. 2010). Dlg1 localization at the basolateral side of the 
intestinal epithelium requires CASK, another MAGUK protein, however dlg1 mutations 
there cannot affect epithelial polarity (Lozovatsky et al. 2009). Data from the C. elegans 
intestinal epithelium show that Arp2/3, which promotes nucleation of branched actin, 
junction initiation and maturation, affects the subcellular distribution of Dlg (Bernadskaya 
et al. 2011). 
Dlg, Scrib and Lgl are also important in follicular epithelium morphogenesis and 
subsequent polarization of the Drosophila oocyte, albeit in a different way as in other 
epithelia. The work of several groups has shown that Lgl is an essential regulator of 
posterior follicle cells and that phosphorylation of Lgl together with Par-1 and Par-3 is 
required for the posterior translocation of oocyte-specific proteins and germline 
determinants (Fichelson et al. 2010, Doerflinger et al. 2010, Li et al. 2008). Mutation of the 
aPKC phosphorylation site in Par-1 results in the uniform cortical localization of Par-1 and 
the loss of cortical microtubules (Doerflinger et al. 2010). Dlg and Scrib are required 
differentially for patterning in both the anterior and posterior follicular epithelium (Li et al. 
2009) and genetically interact with Lgl for posterior follicle cell induction (Li et al. 2011), 
suggesting a common regulatory pathway in this process. At the same time, Lgl functions in 
a subdivision of anterior follicle cells into functionally distinct subpopulations and controls 
collective border cell migration at mid-oogenesis (Li et al. 2011).  
The multifunctional role of these TSGs can also be seen in the diverse binding partners and 
regulators in various cell environments. For example, Scrib1 was found to interact with LPP, 
a zyxin-related protein, which has been described as a partner in fusion proteins associated 
with different types of cancers (Petit et al. 2005, Lelievre 2010). Both Scrib and LPP localize 
at cell-cell contacts whereas LPP is also localized in the focal adhesions and the nucleus. This 
interaction links Scrib to a communication pathway between cell-cell contacts and the 
nucleus (Petit et al. 2005). A nuclear shuttling mechanism has also been described for Dlg1 
(Carr et al. 2009). Mammalian Scrib regulates also E-cad activity by stabilizing E-cad 
coupling to catenins (Qin et al. 2005). The stability and function of the mammalian Lgl is 
regulated by direct binding to the scaffolding RanBPM, a Ran-binding protein (Suresh et al. 
2010). Moreover, Dlg1, which is highly expressed in embryonic and adult tissues such as the 
brain, kidney, ovaries, olfactory bulb and cerebellum, can interact with Dlg3 (Mao et al. 
2008). In addition, Dlg1 can interact with the gap junction protein Connexin-32 through its 
SH3 domain (Duffy et al. 2007). Recent work on caspase target genes has provided evidence 
that Dlg1 is a direct target of caspase-3 and the unique cleavage site identified separates the 
C-terminal part of Dlg1 (containing PDZ3, SH3 and GUK domain) from the rest of the 
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protein. Interestingly, this exact C-terminal part is missing from the classical null allele 
(dlgm52) of the Drosophila Dlg mutant protein (Gregorc et al. 2005). This cleavage of Dlg1 
results in translocation away from sites of cell-cell contacts and is presumably an early step 
in disassembly of septate and adherens junctions and consequently intercellular detachment 
(Gregorc et al. 2005). 
 
 
Fig. 1. Overview of the multitasking role of Dlg, Scrib and Lgl in different cellular and tissue 
contexts. 
Dlg is also involved in T-cell receptor (TCR) signaling (Round et al. 2007), as Dlg1 
downregulation blocks TCR-induced activation of p38 and the transcription factor NFAT, 
but not the alternative protein kinase JNK or the NF-B transcription factor. Dlg1 directly 
binds p38, to drive signaling downstream of TCR towards the NFAT branch of the cascade 
and it has been shown to act as an orchestrator of TCR specificity (Round et al. 2007). Rho 
signaling plays an important role in TJ function and several studies of dominant active and 
negative mutants of rhoA, Rac and cdc42 revealed that they all disrupt the barrier function of 
TJs, with the most intense effect obtained with dominant active rhoA mutants (Gonzalez-
Mariscal, Tapia and Chamorro 2008). The RhoA/ROCK signaling pathway participates both 
in the assembly and disassembly of TJs. Moreover PKN1, a Rho effector protein, participates 
in the regulation of TJ sealing in the mammary gland by interfering with glycocorticoid 
signaling, consistent with observations that Rho activation perturbates TJ function in 
various experimental systems (Fischer et al. 2007). Furthermore, Net1 (neuroepithelioma 
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transforming gene), a RhoGEF specific for the RhoA subfamily of small G proteins, interacts 
with the PDZ domains of Dlg1 and relocalizes Dlg1 to the nucleus whereas the oncogenic 
mutant of Net1 sequesters Dlg1 in the cytosol (Garcia-Mata et al. 2007). In particular, Net1 
binding to Dlg1 in MCF7 breast cells, which is regulated by E-cad-mediated cell-cell 
interaction, enhances Net stability and increases Net1 ability to stimulate RhoA activation in 
these cells (Carr et al. 2009).  
2.2 Dlg, Scrib and Lgl in planar cell polarity 
The planar cell polarity (PCP) pathway, incorporating the non-canonical Wnt pathway, is 
best known for directing polarization of cells orthogonal to the apical-basal polarity axis 
within the plane of an epithelium. Apart from regulating the patterning of external 
epidermal structures such as wing hair cells in Drosophila and ciliary orientation, PCP 
controls embryonic convergent extension (CE), polarized cell division, cell direction and 
movement (Yates et al. 2010a). dlg, scrib and lgl are essential for planar cell polarity (PCP), by 
establishing a cross-talk between apical-basal and planar cell polarity. Dlg and Scrib have 
been shown to bind components of the core PCP machinery, including Frizzled receptors 
and the membrane protein Strabismus/Van Gogh (Stbm/Vang) (Montcouquiol et al. 2006, 
Kallay et al. 2006, Lee et al. 2003, Hering and Sheng 2002). The direct interaction of Dlg4 
with receptors of the Wnt signaling pathway, Frizzled 1-7, link mammalian Dlg to the 
Frizzled signaling (Humbert et al. 2003, Hering and Sheng 2002). Dlg1 is also required for 
smooth muscle orientation in the mouse ureter (Mahoney et al. 2006). In addition, Dlg binds 
through its PDZ1 and PDZ2 domains to Stbm/Vang in order to recruit membrane-
associated proteins and lipids from internal membranes to sites of new plasma membrane 
formation (Lee et al. 2003). In C. elegans, the unique PCP protein Vang-1 interacts with the 
PDZ2 domain of Dlg for its proper localization, which is required for intestinal tube 
formation, since in vang-1 mutant embryos the epithelial cells of the intestine are not 
correctly arranged along the anterior-posterior axis (Hoffmann et al. 2010). Moreover, the 
Pins/Dlg complex is required to establish PCP during asymmetric cell division in the 
sensory organ precursor cell of the notum (Bellaiche et al. 2001).  
Interestingly, the mouse scrib gene genetically interacts with the vangl2 gene, a mammalian 
homologue of the Drosophila stbm/vang gene, involved in PCP (Montcouquiol et al. 2003). 
Analysis of PCP in hair cell stereociliary bundles within the cochlea in mammals, showed 
that Scrib is a prerequisite for the proper localization and function of PCP proteins among 
which is also Vangl2 (Montcouquiol et al. 2003). Further studies revealed that both 
mammalian and Drosophila Scrib physically interact with Vangl2 (Kallay et al. 2006) and 
Stbm/Vang (Courbard et al. 2009) respectively, through their PDZ domains to regulate 
normal development in Drosophila wing imaginal discs (Courbard et al. 2009), heart tube 
and cardiomyocyte organization (Phillips et al. 2007), and neural tube closure (Wen et al. 
2010, Wansleeben et al. 2011). Scrib is also implicated in PCP-mediated neural tube closure 
through binding to Cdx, a homeodomain transcription factor which regulates transcription 
of the Ptk7 PCP gene (Savory et al. 2011). A PCP-mediated requirement of Scrib has also 
been demonstrated for lung development (Wansleeben et al. 2011) and branching 
morphogenesis (Yates et al. 2010b), for kidney-branching morphogenesis and glomerular 
maturation (Yates et al. 2010a), and for the tangential migration of facial branchiomotor 
(FBM) neurons (Walsh et al. 2011). All these later studies provide insights on a very 
interesting and yet poorly understood role of Scrib on PCP-mediated organogenesis and the 
interplay of apicobasal and PCP pathways.  
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Spatial organization of cells and their appendages is controlled through the PCP by a 
signaling cascade initiated by the protocadherin Fat in Drosophila. Fat acts through two 
distinct branches: the Fat polarity pathway and the Fat tumor suppressor/Hippo pathway. 
Vertebrates express four Fat molecules, Fat1-4. Indeed, Scrib provided the link between the 
Fat and the Hippo signaling cascade in vertebrates. Fat1 depletion causes abnormal cyst 
formation in the zebrafish pronephros, a phenotype underlying a strong genetic and direct 
interaction between Fat1 and Scrib. The observation that depletion of Yes-associated protein 
1, a transcriptional co-activator inhibited by the Hippo pathway, ameliorated the changes 
caused by fat1 and scrib knockdown, shows that in the absence of Scrib and Fat1, it is the 
deregulation of the Hippo pathway which contributes to the formation of abnormal 
pronephric cysts (Skouloudaki et al. 2009). 
As already mentioned, the non-canonical Wnt/Wg pathway plays a central role in PCP. A 
key switch at its branch point appears to be the Dishevelled (Dsh) protein, which is required 
for both PCP and the canonical Arm/β-Catenin pathway (Wodarz and Gonzalez). 
Interestingly, a physical and functional interaction has been reported between Lgl and the 
signaling protein Dishevelled (Dsh) (Dollar et al. 2005). Asymmetric localization of Dsh 
leads to spatially defined areas of Lgl upregulation, which allows directional tissue 
morphogenesis and PCP organization of epithelial sheets in Drosophila embryos (Kaplan and 
Tolwinski 2010). In humans, Lgl2 plays a critical role in branching morphogenesis during 
placental development. Lgl2 regulates cell polarization and polarized-cell invasion guiding 
trophoblast invasion, yet a connection to the PCP pathway is not established so far 
(Sripathy, Lee and Vasioukhin 2011).  
2.3 Orientation of cell division, spindle, microtubule and centrosome positioning 
Orientation of cell division is important in establishing and maintaining normal 
development and tissue homeostasis from bacteria to mammals. A correct cell division 
plane is critical during asymmetric cell division, spindle orientation, microtubule and 
centrosome positioning. Several studies point out the key roles of Dlg, Scrib and Lgl in 
multiple aspects of cell division orientation.  
One of the most well studied systems is the asymmetric division of the Drosophila neural 
stem cells, the so-called embryonic neuroblasts. These studies indicate that dlg, scrib and 
lgl have a function in the correct placement of cell-fate determinants, in dividing 
neuroblasts. Dysregulation of the mechanisms, which control the neuroblast asymmetric 
division, results in compromised inheritance of cell-fate determinants, triggers neoplastic 
transformation and promotes brain tumors (Merz et al. 1990, Caussinus and Gonzalez 
2005, Betschinger, Mechtler and Knoblich 2006, Lee et al. 2006). Neuroblast division gives 
rise to a larger daughter cell that remains a neuroblast and a smaller daughter cell that 
becomes a ganglion mother cell (GMC). This process involves the segregation of the 
basally localized cell-fate determinants Numb, Prospero (Pros) and Brain tumor (Brat) 
proteins and their adaptor proteins Partner of Numb (Pon) and Miranda (Mira), into the 
basal GMC. This segregation is controlled by apically localized components including the 
Par-complex (Baz/Par3, Par6 and aPKC), as well as the Inscutable (Insc) and Partner of 
Inscutable (Pins) proteins. Dlg, Scrib and Lgl proteins display a cortical localization, with 
apical enrichment during early mitosis. Insc and Insc-dependent proteins (Insc/Par 
pathway) are required for the maintenance and apical enrichment of Dlg and Scrib 
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proteins whereas Dlg controls the cortical recruitment of both Scrib and Lgl. In dlg, scrib 
and lgl mutants the localization of the apical proteins is normal but the basal protein 
targeting is defective, resulting in a reduced apical cortical domain and a smaller size of 
the apical spindle. Therefore, Dlg, Scrib and Lgl are important in regulating cortical 
polarity, cell size asymmetry and mitotic spindle asymmetry in Drosophila neuroblasts 
(Albertson and Doe 2003). 
The fact that apical Dlg, Scrib and Lgl may promote apical spindle pole growth is consistent 
with the observation that vertebrate Dlg orthologues physically interact with known 
microtubule-binding proteins (Albertson and Doe 2003, Brenman et al. 1998, Niethammer et 
al. 1998, Matsumine et al. 1996, Hanada et al. 2000). In Drosophila, kinesin Khc-73 and Dlg 
induce cortical polarization of Pins/Gai, acting in parallel to the Insc/Par pathway. 
Interestingly, Khc-73 localizes to astral microtubule plus ends and the Dlg/Khc-73 and 
Dlg/Pins protein complexes have been found to co-immunoprecipitate, suggesting that 
microtubules induce Pins/Gai cortical polarity through Dlg/Khc-73 interactions (Siegrist 
and Doe 2005, Ahringer 2005). The recent identification of an evolutionary conserved 
PinsLINKER domain uncovered a linear PinsLINKER/Aurora-A/Dlg spindle orientation 
pathway, which links the plus ends of astral microtubules to the Dlg cortical domain 
(Johnston et al. 2009).  
Additionally, Dlg1 is important for centrosome positioning in the astrocytes. During 
wound-induced cell migration Cdc42 acts through Dlg1, in order to regulate the interaction 
of dynein with microtubules of the cell front (Manneville, Jehanno and Etienne-Manneville 
2010). Dlg1 interacts with dynein via the scaffolding protein GKAP and all three proteins 
together control microtubule dynamics and organization near the cell cortex and at the 
microtubule-organizing center (MTOC), ultimately leading to centrosome positioning. 
Moreover, Dlg1 colocalizes with APC at microtubule plus-ends to promote microtubule 
polarization and centrosome reorientation (Etienne-Manneville et al. 2005, Etienne-
Manneville and Hall 2003). However, the Dlg1-mediated recruitment of dynein is 
independent of its interaction with APC (Manneville et al. 2010). A crucial function of Dlg1 
on microtubules has also been established for immunological synapses (Lasserre et al. 2010, 
Lasserre and Alcover 2010). Dlg1 and the cell cortex membrane-microfilament linker Ezrin 
are key players for synapse stability and symmetry. Ezrin silencing alters cell spreading and 
microtubule network organization at the immune synapse and leads to enhanced T-cell 
receptor (TCR) signaling (Lasserre et al. 2010). Ezrin-Dlg1 interaction keeps the microtubule 
architecture at the synapse, which in turn drives signaling microcluster dynamics and 
downregulation of the TCR receptor signaling. Similar to the role of Dlg1 in MTOC 
positioning during astrocyte migration (Etienne-Manneville et al. 2005), Ezrin and Dlg1 are 
necessary for a similar positioning of microtubules at the periphery of the immunological 
synapse (Lasserre et al. 2010). 
Finally, Scrib is required for oriented cell division in the neural keel to promote 
morphogenesis of the neural tube epithelium (Zigman et al. 2011). Analysis of scrib mutants 
revealed a role of Scrib in controlling clustering of -catenin foci in dividing progenitors that 
correspond to the future subapical junctional complexes of the mature epithelium. This 
function of Scrib, which is independent of the canonical apicobasal polarity and PCP 
pathways, stresses the importance of single-cell orientation for tissue-level morphogenesis 
(Zigman et al. 2011).  
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2.4 Trafficking, exocytosis and polarized membrane insertion  
Exocytosis is an important membrane traffic event that mediates the transport of secreted 
and transmembrane proteins, as well as lipids to the cell surface (Hsu et al. 2004). This 
transport is highly polarized and tightly regulated, so that the molecular identity of the 
apical and basolateral membrane domains is maintained. It has already been proposed that 
the junctions in mammalian epithelial cells promote the correct spatial organization of 
cellular components by acting as sorting sites for a subset of vesicles (Humbert et al. 2008).  
The mechanisms that specify vesicle docking and fusion of intracellular membranes rely on 
the SNARE proteins, with t-SNAREs localized in a polarized distribution on the target 
membranes and v-SNAREs on the vesicles. When a v-SNARE encounters its cognate t-
SNARE they assemble into a tight complex, which brings together the apposed membranes 
sufficiently close to each other for fusion to occur. As an example, Drosophila embryos with 
mutated Syntaxin 1 (Syn1), a t-SNARE protein uniformly distributed on target membranes, 
fail to cellularize (Burgess, Deitcher and Schwarz 1997). The spatial specificity of vesicle 
trafficking also relies on the tethering of exocytic vesicles, at defined membrane sites, by the 
eight-subunit exocyst (or Sec6/7) complex. Recent work has shown that the Exo84 
component of the exocyst complex is required for membrane trafficking from the recycling 
endosome to the cell surface and the apical localization of the transmembrane protein 
Crumbs, whereas the mutant phenotype is suppressed by down-regulation of the Dlg and 
Lgl proteins (Blankenship, Fuller and Zallen 2007). Interestingly, in yeast the Lgl 
homologous proteins Sro7p and Sro77p directly interact with Exo84p and the t-SNARE 
protein Sec9p (Zhang et al. 2005), whereas the mammalian Lgl binds Syntaxin-4, a t-SNARE 
protein that mediates vesicle fusion, in order to direct protein trafficking (Musch et al. 2002). 
As the exocyst decides not only what fuses with the plasma membrane but also the site of 
fusion, we can conclude that Lgl family proteins affect asymmetric protein localization by 
targeted vesicle fusion (Wirtz-Peitz and Knoblich 2006). Furthermore, type V myosin 2 
(Myo2) physically binds Sro7 and negatively regulates Sro7 function in vesicle clustering 
(Rossi and Brennwald 2011). Myo2 serves in a dual function: to recruit Sro7 to secretory 
vesicles and to inhibit its Rab-dependent tethering activity until vesicles reach the plasma 
membrane. Taken together, Sro7 appears to coordinate the spatial and temporal nature of 
both Rab-dependent tethering and SNARE-dependent membrane fusion of exocytic vesicles 
with the plasma membrane (Rossi and Brennwald 2011). 
Furthermore, Scrib has been shown to have an important role in regulating exocytosis in 
neuroendocrine cells through its association with the -Pix-GIT1 complex (Audebert et al. 
2004, Humbert et al. 2008). Scrib acts as a membrane anchor for -Pix, a guanine exchange 
factor (GEF), which activates Rac1 and recruits it to a functional complex regulating 
exocytosis of Ca++-regulated hormone release (Momboisse et al. 2009). Since small Rho-
GTPases have emerged as key players in membrane trafficking and Rac isoforms have been 
involved in various processes of exocytosis, this recent work uncovers the actual function of 
Scrib, -Pix and Rac1 in exocytosis, in addition to their well-established role in cancer 
(Momboisse et al. 2009). 
While polarized exocytosis of proteins is one of the most studied mechanisms responsible 
for the maintainance of cell polarity, polarized transport of specific mRNAs represents an 
alternative pathway (Vasioukhin 2006). It has been demonstrated that Lgl genetically 
interacts and is present in a complex with the fragile X syndrome protein FMRP, which is 
responsible for mRNA transport (Zarnescu et al. 2005). This interesting finding suggests that 
Lgl may be involved in polarity by regulating the localization of specific mRNAs.  
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Dlg plays an important role in polarized membrane insertion during cellularization. It is 
known that polarized membrane growth relies on the guiding cues of junctional and peri-
junctional proteins (Lecuit and Wieschaus 2002). The Drosophila cellularizing blastoderm 
provides an excellent system for studying the genetic analysis of how polarity is established, 
reinforced and maintained in vivo. During cellularization, an epithelium is formed de novo by 
growth and invagination of plasma membrane between the cortical nuclei, leading to a 20-30 
fold increase of membrane surface and formation of the first columnar epithelial cells 
(~30µm) (Mazumdar and Mazumdar 2002). This process requires the remobilization of the 
intracellular membrane reservoir from the endoplasmic reticulum (ER) and Golgi. 
Membrane trafficking is regulated in a way that allows polarized membrane delivery, with 
the secretory pathway and the membrane-recycling pathway guiding the membrane 
deposition (Dudu, Pantazis and Gonzalez-Gaitan 2004, Strickland and Burgess 2004). In the 
secretory pathway, membrane proteins are recruited from post-Golgi vesicles to the lateral 
domain of growing membranes by the Strabismus/Van Gogh (Stbm/Vang)-Dlg complex. 
Dlg localizes to the plasma membrane along the newly formed invaginating membrane, 
whereas Stbm/Vang is localized initially to the Golgi. Both Stbm/Vang and Dlg are 
required for membrane deposition during cellularization and their simultaneous 
overexpression induces expansion of the lateral membrane (Lee et al. 2003). In the 
membrane-recycling pathway, the apical membrane is internalized through a Dynamin-
dependent process, travels through the Rab5 early endosome and Rab11 recycling 
endosome acting together with Nuf, and finally becomes exocytosed at the lateral 
membrane (Dudu et al. 2004, Strickland and Burgess 2004, Pelissier, Chauvin and Lecuit 
2003, Riggs et al. 2003, Lecuit 2004).  
2.5 Critical functions in neuromuscular junctions and synapses  
One of the most broadly used systems to study Dlg and Scrib function has been the 
neuromuscular junctions (NMJs). Dlg was shown to be present in glutamatergic larval 
NMJs. Glutamate receptors (GluR) in Drosophila NMJs are of two different types, 
comprised of either GluIIA (A-type) or GluIIB (B-type) subunits, as well as the common 
subunits GluIIC, GluIID and GluIIE (Collins and DiAntonio 2007). Dlg controls the 
subunit composition of the receptor by selectively stabilizing B-type receptors at the 
synapse, whereas Coracle is required for A-type receptors (Chen and Featherstone 2005, 
Chen et al. 2005). Dlg is abundantly expressed through the postsynaptic membrane 
surrounding the presynaptic motor axon terminals. During larval development, the 
postsynaptic membrane increases enormously leading to a highly convoluted and 
multilayered postsynaptic membrane structure, the subsynaptic reticulum (SSR). Several 
years of research in this field have shed light on the role of the different Dlg protein 
domains (Thomas et al. 2000) and their binding partners (Thomas et al. 2000, Thomas et 
al. 1997a, Zito et al. 1997), the role of phosphorylation on Dlg regulation (Koh et al. 1999, 
Beumer et al. 2002, Zhang et al. 2007) and the key role of Dlg on membrane proliferation 
in the SSR of GluIIB-type receptors (Chen and Featherstone 2005, Roche et al. 2002). The 
synaptic targeting and localization of Dlg is a stepwise process controlled by different 
domains of the protein (Thomas et al. 2000). The localization of the postsynaptic Dlg was 
also investigated during synapse remodeling of larval NMJs, whereby the adult-specific 
synapses are generated. During synapse dismantling, postsynaptic Dlg becomes diffuse 
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and then undetectable, followed by SSR vacuolization, through a mechanism different 
than that of GluRs elimination (Liu et al. 2010b). 
Dlg is important for proper NMJ establishment as dlg- NMJs have defects in synapse 
structure and function, including an increase in bouton size and number of active zones 
presynaptically, as well as a poorly developed SSR (Chen and Featherstone 2005). Dlg 
regulates SSR expansion and is also required for clustering Fasciclin II (FasII) and Shaker 
proteins (Thomas et al. 1997a, Zito et al. 1997). Dlg-dependent localization of FasII to the 
Drosophila GluRIIB NMJs is negatively regulated by Ca++/calmodulin dependent kinase 
II (CaMKII) (Koh et al. 1999), with βPS-Integrin (encoded by myospheroid in Drosophila) 
acting upstream of CamKII. Upon increased synapse activity, CaMKII phosphorylates 
Dlg, which dissociates from the synaptic protein complex, releases FasII, and allows for 
developmental growth in signal response (Beumer et al. 2002). However, sh and fasII 
mutations do not affect the SSR, meaning that Dlg plays a role in postsynaptic membrane 
regulation independent of its interaction to Sh and FasII (Schuster et al. 1996a, Schuster et 
al. 1996b). Further studies have shown that expression of a constitutively active form of 
CaMKII abolishes the accumulation of Dlg at synapses, while exerting no significant effect 
on the presynaptic area and localization of FasII (Morimoto et al. 2010). Postsynaptic 
targeting of Dlg is negatively regulated by PAR-1, which phosphorylates Dlg at a 
conserved Ser residue within the GUK domain (Zhang et al. 2007). PAR-1 and Dlg both 
affect pre- and post-synaptic development and function in a dose-dependent way. PAR-1 
overexpression and Dlg inactivation lead both to active zone increase and SSR loss, 
whereas loss of PAR-1 and Dlg overexpression have the opposite effect and therefore 
confirm the antagonistic effect of PAR-1 on Dlg (Zhang et al. 2007). Like Dlg, Pumilio 
(Pum), a known transcriptional regulator of embryonic patterning and germline 
development, appears to have both pre- and post-synaptic effects in NMJs and is co-
localized with Dlg and GluIIB-type boutons (Chen et al. 2008). Notable Pum directly 
regulates dlg by binding to the Dlg-3’UTR, thereby antagonizing the effects of Dlg on 
neuronal structure and/or function also in the adult mushroom bodies, the anatomical 
site of memory storage (Chen et al. 2008). 
The Drosophila dlg gene codes for two isoforms, the DlgA and DlgS97 collectively referred 
to as Dlg, which have been individually studied in NMJs. Both isoforms are present at the 
NMJs, but mutations that specifically abolish DlgS97 leave FasII largely unaffected 
(Albornoz et al. 2008). DlgS97 exerts its function at the NMJs by binding to Metro, a novel 
MAGUK protein, which stabilizes the complex of DlgS97 and the adaptor protein DLin-7 
(Bachmann et al. 2010). In a remarkably interdependent manner, Metro and DLin-7 act 
downstream of DlgS97 to control NMJ expansion and proper establishment of synaptic 
boutons, making this tripartite an important perisynaptic scaffolding complex (Bachmann 
et al. 2010).  
Membrane addition by vesicle fusion commonly involves SNARE proteins. Recent work 
has shown that Dlg binds and controls postsynaptic localization of the t-SNARE GUK-
interacting syntaxin (Gtaxin). Gtaxin is required for proper SSR expansion and controls 
synaptic and muscle development in a dose-dependent manner (Gorczyca et al. 2007). 
Gtaxin’s closest Homologues, Syntaxin 18 and Ufe1p, can mediate homotypic 
endoplasmic reticulum (ER) membrane fusion in the absence of other known SNAREs 
(Lewis and Pelham 1996, Patel et al. 1998, Hatsuzawa et al. 2000). The presumptive role of 
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Gtaxin as part of the ER-specific vesicle fusion machinery, together with its requirement 
for SSR development, supports the idea that SSR bears at least some ER-like properties 
(Gorczyca et al. 2007).  
Moreover, Dlg interacts at the synapses with Scrib, through simultaneous binding of both 
the Dlg-GUK domain and the Scrib-PDZ2 domain to the synaptic protein GUK-holder 
(Gukh) (Mathew et al. 2002). Apart from an increased number of active zones and reduced 
SSR, dlg- NMJs show severe mislocalizaton of synaptic Scrib. Loss of scrib in NMJs  
results in synaptic vesicle increase, decrease in the number of active zones and a 
thickened basal lamina, however Dlg localization and the SSR remain unaffected (Mathew 
et al. 2002). Apparently, the synaptic levels of Scrib have an opposite effect than Dlg in 
active zone number and Scrib negatively regulates Dlg function in NMJs, in contrast to 
their cooperation in epithelial cells and neuroblasts (Roche et al. 2002). This probably 
reflects the ability of Dlg and Scrib to exert their function through binding to different 
protein partners with distinct functions, according to their availability in the various 
tissues.  
Scrib is also capable of influencing the morphology and function of synapses (Moreau et 
al. 2010). It is expressed in the soma and dendrites of adult hippocampal pyramidal cells, 
to regulate neuron maturation, with the synaptic strength and plasticity severely affected 
in scrib mutant mice. In the hippocampus of these mutants, the phenotype is associated 
with Rac1 activation and defects in actin reorganization, which ultimately affect memory 
consolidation. Scrib effects on brain function and the corresponding effects on enhanced 
learning, memory abilities and impaired social behavior, provide a step forward in the 
dissection of Scrib roles in the pathophysiology of behavior (Moreau et al. 2010). Dlg is 
also found at the lamina of the photoreceptor synapses. Immuno-electron microscopy 
revealed that Dlg marks the round profiles of R1-R6 ommatidia terminals and the 
photoreceptor membrane around the invaginating head of capitate projection organelles, 
which are the organelles from the surrounding glia (Hamanaka and Meinertzhagen  
2010). 
2.6 Tubulogenesis and trachea development 
A less studied role of these tumor suppressor genes involves their function in 
tubulogenesis, which is the regulation of epithelial tube morphogenesis and size control 
in organs such as kidney, lungs, vascular system and the Drosophila trachea. So far, several 
studies pointed the significance of septate junctional proteins in trachea tube-size 
regulation (Paul et al. 2003, Wu and Beitel 2004) but more recent studies reveal a novel 
mechanistic framework for understanding epithelial tube size regulation in trachea. In the 
Drosophila trachea, tube dimensions are regulated by the luminal extracellular matrix 
(ECM). ECM organization requires the apical secretion of the protein Vermiform (Verm), 
which depends on the basolateral septate junctions (SJs) (Wang et al. 2006, Swanson and 
Beitel 2006). Scrib and Yurt (Yrt), another SJ-associated protein, cause tracheal tube 
expansion through a Verm-independent pathway (Laprise et al. 2010). Zygotic loss of 
scrib, dlg and lgl result in excessively long dorsal trunks, indicating that these genes are 
critical for tube size control. Zygotic loss of lgl expression causes fully penetrant defects in 
SJ paracellular barrier function, whereas zygotic scrib and dlg mutants do not have 
compromised transepithelial barriers. Furthermore, Lgl together with Crumbs have an 
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additional role in apical constriction of tracheal cells, independent of their apicobasal 
polarity function in trachea epithelial cells (Letizia et al. 2011). Interestingly, Scrib and 
Crumbs do not display, during trachea elongation, the antagonistic functional interactions 
they have during apicobasal polarity establishment (Laprise et al. 2010). Therefore, it 
becomes obvious that the mechanism regulating trachea morphogenesis involves 
functional interactions between polarity proteins, which are different from those involved 
in epithelial apicobasal polarity.  
2.7 Lgl and salivary gland histolysis in Drosophila 
Although the architecture of the cells is defective in the neoplastic tissues, the structure of 
the other tissues is nearly normal, indicating that the loss of cell polarity may not 
necessarily be the major cause of cell transformation. Therefore, further investigations of 
lgl mutant tissues and organs are important in order to unravel distinct mechanisms with 
critical roles in tumorigenesis. Along these lines the larval salivary glands constitute a 
particularly suitable model system for studying developmental cell fate, as the glands are 
essentially made of one single type of large epithelial cells, containing highly polyploidy 
nuclei with polytene chromosomes. The salivary glands produce and secrete glue proteins 
at the onset of metamorphosis and all the cells then degenerate synchronously in a rapid 
process resulting in a full histolysis of this tissue in about 14 hours. The lgl gene critically 
controls the degenerative process leading to salivary gland histolysis (Farkas and Mechler 
2000 and references therein) and recent studies revealed that the lgl gene controls this 
degenerative process, which is induced by the steroid hormone ecdysone during 
metamorphosis. This process happens to be fully independent from the function of lgl in 
cell polarity (Farkas and Mechler 2000). Previous results have shown that reduced lgl 
expression delays salivary gland histolysis whereas over-expression accelerates this 
process without affecting larval and pupal development. More recent investigations have 
shown that the Lgl protein in combination with nonmuscle myosin regulate in the 
cytoplasm access to chromatin modifiers, remodeling and transcription factors necessary 
for the implementation of salivary gland degeneration (Farkas et al. 2011). This process is 
relatively complex and involves the steroid activation of Broad-Complex (BR-C), a 
BTB/POZ-transcription factor and primary response component in this cascade, which 
leads to salivary gland histolysis and induction of a set of secondary genes. In wild type 
salivary glands, chromatin remodeling factors are localized in the nucleus to bind 
chromatin. In lgl salivary glands the BR-C Z1 factor is synthesized, but is unable to bind to 
chromatin, and accumulates in the cytoplasm and in the cortical nuclear zone devoid of 
chromatin (Farkas et al. 2011) and additionally the secondary genes remain quiescent 
(Ashburner 1974; Richards 1976). Through a cascade of gene expression the salivary 
glands undertake profound morphological changes, characterized by the secretion of 
cellular components into the lumen of the gland, which ultimately leads to the death of 
the cells upon activation of death genes and caspases. Although the mechanism by which 
chromatin access of remodeling and transcription factors is regulated by lgl is poorly 
understood, the occurrence of WD40 motifs in the Lgl protein and the requirement of non-
muscle myosin heavy chain suggest that these factors may bind to Lgl in order to be 
assembled together with other components or alternatively become modified to get access 
to chromatin.  
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3. Dlg, Scrib and Lgl in cancer development 
3.1 New emerging roles for vertebrate dlg, scrib and lgl  
Neoplastic growth depends on the cooperation of several mutations, ultimately leading to 
major rearrangements in cellular behavior. Changes in tissue homeostasis, acquisition of 
invasive cell characteristics and tumor formation are often linked to the loss of epithelial cell 
polarity. During carcinogenesis, the grade of neoplasia correlates with impaired cell 
polarity. dlg, scrib and lgl encode tumor suppressor proteins and orthologs of this 
evolutionary conserved pathway are lost in human carcinomas with high frequency 
(Humbert et al. 2003, Humbert et al. 2008, Yamanaka and Ohno 2008, Reischauer et al. 2009). 
Although the role of these genes in mammals is still not well understood and often 
controversial, accumulated evidence has shed light on their oncogenic and tumor-
suppressing function.  
Scrib and Dlg1 are targeted for ubiquitin-mediated proteolysis by the E6 oncoprotein from 
high-risk strains of human papillomavirus (HPV) (Humbert et al. 2003, Gardiol et al. 1999, 
Nakagawa and Huibregtse 2000, Tomaic, Pim and Banks 2009), which has a causal role in 
the development of cervical cancer (Nakagawa et al. 2004). Furthermore, the viral human T-
Lymphoma virus type 1 (HTLV1) Tax protein, crucial for viral replication and malignant 
transformation leading to T-cell leukemia, binds directly to Dlg1 resulting in 
hyperphosphorylation of Dlg, which promotes abnormal proliferation of cells (Grassmann, 
Aboud and Jeang 2005, Hall and Fujii 2005). Both Tax and high-risk HPV E6 bind to the PDZ 
domains of Dlg through their specific PDZ-binding motif (PBM) they contain (Hall and Fujii 
2005). In addition, the PBM-containing Tax and APC compete for binding to Dlg (Hall and 
Fujii 2005), thereby providing insights on how viral proteins interfere with normal cell 
function. Similarly, the PBM domain of the NSI protein, from the highly pathogenic avian 
influenza A virus H5N1, contains an ESEV motif, which allows it to bind directly to Dlg, 
Scrib and other PDZ-containing proteins (Liu et al. 2010a). Notably, NSI proteins, with an 
ESEA-containing PBM domain, can enhance viral replication up to 4-fold, relocalize Scrib 
into cytoplasmic puncta concentrated in perinuclear regions and also protect cells from 
apoptosis. As this latter effect on apoptosis can be reversed by introducing scrib-siRNAi, 
these viruses most likely perform their function by disrupting the Scrib proapoptotic 
function (Liu et al. 2010a). 
Several pieces of evidence show that human Dlg and Scrib are downregulated during 
malignant progression of colon and lobular breast cancers (Gardiol et al. 2006, Navarro et al. 
2005). Both proteins colocalize in colon mucosa and changes in their expression patterns are 
correlated with loss of tissue architecture during carcinogenesis in the colon (Gardiol et al. 
2006). Another study shows that Dlg1, Scrib and Lgl1 are widely distributed in normal 
ocular tissues, particularly in the retinal neurons, but upon ocular carcinogenesis these 
proteins are initially mislocalized in retinal layers and subsequently downregulated. The 
decreased levels of these proteins are related to the late invasive stage of this cancerous 
process (Vieira et al. 2008). In the mammary epithelia, Scrib depletion disrupts cell polarity, 
blocks three-dimensional morphogenesis, inhibits apoptosis and induces dysplasia in vivo 
(Zhan et al. 2008). In this tissue type, Scrib cooperates with c-Myc in order to induce 
epithelial changes and tumors, by blocking activation of the apoptotic pathway. 
Interestingly, spontaneous mammary tumors in mice and humans exhibit both 
downregulation and mislocalization of Scrib (Zhan et al. 2008). Decreased expression and 
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changed localization of Scrib is also associated with histopathological differentiation and 
lymph node metastasis in endometrial cancer (Ouyang, Zhan and Dan 2010) whereas 
Scrib cytoplasmic mislocalization is also associated with T-cell leukemia (Okajima et al. 
2008).  
A study performed in colorectal adenomas and adenocarcinomas suggested that Scrib could 
also be involved in the early steps of colon carcinogenesis (Kamei et al. 2007), as 
overexpression and cytoplasmic distributions of Scrib were primarily identified as early 
events of this process. In these colon cells, Scrib accumulation was shown to overlap with 
the cytoplasmic accumulation of -Catenin, suggesting that changes in the APC/-Catenin 
pathway during colon carcinogenesis could be involved in Scrib mislocalization (Kamei et 
al. 2007). A very recent study has shown that Scrib is universally overexpressed in cultured 
tumor cell lines and genetically disparate cancer patient series of tissues such as colon, liver, 
lung, bladder, breast, ovary, uterus, testis, prostate and CNS (Vaira et al. 2011, Namdarian et 
al. 2011). Likewise, normal membrane association of Scrib is altered in tumors where Scrib is 
mislocalized in the cytosol. In a lung adenocarcinoma model, small interfering RNA 
silencing of Scrib inhibited tumor cell invasion (Vaira et al. 2011). Furthermore, the small 
non-coding RNA microRNA 296 (miR-296), which is progressively lost during tumor 
progression in a number of cancers, transcriptionally represses Scrib. In turn, loss of miR-
296 causes aberrant increase and mislocalization of Scrib in human tumors, uncovering a 
new regulation of Scrib in cancer (Vaira et al. 2011). Lgl1 has also been associated with poor 
clinical prognosis for cancer patients. In colorectal and breast carcinoma lines, ZEB1 (a Zfh-1 
family member of transcription factors) regulates the levels of Lgl2 (Reischauer et al. 2009). 
In zebrafish, the observation that epidermal neoplasia and epidermal-to-mesenchymal 
transition (EMT) in lgl2 mutants is promoted by the ErbB signaling, a pathway of high 
significance in human carcinomas, provides another mechanistic link between neoplasia and 
TSGs (Reischauer et al. 2009).  
3.2 New insights into the mechanisms of cancer initiation and progression 
In the last years, a great number of very interesting publications provided us with 
information on new and unexpected findings on the role of scrib, lgl and dlg in cancer 
initiation and the progressive steps leading to tumorigenesis. In particular, these TSGs 
helped us to understand the role of cell competition and of the tumor microenvironment in 
tumor survival and progression, as well as the role of JNK-mediated apoptosis in this 
system. To date, research on scrib, lgl and dlg has focused on their similar effects and 
phenotypes, the interdependent localization in various tissues and the cooperation of the 
three genes in establishing polarity. Nowadays, it becomes obvious that they play a broader 
role than initially thought, through the cooperation with individual partners and signaling 
pathways, in a tissue and cell-type specific context. The cellular context and the 
neighbouring cells of the surrounding tumour environment are recognized as important 
regulators in cancer progression (Brumby and Richardson 2005, Humbert et al. 2008, 
Mohamet, Hawkins and Ward 2011, Pagliarini and Xu 2003, Schmeichel 2004, Woodhouse 
and Liotta 2004). Along these lines, the analysis of cancer-disposing mutations in only a 
subset of cells or in clones within the context of a wild type surrounding is gaining more 
interest, compared to the analysis of the multi-step nature of tumor progression in the 
context of a whole organism, since it offers a reasonable approximation to the clonal nature 
of human cancers.  
Refining the Role of Dlg, Scrib and Lgl in  
Tumor Suppression and Beyond: Learning from the Old Time Classics 
 
197 
Analysis of scrib- mutant clones in the Drosophila eye imaginal discs has shown that tumor 
development is suppressed by the JNK-mediated apoptotic pathway activated by the 
surrounding wild-type cells, whereas the neoplastic and metastatic potential is regained 
through the synergistic effect of a simultaneous up-regulation of Ras signalling within the 
same clones (Pagliarini and Xu 2003, Brumby and Richardson 2003, Leong et al. 2009). 
These results underline the effect of the surrounding normal cells on the transformed 
scrib- clonal cells, which leads to a cell competition similar to the one observed in the 
mammalian cancers (Etienne-Manneville 2009, Tapon 2003, Kango-Singh and Halder 
2004, Vidal et al. 2010, Leong et al. 2009, Wu, Pastor-Pareja and Xu 2010) (Figure 2). In a 
model for Scrib tumorigenesis, analysis of the downstream pathways in scrib- epithelial 
clones revealed that the polarity defects are mediated by aPKC, independent of Crumbs, 
whereas an excessive cell proliferation is restrained by JNK-mediated apoptosis. Upon 
simultaneous activation of either Ras or Notch, JNK-mediated apoptosis is blocked, and 
Ras/Notch together with JNK cooperatively promote tumor growth and invasion (Leong 
et al. 2009). In other words, while JNK activation promotes the death of scrib- clones, JNK 
drives tumor progression in the context of Rasv12scrib- clones (Vidal 2010). Another report 
provided a molecular link between loss of polarity and tumorigenesis, since scrib-, dlg- and 
lgl- clonal cells in a wild type surrounding become metastatic only in combination with 
Rasv12 activation, resulting in JNK activation and E-cad inactivation (Igaki, Pagliarini and 
Xu 2006). A study in malpighian tubules proceded a step further, showing that indeed Ras 
functions downstream of Scrib to regulate the transformation of normal stem cells to 
cancer stem cells, and that several signal transdunction pathways (including MAPK, 
RhoA, PKA and TOR) mediate the function of Ras to promote this stem cell 
transformation (Zeng et al. 2010). Competition between clonal tissues and wild type 
surrounding can involve several players, since in Rasv12scrib- epithelial clones 
overexpression of sds22, a new tumor suppressor gene in Drosophila, can prevent tumor 
formation and metastasis by inhibiting myosin II and JNK activity (Jiang et al. 2011). A 
genome-wide screen for genes cooperating with Ras (Brumby et al. 2011), confirmed the 
competitive advantage of Rac1, RhoGEF2 and pbl together with Ras in the clonal system, 
which leads to JNK upregulation. Remarkably, this JNK activation was sufficient to confer 
invasive growth in the clonal setting but not in the whole-tissue system. The fact that 
JNK-mediated tumorigenesis, in cooperation with Ras in the clonal system, resembled the 
situation in mammalian breast epithelial cells shows that the knowledge gained from 
clonal analysis in Drosophila can help us elucidate tumorigenesis in the mammalian 
system. Interesting is also that, Rho1 and Rac are critical for the cooperation of Dlg with 
Ras in the whole-tissue context (Brumby et al. 2011). Along the same line, when lgl is 
mutated in a mosaic tissue, the lgl- clonal cells become the “losers” in cell competition. 
However, simultaneous overexpression of the Ras signalling pathway or of the yorkie (yki; a 
transcription factor, which is suppressed by the Salvator/Warts/Hippo pathway) in lgl- 
clones, causes overgrowths and JNK-mediated apoptosis at the periphery of the 
transformed clones (Grzeschik et al. 2010a, Grzeschik, Parsons and Richardson 2010b, 
Tamori et al. 2010, Mair 2010, Alderton 2010, Menendez et al. 2010). Moreover, JNK-
mediated elimination of lgl- clonal cells was relieved and the overgrowth potential was re-
established by upregulation of c-Myc, proving that lgl- clonal death is driven mainly by c-
Myc-induced cell competition (Froldi et al. 2010). Simultaneous downregulation of the lgl 
and the JNK pathway in the whole-tissue system results in phenotype reversion of tumor 
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growth, absence of the giant larvae and recurrence of pupariation, thereby showing that 
JNK activity is essential for overgrowth and invasion of lgl tumorous discs (Zhu et al. 2010).  
Among the wide palette of cellular events leading to JNK activation is the dTNF (tumor 
necrosis factor)/Eiger. Eiger is the sole Drosophila member of the TNF superfamily and its 
dysregulated expression in imaginal disc cells results in JNK-mediated apoptosis (Vidal 
2010, Cordero et al. 2010). The role of mammalian TNF in both pro-tumor and anti-tumor 
function are well documented and recent work suggests that both aspects of TNF function 
are also conserved in Drosophila. On one hand, JNK-dependent cell death in scrib and dlg 
clones requires dTNF, consistent with its role as a “tumor death factor” (Igaki 2009). On the 
other hand, in tumors deficient for scrib and dlg that also express Ras, the TNF signal is 
converted into a signal which promotes tumor growth and invasion, in accordance with the 
“tumor promoting” function of mammalian TNF (Cordero et al. 2010). More precisely, upon 
dTNF downregulation, cell death in dlg and scrib clones is blocked and in situ outgrowths 
appear, probably by TNF-mediated extra-cellular matrix (ECM) remodelling (Vidal 2010, 
Cordero et al. 2010). However, a similar effect on clone survival by dTNF knockdown in lgl 
clones was not observed, meaning that there are gene-specificities among the three TSGs 
(Vidal 2010). When generated in a dTNF mutant background, Rasv12scrib- clones displayed 
non-invasive in situ overgrowth. Similarly, in whole Rasv12scrib-dTNF- animals, development 
proceeded up to pupal stages, overcoming the “giant larvae” phenotype (Figure 2) (Vidal 
2010, Cordero et al. 2010). These recent results suggest that several of the critical overgrowth 
phenotypes of scrib, dlg and lgl in the clonal and whole-tissue context are mediated by dTNF 
and that dTNF pro-tumor function depends partially on JNK activation in tumor cells, 
which provides a switch from in situ to invasive growth. Immunostaining experiments that 
detected dTNF in a punctuated, intracellular vesicle pattern at the periphery of hemocytes 
associated with the dlg-group clones, indicate that dTNF expression in hemocytes is 
sufficient for dTNF/JNK pathway activation within dlg-group clones, and mark the 
importance of hemolymph and non-cell autonomous immune response in tumor 
progression (Vidal 2010, Cordero et al. 2010). 
So far, the mechanism by which the surrounding normal tissue exerts antitumor effects 
against dlg, scrib or lgl clones remained elucive. New results from clonal analysis in 
Drosophila imaginal discs have shown that JNK activation from the wild type surrounding 
leads to upregulation of PVR, the Drosophila PDGF/VEGF receptor, which subsequently 
activates the ELMO/Mbc phagocytic pathway, and which in turn eliminates the oncogenic 
clonal cells by engulfment (Ohsawa et al. 2011). From an evolutionary point of view, the 
development of such mechanism, which senses and eliminates “neoplastic” tumor-
suppressor mutant cells such as those of scrib- and dlg- but not “hyperplastic” ones (in which 
despite of overproliferation, cells are normally shaped and retain a differentiated epithelial 
monolayer, such as those of the Hippo pathway and PTEN) (Ohsawa et al. 2011), shows the 
necessity to specifically eliminate the high-risk malignant neoplastic cells before they confer 
any harm to the organism. The recent results concerning the function of these TSGs are of 
great importance as they: (1) promote the basic understanding on cancer development in a 
tissue and cell-type specific context, (2) recapitulate the situation of cancer development and 
metastasis in humans, and (3) recognize the advantage of Drosophila as a model system of 
choice in order to elucidate the role of these proteins at a mechanistic level and the 
molecular wiring that swifts the balance from normal to transformed cells in an otherwise 
wild type organism.  
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Fig. 2. Simplified model showing the most important genetic interactions of scrib, dlg and lgl 
TSGs with the TNF, JNK and Ras signalling pathways at the clonal and the whole-tissue 
system (for a more detailed analysis and the gene-specific interactions of the individual 
TSGs refer to the text). 
4. Dlg, Scrib and Lgl in the Drosophila testis 
So far, the role of Dlg, Scrib and Lgl in testis development has been underestimated, as 
mutations in these genes do not result in tumors. On the other hand, testes do not possess an 
epithelium similar to the ovarian follicular epithelium, which facilitates the analysis of 
apicobasal polarity. The more intensive investigation of the Drosophila testis in the last 15 
years has shed light on basic mechanisms, signaling molecules and cytoskeletal proteins 
involved in the progressive development of male gonads to adult testis, which provided 
markers and tools required for subsequent analysis. In the Drosophila testis, the somatic cells 
of the hub form the organizing center that recruits the germline stem cells (GSCs), creating 
the male stem cell niche (Fuller and Spradling 2007, Lin 2002). Upon asymmetric stem cell 
division, each GSC produces a new GSC attached to the hub and a distally located 
gonialblast, whereas each somatic stem cell (SSC) pair divides to generate two SSCs and two 
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somatic cyst cells (SCCs) (Figure 3). The gonialblast divides mitotically four times in 16 
interconnected spermatogonial cells surrounded by the two SCCs (Yamashita et al. 2007, 
Fuller and Spradling 2007, Wong, Jin and Xie 2005). The spermatogonial cells differentiate to 
primary spermatocytes, which enter the pre-meiotic phase (Fuller 1993). The physical 
contacts among the testis cell populations are critical as they allow the exchange of signals 
among GSCs and SSCs as well as SCCs, spermatogonial cells and spermatocytes that 
promote tissue survival and testis homeostasis.  
 
 
Fig. 3. Diagram depicting early spermatogenesis in Drosophila. Abbreviations: GSCs, 
germline stem cells; SCCs, somatic cyst cells; SSCs, somatic stem cells. 
We have recently investigated a new role of dlg in the Drosophila testis (Papagiannouli and 
Mechler 2009, Papagiannouli and Mechler 2010). In contrast to the overgrowth phenotypes 
observed in imaginal discs and brain hemispheres, dlg inactivation leads to testis 
degeneration during early larval development. The dlg testes are extremely small, with 
reduced number of GSCs loosely attached to the hub (Figure 5B, F). The Dlg protein is 
present in all somatic cells including the hub, SSCs and SCCs (Figure 4A-D) and the specific 
requirement of dlg in these cells is further supported by the finding that the mutant 
phenotype is rescued by expressing dlg in somatic cells but not in germ cells (Papagiannouli 
and Mechler 2009). In SSCs and early SCCs dlg plays a critical role in the establishment of a 
normal cyst structure, whereas in spermatogonial and spermatocyte stages dlg is critical for 
cyst survival, growth, expansion and maintenance of the integrity of the cysts’ 
microenvironment. Presumably, dlg is required for establishing and maintaining a tight 
connection between GSCs and SSCs around the hub. The connection between gonialblasts 
and SCC is also maintained during the mitotic divisions. In SSCs and early SCCs, dlg acts 
critically to establish a normal cyst structure, whereas in further spermatogonial and 
spermatocyte stages dlg is significant to the survival, growth and expansion of the cyst 
(Papagiannouli and Mechler 2010). 
A very interesting finding was the formation of wavy and ruffled plasma membrane in dlg 
over-expressing cells capping the spermatocyte cysts. Up to now, there is no mechanism 
describing how SCCs in Drosophila testis grow enormously, elongate and ensheath the germ 
cells of spermatogonial and spermatocyte cysts or how spermatid differentiation and 
individualization is guided by the polarized head and tail SCC. One way to interpret this 
result would be to consider that Dlg regulates the intensity of germ cell encapsulation 
through the Egfr pathway, which is the major signaling pathway active at the 
microenvironment of the spermatogonial cysts (Kiger, White-Cooper and Fuller 2000, Tran, 
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Brenner and DiNardo 2000). Membrane ruffling, detected in somatic cells upon dlg over-
expression, is highly reminiscent of the formation of lammellipodia-like structures, formed 
upon up-regulation of Rac1 in SCCs (Sarkar et al. 2007). Rac1 is a downstream component of 
the Egfr pathway and acts antagonistically to Rho in order to regulate germ cell 
encapsulation; moreover, Rho activation perturbates TJ function in various experimental 
systems (Fischer et al. 2007). It has already been shown that Dlg regulates membrane 
proliferation in a subset of NMJs in a dose-dependent fashion (Budnik et al. 1996) and is an 
important player in the process of polarized membrane insertion during cellularization 
(Lecuit and Wieschaus 2000, Dudu et al. 2004, Strickland and Burgess 2004, Lee et al. 2003). 
The fact that membrane proliferation is also involved in mechanisms such as tissue 
spreading and cell surface extensions, including membrane ruffles (Lecuit and Pilot 2003, 
Albertson, Riggs and Sullivan 2005) and combined with our results on SCCs membrane 
ruffling upon Dlg overexpression, could mean that polarized membrane insertion, mediated 
by Dlg, might conduct SCCs growth, expansion and spreading over the germ cells of 
testicular cysts.  
Interestingly, our recent results have also shown a requirement of Scrib and Lgl for normal 
testis development. Scrib and Lgl are localized in the somatic hub, SSCs and SCCs. Scrib is 
also present in the germline including the spermatocytes and the fusome (Figure 4E-H), 
with its localization in fusome being dispensable (Lighthouse, Buszczak and Spradling 
2008). Lgl has a marked localization at the fusome (Figure 4I-L). The germline localization of 
Scrib and Lgl is particularly interesting as it distinguishes them from Dlg, which is localized 
and is exclusively required in the somatic lineage. Examination of 6-7 days-old scrib and lgl 
mutant testis from giant larvae, revealed a dramatic reduction in the size of scrib and lgl 
testis. scrib testes show defects in the male stem cell niche, with less GSCs, gonialblasts and 
reduction in the transit amplifying spermatogonial cells (Figure 5C, G). The phenotype of 
the lgl testes was more severe, with defects in the male stem cell niche, fewer GSCs loosely 
attached to the hub and few spermatogonial cysts and with progressive spermatocyte cyst 
disappearance leading to testis atrophy (Figure 5D, H). The extensive defects in dlg, scrib and 
lgl mutant testes, underline their importance in the establishment and maintenance of the 
male stem cell niche and proper testis differentiation.  
Results obtained in the cancer and testis fields, regarding the role of the microenvironment 
and of apoptosis, point out the similarities of the basic mechanisms underlying the function 
of these genes. Our results from the Drosophila testis are in agreement with the newly 
investigated role of these genes in the cancer field. The importance of neighboring cell 
populations is illustrated in the case of testis where the somatic and germline cells create a 
microenvironment in the male stem cell niche and in the spermatogonial and spermatocyte 
cysts, which is required for mutual somatic and germline survival that promotes GSC 
maintenance and testis differentiation. The effect of Dlg, Scrib and Lgl, when signaling 
pathways emanating from the somatic and germ cells are affected, and the comparative 
analysis of apoptosis in the testis and in mosaic clones of the tumor microenvironment are 
some of the questions we try to investigate. Answering these questions will help us 
understand how the cell type-specific cellular content (cell intrinsic effects), 
microenvironment and signaling pathways cooperate with dlg, scrib and lgl in the various 
tissues. Although Dlg, Scrib and Lgl act in a slightly variable way in the various tissues and 
bind to different partners according to the protein availability (Roche et al. 2002), they can 
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still be considered as major players in the pathways they participate in, with a conserved 
function in the broader sense. Using the knowledge obtained in these systems will allow us 
to study their function in the testis in a comparative way. 
 
 
Fig. 4. Pattern of Dlg, Scrib and Lgl distribution in 3rd instar larval testis. (A-D) Wild type 
testis stained for F-actin with phalloidin (green), DNA with DAPI (blue) and immuno-
stained for Dlg (red). (C) and (D) are enlargements of (A) displaying the spermatocyte cysts, 
(B) and (D) display only the Dlg staining, marking the hub, SSCs and SCCs. (E-H)  
Scrib-GFP enhancer trap line showing Scrib localization (red) and stained for F-actin with 
phalloidin (green) and DAPI (blue). (G) and (H) are enlargements of (E) displaying the 
spermatocyte cysts, (F) and (H) display only the Scrib-GFP, marking the hub, SSCs, SCCs 
and the spermatocytes with the fusome (yellow arrows). (I-L) Lgl-GFP enhancer trap line 
showing Lgl localization (red), stained for F-actin with phalloidin (green) and DAPI (blue). 
(K) and (L) are enlargements of (I) displaying the spermatocyte cysts, (J) and (H) display 
only the Lgl-GFP, marking the hub, SSCs (arrowheads in J), SCCs and the spermatocytes 
with the fusome (yellow arrows). Testis hub is oriented towards the left (white arrows).  
Bar: 15μm. 
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Fig. 5. Testis in wild type, dlg, scrib and lgl 3rd instar larvae. Testes from (A, E) wt, (B, F) dlg, 
(C, G) scrib and (D, H) lgl larvae stained for Vasa (red), Tj (green), and Arm+α-Spectrin 
(blue). Low panel pictures (E-H) are enlargements of the hub region shown in (A-D), 
showing only the co-staining of Arm and α-Spectrin. Testis hub (arrowheads) is oriented 
towards the left. Bar: 15μm. Staining reveals a dramatic reduction in the size of scrib and lgl 
testis. scrib testes show defects in the male stem cell niche, with less GSCs, gonialblasts and 
reduction in the transit amplifying spermatogonial cells. lgl testes show defects in the male 
stem cell niche with fewer GSCs loosely attached to the hub and few spermatogonial cysts, 
leading to spermatocyte cyst disappearance and testis atrophy, reminiscent of the dlg 
mutant testis (Papagiannouli & Mechler, 2009). 
5. Conclusions 
Cancer is generally considered as a failure in the normal progression of differentiation. In 
recent years, developmental biology has contributed a great deal to cancer research. The 
reason of this success lies mainly in the recognition that cancer is a genetic disease, in which 
the normal pathway of cell fate and cell differentiation has been altered. The role of the 
tumor suppressor genes dlg, scrib and lgl as key junctional components in cell-type and 
tissue specific contexts has been analyzed in this review. It becomes obvious that the 
cytoskeleton is not seen anymore as a fixed structure but a dynamic and adaptive structure, 
whose components and regulatory proteins are in constant flux. Furthermore, it organizes 
the content of the cell, connects the cell with the external environment and coordinates 
forces that enable the cell to move and change shape. Looking at the cell not as an “inert 
playground for a few masterminding molecules” (Weiss 1961) but as an integrated whole, 
“an hierarchical ordered system of mutually interdependent molecular groupings and 
supramolecular entities” (Weiss 1961, Fletcher and Mullins 2010) can help us understand the 
role of these TSGs as safeguards of normal development, tissue homeostasis and tumor 
prevention.  
Over the last three decades Drosophila has become the organism of choice for molecular and 
genetic investigations in eukaryotic biology. Its emergence as an animal model system is 
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closely related to the rapid advances in recombinant DNA technology and other methods 
established in decades of classical genetics and embryology. Given the striking degree of 
evolutionary conservation of genes and signaling pathways, in particular of disease-causing 
genes, and the general principles that govern biological processes, sometimes even to the 
extent that a mouse gene can functionally replace its fly homologue, what we can learn from 
flies is often relevant to higher organisms, including humans (Gonzalez 2007, Jaekel and 
Klein 2006). This surprising conservation, together with the recent advances in genetic tools, 
such as MARCM (Lee and Luo 2001, Wu and Luo 2006), lineage tracing (Potter et al. 2010), 
multi-color cell labeling (Hadjieconomou et al. 2011, Hampel et al. 2011, Cachero and Jefferis 
2011), cell-type specific RNAi (Brand and Perrimon 1993) and genome-wide analysis made 
Drosophila a powerful model organism in elucidating basic cellular and tissue functions and 
in modeling cancer and other diseases. In the last years, a handful of review articles and 
conferences focused on the efforts and advances in modeling human diseases in Drosophila 
(Pfleger and Reiter 2008, Crnic and Christofori 2004, Gilbert 2008, Botas 2007, Caldeira et al. 
2009, Froldi et al. 2008, Reiter et al. 2001) from cancer, metastasis and neurogenerative 
diseases to obesity, metabolism and congenital heart disease. All these studies have shown 
that analysis of human diseases in Drosophila can go further than the phenotypic results and 
the ability to assign a function, in elucidating the mechanisms underlying disease pathology 
through a straightforward experimental design, thereby providing valuable entry points for 
later validation in mammalian systems and humans and identify candidate therapeutic 
agents. The fact that cancer and tumor suppressors underlie almost all basic cellular 
mechanisms from polarity, cell architecture and adhesion to gene regulation and cell 
specification, and from trafficking and proper cell compartmentalization to 
microenvironment signal exchange and neighboring cell competition, prove the necessity 
of Drosophila as a workhorse in unraveling the mechanisms of normal development. 
Compared with experiments in vertebrates, the large screens facilitated in Drosophila due 
to the low cost, the short generation time, the capacity for experiments with large 
numbers of animals and the availability of large collections of loss-of-function and 
overexpression mutant strains together with the power of genetics, that allows researchers 
to manipulate the fly genome at the level of precision, made the tiny fruit fly the organism 
of choice in several cases (Botas 2007, Froldi et al. 2008). Finally, the use of innovative 
technologies such as microarrays and nanotechnology, combined with novel computation 
and bioinformatics, has allowed genome-wide analysis of Drosophila, comprehensive 
analysis of the chromatin landscape (Kharchenko et al. 2011), cis-regulatory map of the 
Drosophila genome and transcription co-binding relationships (Negre et al. 2011), and 
high-resolution of transcriptome dynamics throughout development (Graveley et al. 
2011). All these studies have laid the carpet for identifying gene networks and complex 
gene and pathway interactions. Therefore, it becomes clear that we have still a long way 
to go on the enormous potential to study human genetic conditions and modeling cancer 
and metastasis in this simple invertebrate.  
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1. Introduction  
1.1 Epidemiology of pituitary adenomas 
Pituitary adenomas are usually benign tumors. Although many of them do not cause clinical 
symptoms and remain undetected, some leads to hormonal and/or neurological disorders. 
Because a large proportion of pituitary adenomas are discovered incidentally, the estimation 
of their prevalence may be difficult. Recently Daly et al. summarized the reported 
prevalence rate based on autopsies and radiological series showing a mean prevalence of 14.4 
and 22.3% respectively, and a combined analysis yielded a final prevalence rate of 16.7%. 
Based on three different population studies they found that the mean prevalence is 1:1064 
(Daly et al., 2009). The most frequent tumors were prolactinomas, followed by non-
functioning and growth-hormone (GH) producing tumors (66.2%, 14.7% and 13.2%, 
respectively). Based on results of an international, multicentre study the prevalence of 
clinically relevant pituitary adenoma is 1:1388 which is 3–5 times higher than that 
previously reported (Daly et al., 2009). 
According to data obtained from 8276 patients the incidence rate of pituitary adenomas is 
increasing with age, and they occur more frequently in females in early life and in males in 
later life. Males had larger tumors than females, and a higher incidence was detected in 
American Blacks compared with other ethnic groups (McDowell et al., 2011). 
1.2 Pathogenetic mechanisms leading to pituitary tumorgenesis 
Pituitary adenomas usually occur sporadically and most of them have monoclonal origin 
(Alexander et al., 1990; Herman et al., 1990). Both hypothalamic and hypophyseal mechanisms 
including alterations in hypothalamic control of pituitary hormone secretion and somatic 
mutations in pituitary cells have been considered as possible pathogenetic factors in 
pituitary tumor development. In experimental models overproduction of GH-releasing 
hormone may lead to the development of GH-secreting adenoma, while decreased level of 
dopamine may be associated with prolactinoma development. 
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Familial pituitary adenomas represent only 5% of all pituitary tumors. Most of these tumors 
are associated with known genetic defects predisposing to hereditary endocrine tumor 
syndromes. The most common is multiple endocrine neoplasia type 1 (MEN1), a disorder 
transmitted in an autosomal dominant manner due to mutations of the MEN1 tumor 
suppressor gene. However, in about 20-30% of clinically MEN1 cases mutation analysis 
failed to reveal mutations of the MEN1 gene. Mutations in cyclin-dependent kinase inhibitor 
1B (CDKI1B) gene coding for p27 have been demonstrated in a small subset of patients, and 
the clinical syndrome has been named MEN4 (Dworakowska & Grossman, 2009). 
Another familial disease that includes pituitary adenoma is Carney complex (CNC). This 
syndrome is caused by mutations of the gene encoding the protein kinase A regulatory 
subunit-1-alpha (PRKAR1A) (Stratakis et al., 2001). PRKAR1A is known to be an important 
effector molecule in many endocrine signaling pathways and its defect leads to various 
endocrine and nonendocrine tumor formation. 
A separate entity among familial pituitary tumors is the familial isolated pituitary adenoma 
(FIPA) presenting most frequently as familial somatotropinomas or prolactinomas. Patients 
with FIPA are significantly younger, and their adenoma size is larger compared to sporadic 
pituitary adenoma counterparts. About 15% of the FIPA patients have mutations of the gene 
encoding the aryl hydrocarbon receptor-interacting protein (AIP), which indicates that the 
FIPA may have a diverse genetic pathophysiology (Daly et al., 2009; Dworakowska & 
Grossman, 2009).  
Although McCune–Albright syndrome (MAS) is not a hereditary disorder, it represents a 
genetic condition related to mosaicism for a mutation of the guanine nucleotide-activating 
alpha-subunit (GNAS) gene. In addition, somatic mutation of the GNAS gene is present in 
30–40% of GH-secreting pituitary adenomas (Lania et al., 2003; Spada et al., 1990,). Mutation 
of this gene leads to the constitutive activation of the GH receptor and thereby contributes to 
GH-producing adenoma formation. 
Genetic changes of classical tumor suppressor genes (TSGs) such as TP53, PTEN and RB1,  
or oncogenes (such as Ras) rarely contribute to pituitary tumorigenesis. However, 
overactivation of the PI3K/Akt/mTOR signaling pathway has been demonstrated in pituitary 
adenomas as frequently as in other solid tumors (Rodriguez-Viciana et al., 1997). Both 
expression and phopshorylation of the Akt was increased in all types of pituitary adenomas 
with a highest rate in non-functioining pituitary adenomas (NFPA) (Musat et al., 2005). In 
addition to PI3K/Akt/mTOR, the MAPK cascade was also found to be involved in cell 
transformation and proliferation (Ewing et al., 2007; Guan, 1994; Joneson & Bar-Sagi, 1997). 
Recently, microarray studies indicated that the WNT and Notch signaling pathways play a role 
in the pathogenesis of pituitary adenomas, especially in NFPA (Moreno et al., 2005). 
Among growth factors the N-terminally truncated isoform of fibroblast growth factor 
receptor type 4 (pdt-FGFR4) and fibroblast growth factor type 2 (FGF2) were found to be 
overexpressed in some pituitary tumors, especially in aggressive adenomas while 
overexpression of bone morphogenic protein type 4 (BMP4) was charactheristic for 
prolactinomas (Ezzat et al., 1995; Ezzat et al., 2002; Morita et al., 2008; Qian et al., 2004). 
Cyclin D, a member of cell cycle regulation was shown to be overexpressed in pituitary 
adenomas, especially in NFPAs, while numerous cyclin-dependent kinase inhibitors 
(CDKIs) were reportedly underexpressed due to promoter hypermethylation. These 
alterations will be discussed. 
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Another relatively common alteration in pituitary tumors is overexpression of the oncogene 
pituitary tumor-transforming 1 (PTTG1), that is indirectly involved in cell cycle through an 
interaction with p53 and induction of p21 (Salehi et al., 2008). PTTG1 was found to be 
overexpressed in most pituitary adenomas, particularly in hormone-secreting and 
aggressively behaving tumors (X. Zhang et al., 1999).  
2. Epigenetic mechanisms 
Epigenetic mechanisms denote gene expression variability without coding sequence 
alteration. These mechanisms have important role in development, X chromosome 
inactivation, and modulation of gene expression in tissue specific manner. Epigenetic 
machinery includes DNA methylation, histone modifications and regulation of gene expression 
posttranscriptionally by small, non-coding RNA molecules.  
The compact DNA structure called chromatin is built from nucleosome units. These 
nucleosomes consist of approximately 150-200 bp of DNA, which is coiled twice around an 
octamer protein complex composed of core histones (H2A, H2B, H3 and H4). The adjacent 
nucleosomes are connected by the “linker” H1 histone. From nucleosomes DNA is 
assembled into a higher structure by covalent modifications of histone proteins. These 
modifications include methylation, acetylation, phosphorylation and ubiquitination at the 
N- and C-terminal domains of core histones. DNA and histone modifications influence 
DNA compactation thereby affect DNA availability for transcription factors and determine 
transcriptional activity. 
2.1 DNA methylation 
DNA methylation occurs as a methyl-group on 5’ position of cytosine in a CpG dinucleotide 
(5-methylcytosine). Although CpG dinucleotides are relatively infrequent (~1 per 100 bp) 
throughout the genome, approximately 7% of them are mapped within CpG islands, which 
in turn are associated with the promoter regions of approximately 40–50% of all transcribed 
genes (Baylin & Herman, 2000; Gardiner-Garden & Frommer, 1987; Rollins et al., 2006.) and 
about 45% of all CpGs can be found in repetitive elements (Ehrlich et al., 1982).  
Methylation is accomplished by DNA methyltransferases (DNMT). These enzymes create 
“de novo” (DNMT type 3a and 3b) or maintain (DNMT1) the methylation pattern, which is 
a replication-dependent process passing off during S-phase of the cell cycle (Klose & Bird, 
2006). Methylation of CpG islands cause gene expression silencing by direct inhibition of 
transcription factors binding and by recruitment of methyl-binding domain proteins (MBDs) 
occurring in transcription repressor complexes. 
CpG island methylation is correlated with condensed heterochromatin. On the contrary, 
hypomethylation allows an open chromatin structure and it usually occurs in promoter 
regions of active genes. 
In primary human tumors, methylation patterns are frequently disorganized. Promoter 
regions of genes are often hypermethylated and, therefore, their expressions are silenced. In 
general, aberrant CpG island methylation tends to be focal, affecting single genes, but not 
their neighbours (Zardo et al., 2002). Tumor suppressor genes involved in the regulation of 
cell cycle, apoptosis or genes participating in DNA repair are often silenced by 
hypermethylation and they do not have other genetic alterations (eg. mutations) (Brena & 
Costello, 2007). Beside hypermethylation genome-wide hypomethylation was also 
implicated in tumor development (Feinberg & Vogelstein, 1983; Gaudet et al., 2003).  
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2.2 Histone modification 
Chemical modification of histones (H) frequently targets lysine residues within their N- 
and C-terminal tails. Core histone modification is frequently called as ‘histone code’ 
which determines transcriptional activity by influencing compaction of DNA structure 
(Jenuwein & Allis, 2001; Turner, 2000). Deacetylated forms of N-tails of H3 and H4 
histones have a positive charge that results in a close nucleosome structure because of the 
negatively charged DNA. Acetylations of lysine residues on histone tails neutralize the 
positive charge of histones thereby lead to a loose, “opened” chromatin structure (Struhl, 
1998) (Fig.1.). 
In addition to acetylation, histone modifications may include methylation, phosphorylation, 
sumoylation, ubiquitination and ADP-ribosylation. Among these mechanisms covalent 
modifications, such as acetylation of H3 and H4 and methylation pattern on gene expression 
have been extensively investigated in tumor development. Several enzymes including 
histone acetyltransferases (HAT), histone deacetylases (HDAC), histone methyltransferases 
(HMT) and histone demethyltransferases (HDMT) may modify histones. Acetylation of 
lysine (K) residues associated with H4 and methylation of lysine 9 (K9) in H3 may be 
present at inactive gene loci. Alternatively, acetylation on K9, K14 and methylation on K4 of 
H3, or acetylation on K5 of H4 can be found both at active or activating gene loci, reviewed 
by Tateno et al, 2010 (Tateno et al., 2010; Ezzat, 2008). 
 
 
 
 
Fig. 1. Histone and DNA modifications. 
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2.3 Genomic imprinting 
Genomic imprinting is related to a special form (or a subgroup) of DNA methylation, which 
allows monoallelic gene expression in a “parent-of-origin-specific” manner (Wong et al., 
2007). Diploid cells have two alleles of each autosomal gene inherited from each parent. 
Generally both parental alleles are expressed equally, but a subset of genes is expressed by 
either the maternal or the paternal allele, and this ‘genomic imprinting’ is regulated by 
epigenetic mechanisms. This process may be also responsible for tissue specific gene 
expression.  
Imprinted expression is restricted to a few hundred genes in the mammalian genome, most 
of which are found in small clusters. Imprinted clusters have an imprinting control region 
(ICR) that is usually 1–5 kb. long, differentially methylated and it regulates the imprinting 
mechanism across the entire domain. Imprinted genes are regulated also by methylation. 
Many imprinted genes inside of an imprinted cluster are protein-coding genes, however, 
recently the role of ncRNAs in imprinting regulation was also raised (Zhou et al., 2010). 
The most commonly cited example for imprinting mechanism leading to tumorigenesis is 
the gene encoding insulin-like growth factor type 2 (IGF2). IGF2 is paternally imprinted in 
most tissues (Ohlsson et al., 1994). It is an embryonic mitogen and it acts as a paracrine 
and autocrine regulator of cell proliferation (Yu & Rohan, 2000). In cells that express both 
parental IGF2 alleles, the increased amount of IGF2 may lead to tumor formation. Loss of 
imprinting (LOI) of IGF2 has been reported in many tumors including colorectal 
carcinomas (Cui et al., 2003), Wilm’s tumor (Ogawa et al., 1993), esophageal carcinoma 
(Zhao et al., 2009), acute lymphoblastic leukemia (Vorwerk et al., 2003) and prostate 
cancer (Jarrard et al., 1995). 
2.4 Regulation by non-coding RNAs (ncRNAs) and microRNAs (miRs) 
Thus far small RNAs do not belong tightly to classical epigenetic mechanisms, but based on 
recent findings we have to classify them into this group as they regulate gene expression 
without modification of the genetic code. For instance, miRs provide fine tuning of protein 
expression level, and their role in tumorigenesis has been widely demonstrated. 
MicroRNAs belong to non-codingRNAs (ncRNAs) that can regulate gene expression. It was 
found that about 98% of all transcripts originate from ncRNAs (Mattick, 2001). These arise 
from exons and introns of protein non-coding genes and from introns of protein-coding 
genes (Mattick & Makunin, 2005). Non-coding RNAs include transfer-RNAs (tRNAs) 
involved in mRNA translation, small nucleolar RNAs (snoRNAs) involved in modification 
of ribosomal RNAs (rRNAs) and small nuclear RNAs (snRNAs) implicated in mRNA 
splicing (Mattick & Makunin, 2005). Beyond these, several small RNAs (categorized into 13 
functional classes) were discovered with diversified biological functions including 
heterochromatin formation, histone and DNA methylation, mRNA cleavage and 
transcriptional repression (summarized by Zhou et al., 2010). 
MicroRNAs (miRs) are approximately 19-25 nucleotide long, non-coding RNA molecules 
which posttranscriptionally regulate gene expression via RNA interference by binding 3’ 
untranslated region (3’UTR) of protein coding mRNA (Lagos-Quintana et al., 2001). This 
pairing is not a perfect match in the case of mammals but it is in plants. By interacting the 
target mRNAs miRs repress the target protein expression by three major processes: i) 
mRNA cleavage, ii) mRNA degradation by deadenylation or iii) inhibition of translation 
initiation. In addition, miRs regulate expression of other types of ncRNAs (Fig.2.). 
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It has been proposed that 30-50% of all protein coding genes may be controlled by miRs 
(Chen & Rajewsky, 2006; Lewis et al., 2005). As miRs may influence numerous mRNA they 
may participate in the regulation of numerous physiological and pathological cellular 
processes. Their roles were considered in development (Lee & Ambros, 2001), cell 
proliferation (O’Donnel et al., 2005), differentiation (Chen & Stallings, 2007), apoptosis 
(Cimmino et al., 2005) and tumorigenesis (reviewed by Deng et al., 2008) including tumors 
of endocrine system such as the pituitary gland (Bottoni et al., 2005, 2007; Amaral et al., 
2009, Butz et al., 2010, 2011). 
 
 
Fig. 2. MicroRNAs’ biogenesis and function. 
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3. Epigenetic alterations involving tumor suppressor genes 
3.1 Hypermethylated tumor suppressors 
3.1.1 Genes encoding cell cycle regulators 
The sensitively balanced cell cycle involves numerous negative and positive regulators. The 
main proteins involved in this process are the cyclins, cyclin-dependent kinases (CDK) and 
their inhibitors (CDKI). Alterations of several cell cycle-related genes, especially those 
involved in the G1/S transition have been associated with pituitary adenomas. Several cell 
cycle inhibitors (CDKIs) were found to be underexpressed through promoter 
hypermethylation in pituitary adenomas. CDKIs as members of the INK4 families (p16Ink4a, 
p15Ink4b, p18Ink4c) and the Cip/Kip (p21Cip1, p27Kip1, p57Kip2) inhibit CDK-cyclin complexes 
thereby prevent checkpoint transitions (Fig. 3.). 
 
 
Fig. 3. Regulation of cell cycle. 
The restriction point of the G1/S transition requires inactivation of retinoblastoma (Rb) 
protein via phosphorylation by CDKs. In this process E2F transcription factors are released 
and transcription of S-phase genes are allowed. The majority of pituitary adenomas express 
Rb and inactivation of CDKIs (detailed in Table 1) may lead to cell proliferation in pituitary 
adenomas. 
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Gene 
Name Alterations in pituitary adenomas 
pRb (RB1) 
 Promoter hypermethylation in 28.6% (12/42) and 35% (12/34) of 
adenomas (Ogino et al., 2005; Yoshino et al., 2007) 
 90% of adenomas expressed Rb (18/20) and in 60% of Rb-non-expressing 
adenomas promoter methylation was found (Simpson et al., 2000) 
 LOH of the RB locus in 100% of invasive and malignant tumors (Pei et 
al., 1995)
p53  Somatic inactivating mutation and increased expression in 33% (2/6) of pituitary carcinomas (Tanizaki et al., 2007)
p14ARF  Promoter hypermethylation in 6% (2/24) of adenomas (Yoshino et al., 2007) 
p15INK4b 
(CDKN2B) 
 Promoter hypermethylation in 32% (11/34) and 35.7% (15/42) of 
adenomas (Yoshino et al., 2007; Ogino et al., 2005) 
p16INK4a 
(CDKN2A) 
 Promoter hypermethylation in 59% (20/34) and 71.4% (30/42) of 
adenomas (Yoshino et al., 2007; Ogino et al., 2005) 
p18INK4c 
(CDKN2C) 
 Promoter hypermethylation in 39.5% (15/38) of adenomas (Kirsch et 
al., 2009; Morris et al., 2005) 
p21Waf1/Cip1 
(CDKN1A) 
 Promoter hypermethylation in 3% (1/34) of adenomas (Yoshino et al., 
2007) 
 Decreased expression in 71% (10/14) of NFPAs (Neto et al., 2005) 
 Increased expression in 77% (31/40) of hormone producing and 92% 
(11/12) of GH producing adenomas (Neto et al., 2005)
p27Kip1 
(CDKN1B) 
 Absence of promoter hypermethylation in 34 pituitary adenomas 
(Yoshino et al., 2007) 
 Decreased expression in adenomas especially in corticotrop adenomas 
(21/21) (Lidhar et al., 1999; Lloyd et al., 1997; Bamberger et al., 1999) 
GADD45γ  Promoter methylation in 58% (19/33) of adenomas (Bahar et al., 2004a; Zhang et al., 2002)
MEG3A  Promoter methylation (11/11) of adenomas (Gejman et al., 2008; Zhao et al., 2005)
DAPK 
 Loss of expression in 59% (10/17) of invasive adenomas caused by 
hypermethylation (45%) or homozygous deletion (36%) (Simpson et 
al., 2002)
PTAG  Loss of expression in 79% (30/38) of adenomas caused by hypermethylation in 20% (Bahar et al., 2004b) 
ZAC  Loss or decreased expression in (34/34) NFPAs (Pagotto et al., 2000) 
Table 1. Hypermethylated tumorsuppressors involved in pituitary tumorigenesis. 
GADD45γ, also known as cytokine response 6 (CR6) was found to be involved in growth 
suppression and apoptosis (Zhang et al., 1999). The GADD45 family genes (GADD45α: 
GADD45, GADD45β: MyD118 and GADD45γ: CR6) are regulated by p53. They influence the 
expression of p21WAF1/CIP1 and proliferating cell nuclear antigen (PCNA) and have a role in 
DNA damage repair (Fan et al., 1999; Smith et al., 1994; Xiao et al., 2000). They disrupt 
interaction between CDK1 kinase and cyclin B1 and, therefore, they suppress cell 
proliferation not only by inhibiting G1/S transition but they also cause G2/M arrest. (Zhan 
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et al., 1999). They are also involved in apoptosis regulation by activating MAPK and Jun 
kinase signaling pathways and they cause DNA fragmentation (Takekawa & Saito, 1998). 
Further studies demonstrated that they are not expressed in the majority of NFPA and GH- 
or PRL-secreting tumors. Reexpression of GADD45 in human and rodent pituitary-derived 
cell lines inhibited cell proliferation suggesting that loss of GADD45 may have a role in 
pituitary tumorigenesis. Methylation of CpG islands of the GADD45γ gene was identified in 
19/33 (58%) of pituitary adenomas including NFPA, GH- and PRL secreting tumors (Bahar 
et al., 2004a). 
Zhao and coworkers showed that a gene named maternally expressed 3 (MEG3) was 
strongly expressed in normal pituitary gland while its expression was almost undetectable 
in pituitary tumors and other cancer cell lines (Zhao et al., 2005). In functional studies 
methylation inhibitor restored MEG3 expression in human cell lines. MEG3 protein non-
coding RNA has multiple splice isoforms and all of them suppress cell growth in vitro by 
stimulating p53-mediated transactivation (Zhou et al., 2007). All human pituitary cell types 
express MEG3, while in adenomatous pituitary samples the loss of MEG3 was limited to 
NFPAs of gonadotroph origin (Gejman et al., 2008). It has been shown that inactivation of 
the MEG3 gene was exclusively due to methylated CpGs in its promoter. (Zhao et al., 2005; 
Gejman et al., 2008). 
3.1.2 Genes encoding regulators of apoptosis 
The gene encoding death-associated protein kinase (DAPK) was found to be frequently 
altered by epigenetic mechanisms in pituitary tumors. Simpson and his collegues 
demonstrated that in 34% (11/32) of pituitary tumors expression of the DAPK was 
undetectable and that almost half of the cases had CpG island methylation in the DAPK 
promoter region. In addition, loss of DAPK expression was associated with tumor 
invasiveness. However, only a minority of non-invasive pituitary adenomas (2/35; 5.7%) 
showed underexpression of the DAPK caused by methylation (Bello et al., 2006). Another 
protein involved in apoptosis regulation is the pituitary tumor apoptosis gene (PTAG). Its 
expression was reduced in a significant percent (79%, 30/38) of pituitary adenomas. All 
corticotropinomas and prolactinomas, 73% of somatotropinomas and 64% of NFPAs 
showed reduced expression of PTAG. Reexpression of PTAG alone failed to influence 
pituitary cell proliferation or cell viability but significantly augmented the apoptotic 
response to bromocriptin induction. This „apoptosis sensitization” effect was described also 
in colon cancer (Bahar et al., 2007). It was also suggested that PTAG loss in pituitary 
adenomas may be an early step in pituitary tumorigenesis leading to a blunted apoptotic 
response (Bahar et al., 2004b). 
Among other methylated genes involved in the regulation of apoptosis in pituitary cells are 
ZAC and RASSF1. The ZAC (zinc finger protein which regulates apoptosis and cell cycle 
arrest, or PLAGL1, pleiomorph adenoma gene like-1) encoding a zink finger protein was 
found to be strongly underexpressed in NFPAs compared to other types of pituitary 
adenomas or normal pituitary tissue (Pagotto et al., 2000). ZAC inhibited cell proliferation 
and colony formation in functional in vitro experiments and abolished tumor formation in 
nude mice. It induced apoptosis and cell cycle arrest independently of pRb, p21Waf1/Cip1, 
p16INK4a, p27KIP2 and p57KIP3 (Spengler et al., 1997). Underexpression of ZAC was related 
either to loss of heterozigosity (LOH) (Pagotto et al., 2000) of the ZAC locus or to 
hypermethylation. RASSF1A (Ras association domain family 1) was found to exert a tumor 
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suppressor function in several neoplasms including pituitary tumors. Qian demonstrated that 
inactivation of the RASSF1A was caused by promoter methylation in 38% of all pituitary 
adenomas and in 83% of higher grade adenomas (Qian et al., 2005). RASSF1 promoted 
apoptosis and inhibited cell growth in different cell lines suggesting its general role in 
apoptosis. This apoptosis promoting effect of RASSF1 was found to be p53-independent (Vos 
et al., 2000) while its effect on cell proliferation and cell cycle was connected to the prevention 
of cyclin D1 accumulation (Shivakumar et al., 2002; Song et al., 2004). 
3.2 Histone modifications in pituitary adenomas 
As mentioned above the key regulators of histone modifications are DNA 
methyltransferases. Among these enzymes, DNMT3b, a “de novo” DNA methylation 
enzyme was found to be overexpressed in functioning pituitary adenomas and NFPAs (Zhu 
et al., 2008a). Using chromatin immunoprecipitation in AtT20 mouse pituitary cells Zhu et 
al. demonstrated that histone modifications resulted in a change of DNMT3b expression 
(Zhu et al., 2008a). 
Another protein with reduced expression due to histone methylation was fibroblast growth 
factor receptor type 2 (FGFR2). The FGFR2 gene transcript has two splice variants. Deletion 
of the FGFR2-IIIb isoform was associated with inaccurate pituitary development 
(DeMooerloze et al., 2000). FGFR2 was found to be underexpressed in pituitary tumors 
compared to normal pituitary tissue (Abbass et al., 1997; Zhu et al., 2007a). Underexpression 
of the FGFR2 gene was also demonstrated in murine adrenocorticotropic hormone secreting 
pituitary tumor cells (Zhu et al., 2007a). FGFR2 has been previously described as tumor 
suppressor because in functional experiments its enforced expression impeded cell growth 
and enhanced apoptosis in thyroid cancer cell lines via attenuation of Ras/BRaf/MAPK 
phosphorylation (Kondo et al., 2007a). In addition, expression of MAGE-A3 (melanoma 
antigen family A, 3; cancer/testis antigen family 1, member 3), an FGFR2 signaling target 
molecule showed an inverse correlation with FGFR2 expression (Kondo et al., 2007b; Zhu et 
al., 2008b). Activation of FGFR2 signaling resulted in methylation of H3 and deacetylation 
associated to the MAGE-A3/6 promoter down-regulated its expression (Kondo et al., 
2007b). Downregulation of FGFR2 signaling caused hypomethylation of MAGE-A3 
promoter in pituitary tumors originated from female individuals (Ezzat et al., 2008; Zhu et 
al., 2008b). MAGE-A3 and its protein family are encoded on X chromosome and normally 
are expressed in placenta, in testicular germ cells and in several tumors such as melanoma, 
lung cancer and breast cancer (Hussein et al., 2011; Sigalotti et al., 2004; Yanagawa et al., 
2011). MAGE-A3 was found to regulate the expression of p53 and p21 and its 
downregulation resulted in p21 and p53 accumulation that reportedly occurred occasionally 
in specific cases of pituitary adenomas (see Table 1.) (Ezzat et al., 2008; Zhu et al., 2008a,b). 
There may be several links between processes involved in the mechanism of pituitary 
development and tumorigenesis. An example of this complex crosstalk is the function of 
Ikaros (Ik), a zinc-finger DNA binding protein implicated in chromatin remodeling, which 
has a role in the development of GHRH neurons in hypothalamus and plays an important 
role in pituitary tumorigenesis via its tumor suppressor function (Ezzat et al., 2005a; 
Winandy et al., 1995). In pituitary corticotroph cells loss of Ik leads to impaired activation of 
proopiomelanocortin hormone expression and increased mortality (Ezzat et al., 2005a). Ik-
deficient mice have reduced GHRH secretion, a shrunk somatotroph population in pituitary 
and dwarfism (Ezzat et al., 2006). Ik inhibits access of Pit-1 to GH promoter while it 
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facilitates Pit-1 binding to prolactin promoter in mammasomatotroph cells by the histone 
acetylating-deacetylating system (Ezzat et al., 2005a). Ik is also involved in tumorigenesis 
and was found to be down-regulated by hypermethylation in human pituitary tumors (Zhu 
et al., 2007b). One negative isoform of Ik, Ik6 was implicated in pituitary tumorigenesis by 
promoting pituitary cell survival through enhanced antiapoptotic activity through Bcl-XL 
induction by chromatin histone acetylation (Ezzat et al., 2005b). In addition to apoptosis 
regulation Ik6 contributes to dysregulated expression of Ik target genes including growth 
factor receptors such as FGFR4 which are essential for development. In pituitary tumor cells 
Ik6 interrupts activation of the FGFR4 promoter through its deacetylation, that results in 
transcription from a criptic promoter in intron 4 leading to a truncated tumor derived 
receptor isoform (pituitary derived ptd-FGFR4) with an oncogenic potential (Ezzat et al., 
2004; Yu et al., 2003). 
3.3 Loss of imprinting  
Our knowledge about loss of imptinting (LOI) and its relation to the pituitary tumorigenesis 
is limited. As imprinting is executed by methylation, altered methylation may lead to LOI. 
Regarding to the pituitary we already discussed two imprinted tumor suppressor genes, 
MEG3A and ZAC, which may be silenced by hypermethylation of both alleles. 
In addition, the gene encoding the alpha-subunit of the GTP-binding protein, Gs alpha was 
found to be expressed only from the maternal allele in normal pituitary tissue. However, some 
GH-secreting pituitary tumors containing Gsα mutation express Gsα from the non-mutated 
paternal allel too. This biallelic expression was also present in Gsα mutation negative 
adenomas too (Hayward et al., 2001). In the latter cases relaxation of imprinting occurred. 
4. Role of miRs in pituitary adenoma development 
Because 30-50% of all protein coding genes may be controlled by miRs (Chen & Rajewsky, 
2006; Lewis et al., 2005), it is not surprising that they are implicated in pituitary 
tumorigenesis. Bottoni et al. described that miR-15a and miR-16-1 may have a pathogenic 
role in the development GH- and PRL-secreting adenomas (Bottoni et al., 2005). They found 
that these two miRs were significantly underexpressed in these adenomas. The genes 
encoding miR-15a and miR-16-1 are located in chromosome 13q14, a region which is 
frequently deleted in pituitary tumors. These two miRs were found to be negatively 
correlated with the tumor diameter and miR-16-1 expression showed negative correlation 
with arginyl-tRNA synthetase (RARS) expression, a putative target in pituitary tumor cells. 
In addition, RARS associated with the p43 in the aminoacyl-tRNA synthetase complex, and 
it was suggested that p43 has anti-neoplastic properties in mice. Based on these data it was 
suggested that in pituitary adenomas miR-16-1 expression may modify RARS level, which 
associates with p43 in the formation of the ARS complex and that this process may influence 
tumor growth. Cimmino et al. showed that the antiapoptotic B cell lymphoma 2 (Bcl2) 
protein is an additional target of miR-16-1. Interaction between miR-16-1 and Bcl-2 may be 
persent in the majority of B-cell lymphoma cases (Calin et al., 2002; Cimmino et al., 2005). 
The Bcl2 was found to be overexpressed in approximately one-third of pituitary adenomas, 
while its expression was not detected in normal pituitary tissues (Wang et al., 1996), 
suggesting that Bcl2 may be implicated in pituitary tumorigenesis through regulation of 
apoptosis (Bottoni et al., 2007). 
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The connection between pituitary development and tumorigenesis is further supported by the 
dual role of a protein, named high-mobility group A2 (HMGA2). HMGA2 is a small nuclear 
non-histone chromatic protein involved in the regulation of chromatin structure (Fashena et 
al., 1992) and gene transcription (Grosschedl et al., 1994). In transgenic mice overexpression of 
HMGA2 leads to initiation of mixed GH/prolactin secreting pituitary adenomas (Fedele et al., 
2002). Although the HMGA2 gene was not expressed in normal pituitary, its expression was 
present in human prolactinomas and NFPA. In prolactinomas its expression was related to 
amplification and/or rearrangement of its chromosomal loci (Finelli et al., 2002), but in the 
case of NFPA genetic alteration was absent (Pierantoni et al., 2005). In 2007 two studies using 
reporter gene experiments showed that expression of HMGA2 was repressed by miR let-7 (Lee 
& Dutta, 2007; Mayr et al., 2007). In addition, Qian et al. confirmed an inverse correlation 
between let-7 and HMGA2 expressions in NFPA (Qian et al., 2009). 
Our group using whole genome miR expression profiling combined with bioinformatical 
tools and luciferase reporter systems showed that Wee1 kinase, a kinase involved in the 
regulation of G2/M transition, was targeted and downregulated by miRs in pituitary tumor 
samples compared to normal pituitary tissues (Butz et al., 2010). We showed that both the 
total and phosphorylated forms of Wee1 protein was decreased in NFPA and GH producing 
adenomas compared to normal pituitary tissues (Fig. 4A.). 
After cloning Wee1 3’UTR into a luciferase reporter plasmid we demonstrated that Wee1 
downregulation was, at least in part, due to overexpression of miR-128a, miR-516a-3p and 
miR-155 in NFPA and overexpression of miR-155 in GH producing adenomas. In addition 
using site directed mutagenesis we validated binding sites (Fig. 4C.) predicted by three 
different target prediction algorithms in Wee1 3’UTR for miRs: miR-128a, miR-155 and miR-
516a-3p, further confirming that downregulation of Wee1 may be related to the overexpression 
of these miRs in pituitary adenomas. In another study Qi et al exprerimentally validated two 
other miRs, miR-195 and miR-372 targeting Wee1 in human embryonic stem cells (hESCs) (Qi 
et al., 2009). Our group found that miR-195 was moderately overexpressed (1.5 fold) in NFPA 
and down-regulated in GH-producing adenomas. In pituitary adenomas impairment of cell 
cycle regulation by Wee1 downregulation may lead to the loss of the G2/M checkpoint, which 
in turn may allow DNA damage accumulation leading to tumor development (Butz et al., 
2010). In addition, multivariate analysis suggested that in non-small-cell lung cancer 
expression of Wee1 was a prognostic factor: its decreased expression negatively correlated 
with a higher rate of recurrence and higher Ki-67 proliferation index (Yoshida et al., 2004). 
Backert et al. reported that Wee1 was underexpressed in colon cancer tissues and cell lines 
further supporting its tumor suppressor function (Backert et al., 1999). 
In addition to cell cycle alterations through Wee1, the TGFβ signaling pathway may also 
play a role in the pathogenesis of pituitary adenomas. This pathway was shown to exert a 
prominent role in the regulation of pituitary tumor growth and prolactin secretion from 
pituitary lactotrope cells, and microarray studies indicated that FSH, LH and TSH β-
subunit, which are under TGFβ regulation, are underexpressed in NFPA (Kulig et al., 1999; 
Wang et al., 2008). In addition, TGFβ administration decreased proliferation and increased 
apoptosis of HP75 cell line derived from a clinically non-functioning pituitary tumor [Kulig 
et al., 1999; Danila et al., 2002]. In our study after performing microRNA expression 
profiling with TaqMan microfluidic card on pituitary adenomas we executed complex 
bioinformatical procedures including target prediction following pathway analysis using 
DIANA miR-PathTool software for differentially expressed miRs. Our results suggested 
involvement of several altered pathways. Of these we selected TGFβ signaling and found that 
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members of TGFβ signaling, Smad3, Smad6 and Smad9 were significantly underexpressed in 
NFPA compared to normal pituitary tissues using quantitative RT-PCR. In addition, in silico 
target prediction analysis for Smad3 identified five overexpressed miRs in NFPA compared to 
normal tissues (miR-135a, miR-140-5p, miR-582-3p, miR-582-5p and miR-938). Our results 
suggest that these overexpressed miRs may produce downregulation of the TGFβ signaling 
through Smad3, and these miRs may have a possible role in the complex regulation of the 
TGFβ signaling pathways involved in the tumorigenesis process of NFPA. (Butz et al., 2011) 
Also, our miR expression profile analysis suggested that a decrease of TGFβ signaling via 
Smad3 may result in a shift toward alternative, non-Smad pathways including Ras-MAPK, 
p38, c-Jun, and PI3K-Akt, which have been already considered as contributing factors in 
pituitary tumorigenesis (Fig. 5.) (Butz et al., 2011). 
 
 
Fig. 4. A: Wee1 immunhistochemistry in normal and adenomatous pituitary. B: Wee1 and its 
targeting miRs’ expression. C: miRs’ binding sites at Wee1 3’UTR. (partly presented in paper 
Journal of Clinical Endocrinology & Metabolism. Vol.95, No.10, (October, 2010), pp. E181-
191, ISSN 0021-972X) 
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Fig. 5. TGFβ signaling. Smad3 indicated with blue is targeted by several miRs in pituitary. 
Another interesting connection between Smad3 and pituitary tumorigenesis arises from a 
direct interaction of Smad3 with the tumor suppressor menin. Inactivation of menin blocked 
TGFβ and activin signaling and antagonized their growth-inhibitory properties in anterior 
pituitary cells (Hendy et al., 2005). It is known that MEN1 gene mutations play a role in 
MEN1-related pituitary tumorigenesis, but MEN1 gene mutations seem to be very rare in 
sporadic pituitary adenomas (Prezant et al., 1998; Wenbin et al., 1999). Some reports showed 
increased menin expression in sporadic pituitary adenomas (Wrocklage et al., 2002). 
However, there are some conflicting data about menin expression because other reports 
indicated a significant reduction of menin protein in a high percentage of pituitary 
adenomas (Theodoropoulou et al., 2004), and studies by several groups using RT-PCR (Asa 
et al., 1998; Farrel et al, 1999; Satta et al., 1999) showed no differences in MEN1 mRNA levels 
between pituitary tumors and normal pituitary tissues. All these data may raise the 
possibility of posttranscriptional mechanisms regulating menin expression via altered 
expression of miRs. Indeed, in our study we identified 4 miRs (miR-149, miR-570, miR-592, 
miR-769-5p) potentially targeting MEN1 3’UTR showed a significant overexpression, but 
further studies are needed to confirm regulation of menin expression by these miRs (Butz et 
al., 2011). 
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5. Conclusions and future perspectives 
As already shown in several tumor types, the pathogenesis of pituitary adenomas involves 
epigenetic mechanisms which play a prominent role in the regulation of gene expression. The 
question is that whether epigenetic alterations, such as DNA and histone modifications are a 
cause or a consequence in pituitary tumorigenesis. New discoveries and new methodologies in 
the fields of cell biology, genetics, and genomics open new paths in understanding the 
complexity of regulatory networks of tumor development. The small RNA systems and their 
regulatory roles are still uncovered fields in pituitary tumor pathology. To date only miRs of 
small RNAs have been investigated in pituitary tumorigenesis. It is expected that using novel 
tools new players and/or new roles for old players will be identified, which may help to 
develop novel diagnostic and therapeutic approaches. 
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1. Introduction 
Meningiomas are solid tumors of the Central Nervous System arising from arachnoid layer 
cells, which cover the brain and spinal cord. Meningiomas account for about 34% of primary 
intracranial tumors, with an annual incidence rate of 6.17 per 100,000 person-year, as 
reported in a recent population-based study (Yee G. 2009). Many small meningiomas go 
unnoticed during life and are found incidentally in up to 1.4% of people in autopsy series 
(Rohringer, Sutherland et al. 1989).  
In general, meningiomas display a broad range of histological patterns. The current World 
Health Organization (WHO) classification lists 16 different variants or subtypes, falling into 3 
grade designations. The WHO classification of tumors of the nervous system distinguishes 
between grade I (benign), grade II (atypical) and grade III (anaplastic or malignant) 
meningiomas (Table 1, Fig. 1) (Perry, Louis et al. 2007). About 90% of all meningiomas are 
slowly growing benign tumors of WHO grade I. Atypical meningiomas constitute about 6-8% 
of cases, although using more current definitions, it has been reported in up to 20%. These 
WHO grade II meningiomas are histologically defined by increased mitotic activity (four or 
more mitoses per 10 high-power microscopic fields) and/or at least three of the following 
criteria: increased cellularity, high nucleus/cytoplasm ratio, prominent nucleoli, uninterrupted 
patternless or sheet-like growth and necrosis. Approximately 2-3% of all meningiomas show 
histological features of frank malignancy, including a high level of mitotic activity (20 or more 
mitosis per 10 high-power microscopic fields) and/or a histological appearance similar to 
sarcoma, carcinoma or melanoma (Perry, Louis et al. 2007).  
Tumor recurrence is the major clinical complication in meningiomas, occurring in 10-15% 
and 25-37% of patients undergoing curative surgery after 5- and 10-year follow-up periods, 
respectively (Mirimanoff, Dosoretz et al. 1985; Maillo, Orfao et al. 2007). The most important 
factors that determine the recurrence of meningiomas are the extension of the tumor 
resection and the histologic grade (Riemenschneider, Perry et al. 2006; Louis, Ohgaki et al. 
2007). Therefore, prediction of relapse occurrence in meningiomas during the first few years 
following diagnostic surgery still remains a major challenge. 
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Up to date, none of the common genetic alterations of meningiomas have acquired clinical 
relevance. However, the analysis of these alterations in relation to histological grade has led 
to a model in which genetic aberrations are presumably involved in the formation of 
meningiomas, with subsequent alterations associated with tumor progression (Lomas, Bello 
et al. 2005; Martinez-Glez, Franco-Hernandez et al. 2008). 
Meningiomas were among the first solid tumors recognized as being characterized by a 
specific cytogenetic alteration, which is monosomy 22. Since then, loss of genetic material 
from chromosome 22 has been the most consistent aberration, observed in up to 70% of 
tumors (Perry, Louis et al. 2007; Martinez-Glez, Franco-Hernandez et al. 2009).  
Familial occurrence of meningiomas is found in patients with neurofibromatosis type 2 (NF2), 
usually with multiple meningiomas, as also occurs in other non-NF2 families with 
predisposition to meningioma. Approximately 50% of NF2 patients suffer from meningiomas, 
making them the second most frequent neoplasm associated with this tumor syndrome. 
Sporadic meningiomas were then screened for mutations in the NF2 gene, which was found to 
be frequently inactivated in up to 60-70% of meningiomas. Therefore, the NF2 gene, located at 
22q12.2, is considered the main candidate for the genesis of meningiomas, having a role as a 
tumor suppressor gene (TSG) (Louis DN and JJ 2000; Martínez-Glez V. 2007). 
 
Meningiomas with low risk of recurrence and aggressive growth
WHO grade I 
Meningothelial meningioma 
Fibrous (fibroblastic) meningioma
Transitional (mixed) meningioma
Psammomatous meningioma
Angiomatous meningioma
Microcystic meningioma
Secretory meningioma
Lymphoplasmacyte-rich meningioma
Metaplasic meningioma
Meningiomas with greater risk of recurrence and aggressive growth
WHO grade II 
Chordoid meningioma 
Clear cell meningioma
Atypical meningioma
WHO grade III 
Papillary meningioma 
Rhabdoid meningioma 
Anaplastic (malignant) meningioma 
Table 1. Meningioma grouped by likelihood of recurrence and grade (Perry, Louis et al. 2007). 
Other cytogenetic changes secondary to the 22q anomaly, and which are involved in tumor 
progression to atypical and anaplastic meningiomas, are losses of 1p, 6q, 14q, chr.10, 18q, 
and gains of 1q, 9q, 12q, 15q, 17q, and 20q (Bello, de Campos et al. 1994; Perry, Gutmann et 
al. 2004; Perry, Louis et al. 2007; Martinez-Glez, Franco-Hernandez et al. 2009). 
Epigenetic alterations seem also to play an important role in the tumorigenesis of 
meningiomas, as occurs in many other tumor types. These alterations indicate that the 
silencing by aberrant hypermethylation of gene promoter regions contributes to the genesis 
and tumor progression of meningiomas (Martinez-Glez, Franco-Hernandez et al. 2008). In 
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these tumors, aberrant promoter hypermethylation of CpG dinucleotides of several TSG has 
been described, including NF2 (26%), THBS1 (15-30%), TIMP-3 (24%), CDKN2A (10-17%), 
MGMT (6-16%), p73 (15%), ER (15%), GSTP1 (27%), RB1 (10%), DAPK1 (4%), VHL (4%) and 
CDKN2B (4-13%) (Bello, Amiñoso et al. 2004; Liu, Pang et al. 2005).  
2. Molecular alterations involved in the pathogenesis of meningiomas 
2.1 The NF2 gene 
The tumor suppressor gene NF2, located at 22q12.2, is considered the main candidate for the 
genesis of meningiomas (Martinez-Glez, Franco-Hernandez et al. 2009). Allelic losses of the 
22q12.2 chromosomal region encompassing the NF2 gene are found in 40–70% of the sporadic 
and the vast majority of NF2 associated meningiomas. Additionally, NF2 mutations are found in 
up to 60-70% of tumors, consistent with a classic two-hit mechanism of tumor suppressor gene 
inactivation (Ruttledge, Sarrazin et al. 1994). Most of these NF2 mutations are small insertions, 
deletions, or nonsense mutations affecting splicing sites, with a frequency of NF2 mutations 
roughly equal among different WHO grades, suggesting that it represents an important initiation 
rather than progression-associated alteration (Wellenreuther, Kraus et al. 1995).  
 
 
Fig. 1. Histopathological images of a WHO grade I secretory meningioma (A), a WHO grade 
I fibrous meningioma (B), a WHO grade II atypical meningioma (C), and a WHO grade III 
anaplastic meningioma (D). 
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In contrast, differences in the frequency of NF2 alterations have been noted based on variant 
histology, with higher rates in fibroblastic, transitional and psammomatous than in 
meningothelial or secretory grade I meningiomas (Wellenreuther, Kraus et al. 1995; 
Hansson, Buckley et al. 2007; Mawrin and Perry 2010). Thus, NF2 alterations appear to play 
a preferential role in the mesenchymal like phenotype of meningiomas. Support for this 
comes from the observation that non-NF2 meningioma families are more likely to develop 
meningothelial tumors. 
Transcriptional silencing by hypermethylation of CpG islands in the promoter region has 
been accepted as an alternative mechanism to genetic inactivation of tumor-suppressor 
genes. In fact, site directed mutagenesis demonstrated that a 70-bp region on the NF2 
promoter (-591 to -522 bp from the transcription start site) was essential for the basic 
expression of the NF2 gene (Kino, Takeshima et al. 2001). At least three CpG sites within this 
region (at positions -591, -586 and -581) appeared to be of particular importance for silencing 
of the NF2 gene upon methylation in schwannomas, with the methylation status consistent 
with the expression/silencing of NF2 mRNA. 
In this sense, aberrant methylation of the NF2 gene was detected as the sole alteration in 
samples of sporadic meningiomas, most of which from grade I tumors (Lomas, Bello et al. 
2005). Methylation analysis in two other studies, however, concluded that methylation of 
the NF2 promoter is unlikely to play a major role in the silencing of the NF2 gene in 
meningiomas (van Tilborg, Morolli et al. 2006; Hansson, Buckley et al. 2007). 
Alternatively, the NF2 gene may also be inactivated in meningiomas by increased calpain-
mediated proteolysis of merlin. Kimura et al. demonstrated cleavage of merlin by the 
ubiquitous protease calpain in meningioma tumors, together with considerable activation of 
the calpain system resulting in the loss of merlin expression (Kimura, Koga et al. 1998). 
The protein product of the NF2 gene is termed merlin or schwannomin, and meningiomas 
with associated NF2 alterations commonly result in a truncated, non-functional merlin 
protein. Merlin is a member of the 4.1 family of membrane-associated proteins, which also 
includes proteins ezrin, radixin and moesin. These proteins contribute to the interaction 
between glycoproteins of the cellular surface and the actin cytoeskeleton, functioning to link 
cell surface signaling to intracellular pathways (Curto and McClatchey 2008). Thus, 
alterations in merlin may subtantially affect cell shape and might favor the appearance of a 
more mesenchymal-like phenotype rather than the epithelioid one, seen more commonly in 
NF2 intact meningiomas.  
2.2 DAL1/4.1B, a member of the 4.1 protein family 
In addition to NF2, another gene coding for a member of the 4.1 family of proteins is DAL1. 
This gene encodes for the Protein 4.1B, located on chromosome 18p11.3. DAL1 gene is 
generally expressed at high levels in the brain and low levels in the kidney, intestine and 
testicles (Martinez-Glez, Franco-Hernandez et al. 2008).  
DAL1 loss, together with reduced protein expression of its gene product was detected in 
sporadic meningiomas, affecting more than 70% of tumors regardless of histological grade 
(Gutmann, Donahoe et al. 2000; Perry, Cai et al. 2000).  
This frequency is similar to that of NF2 absence of protein expression, suggesting that DAL1, 
similarly to NF2, could play an important role as an early event in the tumorigenesis of 
meningiomas.  
The similarity between the DAL1 protein and merlin, with their high levels of expression in 
the brain and their recurrent loss in meningiomas, led to a mutational study of DAL1 in a 
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series of sporadic meningiomas (Martinez-Glez, Bello et al. 2005). The low mutational 
frequency of this gene discounts sequence variations in DAL1 as the main mechanism 
underlying participation of this gene in the neoplastic transformation of meningiomas, and 
suggests that other inactivating mechanism, such as epigenetic changes, may participate in 
DAL1 silencing (Martinez-Glez, Bello et al. 2005).  
Additional analyses have shown that DAL1 suppresses the growth and cellular proliferation 
in meningiomas by activating, among others, the Rac1-dependent c-Jun-NH(2)-kinase 
signaling pathway (Martinez-Glez, Franco-Hernandez et al. 2008). However, the fact that 
transgenic mice lacking DAL1 do not develop tumors (Yi, McCarty et al. 2005), suggests that 
DAL1 alterations may represent an early progression associated rather than an initiation 
event for the development of meningiomas. This suggestion is also supported by the 
observation of losses of chromosome 18 not preferentially of the 18p11.3 region, but instead 
associated with clinically aggressive tumors. 
The absence of expression of two proteins of the Protein 4.1 family in most of sporadic 
meningiomas suggests that membrane-associated alterations are important events for the 
development and/or progression of meningiomas. Future experiments however would be 
necessary to address the functional role of these proteins in leptomeningeal and 
meningioma cells which may lead to define membrane- or cytoskeletal-associated pathways 
in tumorigenesis of meningiomas. 
2.3 TSCL1 and 14-3-3 are DAL1/4.1B interacting proteins 
A potential interaction with protein 4.1B has been reported for the Tumor Suppressor in Lung 
Cancer-1 (TSLC1) gene, prompting the study of TSCL1 in meningiomas. TSCL1 was 
originally identified as a transmembrane protein involved in specifying cell adhesion. 
TSLC1 interacts with the actin filament through DAL-1 at the cell-cell attached site where 
the complex formation of TSLC1 and DAL-1 is dependent on the integrity of actin 
cytoskeleton (Yageta, Kuramochi et al. 2002).  
Surace et al. demonstrated that TSCL1 is expressed in human leptomeningeal tissues, but is 
absent in 30% to 50% of benign meningiomas, 70% of atypical, and 85% of anaplastic 
meningiomas. Atypical meningiomas with high proliferative indices and most of WHO 
grade III meningiomas showed loss of TSCL1 expression, while atypical meningiomas with 
brain invasion but low mitotic index had a similar frequency of loss to that of the benign 
meningiomas (Surace, Lusis et al. 2004).  
Moreover, these authors reported a strong correlation between loss of TSCL1 expression and 
decreased patient survival. When WHO grade II were stratified by their TSCL1 expression 
status, TSCL1 loss was correlated with reduced patient survival, irrespective of mitotic 
index. These findings raise the possibility that TSCL1 may be an independent predictor of 
survival for patients with atypical meningioma (Surace, Lusis et al. 2004). 
Similarly, other study identified 14-3-3 as a 4.1B–specific interacting protein (Yu, Robb et al. 
2002). The 14-3-3 family of proteins are adaptor proteins involved in signal transduction 
regulation, with a role in cell growth, survival or apoptosis. However, impaired 14-3-3 
seems not to affect 4.1B function, suggesting additional proteins involved in 4.1B signaling. 
The potential importance of 14-3-3 proteins for meningioma growth control is underlined by 
a recent report showing reduced immunoexpression of certain 14-3-3 protein isoforms in 
aggressive meningiomas (Mawrin and Perry 2010). Thus, the precise roles of protein 14-3-3 
interactions with 4.1B have yet to be determined. 
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2.4 Other 22q tumor suppresor genes 
The close association of NF2 mutations in meningiomas with allelic loss on chromosome 22 
suggests that NF2 is the major meningioma tumor suppressor gene on that chromosome 
(Xiao, Gallagher et al. 2005; van Tilborg, Morolli et al. 2006; Simon, Boström et al. 2007; 
James, Lelke et al. 2008; Striedinger, VandenBerg et al. 2008; Martinez-Glez, Franco-
Hernandez et al. 2009; Shen, Nunes et al. 2009). Nonetheless, deletion studies of 
chromosome 22 have detected losses and translocations of genetic material outside the NF2 
region, thus raising the possibility of other meningioma genes residing on chromosome 22. 
Candidate genes, among others, include BAM22, BCR and TIMP3 (Fig 2). 
BAM22 gene belongs to the human β-adaptin gene family. Adaptins are essential for the 
formation of clathrin coated vesicles in the course of intracellular transport of receptor-
ligand complexes.  
The BAM22 gene has been proposed as a second chromosome 22 locus important in 
meningioma development, after the neurofibromatosis type 2 gene (Peyrard, Fransson et al. 
1994; Guilbaud, Peyrard et al. 1997). 
Recently, reduced expression of breakpoint cluster region (BCR) mRNA was found. It has 
appeared to be downregulated in meningiomas with loss of heterozygosity of 22q. The  
BCR gene is an extremely interesting tumor suppressor candidate, since NF2 and BCR 
proteins perform similar functions (Wozniak, Piaskowski et al. 2008). BCR contains a 
serine/threonine kinase that functions as a GTPase-activating protein for p21. The 
inactivation of BCR as well as NF2 might lead to hyperactivation of RAC pathway, and 
together with the downregulation of the gene, suggest that BCR can be considered as a 
tumor suppressor candidate (Wozniak, Piaskowski et al. 2008). 
Matrix metalloproteinases (MMPs) are proteases capable of degrading extracellular matrix 
proteins. They are involved in the cleavage of cell surface receptors, the release of apoptotic 
ligands, and chemokine/cytokine inactivation, playing an important role on cell 
proliferation, migration (adhesion/dispersion), differentiation, angiogenesis, apoptosis and 
host defense. The TIMP3 (tissue inhibitor of metalloproteinase 3) gene on 22q12.3 codes for a 
protein that can specifically inhibit MMPs by covalent binding to the active site of the 
enzymes and thus reduces the invasion and the metastatic potential of tumor cells. In 
addition, overexpression of TIMP3 in vitro induces apoptosis and suppresses tumor growth 
and angiogenesis in different cell line models (Barski, Wolter et al. 2010). 
Numerous reports have demonstrated the loss of expression of TIMP3 in meningiomas 
using diverse approaches, such as microarray expression profiling, real-time reverse 
transcription PCR analyses or immunohistochemical protein expression studies (Carvalho, 
Smirnov et al. 2007; Fèvre-Montange, Champier et al. 2009; Barski, Wolter et al. 2010; Pérez-
Magán, Rodríguez de Lope et al. 2010). In addition, hypermethylation of the promoter 
region of TIMP3 gene has been analyzed showing controversial results (Bello, Amiñoso et al. 
2004; Liu, Pang et al. 2005). Recently, TIMP3 hypermethylation has been associated with 
meningioma progression, due to 67% of anaplastic meningiomas showed hypermethylation 
of the TIMP3 promoter, while this was true for only 22% of atypical and 17% of benign 
meningiomas. In addition, TIMP3 hypermethylation and transcriptional downregulation 
were found exclusively in meningioma with allelic losses on 22q12, in contrast to NF2 
mutation (Barski, Wolter et al. 2010; Pérez-Magán, Rodríguez de Lope et al. 2010). Taken 
togheter, all these results point out TIMP3 as an important candidate tumor suppressor gene 
located in 22q, besides NF2. 
Other genes located on chromosome 22q have also been proposed as possible TSG 
candidates: MN1, SMARCB1, LARGE, RRP22 and GAR22. The MN1 gene (22q12.1) was 
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found to be disrupted by a balanced translocation in meningioma, although more recent 
studies suggest a role as a co-activator of the oncogenic transcription than as a TSG 
(Martínez-Glez V. 2007; Perry, Louis et al. 2007). The protein encoded by the SMARCB1 gene 
(22q12.3) is part of a complex that relieves repressive chromatin structures, allowing the 
transcriptional machinery to access its targets more effectively.  
 
 
Fig. 2. View of chromosome 22 including candidate TSG involved in meningiomas. 
This gene has been found to be a tumor suppressor, and mutations in it have been 
associated with malignant rhabdoid tumors (Oruetxebarria, Venturini et al. 2004; Martinez-
Glez, Franco-Hernandez et al. 2008). In addition, the LARGE gene (22q12.3) might be 
involved in genomic rearrangements associated with tumors (Martinez-Glez, Franco-
Hernandez et al. 2008). This gene, which is one of the largest in the human genome, encodes 
a member of the N-acetylglucosaminyltransferase gene family. Other genes identified in the 
long arm of chromosome 22 are tumor suppressor genes and are located on 22q12.2, near to 
NF2: RRP22 and GAR22. The RRP22 have been identified as a novel, farnesylated member of 
the Ras superfamily that exhibits the properties of a potential neural-specific tumor 
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suppressor and is implicated in the regulation of nucleolar transport processes (Elam, 
Hesson et al. 2005). The protein encoded by the gene GAR22, a member of the GAS2 family, 
is an actin-associated protein expressed at high levels in growth-arrested cells (Goriounov, 
Leung et al. 2003) 
3. Molecular alterations involved in meningioma progression 
Meningiomas are generally thought to progress from low-grade to high-grade tumors, 
although this is not always easy to demonstrate clinically. Indeed, none of the typical 
genetic aberrations found in meningiomas have acquired clinical relevance. Nevertheless, 
the analysis of the genetic aberrations in relation to the histologic grade pointed out that 
malignant progression in meningiomas is associated with the acquisition of additional 
genetic changes, in a stepwise model for acquisition of chromosomal gains and losses 
during meningioma progression (Weber, Boström et al. 1997).  
As mentioned before, chromosome 22 monosomy or 22q deletions are the most frequent 
genetic alteration found in meningiomas, and thus are considered as an early event involved 
in the pathogenesis of meningiomas. Secondary to 22q alterations, genetic changes most 
frequently associated with meningiomas include 1p and 14q deletions. Moreover, these 
alterations have been related to tumoral progression in meningiomas (Leone, Bello et al. 
1999; Buckley, Jarbo et al. 2005; Espinosa, Tabernero et al. 2006; Maillo, Orfao et al. 2007; 
Martinez-Glez, Franco-Hernandez et al. 2008).  
Genetic alterations in atypical meningiomas include allelic losses of 1p, 6q, 10, 14q and 18q and 
gains of 1q, 9q, 12q, 15q, 17q and 20q. Anaplastic meningiomas frequently show losses of 6q, 
10q and 14q as well as gains and/or amplifications on 17q23 (Weber, Boström et al. 1997; Louis 
DN and JJ 2000; Martínez-Glez V. 2007; Martinez-Glez, Franco-Hernandez et al. 2008). 
Genetic alterations in atypical meningiomas include allelic losses of 1p, 6q, 10, 14q and 18q and 
gains of 1q, 9q, 12q, 15q, 17q and 20q. Anaplastic meningiomas frequently show losses of 6q, 
10q and 14q as well as gains and/or amplifications on 17q23 (Weber, Boström et al. 1997; Louis 
DN and JJ 2000; Martínez-Glez V. 2007; Martinez-Glez, Franco-Hernandez et al. 2008). 
4. Altered regions in meningioma progression 
4.1 Loss of 1p  
Loss of 1p represent the most frequent genetic alteration secondary to chromosome 22 
tumor suppressor gene inactivation (NF2/others), which seems to participate in the genesis 
of the aggressive meningiomas, as this anomaly is found predominantly in atypical (40-76%) 
and anaplastic forms (70-100%), as opposed to benign meningiomas (13-26%) (Bello, de 
Campos et al. 1994; Bello, de Campos et al. 2000; Maillo, Orfao et al. 2007; Pérez-Magán, 
Rodríguez de Lope et al. 2010).  
Loss of heterozygosity assays revealed two regions mainly involved in meningioma 
progression, including 1p36 and 1p32-34, although other regions less frequently lost were 
also detected at 1p22 and 1p21.1-p13 (Bello, de Campos et al. 2000). Furthermore, a 
comprehensive study of DNA copy number profiling analysis in meningiomas revealed 
three 1p and one 1q candidate sites of genomic imbalance on chromosome 1, which may be 
relevant for meningioma development and progression (Buckley, Jarbo et al. 2005). 
Therefore, these regions may contain one or more tumor suppressor genes important for 
meningioma progression. Candidate genes have been pointed out, among others: ALPL, 
TAp73, EPB41, RAD54L, GADD45A, CDKN2C, and LMO4. 
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Fig. 3. Molecular alterations associated with tumor progression in meningiomas. 
4.1.1 Candidate genes located at 1p36: ALPL and TAp73 
The ALPL gene maps to chromosome 1p36.12, and codes for the tissue non-specific form of 
alkaline phosphatases (APL). In contrast to the brain tissue, the meninges constitutionally 
exhibit a strong cellular activity of this enzyme, being present in both cytoplasmic 
membrane and cytosol. Alterations of 1p together with loss of enzyme activity were found 
in meningiomas, revealing this gene as a good candidate TSG (Müller, Henn et al. 1999). 
Additionally, the functional expression of the alkaline phosphatase has been related to the 
mineralization capacity observed in meningiomas, and its loss of expression was associated 
with increased tumor aggressiveness (Müller, Henn et al. 1999; Sayagués, Tabernero et al. 
2007). Further studies of this gene, however, are required. 
TAp73 encodes for a protein with significant homology to the p53 tumor suppressor gene 
throughout its DNA-binding, transactivation, and oligomerization domains. Despite this 
similarity, animal models showed that p73 is an important player in neurogenesis, sensory 
pathways and homeostatic control, but its function in tumorigenesis is controversial (Moll 
and Slade 2004). Mutational analyses of p73 have been performed in a wide variety of tumor 
types and, up to date, p73 is not the target of inactivating mutations in human cancers, 
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including meningiomas (Lomas, Bello et al. 2001). Aberrant p73 hypermethylation was also 
analyzed in meningiomas, showing that although it was more frequent in those tumors with 
1p deletion, an independent association of p73 promoter methylation with the grade of 
malignancy could not be established (Lomas, Amiñoso et al. 2004). Nevertheless, another 
study detected 1p LOH and p73 promoter hypermethylation in the malignantly transformed 
tumors but not in the lower-grade primary ones (Nakane, Natsume et al. 2007). 
4.1.2 Candidate genes located at 1p33-32: EPB41, RAD54L and CDKN2C 
The 4.1R gene (1p33-32), or EPB41, belongs to the Protein 4.1 family, which also includes the 
products of the NF2 and DAL1 genes, merlin and Protein 4.1B, respectively. EPB41 was 
described to function as a tumor suppressor gene in meningiomas, through the 
demonstration of both, allelic loss of the 4.1R gene by FISH, and loss of Protein 4.1R 
expression in sporadic meningiomas and cell lines by using immunohistochemical assays 
and western blotting. Moreover, in vitro functional experiments in meningioma cell lines 
supported a tumor suppressor function in these tumors (Robb, Li et al. 2003). Opposite 
results were obtained by Piaskowski et al. (2005) who find no change of mRNA expression 
between meningionmas with 1p LOH and those without it (Piaskowski, Rieske et al. 2005).  
The human homologue of the Saccharomyces cerevisiae RAD54 DNA repair gene (hRAD54) is 
located at 1p32 (Rasio, Murakumo et al. 1997). The protein encoded by this gene plays a role 
in homologous recombination related repair of DNA double-strand breaks. The RAD54L 
gene was proposed as a candidate for a tumor-associated gene in neoplasms that display 1p 
allelic imbalance, such as in meningiomas. However, mutational analysis of this gene in a 
series of 25 oligodendrogliomas and 18 meningiomas failed to identify any deletions or 
inactivating mutations of the gene (Mendiola, Bello et al. 1999; Bello, de Campos et al. 2000; 
Bello, de Campos et al. 2000). 
The p18INKC gene (CDKN2C, 1p32) is a member of the INK4 family of cycline-dependent 
kinase (CDK) inhibitors, together with p16INK4a, p15INK4b, and p19INK4d. These inhibitors 
participate in cell cycle regulation by inhibiting the activity of CDK–cyclin complexes. 
CDKN2C was considered a potential tumor suppressor gene in meningiomas due to its 
similarities with other members of the INK4 family.  
However, absence of genetic and epigenetic alterations of CDKN2C, together with no altered 
protein expression in meningiomas ruled out this gene as the major target of the frequent 1p32 
losses in meningiomas (Santarius, Kirsch et al. 2000; Boström, Meyer-Puttlitz et al. 2001).  
4.2 Loss of 14q 
Another frequent cytogenetic anomaly in meningiomas is the loss of 14q, which shows 
increasing frequencies paralleling the increase in tumor grade. Therefore, about a third of 
benign meningiomas show the 14q loss, while 40-57% and 55-100% of atypical and 
anaplastic tumors, respectively, present this loss (Weber, Boström et al. 1997; Ozaki, 
Nishizaki et al. 1999; Cai, Banerjee et al. 2001; Simon, Boström et al. 2007; Tabernero, Maillo 
et al. 2008). Various studies have described different regions ranging from 14q21 to 14q32 
(Weber, Boström et al. 1997; Martinez-Glez, Franco-Hernandez et al. 2008). To date, 
however, the actual targets of this chromosomal lost have been remained large elusive and 
thus, no 14q tumor suppressor genes have been confirmed in meningiomas. Nevertheless, 
several 14q tumor suppressor candidate genes have been evaluated, namely NDRG2 and 
MEG3. 
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4.2.1 NDRG2 (14q11.2) 
This gene is a member of the N-myc downstream-regulated gene family. The protein 
encoded by this gene is a cytoplasmic protein that has been found involved in a variety of 
cancers. It is expressed in low-grade gliomas, but present at low levels or absent in primary 
glioblastoma. In meningioma tumors, Lusis et al. used a differential gene expression 
approach leading to the identification of NDRG2 as a potential meningioma associated 
tumor suppressor gene that is inactivated during meningioma progression. Furthermore, 
these authors showed that the loss of NDRG2 expression was significantly associated with 
hypermethylation of the NDRG2 promoter (Liu, Pang et al. 2005; Lusis, Watson et al. 2005). 
4.2.2 MEG3 (14q32) 
Recently, it has been reported that the maternally expressed gene 3 (MEG3), which encodes 
a noncoding RNA, could be a tumor suppressor gene at chromosome 14q32 involved in 
meningioma progression (Zhang, Gejman et al. 2010). Zhang et al. showed that MEG3 is 
expressed in normal human meningothelial cells, but is low or absent in the majority of 
meningioma tumors and meningioma cell lines. Moreover, loss of MEG3 RNA expression as 
well as loss of MEG3 gene copy number is more common in higher grade meningiomas, and 
there is an overall increase in CpG methylation in tumors associated with tumor grade. 
Finally, MEG3 RNA expression in human meningioma cell lines strongly suppresses tumor 
cell growth in vitro, which is independent of merlin, and activates p53-mediated 
transactivation. As an imprinted gene encoding a noncoding RNA, MEG3 seems to suppress 
tumor development in meningioma via entirely novel mechanisms (Zhang, Gejman et al. 
2010). 
4.3 Alterations of 9p: CDKN2A, p14ARF, and CDKN2B genes 
Losses of chromosome 9p, particularly at the 9p21 region, were frequently found in 
anaplastic meningiomas but only rarely in atypical and benign meningiomas (Weber, 
Boström et al. 1997; Boström, Meyer-Puttlitz et al. 2001). Alterations of 9p21 have been 
found to represent losses of the well-known tumor suppressor genes CDKN2A (p16INK4a), 
p14ARF, and CDKN2B (p15INK4b), involved in control of cell-cycle, and inactivated at high 
frequency in a large variety of human tumors.  
Analysis of the alterations (deletions, mutations and promoter hypermethylation) of these 
tumor suppressor genes in meningiomas revealed that most of anaplastic meningiomas either 
show homozygous deletions, mutations (mainly in CDKN2A and p14ARF), or lack of expression 
of one or more of these genes. Therefore, inactivation of the G1/S-phase cell-cycle checkpoint 
is an important feature of meningiomas of advanced stage (anaplastic) that likely contributes 
to the rapid growth and malignant behavior of these tumors, and point it out as a progression 
associated alteration in meningiomas (Boström, Meyer-Puttlitz et al. 2001). Moreover, by using 
FISH, other authors reported higher frequencies of 9p or CDKN2A alterations in meningiomas, 
mostly in anaplastic tumors (74% of anaplastic meningiomas, 52% of atypical, and 17% of 
benign meningiomas). Interestingly, in this study CDKN2A deletion was strongly associated 
with outcome, with 9p deleted anaplastic tumors showing a high risk ratio for death. On the 
other hand, absence of deletion identified a subset of anaplastic meningioma patients (26%) 
with prolonged survival (Perry, Banerjee et al. 2002). Therefore, these studies support that 
chromosome 9p21 deletions are associated with malignant progression of meningiomas, and 
that it is a poor prognostic factor in anaplastic meningiomas. 
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4.4 Amplification of 17q region 
Amplification of the 17q21-qter region was associated with the mechanism of progression 
from atypical to anaplastic tumors, due to high-level amplification on 17q was identified in 
48-60% of anaplastic meningiomas and in few or none of atypical and benign tumors 
(Weber, Boström et al. 1997).  
The S6 kinase (S6K) gene (17q23) was evaluated as the target of the 17q amplification in 
anaplastic meningiomas, based on its location (Cai, James et al. 2001) and on the 
observation of increased S6K mRNA expression in these tumors compared with benign 
meningiomas (Surace, Lusis et al. 2004). Experiments performed in meningioma cell lines 
revealed no effect of S6K overexpression on meningioma cell growth, motility, or 
adhesion in vitro, although S6K overexpression resulted in increased tumor size in vivo 
(Surace, Lusis et al. 2004). Therefore, although previous studies revealed no high-level 
amplification of the S6K candidate gene (Büschges, Ichimura et al. 2002), the study of 
Surace and coworkers suggests that S6K may be functionally important for meningioma 
progression (Surace, Lusis et al. 2004). Further studies are needed to map the 17q23 
amplicon to determine whether additional genes in this region are amplified in high-
grade meningiomas. 
5. Molecular pathology of meningioma recurrence 
As mentioned before, histological grade and extent of surgical resection are the two most 
important variables in meningiomas. However, 5% and 40% of benign and atypical tumors, 
respectively, recur within 5 years even after total gross resection (Riemenschneider, Perry et 
al. 2006). 
The loss of 1p and 14q was suggested as one of the alterations observed in meningioma 
recurrence (Maillo, Orfao et al. 2007; Tabernero, Espinosa et al. 2007; Pfisterer, Coons et al. 
2008). Recently, a higher recurrence rate of meningiomas with 1p36 loss (33%) than that of 
meningiomas with normal chromosome 1p36 (18%) has been reported (Ruiz, Martínez et al. 
2010). In addition, a differential gene expression pattern that distinguishes between original 
and recurrent meningiomas identified a subset of meningioma recurrence associated genes, 
and reported novel candidate genes of recurrence. Most of these candidate genes are located 
at chromosomal regions previously associated with a higher risk of recurrence or malignant 
progression of meningiomas: 1p, 6q and 14q (Fig 4) (Pérez-Magán, Rodríguez de Lope et al. 
2010). Furthermore, an additional comprehensive copy number and gene expression study 
also identified 6q and 14q loss significantly more common in recurrent tumors and 
associated with anaplastic histology (Lee, Liu et al. 2010). Finally, an abnormal cDNA gene 
expression pattern was identified associated with meningiomas displaying genomic 
deletions at 1p and 14q (Martínez-Glez, Alvarez et al. 2010). 
In general, these recurrence-associated genes are underexpressed relative to non-tumoral 
meningothelial tissue, denoting an overall underexpression of genes in recurrent 
meningiomas (Lee, Liu et al. 2010; Pérez-Magán, Rodríguez de Lope et al. 2010). Conversely, 
overexpression of few genes were identified in recurrent meningiomas, remarkably genes of 
the histone cluster 1 (6p) (Pérez-Magán, Rodríguez de Lope et al. 2010). 
Among the 1p candidate genes, the LMO4 (LIM-only protein 4) gene is one of the candidates 
consistently reported on several gene expression studies on meningioma recurrence 
(Carvalho, Smirnov et al. 2007; Fèvre-Montange, Champier et al. 2009; Pérez-Magán, 
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Rodríguez de Lope et al. 2010) and progression (Carvalho, Smirnov et al. 2007; Fèvre-
Montange, Champier et al. 2009). This gene maps to 1p22.3 and belongs to a family of four 
mammalian LMO proteins which are short transcriptional regulators that play roles in 
mammalian development; LMO4 is required for the proper closure of the neural tube 
(Lee, Jurata et al. 2005). Two members of the family, LMO1 and LMO2 act as oncogenes in 
acute lymphoblastic leukemia and previous studies have defined LMO3 as an oncogene in 
neuroblastoma (Lu, Lam et al. 2006). Furthermore, overexpression of LMO4 has been 
reported to induce cell invasion and to be associated with outcome in breast cancer, 
especially in estrogen receptor negative tumors (Sum, Segara et al. 2005). In pancreatic 
tumors it was also found overexpressed (Sum, Segara et al. 2005; Yu, Ohuchida et al. 
2008), but high LMO4 expression was associated with survival advantage (Murphy, 
Scarlett et al. 2008). 
 
 
Fig. 4. Location of the genes differentially expressed in original and recurrent meningiomas 
on chromosomes 1, 6 and 14, plotted according to their map position. Genes with lower 
(green) and higher (red) levels of expression in recurrences than in original tumors are 
shown on the left and right, respectively, of the chromosome ideogram.  
Surprisingly, underexpression of LMO4 was detected associated with progression and 
recurrence of meningiomas, as reported on gene expression profiling studies (Carvalho, 
Smirnov et al. 2007; Fèvre-Montange, Champier et al. 2009); (Pérez-Magán, Rodríguez de 
Lope et al. 2010). A recent report suggested that LMO4 modulates TGF- signaling through 
its interaction with receptor-activated SMADs (Lu, Lam et al. 2006), however its role in 
meningiomas should be further studied.  
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Fig. 5. Immunohistochemistry of meningioma samples with (A) positive and (B) negative 
expression of LMO4 (original magnification, ×400). 
6. Signal transduction pathways altered in meningiomas 
The hallmarks of cancer proposed by Hanahan and Weimberg in a multistep process in 
which cancer cells acquire the subsequent features that enable them to become tumorigenic 
and ultimately malignant include: sustaining proliferative signaling, evading growth 
suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, 
and activating invasion and metastasis (Hanahan and Weinberg 2011). Abnormalities of 
these processes involve alteratinos of multiple cell signaling pathways affected in 
meningioma tumorigenesis, such as the beta-catenin/WNT, NOTCH, TGF-beta or p53 
pathways (Ragel and Jensen 2010). 
6.1 The beta-catenin/WNT pathway 
The Wnt (wingless) signaling pathway involves proteins that regulate the production of 
Wnt signaling molecules, their interaction with receptors, and the physiological responses 
that result from the exposure of cells to the extracellular Wnt ligands. The series of events 
that occur when Wnt proteins bind to cell-surface receptors of the Frizzled family ultimately 
results in a change of the amount of β-catenin that reaches the nucleus. 
Studies using microarray-based gene expression profiling identified altered expression of 
genes associated with the beta-catenin/WNT signaling pathway in meningiomas with losses 
of 14q, such as the genes for beta-catenin (CTNNB1), the regulatory subunit of cyclin-
dependent kinase 5 (CDK5R1), ectodermal-neural cortex 1 (ECN1) and cyclin D1 (CCND1), 
which were upregulated in atypical and anaplastic meningiomas (Wrobel, Roerig et al. 
2005). Increased CTNNB1 and CDK5R1 mRNA levels may result in aberrant WNT pathway 
activity due to increased levels of cytoplasmic β-catenin, which may translocate to the 
nucleus, where it functions as a transcriptional activator of a number of genes. 
The beta-catenin/WNT pathway has also been recently implicated as important in 
meningioma recurrence, showing loss of expression of SFRP1 (Wrobel, Roerig et al. 2005; 
Pérez-Magán, Rodríguez de Lope et al. 2010). This gene belongs to the family of the secreted 
frizzled-related proteins (SFRP), which are able to downregulate Wnt signaling by forming 
an inhibitory complex with the Frizzled receptors. The role of SFRP1 as a tumor suppressor 
has been proposed in many other cancers (Caldwell, Jones et al. 2004; Chung, Lai et al. 
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2009). In gliomas, lower expression of SFPR1 and promoter hypermethylation has recently 
been reported (Götze, Wolter et al. 2009). 
6.2 The Notch signaling pathway 
The Notch signaling pathway consists of a family of four cell-spanning proteins that enable 
extracellular-to-intracellular signaling. Ligand proteins bind to the extracellular portion of 
the Notch protein, resulting in the proteolytic cleavage and release of the intracellular 
portion. This cleaved portion translocates to the cell nucleus to alter gene expression. This 
signaling pathway is important for cell–cell communication and has multiple functions 
during development as well as adult cellular functions. This signaling pathway is 
dysregulated in many cancers.  
Cuevas et al. have identified three components of the Notch signaling pathway: the 
transcription factor, hairy and enhancer of Split1 (HES1), which is induced in meningiomas 
of all grades; and two members of the Groucho/transducin-like enhancer of Split family of 
corepressors, TLE2 and TLE3, altered in high grade meningiomas (Cuevas, Slocum et al. 
2005). 
Furthermore, it has been reported that activated Notch1 and Notch2 receptors induced 
endogenous HES1 expression and were associated with tetraploidy in meningiomas. 
Therefore, a novel function for the Notch signaling pathway in generating tetraploidy and 
contributing to chromosomal instability in meningiomas was reported. This abnormal 
Notch signaling pathway may be an initiating genetic mechanism for meningioma 
tumorigenesis and potentially may promote tumor development (Baia, Stifani et al. 2008). 
6.3 p53 signaling pathway 
Cell-cycle proteins in human tumors comprise both positive and negative regulators. 
Negative cell cycle regulators include tumor-suppressor genes, of which p53 has been 
widely studied in different kinds of human tumors. The p53 gene is located on chromosome 
17p13.1 and composed of 11 exons.  
p53 protein is a key player in the cellular response to stress. It is a nuclear phosphoprotein 
that by binding to DNA in a sequence-specific manner functions as a transcription factor 
regulating a wide diversity of cellular processes such as cell proliferation, differentiation, 
apoptosis, senescence, DNA repair, or changes in metabolism.  
p53 responds to various forms of cellular stresses by activating the expression of 
downstream genes that inhibit growth, invasion and/or apoptosis, thus functioning as a 
tumor suppressor (Vousden and Prives 2009). 
The expression of p53 protein is mainly regulated at the post-transcription stage and 
maintained at a very low level in normal cells. MDM2 is an important regulator of p53; it binds 
to p53 and inhibits its function by concealing the p53 activation domain and by promoting its 
degradation. In response to DNA damage, the MDM2 binding site of p53 is phosphorylated 
and the p53–MDM2 interaction is attenuated inducing the rapid accumulation of p53, relieved 
from MDM2-mediated suppression. The p14ARF protein, another component of the p53 
pathway, binds to the p53/MDM2 complex and inhibits MDM2-mediated degradation of p53, 
which indicates that p14ARF is an upstream regulator of p53 via MDM2. In addition, p53 
downregulates the expression of p14ARF and MDM2, in an autoregulatory feedback loop 
between p53, MDM2, and p14ARF (Zhang, Xiong et al. 1998).  
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Analysis of this pathway in meningiomas has shown that deregulations of p14-MDM2-p53 
pathway may contribute to the malignant progression of meningioma. Amatya et al. found 
that methylation of p14ARF gene is more common to atypical and anaplastic meningioma 
than in benign meningiomas (Amatya, Takeshima et al. 2004). In addition, high expression 
of p53 was found in atypical and anaplastic meningiomas (Amatya, Takeshima et al. 2001), 
although low frequency or absence of mutation of p53 gene was reported by these and other 
authors (Weber, Boström et al. 1997). Moreover, frequencies of p14ARF hypermethylation of 
the promoter region increases with the tumoral grade in meningiomas, with higher 
expression of MDM2 protein the cases with methylation of p14ARF gene (Amatya, Takeshima 
et al. 2004). 
6.4 TGF- signaling pathway 
The TGF beta signaling pathway is involved in a wide range of cellular process such as cell 
growth, differentiation and apoptosis among other cellular functions. Therefore, it is a very 
heavily regulated pathway. The ligands of the TGF-beta superfamily bind to a type II 
receptor, recruiting and phosphorylating a type I receptor. As a consequence, the type I 
receptor activates receptor-regulated SMADs (e.g. SMAD2, SMAD3) which can now bind 
coSMADs (SMAD4). These complexes accumulate in the nucleus where they act as 
transcription factors and participate in the regulation of target gene expression. 
In vitro studies of this pathway in meningioma cell lines suggest that TGF- has an 
inhibitory effect on meningioma proliferation, possibly through Smad 2/3 apoptotic 
pathways (Johnson, Okediji et al. 2004). However, a recent study of the most relevant 
molecules of the TGF-beta pathway on meningioma tumors concluded that only attenuated 
TGF-βRIII expression and TGFB growth inhibition may occur in select higher grade 
meningiomas (Johnson, Shaw et al. 2011). 
7. Conclusions 
Meningiomas show a broad range of histopathological patterns that in most of the tumors 
are featured by similar biological and clinical behaviors. Nevertheless, some difficulties 
still remain, particularly for designation of atypical WHO grade II meningiomas. In 
addition, different clinical outcomes and recurrence rates even within the same 
histopathological grade have been observed. Therefore, it is of relevance the identification 
of prognostic biomarkers for a proper individualized management of the patients. In these 
sense, useful genetic models for the mechanisms of tumorigenesis and progression in 
meningiomas have been described, proposing a number of candidate target genes. 
However, a big amount of genetic and epigenetic research still has to be done in order to 
identify patients at risk and to translate this information into effective forms of targeted 
therapies. 
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1. Introduction 
Tumor suppressor genes are so named because of their actions in preventing cancer – but it 
is often overlooked that they also have normal functions in non-pathological cellular 
contexts. Here we review the evidence that tumor suppressor genes are key regulators of 
developmental events, focusing on the neural retina as a model system. At no other time 
during an organism’s lifespan are the biological processes that tumor suppressor genes 
control - including cell division, differentiation, migration and programmed cell death, more 
pronounced than during the embryonic and early postnatal period. The developing retina 
serves as an excellent model of tissue development based on its experimental accessibility, 
well-characterized cell types, and sophisticated laminar organization. The retina also has an 
important physiological function - processing light signals so that vision is possible. Visual 
processing requires functional neural circuits, the formation of which requires that appropriate 
numbers of the correct types of neuronal and glial cells differentiate during development.  
Here we introduce our current knowledge of how the retina develops and then review the 
evidence that tumor suppressor genes control several aspects of this process, including: 1) cell 
division/proliferation, 2) appropriate cell fate specification/differentiation, 3) cell migration, 
and 4) cellular apoptosis. By better understanding the normal functions that tumor 
suppressor genes play in the developing embryo, we are better positioned to understand 
why their deregulated expression leads to tumor growth and cancer. 
1.1 Retinal structure and morphogenesis 
The retina is the neural layer of the eye and is responsible for converting light photons 
into electrical impulses that are transmitted to the brain. It is comprised of one glial and 
six neuronal cell types that are organized into three nuclear layers: 1) an outer nuclear 
layer (ONL) of rod and cone photoreceptors, which receive light signals; 2) an inner 
nuclear layer (INL) of supporting Müller glial cells and bipolar, horizontal and amacrine 
cell interneurons, which refine and transmit signals from photoreceptors; and 3) a 
ganglion cell layer (GCL) of retinal ganglion cells (RGCs) – the output neurons of the 
retina (Figure 1).  
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Fig. 1. Structure and connectivity of the mature retina. Animated neurons are drawn on top 
of a photomicrograph of a hematoxylin & eosin stained adult retina. Rod and cone 
photoreceptors are located in the ONL, horizontal, amacrine and bipolar cell interneurons 
and Müller glia are located in the INL, and RGCs and displaced amacrine cells are in the 
GCL. Light enters the eye and is first processed by the outer segments of rod and cone 
photoreceptors in the ONL. This information is then passed to the OPL, where connections 
between photoreceptors and bipolar cells are made, and signals are modulated by 
horizontal cells. Finally, bipolar cell axons pass visual information to RGC dendrites in the 
IPL – signaling that is refined by amacrine cells. Information is finally transmitted by RGC 
axons to the brain for further processing. (A,amacrine cell, B,bipolar cell; C,cone 
photoreceptor; G, retinal ganglion cell; GCL, ganglion cell layer; H, horizontal cell; INL, 
inner nuclear layer; IPL, inner plexiform layer; M, Müller glia; ONL, outer nuclear layer; 
OPL, outer plexiform layer; R, rod photoreceptor). 
The GCL also contains some displaced amacrine cells. The three nuclear layers are separated 
by two synaptic layers; the inner plexiform layer (IPL), which separates the GCL/INL and 
the outer plexiform layer (OPL), which separates the INL/ONL.  
In the embryo, the retina begins as a small bilateral outpocketing of the rostral diencephalon, 
first emerging at around embryonic day (E) 8.5 in mice (Svoboda and O'Shea 1987; Wawersik 
and Maas 2000; Fuhrmann 2010). As the evaginated diencephalon comes into contact with the 
surface ectoderm, it induces formation of the lens placode in the overlying epithelium. At E9.5, 
the lens vesicle signals to the adjacent diencephalic neuroepithelial cells to invaginate and 
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form an optic cup (Svoboda and O'Shea 1987; Fuhrmann 2010). The inner and outer layers of 
the optic cup form the neural retina and retinal pigmented epithelium (RPE), respectively. 
Thus, by E10.5 the neural retina is morphologically distinct, and is comprised of actively 
proliferating, progenitor cells (Kagiyama et al. 2005; Hirashima et al. 2008). Based on lineage 
tracing and clonal analyses, all seven retinal cell types are generated from this common pool of 
multipotent retinal progenitor cells (Turner and Cepko 1987; Holt et al. 1988; Wetts and Fraser 
1988; Fekete et al. 1994; Alexiades and Cepko 1997). There is also, however evidence for the 
existence of some restricted retinal cell lineages (Alexiades and Cepko 1997; Li et al. 2004; Pearson 
and Doe 2004; Cayouette et al. 2006). Currently, the proportion of retinal progenitors that are 
multipotent versus lineage-restricted is not known (Cayouette et al. 2003; Cayouette et al. 2006). 
1.2 Retinal cell fate specification and differentiation 
Retinal cell differentiation commences at around E10.5 in mouse and is not complete until 
postnatal day (P) 12, preceding in a medial-to-lateral gradient (Young 1985a; Wallace 2011). 
The seven retinal cell types are generated in a stereotyped, overlapping sequence and can be 
grouped into two major, overlapping phases; a prenatal and postnatal phase (Young 1985b; 
Young 1985a; Stiemke and Hollyfield 1995; Cepko et al. 1996) (Figure 2). In the prenatal 
phase, RGCs first begin to differentiate, starting at approximately E10.5, followed closely by 
horizontal cells and cone photoreceptors, and slightly later by amacrine cells. This prenatal 
phase of retinal histogenesis peaks around E15.5 and continues until approximately P2 in 
mice. In the postnatal phase of retinal cell differentiation, which peaks around P0, rod 
photoreceptors, bipolar cells and Müller glia are generated (Cepko et al. 1996; Livesey and 
Cepko 2001; Wallace 2011). Strikingly, the order of cellular differentiation is grossly 
conserved across vertebrate species despite a wide variance in the overall length of the 
differentiation period that ranges from 25 hours in Xenopus [i.e. stage 28-stage 40; (Holt et al. 
1988)] to approximately 3 weeks in rodents (Young 1985b; Rapaport et al. 2004).  
Over the course of cellular differentiation, temporal cues are thought to gradually reduce 
developmental plasticity such that progenitor cells become biased towards a smaller 
number of cell fates (Competence Model), resulting in the stereotyped order of cellular 
differentiation (Cepko et al. 1996; Livesey and Cepko 2001). In both multipotent and lineage 
biased progenitors, transcription factors act combinatorially to specify distinct retinal cell 
fates at different developmental times (Inoue et al. 2002). Thus, by changing the repertoire of 
transcription factors that are expressed and active, unique temporal identities are specified 
and appropriate differentiation programs are initiated (Cepko et al. 1996). Many 
transcription factors that participate in retinogenesis act in a combinatorial manner to 
specify retinal cell fates (Hatakeyama et al. 2001; Inoue et al. 2002). As a consequence, 
misexpression of any one transcription factor does not necessarily induce the generation of 
the cell types that would be predicted based on its pattern of expression and loss-of-function 
phenotype. For example, Math3 and Mash1 are expressed in bipolar cells, a cell type that is 
absent in Math3;Mash1 double mutants, but misexpression of either of these two basic-helix 
loop-helix (bHLH) proteins alone promotes rod rather than bipolar genesis (Tomita et al. 
2000). In contrast, misexpression of Math3 or Mash1 in conjunction with the homeodomain 
protein Chx10 leads to bipolar cell genesis (Hatakeyama et al. 2001). Similarly, amacrine cells 
are specified by the combined activities of the bHLH protein NeuroD in conjunction with 
the homeodomain proteins Pax6 or Six3 (Inoue et al. 2002), whereas Math3 can specify a 
horizontal cell fate in combination with Pax6 or Six3, and a bipolar cell fate in combination 
with Chx10 (Hatakeyama et al. 2001; Inoue et al. 2002). 
 
Tumor Suppressor Genes 
 
272 
 
Fig. 2. Sequential generation of retinal cells during development. 
(A) The competence model of retinal cell differentiation. Progenitors are gradually restricted 
in their developmental potential, resulting in the differentiation of different retinal cell types 
as developmental time proceeds. RGCs are born first, quickly followed in an overlapping 
manner by cones, horizontal cells, and amacrine cells (embryonic phase), and rod 
photoreceptors, bipolar cells and Müller glia (postnatal phase). (B) A schematic illustrating 
that retinal cell neurogenesis occurs in roughly two distinct but overlapping waves.  
1.3 Retinal cell migration 
The three-layered structure of the retina is reminiscent of the six-layered organization of 
the neocortex. However, while neocortical neurons are born in non-overlapping waves 
and migrate radially to sequentially populate the layers in an ‘inside-out’ manner (i.e., 
deep-layers formed first, followed by more superficial layers) (Caviness 1982; Caviness et 
al. 1995; Takahashi et al. 1999), the timing of differentiation and the migratory routes of 
retinal neurons are more complex. For example, during the early-phase of retinal cell 
differentiation, RGCs, horizontal cells, amacrine cells and cone photoreceptors have 
overlapping birthdates, but distinct destinations: RGCs and some amacrine cells migrate 
to the GCL, horizontal cells and some amacrine cells migrate to the INL and cone 
photoreceptors migrate to the ONL (Baye and Link 2008; Galli-Resta et al. 2008). How are 
these distinct migratory routes established? The logic behind radial cell migration begins 
with an understanding of how retinal progenitor cells divide. Most retinal progenitors 
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have a radial morphology and maintain contact with both the apical and basal surfaces of 
the retinal neuroepithelium (Figure 3). During the cell cycle, retinal progenitors undergo 
interkinetic nuclear migration in a cell cycle-dependent fashion, such that mitotic 
divisions, and hence neuronal birth, occur at the apical surface of the retina (Turner et al. 
1990). Horizontal cell precursors are an exception to the rule, as they undergo non-apical 
mitoses near their final location in the INL (Figure 3, 4) (Godinho et al. 2007), while other 
cell types are all thought to be born at the apical surface. As RGCs differentiate, they lose 
their apical attachment, retaining a basal extension that becomes an axon and is thought 
to help drag RGCs into the GCL (Poggi et al. 2005; Zolessi et al. 2006) (Figure 3). In 
contrast, amacrine cells lose both apical and basal contacts upon differentiation, and must 
somehow respond to unknown environmental cues as they migrate into their final 
positions in the INL and GCL (Galli-Resta et al. 2008) (Figure 3). Finally, cone 
photoreceptors remain at their apical site of birth – where the future ONL will develop 
(Figure 3). Similarly, in the second phase of differentiation, rod photoreceptors remain in 
the apical compartment post-differentiation, whereas bipolar cells and Müller glia must 
migrate into the INL (Figure 4).  
The retina also has a unique three-dimensional architecture in the tangential plane, with the 
cell bodies of cone photoreceptors, amacrine cells, horizontal cells and RGCs migrating 
tangentially to position themselves at regular intervals to allow complete sampling of the 
visual field. These non-random cellular arrays are known as mosaics and evenly tile the 
retinal field (Galli-Resta et al. 2008). Individual cellular mosaics are characterized by 
minimal distances between like-cells – a spacing that is achieved by processes that include 
self-avoidance or isoneuronal repulsion and repulsion of like-neighbours or heteroneuronal 
repulsion (Grueber and Sagasti 2010). While the molecular cues that establish retinal cell 
mosaics are poorly understood, individual retinal mosaics are known to develop cell 
autonomously and are not influenced by the mosaics of other cell types (Rockhill et al. 2000).  
1.4 Retinal cell death during development 
Apoptosis is also known as programmed cell death, and is a process whereby a cell induces 
its own death through a well characterized caspase-mediated signalling pathway. During 
development, neurogenesis and apoptosis are both required to occur in a balanced fashion 
so that appropriate numbers of each retinal cell type are present in the mature organ. 
Strikingly, in the CNS, 20-70% of neurons undergo apoptosis (Burek and Oppenheim 1996). 
While it is still not known why organisms generate extra cells and then have to delete them, 
the process of apoptosis has been conserved throughout evolution and is essential for 
proper tissue morphogenesis and to determine the final size of tissues and organs (Burek 
and Oppenheim 1996; Bahr 2000; Buss and Oppenheim 2004). During embryonic retinal 
development there are three waves of cell apoptosis. First, during the optic cup stage (E10-
E11), apoptosis is primarily observed in the presumptive RPE and optic stalk (Pei and 
Rhodin 1970; Silver and Hughes 1973). Next, a second wave of apoptosis is observed during 
the stage of optic fissure closure (E11 to E12), with apoptotic retinal progenitor cells 
observed at the fissure site (Silver and Robb 1979; Hero 1990). The third wave of apoptosis 
happens during the optic nerve enlargement stage (E15.5-E17.5). At this stage, 
neuroepithelial cells close to the optic nerve head undergo degeneration (Silver and Robb 
1979). Cell apoptosis is also observed in all three layers in postnatal stage retinae, occurring 
in a central to peripheral gradient. Studies in rat retinae indicate that around 5%, 50%, and 
 
Tumor Suppressor Genes 
 
274 
51% of the ONL, INL, and GCL populations undergoes programmed cell death, respectively 
(Voyvodic et al. 1995). Cell apoptosis starts in the GCL, and lasts from P2 to P11 with a peak 
at P2-P5 (Young 1984). Two phases of apoptosis are then observed in the INL, with amacrine 
cell degeneration peaking at P3-P8, followed by bipolar and Müller glial cell degeneration 
peaking at P8-P11. Photoreceptor cell apoptosis lasts for two weeks, with a peak from P5 to 
P9 (Young 1984).  
 
 
Fig. 3. Site of neuronal birth and migration patterns for retinal neurons born in the early 
embryonic phase of retinal cell differentiation.  
Cells are schematized on top of a photomicrograph of an E15.5, DAPI stained retina. Cycling 
progenitors (pink) maintain contacts with the apical and basal surface of the retinal 
neuroepithelium. Retinal progenitors then divide asymmetrically at the apical surface of the 
neuroblast layer (NBL), giving rise to immature neurons that must migrate to their correct 
laminar positions within the retina. Cone cells differentiate at the apical surface, where they 
will remain and form the future ONL (not shown). Amacrine cells differentiate at the apical 
surface, lose their apical and basal contacts, and then migrate through the NBL to reach the 
INL (and some go to the GCL). RGCs differentiate at the apical surface and lose their apical 
contact but maintain their basal contact – an extension that will help RGCs migrate into the 
forming GCL. During this time, horizontal cell precursors continue to migrate along the 
apico-basal axis of the NBL, not undergoing terminal differentiation and finding their final 
position until postnatal stages. 
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Fig. 4. Site of neuronal birth and migration patterns for retinal neurons born in the late 
postnatal phase of retinal cell differentiation.  
Retinal cells are schematized on top of a photomicrograph of a P3, DAPI stained retina. 
Cycling progenitors (pink) divide asymmetrically at the apical surface of the NBL to 
eventually give rise to immature neurons that must migrate to their correct laminar 
position within the retina. Bipolar cells migrate through the NBL basally and into the 
middle of the forming INL. Rods remain at the apical surface of the retina, where the ONL 
is developing. Müller glia migrate in a similar fashion to bipolar cells to reach the INL. 
Horizontal cell precursors migrate into the apical surface of the forming INL, undergo a 
terminal symmetric division and migrate in a tangential fashion to find their final position 
in the INL. 
The molecules involved in the apoptotic pathway have been extensively studied in several 
systems, including the retina (Burek and Oppenheim 1996). While a comprehensive 
summary is beyond the scope of this review, apoptotic molecules identified in the retina 
include death receptors, excitotoxic factors, proapoptotic Bcl-2 family proteins, proteases, 
DNases and transcription factors (for review, see (Isenmann et al. 2003)). 
This review will summarize what is currently known and what are some unanswered 
questions about established tumor suppressor genes and their roles in different stages of 
retinal histogenesis.  
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2. Tumor suppressor genes regulate retinal progenitor cell proliferation 
2.1 Introduction to the cell cycle 
All tissues, including the retina, are genetically programmed to acquire an optimal size, 
which is determined both by the total number of cells and the sizes of individual cells 
(Gomer 2001). A major open question is how retinal progenitors know when to switch 
from making one cell type to the next so that appropriate numbers of each of the seven 
cell types are generated. In the retina, the choice of cell fate is intimately coupled, albeit 
not absolutely linked, to the timing of cell cycle exit. Given the central role that tumor 
suppressor genes play in regulating cell cycle exit, it is therefore not surprising that they 
are emerging as key regulators of the normal cell cycle in the developing retina. A general 
introduction to the cell cycle and the tumor suppressor genes that operate in this pathway 
is highlighted below. 
During the cell cycle, dividing cells must replicate their DNA (S-phase) and then segregate a 
2N complement of chromosomes into each daughter cell during mitosis (M-phase). S-phase 
and M-phase of the cell cycle are separated by two Gap phases (G1 before S and G2 before 
M), in which key checkpoints regulate entry into the next cell cycle phase. An important 
checkpoint in G1 is the restriction point, where the decision is made to either commit to 
another round of cell division or to exit the cell cycle and enter G0 (i.e., stop dividing). Two 
major classes of regulatory molecules control cell cycle progression - the cyclins and cyclin-
dependent kinases (CDKs), which together form functional complexes (Nigg 1995). In 
general, CDKs are constitutively expressed whereas cyclin expression is more tightly 
regulated and restricted to specific cell cycle stages (Nigg 1995). Progression past the 
restriction point in G1 is regulated by complex formation between CDK4 or CDK6 with 
members of the Cyclin D family (D1/D2/D3). Active Cyclin D-CDK4/6 complexes 
phosphorylate the retinoblastoma protein (Rb), an important tumor suppressor gene that 
controls G1 progression (Paternot et al. 2010). When Rb is in its hypo-phosphorylated form, 
it is bound to E2F transcription factors, an interaction that is dissociated by 
hyperphosphorylation of Rb, releasing the E2F proteins so that they can initiate the 
transcription of genes required in S-phase of the cell cycle (Figure 5).  
The CDK/cyclin complexes that operate in G1 phase of the cell cycle are negatively 
regulated by cyclin dependent kinase inhibitors (CDKIs), which block cell cycle 
progression. CDKIs fall into two families: 1) Cip/Kip (p21Cip1, p27Kip1 and p57Kip2) and 2) 
INK4 (p16INK4a, p15INK4b, p18INK4c, and p19INK4d) (Besson et al. 2008). In the Cip/Kip 
family, p57Kip2 and p27Kip1 are considered tumor suppressor genes as mutations in these 
genes are associated with tumor formation in humans (Lee and Kim 2009; Guo et al. 2010). 
In contrast, p21Cip1 is not often mutated in human cancers, but its deletion is associated 
with tumor formation in mouse models, suggesting that it does have tumor suppressor 
properties ((Franklin et al. 2000; Poole et al. 2004; Gartel 2009) and references therein). 
Moreover, p21Cip1 mediates cell cycle exit induced in response to DNA damage by p53,  
a well known tumor suppressor that is frequently mutated in human cancers (Gartel 009). 
Finally, in the INK4 family, p16INK4a and p19INK4d are known tumor suppressor  
genes that block the assembly of Cdk4/6-cyclin D complexes, thereby inhibiting 
progression through G1 into S phase of the cell cycle (Besson et al. 2008; Wesierska-Gadek 
et al. 2010). 
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Fig. 5. Tumor suppressor genes and the cell cycle. Schematic illustration of the major phases 
of the eukaryotic cell cycle.  
Progression through the restriction point (R) in G1 is controlled by Cdk4/6~cyclinD1-D3 
complexes, which phosphorylate the Rb protein. When Rb is hypophosphorylated, it is 
bound to E2F transcription factors. When Rb is hyperphosphorylated, it releases E2F 
transcription factors, which can induce the expression of genes required for progression into 
S-phase of the cell cycle. The related pocket proteins p107 and p130 also complex with E2F 
transcription factors. The activities of Cdk4/6~cyclinD1-D3 complexes are negatively 
regulated by CDKIs of the Cip/Kip and INK4 families. Cell cycle regulators that are known 
tumor suppressor genes are listed in blue. 
2.2 CDKIs regulate retinal progenitor cell proliferation 
Of the Cip/Kip family members, only p27Kip1 and p57Kip2 have been studied extensively in 
the developing retina. During embryogenesis and in the early postnatal period, p27Kip1 and 
p57Kip2 are each expressed in a few scattered progenitor cells in the outer neuroblast layer 
(ONBL) as well as in a few postmitotic cells that are forming the INL. However, p27Kip1 and 
p57Kip2 are not co-expressed in the retina, suggesting that they function in distinct 
populations of retinal cells (Dyer and Cepko 2000; Dyer and Cepko 2001). The few cells that 
express CDKIs in the ONBL are thought to be those that are exiting the cell cycle and 
differentiating. Indeed, withdrawal of the growth factor EGF from cultured retinal 
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progenitor cells induces p27Kip1 expression in association with cell cycle exit and cellular 
differentiation (Levine et al. 2000). In gain of function experiments in E14.5 retinal 
progenitors, p27Kip1 promote premature cell cycle exit and differentiation (Dyer and Cepko 
2000; Levine et al. 2000; Dyer and Cepko 2001). Conversely, in p27Kip1 mutants, uncommitted 
retinal progenitor cells, but not committed precursor cells, divide excessively during late 
retinogenesis (Levine et al. 2000; Dyer and Cepko 2001). Similar results were obtained in 
Xenopus retina. In gain-of-function experiments, p27Xic1 promotes cell cycle exit while loss-of-
function conversely promotes retinal progenitor cell proliferation (Ohnuma et al. 1999). 
p57Kip2 is similarly sufficient and required for cell cycle exit of retinal progenitors, but it 
functions during an early stage of retinal development, with ectopic cell divisions observed 
as early as E14.5 in knock-out mice (Dyer and Cepko 2000; Dyer and Cepko 2001).  
In the murine retina, the INK4 family member p19INK4d is expressed in retinal progenitors at 
all embryonic and postnatal stages tested (Cunningham et al. 2002). Mutation of p19INK4d 
results in increased retinal progenitor cell proliferation during early postnatal stages 
(Cunningham et al. 2002). Prolonged retinal progenitor cell proliferation is also observed in 
p19INK4d;p27Kip1 double null retinae, including at P18, a stage when no BrdU+ proliferating 
cells are normally detected in the murine retina (Cunningham et al. 2002). The cause of the 
ectopic cell divisions was shown to be re-entry into the cell cycle by differentiated retinal 
neurons, including horizontal and amacrine cells (Cunningham et al. 2002). 
The activities of p27Kip1 and p19INK4d are thus not temporally restricted in the retina – they 
function both in the embryonic and postnatal stages of retinal development to control cell 
cycle exit. In contrast, p57Kip2 is only required during the embryonic early stage of retinal 
development to control cell cycle exit (Levine et al. 2000; Dyer and Cepko 2001). 
2.3 Rb and its family members regulate retinal progenitor cell proliferation 
The retinoblastoma protein (Rb) encoded by the Rb1 gene was the first tumor suppressor 
gene identified (Chinnam and Goodrich 2011). In humans, mutation of RB1 results in 
retinoblastoma, a devastating childhood tumor of the eye that robs children of their vision 
(DiCiommo et al. 2000). Rb prevents progression from G1 into S phase of the cell cycle by 
binding E2F transcription factors – an inhibition that is released by CDK4/6-cyclinD-
mediated phosphorylation of Rb (Frolov and Dyson 2004; Burkhart and Sage 2008; Paternot 
et al. 2010 ). Rb is a pocket-protein that is highly related to two other family members, p107 
and p130, which are similar in both sequence and function, also acting as nuclear 
phosphoproteins (Ewen et al. 1991; Hannon et al. 1993). Like Rb, p107 and p130 also act as 
negative regulators of cell proliferation through interactions with E2F transcription factors 
(Zhu et al. 1993; Claudio et al. 1994). It is now known that different Rb family proteins 
associate with different E2Fs at different times during the cell cycle (Bernards 1997). 
In mouse models, animals heterozygous for an Rb null allele die at 6-8 months of age due to 
pituitary gland tumours, but display no evidence of retinal abnormalities, proliferation 
defects, or retinoblastoma (Clarke et al. 1992; Jacks et al. 1992). This is in keeping with 
evidence in humans that both Rb alleles must be mutated for tumors to arise (DiCiommo et 
al. 2000). In contrast, animals homozygous for an Rb null allele die in the embryonic period - 
between E12-E15 (Clarke et al. 1992; Jacks et al. 1992). While a detailed analysis of retinal 
development is not possible at these early stages, it is notable that no gross abnormalities or 
enhanced proliferation were observed in surviving Rb mutant embryos at E13.5 (Zhang et al. 
2004). However, more S-phase cells were observed in retinae from homozygous Rb null 
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mutants that were explanted at E13.5 and cultured for 6 days in vitro (DIV - equivalent to 
early postnatal retinae in vivo) (Zhang et al. 2004). This suggested that Rb may only be 
required to regulate the cell cycle during early postnatal stages of retinal development, a 
model that was tested further with the advent of the Cre-LoxP system, and the ability to 
conditionally knock-out (cKO) Rb in the retina (Chen et al. 2004; MacPherson et al. 2004; 
Zhang et al. 2004). Using a Nestin-Cre driver, Rb cKO retinae were generated, and ectopic S- 
and M-phase progenitors were detected in the presumptive IPL/GCL at E18.5, although 
overall numbers of dividing cells were not significantly increased (MacPherson et al. 2004). 
Despite the increases in ectopic cycling and mitotic cells, paternal Nestin-Cre Rb cKO show 
no evidence of retinoblastoma but also die at early postnatal stages (MacPherson et al. 2004), 
likely due to the broad effect of deleting Rb in most of the developing brain.  
One reason why Rb mutants may not display defects in retinal development may be because 
of compensation by p107 and p130 family members. Analyses of retinal development in 
Rb;p107 double mutants was initially precluded by the death of these embryos by E11.5 
(Robanus-Maandag et al. 1998). To circumvent this problem, chimeric embryos were 
generated with Rb;p107 double mutant embryonic stem cells (Robanus-Maandag et al. 1998). 
Rb;p107 double mutant chimeric embryos develop retinoblastoma by E17.5, with tissue 
hyperplasia originating in retinal cells committed to the amacrine cell lineage (Robanus-
Maandag et al. 1998). Subsequently, the floxed Rb allele was used to analyze Rb mutations in 
combination with conventional p107-/- (Chen et al. 2004), p130-/- (MacPherson et al. 2004) or 
p130-/-; p107+/- (Ajioka et al. 2007) mutations. Using a Pax6α-Cre driver, Rb cKO mice were 
generated, knocking out Rb in peripheral and not central retinal progenitors; this mutant 
allele was analyzed on a p107-/- background (Chen et al. 2004). At P0, in both Rb cKOs and 
Rb cKO; p107 double knockouts, BrdU+ cells were not increased in number, but were 
ectopically positioned throughout the differentiated zones of the retina, where dividing cells 
are not usually detected (Chen et al. 2004). It was not until P8 (and up to P18) that Rb cKOs 
and Rb cKO; p107 double knockouts displayed an overall increase in the number of BrdU+ 
cells (Chen et al. 2004; MacPherson et al. 2004). Rb cKO;p107 double null mice also 
developed retinoblastoma as early as P8, with larger tumors apparent in older animals 
(Chen et al. 2004). Many of the ectopic BrdU+ cells were amacrine cells in Rb cKO and Rb 
cKO;p107 double mutants, while tumors cells rarely expressed markers of photoreceptors, 
bipolar cells, or RGCs (Chen et al. 2004). Similar results were observed in Rb cKO;p130 
double knockout mice generated with a nestin-cre driver, which also developed 
retinoblastomas in adulthood, with tumors comprised of syntaxin+ and calretinin+ 
amacrine cells and not other retinal cell types (MacPherson et al. 2004). Thus, the Rb family 
of pocket proteins have an important role in regulating cell cycle exit in committed amacrine 
cell precursors, furthermore suggesting that amacrine cells may be the cell of origin for 
retinoblastoma. 
While Rb cKO; p107-/- and Rb cKO; p130-/- double knockouts generated with Pax6-cre and 
Nestin-cre drivers, respectively, both develop retinoblastomas derived from amacrine cell 
precursors, it was recently demonstrated that in Rb cKO;p130-/-;p107+/- animals that were 
generated with a Chx10-cre driver (commonly referred to as “p107 single” mice as they only 
express this one pocket protein), metastatic retinoblastoma develops in adults, with tumor 
cells derived from fully differentiated and synaptically coupled horizontal cells that have 
de-differentiated and re-entered the cell cycle (Ajioka et al. 2007). In contrast, in human 
retina, perinatal-derived retinoblastoma (most clinical cases of human familial 
retinoblastoma are detected during early infancy in children), which requires bi-allelic Rb1 
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mutation and/or inactivation, seems to arise from Rb mutant cells of the cone photoreceptor 
precursor lineage (Xu et al. 2009), rather than an amacrine or horizontal cell lineage as in 
mouse (Chen et al. 2004; Ajioka et al. 2007). The oncogenes MDM2 and n-Myc are highly 
expressed in cone precursors and are required for the propagation of human retinoblastoma 
(Xu et al. 2009). It was also found that the cone-specific transcription factors RXRγ and TRβ2 
are also required for retinoblastoma proliferation and survival in several human 
retinoblastoma cell lines (Xu et al. 2009). Moreover, RXRγ was found to positively regulate 
the expression of the oncogene MDM2 (Xu et al. 2009). Given the evidence found in this 
human study, it is difficult to say which of the currently generated mouse models of 
retinoblastoma most closely resemble (or successfully “model”) bonafide human 
retinoblastoma. Further studies will be needed to understand the differences observed in 
mouse models and in human tumors with respect to the cell of origin for retinoblastoma.  
2.4 Zac1 and Tgfβ2 regulate retinal progenitor cell proliferation 
Zac1 is a tumor suppressor gene encoding a zinc finger transcription factor that promotes 
cell cycle arrest and apoptosis in cell lines, while germline mutations are associated with 
numerous carcinomas (Abdollahi et al. 1997; Spengler et al. 1997; Pagotto et al. 2000; 
Bilanges et al. 2001; Abdollahi et al. 2003; Koy et al. 2004). Similarly, we have shown that 
Zac1 is required to elicit apoptosis and cell cycle arrest in the developing murine retina (Ma 
et al. 2007a). In Zac1 null mutants, the retina becomes hypercellular in late retinogenesis, an 
increase in cell number that is associated with ectopic cell divisions in the early postnatal 
retina (Ma et al. 2007a). Conversely, in gain-of-function experiments, misexpression of Zac1 
blocks retinal cell proliferation (Ma et al. 2007a). Currently, it is not known how Zac1 
promotes cell cycle exit, either in tumor cells or in retinal progenitor cells (Spengler et al. 
1997; Ma et al. 2007a). It seems unlikely that Zac1 regulates retinal cell cycle exit through 
p27Kip1 or p57Kip2, as Zac1 has a distinct requirement in late retinal progenitors, while p57Kip2 
functions in early progenitors, and p27Kip1 functions throughout retinogenesis (Ma et al. 
2007a).  
We found that Zac1 is required to induce expression of transforming growth factor βII (TGFβII) 
in the retina (Ma et al. 2007a). Notably, TGFβII is also a known tumor suppressor gene, and 
was shown to negatively regulate the proliferation of retinal progenitor cells and Müller glia 
(Close et al. 2005). Interestingly, previous reports have indicated that TGFβ regulates p27Kip1 
expression (Ravitz and Wenner 1997), whereas Zac1 does not regulate p27Kip1 expression (Ma 
et al. 2007a). However, Zac1 is known to associate with and modulate the activity of several 
transcriptional regulators, including p53 (Huang and Stallcup 2000; Huang et al. 2001). p53 
is a well known tumor suppressor that is required for the cellular response to TGFβ 
signaling in Xenopus mesoderm (Cordenonsi et al. 2003; Cordenonsi et al. 2007).  
3. Tumor suppressor genes regulate retinal cell death 
3.1 CDKIs regulate retinal cell death 
Compensatory mechanisms exist in the retina to ensure that the final ratios of individual cell 
types remain constant, with excess proliferation often balanced by an increase in apoptosis. 
This is indeed the case in p27Kip1 and p57Kip2 mutants, where increases in cell death are 
thought to counterbalance the increased retinal progenitor cell proliferation observed in 
these mutants (Dyer and Cepko 2000; Levine et al. 2000; Dyer and Cepko 2001). While 
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19INK4d knockout mouse retinae reported no change in apoptosis at postnatal stages (P10, 
P14, and P18), p19INK4d;p27Kip1 double knockouts did show increased apoptosis at P10 and 
P14 (Cunningham et al. 2002). Thus, despite the increase in cell proliferation, cell number is 
not dramatically changed in p19INK4d;p27Kip1 double null because apoptosis in these retinae is 
five times higher than in wild-type retinae (Cunningham et al. 2002). This cell death was 
unable to be rescued upon co-deletion of p53, as p19INK4d;p27Kip1;p53 triple knockout mouse 
retinae also showed increased levels of apoptosis at postnatal stages (Cunningham et al. 
2002), indicating the underlying mechanism of death signalling is p53-independent.  
3.2 Rb and its family members regulate retinal cell death 
In all Rb mutant eyes, including in conventional Rb knockouts at E13.5 (Zhang et al. 2004), 
chimeric Rb knockouts (from E16 onwards) (Robanus-Maandag et al. 1998), and in Rb 
cKOs generated with Nestin-Cre (at E18.5) (MacPherson et al. 2004) or Pax6α-cre (from 
P0) (Chen et al. 2004; MacPherson et al. 2004), an increase in cell death was observed. 
Notably, this increase in cell death was no longer evident in E13.5 retinal explants from 
conventional Rb knockouts that were cultured for 12 DIV (similar to late postnatal stages 
in-vivo), suggesting that Rb is required to prevent apoptosis only during embryonic and 
early postnatal stages (Zhang et al. 2004). It was also reported that amacrine cells seem to 
be spared from apoptosis since they were not dramatically reduced in number in Rb 
mutants, unlike other retinal cell types (MacPherson et al. 2004). The mechanism behind 
the excessive cell death in Rb mutants is independent of p53, as Rb cKO;p53 double 
knockout retinae displayed the same increase in apoptosis observed in Rb cKO single 
mutants (MacPherson et al. 2004). Rb;p107 double chimeric knockouts (Robanus-Maandag 
et al. 1998) or Rb cKO;p107 double knockouts generated with Nestin-cre (MacPherson et 
al. 2004) or Pax6α-cre (Chen et al. 2004) also displayed enhanced apoptosis from E17.5 
onwards. The cells that were more prone to apoptosis in double knockout retinae was 
investigated in more detail, demonstrating that RGCs and other cell types undergo 
extensive cell death, but amacrine cells were selectively spared from apaoptosis (Chen et 
al. 2004). The authors of this study argue strongly that because amacrine cells are 
intrinsically death resistant in double Rb cKO;p107 knockouts, they are capable of forming 
retinoblastomas, and that resistance to cell death may be a general feature of tumor 
formation. However, what remains to be determined is why amacrine cells are protected 
from cell death in Rb mouse mutants, while all other retinal cell types seem to undergo 
apoptosis when the pocket proteins are mutated. 
3.3 Zac1 regulates retinal cell death 
Our analysis of Zac1 mutant retinae revealed that there are fewer apoptotic cells in E18.5 
explants cultured for both 4 and 8 DIV (Ma et al. 2007a). However, misexpression of Zac1 
was not sufficient to induce cell death in the murine retina (Ma et al. 2007a), although it was 
sufficient to induce apoptosis in the Xenopus retina (Ma et al. 2007b), as well as in mouse or 
human cell lines (Spengler et al. 1997; Varrault et al. 1998). Interestingly, an isoform of 
human Zac1 lacking the first 2 zinc fingers (Zac1Δ2) has a reduced capacity to induce 
apoptosis and an increased ability to arrest cell cycle progression, suggesting that these two 
functions are carried out independently of one another (Bilanges et al. 2001). How Zac1 
induces apoptosis in the retina and elsewhere, remains to be determined. 
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4. Tumor suppressor genes and retinal cell fate specification 
In the retina, the choice of cell fate is intimately coupled, albeit not absolutely linked, to the 
timing of cell cycle exit. This raises the question of how cell fate specification and cell cycle 
exit decisions are coordinated.  
4.1 The CDKIs p27Kip1 and p57Kip2 influence cell fate decisions in the retina 
Misexpression of p27Xic1 in Xenopus promotes Müller glial cell genesis, while conversely, 
inactivating p27Xic1 decreases Müller glial cell number (Ohnuma et al. 1999). p27Xic1 also has the 
ability to modulate the capacity of transcription factors to specify retinal cell fates in Xenopus. 
For example, Xath5 has a more potent ability to induce an RGC fate when co-expressed with 
p27Xic1, whereas Xath5 promotes alternative "later" fates when cell cycle progression is 
stimulated by cyclin E1 (Ohnuma et al. 2002). In murine systems, p27Kip1 appears to function 
differently than its Xenopus homolog. For instance, misexpression of p27Kip1 in mouse or rat 
retinal cells increases the number of rod photoreceptors that differentiate (Levine et al. 2000; 
Dyer and Cepko 2001), suggesting that p27Kip1 may specify a photoreceptor cell fate. Providing 
further support for this idea, rat embryonic retinal progenitors express high levels of p27Kip1 in 
response to the withdrawal of EGF from the culture media, leading to cell cycle exit and 
preferential photoreceptor differentiation (Levine et al. 2000). However, if p27Kip1 is instead 
misexpressed together with Notch in mouse retinae, Müller glial cells are increased in number, 
indicative of a collaborative interaction between Notch and p27Kip1 in the specification of a 
Müller glial cell fate (Levine et al. 2000).  
Despite these striking gain-of-function phenotypes, in mammalian loss-of-function 
experiments, conventional p27Kip1 knockout mouse display no overall changes in the final 
proportions of retinal cells that differentiate (Levine et al. 2000; Dyer and Cepko 2001). This 
indicates that while p27Kip1 is sufficient to alter cell differentiation in mammalian retinae, it 
seems to not be required to do so. This is in contrast to p57Kip2, which does appear to have an 
essential role in cell fate specification in the mammalian retina (Dyer and Cepko 2000). In 
the mature mouse retina, p57Kip2 expression is restricted to a subset of amacrine cells (Dyer 
and Cepko 2000). In p57Kip2 knockouts, more calbindin+ amacrine cells are generated, while 
all other cell types are generated in proper numbers (Dyer and Cepko 2000). Currently, it is 
not known how p57Kip2 influences the genesis of calbindin+ amacrine cells, but it may be 
through collaborative interactions with transcription factors that are involved in specifying 
the identity of this amacrine cell subpopulation. 
4.2 Rb pocket proteins influence cell fate decisions in the retina 
The mutation of Rb by several genetic means results in a reduction in rod photoreceptor 
differentiation in the retina, including: 1) in conventional Rb knockout mice (E13.5 retinal 
explants cultured for 12 DIV) (Zhang et al. 2004), 2) following infection of floxed Rb retinae 
with a cre-expressing retrovirus (Zhang et al. 2004), and 3) in Rb cKO retinae generated with 
Nestin-cre (MacPherson et al. 2004) or Pax6α-cre (MacPherson et al. 2004) drivers. RGCs and 
bipolar cells were also reduced in Rb cKO retinae generated with the Pax6α-cre driver 
(MacPherson et al. 2004), and in Rb cKO;p107 double knockout retinae generated with the 
Pax6α-cre driver, which also had fewer rod photoreceptors (Chen et al. 2004). The loss of 
photoreceptors, bipolar cells, and RGCs in Rb mutants is likely due to increased apoptosis 
(Chen et al. 2004; MacPherson et al. 2004). The only evidence that Rb is involved in 
controlling the terminal differentiation of a retinal cell type comes from the analysis of 
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starburst amacrine cells, which require Rb-mediated inhibition of E2f3a, a cycle regulator 
and oncogene, in order to differentiate (Chen et al. 2007).  
4.3 Zac1 and TgfβII regulate retinal cell fate specification through novel pathways 
Zac1 mutants develop supernumerary rod photoreceptors and amacrine cells, acting in a cell 
autonomous fashion to block rod cell differentiation, while acting non cell autonomously to 
block amacrine cell development (Ma et al. 2007a). Mechanistically, we showed that Zac1 
regulates amacrine cell number via a negative feedback loop that acts as a cell number 
sensor (Ma et al. 2007a). We found that Zac1 acts in amacrine cells late in retinogenesis to 
positively regulate TGFβII expression, which then acts as a negative feedback signal to limit 
amacrine cell production (Ma et al. 2007a). We found that members of the TGFβ family of 
ligands (TGFβII) and receptors (TGFβ receptors I and II) are expressed in amacrine cells in 
wildtype retinae but Zac1 mutant retinae express significantly less TGFβII and 
consequently, phosphorylated Smad2/3, a downstream effector, are reduced (Ma et al. 
2007a). After showing that retinal explants exposed to exogenous antibodies towards TGFβ 
receptor II also generate more amacrine cells, we showed that adding exogenous TGFβII to 
Zac1 mutant retinal explants rescued the supernumary amacrine cell phenotype (Ma et al. 
2007a). Finally, we analyzed the E18.5 retinae of conditional TGFβ receptor II knockout mice 
and also showed qualitatively that there are more amacrine cells present in mutant retinae 
relative to wildtype (Ma et al. 2007a). A Zac1-TGFβII negative regulatory loop thus controls 
amacrine cell differentiation in the retina, ensuring that appropriate numbers of these cell 
differentiate. 
5.Tumor suppressor genes and retinal cell migration 
5.1 Cell cycle regulators and retinal lamination 
The role of CDKIs has been best studied in the cell cycle, but there is growing evidence that 
CDKIs regulate multiple other processes, including cytoskeletal dynamics and cell 
migration (Besson et al. 2008). In the developing nervous system, p27Kip1 has been 
implicated in regulating the migration of neocortical neurons, using domains of the protein 
that are not involved in cell cycle regulation (Nguyen et al. 2006). Consistent with a potential 
migratory role for p27Kip1 in the developing retina, in the mature p27Kip1 knockout mouse 
retinae, bipolar, horizontal and possibly a few amacrine cell bodies are displaced from their 
regular positions within the INL (Levine et al. 2000). Also, in p19INK4d; p27Kip1 double 
knockout mouse retinae, there is apparent displacement of Müller glia and rod 
photoreceptors from their normal positions in the INL and ONL, respectively (Cunningham 
et al. 2002). However, the dysplasia of Müller glial cells and rods is reported to be almost 
completely rescued in p19INK4d; p27Kip1; p53 triple knockout retinae (Cunningham et al. 2002), 
which suggests that p53 contributes to the p19/p27-dependent migration of rods and Müller 
glia. It was also reported that Rb cKO retinae generated with a Chx10-cre driver have ectopic 
Pax6+ cells in the ONL (Donovan and Dyer 2004), indicating that Rb regulates the proper 
radial migration of amacrine and/or RGCs to their proper layer within the developing 
retina. Finally, our analysis of Zac1 mutant retinae revealed that amacrine cells migrate 
aberrantly, forming an ectopic cellular layer between the GCL and INL (Ma et al. 2007a). 
This suggests that Zac1 is required to regulate the proper migration of amacrine cells in the 
retina. In all cases, it is poorly understood how tumor suppressor genes regulate cellular 
migration at the molecular level. 
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5.2 PI3K/PTEN signaling and retinal lamination 
Pten (phosphatase and tensin homolog) encodes a lipid and protein phosphatase that is a 
negative regulator of the PI3K pathway. Pten is also a potent tumour suppressor, with loss 
of 10q23 heterozygosity commonly found in malignant glioblastomas (Li et al. 1997) and 
somatic Pten mutations found in multiple carcinomas (Steck et al. 1997; Ali et al. 1999). In 
the nervous system, Pten mutations are associated with hypertrophy of the cerebellum, 
neocortex and hippocampus (Backman et al. 2001; Groszer et al. 2001; Kwon et al. 2006; 
Lehtinen et al. 2011). Pten mutants also display defects in cell migration, lamination, 
dendrite arborization and myelination in different CNS domains (Marino et al. 2002; Yue et 
al. 2005; Kwon et al. 2006; Fraser et al. 2008). When Pten was deleted in the retinal pigment 
epithelium (RPE), photoreceptor degeneration was observed (Kim et al. 2008). Strikingly, 
PI3K signalling promotes progenitor cell proliferation and decreased apoptosis in the retina 
(Pimentel et al. 2002), and influences cell migration in other systems (Rosivatz 2007). 
Recently, our lab conditionally deleted the tumor suppressor Pten from the developing 
retina using the Pax6α-Cre driver line (Cantrup et al., submitted). We found that amacrine 
cells and RGCs were disorganized and scattered within the normally cell-sparse IPL, 
suggesting that PTEN regulates the proper radial migration of both amacrine and RGC’s 
within the developing retina. We also have evidence that PTEN regulates the tangential 
migration of a subset of amacrine cells. Studies are currently ongoing to determine the 
molecular and cellular mechanisms by which PTEN regulates cell migration. 
6.Tumor suppressor genes not yet characterized in retinal development 
6.1 Runx1 
In other parts of the developing mouse brain, Runx1 is required for the development of 
selective spinal cord interneurons (Stifani et al. 2008), hindbrain cholinergic branchiovisceral 
motor neuron precursors, some sensory neurons in the trigeminal and vestibulocochlear 
ganglia (Theriault et al. 2004), and olfactory receptor sensory neurons (Theriault et al. 2005). 
According to GENSAT (gene expression nervous system atlas from NCBI), Runx1 is 
expressed in the forming RGC layer at E15.5 in mice. Conventional knockouts for Runx1 die 
at E12.5 (Okuda et al. 1996), prohibiting a detailed analysis of mouse retinal development. 
However, floxed-Runx1 mice have been made (Kimura et al. 2010) and could be used to 
generate retinal-specific knock-outs. 
6.2 Tsc1 and Tsc2 
In cultured rat immature hippocampal neurons, overexpression of Tsc1 and Tsc2 together 
inhibits neurite outgrowth, while conversely, knockdown of either Tsc1 or Tsc2 induces 
neurite growth and increases neurite number (Tavazoie et al. 2005). In the developing 
mouse neocortex, Tsc1 conditional knockouts display ectopic axons, an effect also observed 
in E14.5 organotypic cortical slice cultures in which Tsc2 is knocked down (Tavazoie et al. 
2005). Mouse conventional knockouts for Tsc1 and Tsc2 die at E10.5-11.5 (Rennebeck et al. 
1998; Kobayashi et al. 2001), prohibiting a detailed analysis of mouse retinal development. 
Both Tsc1- and Tsc2-floxed mice have been made (Uhlmann et al. 2002; Hernandez et al. 
2007) and could be utilized to study the effect of Tsc1 or Tsc2 during retinal development in 
mice. GENSAT reports a moderate/high mRNA expression of both Tsc1 and Tsc2 in the 
GCL, IPL, INL and RPE at P7 in the mouse retina. 
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6.3 Apc 
In the developing mouse cerebral cortex, the conditional loss of Apc results in an impaired 
formation of the radial glial scaffold, which leads to the defective migration of cortical 
neurons and subsequent layer formation, and the aberrant growth of axonal tracts (Yokota 
et al. 2009). Apc has also shown to be required in the maintenance, differentiation, and 
migration of neurons derived from adult neural stem cells in the subventricular zone and 
hippocampus of mice (Imura et al. 2010). GENSAT reports a moderate expression of Apc 
mRNA in the GCL, and a lower relative expression in the rest of retina, and a very high 
expression in the RPE, all at P7. Mouse conventional knockouts for Apc die before 
gastrulation (around E.5) (Moser et al. 1995), prohibiting any analysis of mouse retinal 
development. Apc-floxed mice have been made (Kuraguchi et al. 2006) and could be utilized 
to study the effect of Apc during retinal development in mice. 
6.4 Nf1 and Nf2 
The conditional inactivation of Nf1 results in the selective increase of neural stem cell 
proliferation and subsequent gliogenesis in the developing brainstem, but not in the 
developing cerebral cortex (Lee da et al. 2010). Conditional deletion of Nf2 in GFAP+ cells 
show increased glial cell proliferation and deletion in adult Schwann cells showed Schwann 
cell hyperplasia, and other characteristics of neurofibromatosis type 2 (Giovannini et al. 2000). 
Nf2 has been deleted in the developing lens as well showing that it is required for proper cell-
cycle exit, differentiation and cell polarity of developing mouse lens cells (Wiley et al. 2010). 
GENSAT reports a moderate ubiquitous expression of Nf1 mRNA in the neural retina, and a 
very high expression in the RPE at P7. GENSAT also reports a moderate “salt & pepper” 
mRNA expression of Nf2 in retinal progenitors in the neuroblastic layer, and a relative higher 
expression in the forming GCL at E15.5. Later at P7, there is high Nf2 expression in both the 
GCL/INL, and high expression in the RPE. Mouse conventional knockouts for Nf2 die before 
gastrulation (around E5) (McClatchey et al. 1997), prohibiting any analysis of mouse retinal 
development. Nf2-floxed mice have been made (Giovannini et al. 2000) and could be utilized 
to study the effect of Nf2 during retinal development in mice. Mouse conventional knockouts 
for Nf1 die at E12.5-13.5 (Brannan et al. 1994), prohibiting a detailed analysis of mouse retinal 
development. Nf1-floxed mice have been made (Zhu et al. 2001) and could be utilized to study 
the effect of Nf1 during retinal development in mice. 
6.5 Cdh1 
In adult mice, it was shown that Cdh1 regulates the proliferation of neural stem cells in the 
subventricular zone (Garcia-Higuera et al. 2008). Cdh1 has also been conditionally knocked 
out in the developing lens and it generated microphthalmia, iris hyperplasia, and lens 
epithelial cell deterioration (Pontoriero et al. 2009). GENSAT reports a very high expression 
of Cdh1 in the INL and RPE, a moderate expression in the GCL, and a lower expression in 
rest of the mouse retina, all at P7. To our knowledge, mouse conventional knockouts for 
Cdh1 were never made. However, Cdh1-floxed mice have been made (Garcia-Higuera et al. 
2008) and could be utilized to study the effect of Cdh1 during retinal development in mice. 
7. Summary 
Formation of a functional nervous system requires that appropriate numbers of the correct 
types of neuronal and glial cells are first generated and then migrate to their final 
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destinations. In some regions of the CNS, including the retina, precisely regulated patterns 
of cell proliferation and migration result in the formation of discrete neuronal layers, each 
comprised of stereotyped proportions of neuronal subtypes. Defective neuronal layering 
results in severe functional and visual deficits. In the last few decades, great strides have 
been made towards understanding how neurons acquire their specific identities during 
development, revealing a central role for both intrinsic and extrinsic factors. In contrast, the 
molecular cues that orchestrate tissue morphogenesis are less well understood. Research in 
the area of tumor suppressor genes has provided key insights into the molecular 
mechanisms that: 1) control neuronal number by regulating specific patterns of progenitor 
cell proliferation and differentiation and, 2) guide the complex migratory routes of 
individual neuronal populations, resulting in the formation of discrete layers in the retina. 
Such studies may aid in the future design of new stem cell therapies in the clinic, where the 
current challenge is to direct appropriate numbers of cells to differentiate, migrate and 
integrate into correct retinal layers, thereby allowing functional recovery. 
8. References 
Abdollahi, A., Pisarcik, D., Roberts, D., Weinstein, J., Cairns, P., and Hamilton, T.C. 2003. 
LOT1 (PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 
6q24-25, is epigenetically regulated in cancer. J Biol Chem 278(8): 6041-6049. 
Abdollahi, A., Roberts, D., Godwin, A.K., Schultz, D.C., Sonoda, G., Testa, J.R., and 
Hamilton, T.C. 1997. Identification of a zinc-finger gene at 6q25: a chromosomal 
region implicated in development of many solid tumors. Oncogene 14(16): 1973-
1979. 
Ajioka, I., Martins, R.A., Bayazitov, I.T., Donovan, S., Johnson, D.A., Frase, S., Cicero, S.A., 
Boyd, K., Zakharenko, S.S., and Dyer, M.A. 2007. Differentiated horizontal 
interneurons clonally expand to form metastatic retinoblastoma in mice. Cell 131(2): 
378-390. 
Alexiades, M.R. and Cepko, C.L. 1997. Subsets of retinal progenitors display temporally 
regulated and distinct biases in the fates of their progeny. Development 124(6): 1119-
1131. 
Ali, I.U., Schriml, L.M., and Dean, M. 1999. Mutational spectra of PTEN/MMAC1 gene: a 
tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 91(22): 1922-
1932. 
Backman, S.A., Stambolic, V., Suzuki, A., Haight, J., Elia, A., Pretorius, J., Tsao, M.S., 
Shannon, P., Bolon, B., Ivy, G.O. et al. 2001. Deletion of Pten in mouse brain causes 
seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat 
Genet 29(4): 396-403. 
Bahr, M. 2000. Live or let die - retinal ganglion cell death and survival during development 
and in the lesioned adult CNS. Trends Neurosci 23(10): 483-490. 
Baye, L.M. and Link, B.A. 2008. Nuclear migration during retinal development. Brain Res 
1192: 29-36. 
Bernards, R. 1997. E2F: a nodal point in cell cycle regulation. Biochim Biophys Acta 1333(3): 
M33-40. 
Besson, A., Dowdy, S.F., and Roberts, J.M. 2008. CDK inhibitors: cell cycle regulators and 
beyond. Dev Cell 14(2): 159-169. 
 
Control of Retinal Development by Tumor Suppressor Genes 
 
287 
Bilanges, B., Varrault, A., Mazumdar, A., Pantaloni, C., Hoffmann, A., Bockaert, J., Spengler, 
D., and Journot, L. 2001. Alternative splicing of the imprinted candidate tumor 
suppressor gene ZAC regulates its antiproliferative and DNA binding activities. 
Oncogene 20(10): 1246-1253. 
Brannan, C.I., Perkins, A.S., Vogel, K.S., Ratner, N., Nordlund, M.L., Reid, S.W., Buchberg, 
A.M., Jenkins, N.A., Parada, L.F., and Copeland, N.G. 1994. Targeted disruption of 
the neurofibromatosis type-1 gene leads to developmental abnormalities in heart 
and various neural crest-derived tissues. Genes Dev 8(9): 1019-1029. 
Burek, M.J. and Oppenheim, R.W. 1996. Programmed cell death in the developing nervous 
system. Brain Pathol 6(4): 427-446. 
Burkhart, D.L. and Sage, J. 2008. Cellular mechanisms of tumour suppression by the 
retinoblastoma gene. Nat Rev Cancer 8(9): 671-682. 
Buss, R.R. and Oppenheim, R.W. 2004. Role of programmed cell death in normal neuronal 
development and function. Anat Sci Int 79(4): 191-197. 
Caviness, V.S., Jr. 1982. Neocortical histogenesis in normal and reeler mice: a developmental 
study based upon [3H]thymidine autoradiography. Brain Res 256(3): 293-302. 
Caviness, V.S., Jr., Takahashi, T., and Nowakowski, R.S. 1995. Numbers, time and 
neocortical neuronogenesis: a general developmental and evolutionary model. 
Trends Neurosci 18(9): 379-383. 
Cayouette, M., Barres, B.A., and Raff, M. 2003. Importance of intrinsic mechanisms in cell 
fate decisions in the developing rat retina. Neuron 40(5): 897-904. 
Cayouette, M., Poggi, L., and Harris, W.A. 2006. Lineage in the vertebrate retina. Trends 
Neurosci 29(10): 563-570. 
Cepko, C.L., Austin, C.P., Yang, X., Alexiades, M., and Ezzeddine, D. 1996. Cell fate 
determination in the vertebrate retina. Proc Natl Acad Sci U S A 93(2): 589-595. 
Chen, D., Livne-bar, I., Vanderluit, J.L., Slack, R.S., Agochiya, M., and Bremner, R. 2004. 
Cell-specific effects of RB or RB/p107 loss on retinal development implicate an 
intrinsically death-resistant cell-of-origin in retinoblastoma. Cancer Cell 5(6): 539-
551. 
Chen, D., Opavsky, R., Pacal, M., Tanimoto, N., Wenzel, P., Seeliger, M.W., Leone, G., and 
Bremner, R. 2007. Rb-mediated neuronal differentiation through cell-cycle-
independent regulation of E2f3a. PLoS Biol 5(7): e179. 
Chinnam, M. and Goodrich, D.W. 2011. RB1, development, and cancer. Curr Top Dev Biol 94: 
129-169. 
Clarke, A.R., Maandag, E.R., van Roon, M., van der Lugt, N.M., van der Valk, M., Hooper, 
M.L., Berns, A., and te Riele, H. 1992. Requirement for a functional Rb-1 gene in 
murine development. Nature 359(6393): 328-330. 
Claudio, P.P., Howard, C.M., Baldi, A., De Luca, A., Fu, Y., Condorelli, G., Sun, Y., Colburn, 
N., Calabretta, B., and Giordano, A. 1994. p130/pRb2 has growth suppressive 
properties similar to yet distinctive from those of retinoblastoma family members 
pRb and p107. Cancer Res 54(21): 5556-5560. 
Close, J.L., Gumuscu, B., and Reh, T.A. 2005. Retinal neurons regulate proliferation of 
postnatal progenitors and Muller glia in the rat retina via TGF beta signaling. 
Development 132(13): 3015-3026. 
 
Tumor Suppressor Genes 
 
288 
Cordenonsi, M., Dupont, S., Maretto, S., Insinga, A., Imbriano, C., and Piccolo, S. 2003. Links 
between tumor suppressors: p53 is required for TGF-beta gene responses by 
cooperating with Smads. Cell 113(3): 301-314. 
Cordenonsi, M., Montagner, M., Adorno, M., Zacchigna, L., Martello, G., Mamidi, A., Soligo, 
S., Dupont, S., and Piccolo, S. 2007. Integration of TGF-beta and Ras/MAPK 
signaling through p53 phosphorylation. Science 315(5813): 840-843. 
Cunningham, J.J., Levine, E.M., Zindy, F., Goloubeva, O., Roussel, M.F., and Smeyne, R.J. 
2002. The cyclin-dependent kinase inhibitors p19(Ink4d) and p27(Kip1) are 
coexpressed in select retinal cells and act cooperatively to control cell cycle exit. Mol 
Cell Neurosci 19(3): 359-374. 
DiCiommo, D., Gallie, B.L., and Bremner, R. 2000. Retinoblastoma: the disease, gene and 
protein provide critical leads to understand cancer. Semin Cancer Biol 10(4): 255-
269. 
Donovan, S.L. and Dyer, M.A. 2004. Developmental defects in Rb-deficient retinae. Vision 
Res 44(28): 3323-3333. 
Dyer, M.A. and Cepko, C.L. 2000. p57(Kip2) regulates progenitor cell proliferation and 
amacrine interneuron development in the mouse retina. Development 127(16): 3593-
3605. 
Dyer, M.A. and Cepko, C.L. 2001. p27Kip1 and p57Kip2 regulate proliferation in distinct 
retinal progenitor cell populations. J Neurosci 21(12): 4259-4271. 
Ewen, M.E., Xing, Y.G., Lawrence, J.B., and Livingston, D.M. 1991. Molecular cloning, 
chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma 
gene product-related protein. Cell 66(6): 1155-1164. 
Fekete, D.M., Perez-Miguelsanz, J., Ryder, E.F., and Cepko, C.L. 1994. Clonal analysis in the 
chicken retina reveals tangential dispersion of clonally related cells. Dev Biol 166(2): 
666-682. 
Franklin, D.S., Godfrey, V.L., O'Brien, D.A., Deng, C., and Xiong, Y. 2000. Functional 
collaboration between different cyclin-dependent kinase inhibitors suppresses 
tumor growth with distinct tissue specificity. Mol Cell Biol 20(16): 6147-6158. 
Fraser, M.M., Bayazitov, I.T., Zakharenko, S.S., and Baker, S.J. 2008. Phosphatase and tensin 
homolog, deleted on chromosome 10 deficiency in brain causes defects in synaptic 
structure, transmission and plasticity, and myelination abnormalities. Neuroscience 
151(2): 476-488. 
Frolov, M.V. and Dyson, N.J. 2004. Molecular mechanisms of E2F-dependent activation and 
pRB-mediated repression. J Cell Sci 117(Pt 11): 2173-2181. 
Fuhrmann, S. 2010. Eye morphogenesis and patterning of the optic vesicle. Curr Top Dev Biol 
93: 61-84. 
Galli-Resta, L., Leone, P., Bottari, D., Ensini, M., Rigosi, E., and Novelli, E. 2008. The genesis 
of retinal architecture: an emerging role for mechanical interactions? Prog Retin Eye 
Res 27(3): 260-283. 
Garcia-Higuera, I., Manchado, E., Dubus, P., Canamero, M., Mendez, J., Moreno, S., and 
Malumbres, M. 2008. Genomic stability and tumour suppression by the APC/C 
cofactor Cdh1. Nat Cell Biol 10(7): 802-811. 
Gartel, A.L. 2009. p21(WAF1/CIP1) and cancer: a shifting paradigm? Biofactors 35(2): 161-
164. 
 
Control of Retinal Development by Tumor Suppressor Genes 
 
289 
Giovannini, M., Robanus-Maandag, E., van der Valk, M., Niwa-Kawakita, M., Abramowski, 
V., Goutebroze, L., Woodruff, J.M., Berns, A., and Thomas, G. 2000. Conditional 
biallelic Nf2 mutation in the mouse promotes manifestations of human 
neurofibromatosis type 2. Genes Dev 14(13): 1617-1630. 
Godinho, L., Williams, P.R., Claassen, Y., Provost, E., Leach, S.D., Kamermans, M., and 
Wong, R.O. 2007. Nonapical symmetric divisions underlie horizontal cell layer 
formation in the developing retina in vivo. Neuron 56(4): 597-603. 
Gomer, R.H. 2001. Not being the wrong size. Nat Rev Mol Cell Biol 2(1): 48-54. 
Groszer, M., Erickson, R., Scripture-Adams, D.D., Lesche, R., Trumpp, A., Zack, J.A., 
Kornblum, H.I., Liu, X., and Wu, H. 2001. Negative regulation of neural 
stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. 
Science 294(5549): 2186-2189. 
Grueber, W.B. and Sagasti, A. 2010. Self-avoidance and tiling: Mechanisms of dendrite and 
axon spacing. Cold Spring Harb Perspect Biol 2(9): a001750. 
Guo, H., Tian, T., Nan, K., and Wang, W. 2010. p57: A multifunctional protein in cancer 
(Review). Int J Oncol 36(6): 1321-1329. 
Hannon, G.J., Demetrick, D., and Beach, D. 1993. Isolation of the Rb-related p130 through its 
interaction with CDK2 and cyclins. Genes Dev 7(12A): 2378-2391. 
Hatakeyama, J., Tomita, K., Inoue, T., and Kageyama, R. 2001. Roles of homeobox and 
bHLH genes in specification of a retinal cell type. Development 128(8): 1313-1322. 
Hernandez, O., Way, S., McKenna, J., 3rd, and Gambello, M.J. 2007. Generation of a 
conditional disruption of the Tsc2 gene. Genesis 45(2): 101-106. 
Hero, I. 1990. Optic fissure closure in the normal cinnamon mouse. An ultrastructural study. 
Invest Ophthalmol Vis Sci 31(1): 197-216. 
Hirashima, M., Kobayashi, T., Uchikawa, M., Kondoh, H., and Araki, M. 2008. 
Anteroventrally localized activity in the optic vesicle plays a crucial role in the 
optic development. Dev Biol 317(2): 620-631. 
Holt, C.E., Bertsch, T.W., Ellis, H.M., and Harris, W.A. 1988. Cellular determination in the 
Xenopus retina is independent of lineage and birth date. Neuron 1(1): 15-26. 
Huang, S.M., Schonthal, A.H., and Stallcup, M.R. 2001. Enhancement of p53-dependent gene 
activation by the transcriptional coactivator Zac1. Oncogene 20(17): 2134-2143. 
Huang, S.M. and Stallcup, M.R. 2000. Mouse Zac1, a transcriptional coactivator and 
repressor for nuclear receptors. Mol Cell Biol 20(5): 1855-1867. 
Imura, T., Wang, X., Noda, T., Sofroniew, M.V., and Fushiki, S. 2010. Adenomatous 
polyposis coli is essential for both neuronal differentiation and maintenance of 
adult neural stem cells in subventricular zone and hippocampus. Stem Cells 28(11): 
2053-2064. 
Inoue, T., Hojo, M., Bessho, Y., Tano, Y., Lee, J.E., and Kageyama, R. 2002. Math3 and 
NeuroD regulate amacrine cell fate specification in the retina. Development 129(4): 
831-842. 
Isenmann, S., Kretz, A., and Cellerino, A. 2003. Molecular determinants of retinal ganglion 
cell development, survival, and regeneration. Prog Retin Eye Res 22(4): 483-543. 
Jacks, T., Fazeli, A., Schmitt, E.M., Bronson, R.T., Goodell, M.A., and Weinberg, R.A. 1992. 
Effects of an Rb mutation in the mouse. Nature 359(6393): 295-300. 
 
Tumor Suppressor Genes 
 
290 
Kagiyama, Y., Gotouda, N., Sakagami, K., Yasuda, K., Mochii, M., and Araki, M. 2005. 
Extraocular dorsal signal affects the developmental fate of the optic vesicle and 
patterns the optic neuroepithelium. Dev Growth Differ 47(8): 523-536. 
Kim, J.W., Kang, K.H., Burrola, P., Mak, T.W., and Lemke, G. 2008. Retinal degeneration 
triggered by inactivation of PTEN in the retinal pigment epithelium. Genes Dev 
22(22): 3147-3157. 
Kimura, A., Inose, H., Yano, F., Fujita, K., Ikeda, T., Sato, S., Iwasaki, M., Jinno, T., Ae, K., 
Fukumoto, S. et al. 2010. Runx1 and Runx2 cooperate during sternal 
morphogenesis. Development 137(7): 1159-1167. 
Kobayashi, T., Minowa, O., Sugitani, Y., Takai, S., Mitani, H., Kobayashi, E., Noda, T., and 
Hino, O. 2001. A germ-line Tsc1 mutation causes tumor development and 
embryonic lethality that are similar, but not identical to, those caused by Tsc2 
mutation in mice. Proc Natl Acad Sci U S A 98(15): 8762-8767. 
Koy, S., Hauses, M., Appelt, H., Friedrich, K., Schackert, H.K., and Eckelt, U. 2004. Loss of 
expression of ZAC/LOT1 in squamous cell carcinomas of head and neck. Head Neck 
26(4): 338-344. 
Kuraguchi, M., Wang, X.P., Bronson, R.T., Rothenberg, R., Ohene-Baah, N.Y., Lund, J.J., 
Kucherlapati, M., Maas, R.L., and Kucherlapati, R. 2006. Adenomatous polyposis 
coli (APC) is required for normal development of skin and thymus. PLoS Genet 2(9): 
e146. 
Kwon, C.H., Luikart, B.W., Powell, C.M., Zhou, J., Matheny, S.A., Zhang, W., Li, Y., Baker, 
S.J., and Parada, L.F. 2006. Pten regulates neuronal arborization and social 
interaction in mice. Neuron 50(3): 377-388. 
Lee da, Y., Yeh, T.H., Emnett, R.J., White, C.R., and Gutmann, D.H. 2010. 
Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial 
differentiation in a brain region-specific manner. Genes Dev 24(20): 2317-2329. 
Lee, J. and Kim, S.S. 2009. The function of p27 KIP1 during tumor development. Exp Mol 
Med 41(11): 765-771. 
Lehtinen, M.K., Zappaterra, M.W., Chen, X., Yang, Y.J., Hill, A.D., Lun, M., Maynard, T., 
Gonzalez, D., Kim, S., Ye, P. et al. 2011. The cerebrospinal fluid provides a 
proliferative niche for neural progenitor cells. Neuron 69(5): 893-905. 
Levine, E.M., Close, J., Fero, M., Ostrovsky, A., and Reh, T.A. 2000. p27(Kip1) regulates cell 
cycle withdrawal of late multipotent progenitor cells in the mammalian retina. Dev 
Biol 219(2): 299-314. 
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S.I., Puc, J., Miliaresis, C., Rodgers, 
L., McCombie, R. et al. 1997. PTEN, a putative protein tyrosine phosphatase gene 
mutated in human brain, breast, and prostate cancer. Science 275(5308): 1943-1947. 
Li, S., Mo, Z., Yang, X., Price, S.M., Shen, M.M., and Xiang, M. 2004. Foxn4 controls the 
genesis of amacrine and horizontal cells by retinal progenitors. Neuron 43(6): 795-
807. 
Livesey, F.J. and Cepko, C.L. 2001. Vertebrate neural cell-fate determination: lessons from 
the retina. Nat Rev Neurosci 2(2): 109-118. 
Ma, L., Cantrup, R., Varrault, A., Colak, D., Klenin, N., Gotz, M., McFarlane, S., Journot, L., 
and Schuurmans, C. 2007a. Zac1 functions through TGFbetaII to negatively 
regulate cell number in the developing retina. Neural Dev 2: 11. 
 
Control of Retinal Development by Tumor Suppressor Genes 
 
291 
Ma, L., Hocking, J.C., Hehr, C.L., Schuurmans, C., and McFarlane, S. 2007c. Zac1 promotes a 
Muller glial cell fate and interferes with retinal ganglion cell differentiation in 
Xenopus retina. Dev Dyn 236(1): 192-202. 
MacPherson, D., Sage, J., Kim, T., Ho, D., McLaughlin, M.E., and Jacks, T. 2004. Cell type-
specific effects of Rb deletion in the murine retina. Genes Dev 18(14): 1681-1694. 
Marino, S., Krimpenfort, P., Leung, C., van der Korput, H.A., Trapman, J., Camenisch, I., 
Berns, A., and Brandner, S. 2002. PTEN is essential for cell migration but not for 
fate determination and tumourigenesis in the cerebellum. Development 129(14): 
3513-3522. 
McClatchey, A.I., Saotome, I., Ramesh, V., Gusella, J.F., and Jacks, T. 1997. The Nf2 tumor 
suppressor gene product is essential for extraembryonic development immediately 
prior to gastrulation. Genes Dev 11(10): 1253-1265. 
Moser, A.R., Shoemaker, A.R., Connelly, C.S., Clipson, L., Gould, K.A., Luongo, C., Dove, 
W.F., Siggers, P.H., and Gardner, R.L. 1995. Homozygosity for the Min allele of Apc 
results in disruption of mouse development prior to gastrulation. Dev Dyn 203(4): 
422-433. 
Nguyen, L., Besson, A., Heng, J.I., Schuurmans, C., Teboul, L., Parras, C., Philpott, A., 
Roberts, J.M., and Guillemot, F. 2006. p27kip1 independently promotes neuronal 
differentiation and migration in the cerebral cortex. Genes Dev 20(11): 1511-1524. 
Nigg, E.A. 1995. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell 
cycle. Bioessays 17(6): 471-480. 
Ohnuma, S., Hopper, S., Wang, K.C., Philpott, A., and Harris, W.A. 2002. Co-ordinating 
retinal histogenesis: early cell cycle exit enhances early cell fate determination in 
the Xenopus retina. Development 129(10): 2435-2446. 
Ohnuma, S., Philpott, A., Wang, K., Holt, C.E., and Harris, W.A. 1999. p27Xic1, a Cdk 
inhibitor, promotes the determination of glial cells in Xenopus retina. Cell 99(5): 
499-510. 
Okuda, T., van Deursen, J., Hiebert, S.W., Grosveld, G., and Downing, J.R. 1996. AML1, the 
target of multiple chromosomal translocations in human leukemia, is essential for 
normal fetal liver hematopoiesis. Cell 84(2): 321-330. 
Pagotto, U., Arzberger, T., Theodoropoulou, M., Grubler, Y., Pantaloni, C., Saeger, W., Losa, 
M., Journot, L., Stalla, G.K., and Spengler, D. 2000. The expression of the 
antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary 
adenomas. Cancer Res 60(24): 6794-6799. 
Paternot, S., Bockstaele, L., Bisteau, X., Kooken, H., Coulonval, K., and Roger, P.P. 2010. Rb 
inactivation in cell cycle and cancer: the puzzle of highly regulated activating 
phosphorylation of CDK4 versus constitutively active CDK-activating kinase. Cell 
Cycle 9(4): 689-699. 
Pearson, B.J. and Doe, C.Q. 2004. Specification of temporal identity in the developing 
nervous system. Annu Rev Cell Dev Biol 20: 619-647. 
Pei, Y.F. and Rhodin, J.A. 1970. The prenatal development of the mouse eye. Anat Rec 168(1): 
105-125. 
Pimentel, B., Rodriguez-Borlado, L., Hernandez, C., and Carrera, A.C. 2002. A Role for 
phosphoinositide 3-kinase in the control of cell division and survival during retinal 
development. Dev Biol 247(2): 295-306. 
 
Tumor Suppressor Genes 
 
292 
Poggi, L., Vitorino, M., Masai, I., and Harris, W.A. 2005. Influences on neural lineage and 
mode of division in the zebrafish retina in vivo. J Cell Biol 171(6): 991-999. 
Pontoriero, G.F., Smith, A.N., Miller, L.A., Radice, G.L., West-Mays, J.A., and Lang, R.A. 
2009. Co-operative roles for E-cadherin and N-cadherin during lens vesicle 
separation and lens epithelial cell survival. Dev Biol 326(2): 403-417. 
Poole, A.J., Heap, D., Carroll, R.E., and Tyner, A.L. 2004. Tumor suppressor functions for the 
Cdk inhibitor p21 in the mouse colon. Oncogene 23(49): 8128-8134. 
Rapaport, D.H., Wong, L.L., Wood, E.D., Yasumura, D., and LaVail, M.M. 2004. Timing and 
topography of cell genesis in the rat retina. J Comp Neurol 474(2): 304-324. 
Ravitz, M.J. and Wenner, C.E. 1997. Cyclin-dependent kinase regulation during G1 phase 
and cell cycle regulation by TGF-beta. Adv Cancer Res 71: 165-207. 
Rennebeck, G., Kleymenova, E.V., Anderson, R., Yeung, R.S., Artzt, K., and Walker, C.L. 
1998. Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in 
embryonic lethality characterized by disrupted neuroepithelial growth and 
development. Proc Natl Acad Sci U S A 95(26): 15629-15634. 
Robanus-Maandag, E., Dekker, M., van der Valk, M., Carrozza, M.L., Jeanny, J.C., 
Dannenberg, J.H., Berns, A., and te Riele, H. 1998. p107 is a suppressor of 
retinoblastoma development in pRb-deficient mice. Genes Dev 12(11): 1599-1609. 
Rockhill, R.L., Euler, T., and Masland, R.H. 2000. Spatial order within but not between types 
of retinal neurons. Proc Natl Acad Sci U S A 97(5): 2303-2307. 
Rosivatz, E. 2007. Inhibiting PTEN. Biochem Soc Trans 35(Pt 2): 257-259. 
Silver, J. and Hughes, A.F. 1973. The role of cell death during morphogenesis of the 
mammalian eye. J Morphol 140(2): 159-170. 
Silver, J. and Robb, R.M. 1979. Studies on the development of the eye cup and optic nerve in 
normal mice and in mutants with congenital optic nerve aplasia. Dev Biol 68(1): 175-
190. 
Spengler, D., Villalba, M., Hoffmann, A., Pantaloni, C., Houssami, S., Bockaert, J., and 
Journot, L. 1997. Regulation of apoptosis and cell cycle arrest by Zac1, a novel zinc 
finger protein expressed in the pituitary gland and the brain. Embo J 16(10): 2814-
2825. 
Steck, P.A., Pershouse, M.A., Jasser, S.A., Yung, W.K., Lin, H., Ligon, A.H., Langford, L.A., 
Baumgard, M.L., Hattier, T., Davis, T. et al. 1997. Identification of a candidate 
tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in 
multiple advanced cancers. Nat Genet 15(4): 356-362. 
Stiemke, M.M. and Hollyfield, J.G. 1995. Cell birthdays in Xenopus laevis retina. 
Differentiation 58(3): 189-193. 
Stifani, N., Freitas, A.R., Liakhovitskaia, A., Medvinsky, A., Kania, A., and Stifani, S. 2008. 
Suppression of interneuron programs and maintenance of selected spinal motor 
neuron fates by the transcription factor AML1/Runx1. Proc Natl Acad Sci U S A 
105(17): 6451-6456. 
Svoboda, K.K. and O'Shea, K.S. 1987. An analysis of cell shape and the neuroepithelial basal 
lamina during optic vesicle formation in the mouse embryo. Development 100(2): 
185-200. 
Takahashi, T., Goto, T., Miyama, S., Nowakowski, R.S., and Caviness, V.S., Jr. 1999. 
Sequence of neuron origin and neocortical laminar fate: relation to cell cycle of 
origin in the developing murine cerebral wall. J Neurosci 19(23): 10357-10371. 
 
Control of Retinal Development by Tumor Suppressor Genes 
 
293 
Tavazoie, S.F., Alvarez, V.A., Ridenour, D.A., Kwiatkowski, D.J., and Sabatini, B.L. 2005. 
Regulation of neuronal morphology and function by the tumor suppressors Tsc1 
and Tsc2. Nat Neurosci 8(12): 1727-1734. 
Theriault, F.M., Nuthall, H.N., Dong, Z., Lo, R., Barnabe-Heider, F., Miller, F.D., and Stifani, 
S. 2005. Role for Runx1 in the proliferation and neuronal differentiation of selected 
progenitor cells in the mammalian nervous system. J Neurosci 25(8): 2050-2061. 
Theriault, F.M., Roy, P., and Stifani, S. 2004. AML1/Runx1 is important for the development 
of hindbrain cholinergic branchiovisceral motor neurons and selected cranial 
sensory neurons. Proc Natl Acad Sci U S A 101(28): 10343-10348. 
Tomita, K., Moriyoshi, K., Nakanishi, S., Guillemot, F., and Kageyama, R. 2000. Mammalian 
achaete-scute and atonal homologs regulate neuronal versus glial fate 
determination in the central nervous system. Embo J 19(20): 5460-5472. 
Turner, D.L. and Cepko, C.L. 1987. A common progenitor for neurons and glia persists in rat 
retina late in development. Nature 328(6126): 131-136. 
Turner, D.L., Snyder, E.Y., and Cepko, C.L. 1990. Lineage-independent determination of cell 
type in the embryonic mouse retina. Neuron 4(6): 833-845. 
Uhlmann, E.J., Wong, M., Baldwin, R.L., Bajenaru, M.L., Onda, H., Kwiatkowski, D.J., 
Yamada, K., and Gutmann, D.H. 2002. Astrocyte-specific TSC1 conditional 
knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol 
52(3): 285-296. 
Varrault, A., Ciani, E., Apiou, F., Bilanges, B., Hoffmann, A., Pantaloni, C., Bockaert, J., 
Spengler, D., and Journot, L. 1998. hZAC encodes a zinc finger protein with 
antiproliferative properties and maps to a chromosomal region frequently lost in 
cancer. Proc Natl Acad Sci U S A 95(15): 8835-8840. 
Voyvodic, J.T., Burne, J.F., and Raff, M.C. 1995. Quantification of normal cell death in the rat 
retina: implications for clone composition in cell lineage analysis. Eur J Neurosci 
7(12): 2469-2478. 
Wallace, V.A. 2011. Concise review: making a retina--from the building blocks to clinical 
applications. Stem Cells 29(3): 412-417. 
Wawersik, S. and Maas, R.L. 2000. Vertebrate eye development as modeled in Drosophila. 
Hum Mol Genet 9(6): 917-925. 
Wesierska-Gadek, J., Maurer, M., Zulehner, N., and Komina, O. 2010. Whether to target 
single or multiple CDKs for therapy? That is the question. J Cell Physiol 226(2): 341-
349. 
Wetts, R. and Fraser, S.E. 1988. Multipotent precursors can give rise to all major cell types of 
the frog retina. Science 239(4844): 1142-1145. 
Wiley, L.A., Dattilo, L.K., Kang, K.B., Giovannini, M., and Beebe, D.C. 2010. The tumor 
suppressor merlin is required for cell cycle exit, terminal differentiation, and cell 
polarity in the developing murine lens. Invest Ophthalmol Vis Sci 51(7): 3611-3618. 
Xu, X.L., Fang, Y., Lee, T.C., Forrest, D., Gregory-Evans, C., Almeida, D., Liu, A., Jhanwar, 
S.C., Abramson, D.H., and Cobrinik, D. 2009. Retinoblastoma has properties of a 
cone precursor tumor and depends upon cone-specific MDM2 signaling. Cell 
137(6): 1018-1031. 
Yokota, Y., Kim, W.Y., Chen, Y., Wang, X., Stanco, A., Komuro, Y., Snider, W., and Anton, 
E.S. 2009. The adenomatous polyposis coli protein is an essential regulator of radial 
glial polarity and construction of the cerebral cortex. Neuron 61(1): 42-56. 
 
Tumor Suppressor Genes 
 
294 
Young, R.W. 1984. Cell death during differentiation of the retina in the mouse. J Comp Neurol 
229(3): 362-373. 
Young, R.W. 1985a. Cell differentiation in the retina of the mouse. Anat Rec 212(2): 199-205. 
Young, R.W. 1985b. Cell proliferation during postnatal development of the retina in the 
mouse. Brain Res 353(2): 229-239. 
Yue, Q., Groszer, M., Gil, J.S., Berk, A.J., Messing, A., Wu, H., and Liu, X. 2005. PTEN 
deletion in Bergmann glia leads to premature differentiation and affects laminar 
organization. Development 132(14): 3281-3291. 
Zhang, J., Gray, J., Wu, L., Leone, G., Rowan, S., Cepko, C.L., Zhu, X., Craft, C.M., and Dyer, 
M.A. 2004. Rb regulates proliferation and rod photoreceptor development in the 
mouse retina. Nat Genet 36(4): 351-360. 
Zhu, L., van den Heuvel, S., Helin, K., Fattaey, A., Ewen, M., Livingston, D., Dyson, N., and 
Harlow, E. 1993. Inhibition of cell proliferation by p107, a relative of the 
retinoblastoma protein. Genes Dev 7(7A): 1111-1125. 
Zhu, Y., Romero, M.I., Ghosh, P., Ye, Z., Charnay, P., Rushing, E.J., Marth, J.D., and Parada, 
L.F. 2001. Ablation of NF1 function in neurons induces abnormal development of 
cerebral cortex and reactive gliosis in the brain. Genes Dev 15(7): 859-876. 
Zolessi, F.R., Poggi, L., Wilkinson, C.J., Chien, C.B., and Harris, W.A. 2006. Polarization and 
orientation of retinal ganglion cells in vivo. Neural Dev 1: 2. 
12 
Properties of Human Tumor Suppressor  
101F6 Protein as a Cytochrome b561 and  
Its Preliminary Crystallization Trials 
Mariam C. Recuenco1, Suguru Watanabe1,  
Fusako Takeuchi2, Sam-Yong Park3 and Motonari Tsubaki1 
1Department of Chemistry, Kobe University Graduate School of Science,  
2Kobe University Institute for Promotion of Higher Education,  
3Protein Design Laboratory, Yokohama City University, 
 Graduate School of Nanobioscience, 
Japan 
1. Introduction 
Identification of the physiological roles and elucidation of the molecular mechanisms 
involving tumor suppressor genes and their gene products are important for a more 
comprehensive understanding of cancer pathogenesis. Since the Knudson’s statistical 
studies on retinoblastoma, neuroblastoma, and pheochromocytoma, which led to the 
conclusion that the occurrence of these tumors fits a two-mutation model (Knudson, 1971; 
Knudson & Strong, 1972), it became recognized that there were some genes that function to 
inhibit tumor development. The model stated that tumorigenesis results when there are 
genetic alterations such as deletions and mutations in both alleles of a gene in a cell 
(Knudson, 1971; Knudson & Strong, 1972). A tumor suppressor gene may have one or more 
functions related to cell division and differentiation, extracellular communication, tissue 
formation or senescence (Hollingsworth & Lee, 1991).  
Several regions of the human chromosome 3 have been identified as susceptible sites for 
homozygous deletions and mutations that may lead to inactivation of one or more tumor 
suppressor genes. A particular tumor suppressor gene candidate 101F6 is located within a 
narrow 630-kb region on chromosome 3p.21.3, called LUCA (lung cancer region) (Lerman & 
Minna, 2000; Zabarovsky et al., 2002). Interestingly, the 101F6 protein is expressed in normal 
lung bronchial epithelial cells and fibroblasts but is lost in most lung cancers (Ohtani et al., 
2007). Previous studies have shown that forced expression of the 101F6 gene via adenoviral 
vector-mediated gene transfer (Ji et al., 2002) or via nanoparticle injection (Ohtani et al., 
2007) caused the inhibition of tumor growth in non-small cell lung cancer cells in vitro and in 
vivo. The treated cancer cells were also found to accumulate ascorbate (AsA) when 
incubated in a medium containing AsA (Ohtani et al., 2007). Apoptosis and autophagy of 
the cancer cells were reportedly to be enhanced by the treatment and were postulated to be 
caused by the synergistic action of the 101F6 gene and AsA though the mechanism of the 
action is still not clear (Ohtani et al., 2007). 
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The human 101F6 gene was found to encode a protein consisting of 222 amino acids and 
was predicted to be a member of the cytochrome b561 protein family (Tsubaki et al., 2005). 
Proteins such as adrenal cytochrome b561 (Tsubaki et al., 1997), duodenal cytochrome b561 
(Mckie et al., 2001), and stromal cell-derived receptor 2 (Vargas et al., 2003) that were 
classified under this family have a common “b561 core domain” consisting of four 
transmembrane -helices that have four totally conserved His residues for the binding of 
two heme b groups (Okuyama et al., 1998; Tsubaki et al., 2005). The adrenal cytochrome b561, 
as a classic representative of this family, is a highly hydrophobic protein, consisting of six 
transmembrane -helices with a molecular mass of 28 kDa and is located in the secretory 
vesicle membranes of adrenal chromaffin cells. This protein is involved in a transmembrane 
electron transfer reaction from cytosolic AsA to intravesicular monodehydroascorbate 
(MDA) radical that replenishes reducing equivalents to maintain physiological levels of AsA 
inside the vesicles (Kobayashi et al., 1998; Seike et al., 2003). AsA is an essential water-
soluble vitamin that maintains the activity of copper-containing enzymes such as dopamine 
-hydroxylase and peptidylglycine -amidating monooxygenase by providing electrons to 
the copper center of the enzyme (Prigge et al., 2000) and to keep the intravesicular side in 
reduced state to protect otherwise very labile catecholamines. For efficient electron transfer, 
adrenal cytochrome b561 contain a putative AsA-binding motif on the cytosolic side close to 
the cytosolic heme center and a putative MDA-radical binding motif on the intravesicular 
side close to the intravesicular heme center, respectively (Okuyama et al., 1998). Such motifs 
were found to be conserved in other subfamilies of cytochrome b561, including duodenal 
cytochrome b561 and plant cytochrome b561 (Tsubaki et al., 2005). 
Comparative analysis on the amino acid sequences of seven subfamilies of the cytochrome b561 
protein family showed that 101F6 protein does not contain the MDA-radical binding motif 
while the AsA-binding motif was significantly modified (“modified motif 1”) (Tsubaki et al., 
2005). These results suggested that redox active biofactor(s) other than AsA or MDA radical 
might be responsible as redox mediators of the 101F6 protein (Tsubaki et al., 2005). It is very 
intriguing to consider that the 101F6 protein has a role for transmembrane redox signal 
transduction via this unknown redox-linked activity. Therefore, the “modified motif 1” may be 
a primary candidate for conducting such transmembrane redox reactions (Tsubaki et al., 2005). 
Thus, clarification of the properties and three-dimensional structure of the 101F6 protein is 
highly necessary in understanding the role of this transmembrane protein as a tumor 
suppressor and as a controlling factor in human lung cancer development. 
Although the cytochrome b561 protein family has a large numbers of its members (human 
tissues contain 6 members), none of them has ever been successfully crystallized for analysis 
by X-ray diffraction. Though we have attempted the crystallization for various members of 
the cytochrome b561 family, we have been limited by the amount of samples for more 
extensive screenings. A major barrier to crystallizing membrane proteins from higher 
eukaryotes (animals and plants) is the inability to purify sufficient amounts of non-
denatured active proteins for conducting the crystallization trials. Indeed, except for the 
classic cytochrome b561 protein from bovine adrenal chromaffin vesicles, purification of 
cytochrome b561 from native tissues has been found to be almost impossible. Further, 
heterologous expression systems for the membrane protein including the members of the 
cytochrome b561 family, by employing the prokaryote Escherichia coli, the yeast Saccharomyces 
cerevisiae, the insect Sf9 cells, and mammalian cells, showed  limited success based on the 
evaluation of their final qualities and/or quantities. Recently, the methylotrophic yeast, 
Pichia pastoris, has proven to be a very useful system to express and purify milligram 
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quantities of membrane proteins (Abramson et al., 2003; Huang et al., 2003; Jiang et al., 
2003). However, instances about its use as a host for the expression of mammalian 
membrane proteins was limited (Long et al., 2005). 
We have previously reported about the functional expression, purification and 
characterization of recombinant human 101F6 protein, which was expressed as a poly-
histidine tagged protein in methylotrophic yeast Pichia pastoris (Recuenco et al., 2009). The 
purified 101F6 protein exhibited characteristic properties as a member of the cytochrome b561 
protein family, particularly with regards to spectral characteristics and electron transfer 
activities with AsA and MDA radical. In this paper, we want to present our optimized 
protocol for the human 101F6 protein expression and purification. Further, we have 
succeeded in the crystallization of recombinant human 101F6 protein for the first time. We 
also present preliminary results on the quality of the human 101F6 protein crystals. 
2. Materials and methods 
2.1 The Pichia pastoris expression system 
In our present study, we employed the Pichia pastoris expression system (Pichia pastoris GS115 
cells and a pPICZB vector; from Invitrogen Corp., Tokyo, Japan) for the successful expression 
of human 101F6 gene. As a single-celled microorganism, yeast Pichia pastoris is easy to 
manipulate and is, therefore, very suitable for culture. However, it is a eukaryote and capable 
of many of post-translation modifications onto the heterologously expressed proteins such as 
proteolytic processing, folding, disufide bond formation, and glycosylation, which are 
performed by higher eukaryotic cells. Most importantly, Pichia pastoris cell is a very suitable 
host for the expression of membrane proteins, particularly for integral membrane proteins, 
because of its eukaryotic nature (e.g., presence of membranes within the cytosolic milieu).  
It was proposed that, compared to insect cells (e.g., Sf9 cell) or other mammalian cultured 
cells, Pichia pastoris cells are much easier to handle, can be grown at lower cost, and can be 
expressed quicker in a large scale (Asada et al., 2011). Such successful examples for 
expressing eukaryotic membrane proteins were reported previously (Weiß et al., 1998; 
Wetterholm et al., 2008; Nakanishi et al., 2009a; Nakanishi et al., 2009b; Alisio & Mueckler, 
2010; Ostuni et al., 2010; Mizutani et al., 2011).  
2.2 Construction of the expression plasmid pPICZB-101F6-His8 
Procedure for a molecular cloning of the human 101F6 gene was described previously 
(Recuenco et al., 2009). Construction of the expression plasmid, pPICZB-101F6-His8, was 
described previously (Recuenco et al., 2009). Briefly, the thrombin-specific sequence 
followed by the eight-histidine residue-tag (QPSALVPRGSSAHHHHHHHH; the underline 
indicates the thrombin-specific sequence) was introduced at the C-terminus of human 101F6 
protein, resulting in a total of 240 aa residue-long with a molecular mass of 25996.9 Da. An 
eight-histidine residue-tag sequence, instead of a usual six-histidine residue-tag, was added 
to provide a stronger binding affinity towards Ni-NTA affinity column. Such a poly-
histidine-residue tag was employed for the expression of mammalian glucose transporter 
(eight-histidine residue) (Alisio & Mueckler, 2010) and G-protein coupled receptors (deca-
histidine residue) (Yurugi-Kobayashi et al., 2009). Introduction of the tag-sequences at the C-
terminus of human 101F6 protein was chosen with considerations about the increase in 
length of the C-terminal part and its successful protein expression in the ER membranes of 
Pichia pastoris cells. 
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2.3 Expression and purification of the human wild-type 101F6 protein 
The pPICZB-101F6-His8 plasmids obtained from the transformed E. coli cells were purified 
and linearized using Pme I and were used for the transformation of Pichia pastoris GS115 
competent cells according to EasyCompTM transformation protocol (Invitrogen Corp., 
Tokyo, Japan). Selection was done by plating onto YPDS medium containing 400 µg/mL 
Zeocin (Invitrogen Corp., Tokyo, Japan), a bleomycin-like compound that kills cells by 
introducing lethal double-strand breaks in chromosomal DNA. In our screening process, the 
concentration of Zeocin was increased four times higher than the recommended 
concentration of 100 µg/mL, to obtain Zeocin hyper-resistant transformants that would 
have multicopy clones. The Zeocin-resistant protein (the product of the Sh ble gene in the 
pPICZB vector) confers resistance to the transformed cells stoichiometrically, not 
enzymatically, by binding to and inactivating the drug. Therefore, such transformants may 
ultimately result in an increase in the level of heterologous 101F6-His8 protein production 
(Romanos et al., 1998).  
Single colonies with a hyper Zeocin-resistant activity from the YPDS-Zeocin plates were 
inoculated into 1000-mL Erlenmeyer flasks with a baffled bottom containing 250 mL BMGY 
media (2% glycerol). During the usual induction procedure of such transformants by the 
addition of methanol (final 2%) as described previously (Recuenco et al., 2009), the color of 
the medium become reddish, indicating a successful expression of a holo-form of the 101F6 
protein in the Pichia pastoris cells. After harvesting the induced cells, microsomal fractions 
were prepared in the presence of protease inhibitor cocktail (Protease Inhibitor Cocktail for 
General Use (100X); Nacalai Tesque, Kyoto, Japan). Then, the cytochrome b561 content based 
on the absorption at 561 nm was calculated. Typical results showed a total yield of 600~1000 
nmoles of cytochrome b561 in microsomal fraction obtained from a 250-mL culture after 96 h 
of incubation (Table 1). 
Solubilization of microsomal membrane fraction was conducted with -octyl glucoside 
(2%)(Anatrace, Maumee, Ohio, USA). All the following steps were conducted at 4°C or on 
ice to avoid the formation of aggregates. Further, to obtain a better yield, we skipped the 
step of DEAE-Sepharose column chromatography, which was included in the original 
purification procedure (Recuenco et al., 2009). Thus, the solubilized membrane proteins 
from the microsomal fraction were directly applied to a pre-packed Ni-NTA-Sepharose (GE 
Healthcare Japan. Tokyo, Japan) column equilibrated with a buffer containing 300 mM NaCl 
and 10 mM imidazole. Removal of interfering proteins was achieved by washing the column 
with the buffers containing 20 mM imidazole and 50 mM imidazole. Then, the 101F6-His8 
protein was eluted with the buffer containing 300 mM imidazole. The purified sample was 
promptly desalted with PD-10 column (GE Healthcare Japan, Tokyo, Japan) equilibrated 
with 50 mM phosphate buffer containing 1 % -octyl glucoside and 10 % glycerol.  
3. Results 
3.1 Properties of the purified 101F6-His8 protein 
Table 1 shows a typical example for the protein yield and the cytochrome b561 content at all 
the purification steps. From a 250-mL culture, which provides about 16-20 grams of wet cell 
bodies expressing the 101F6-His8 protein with an approximate cytochrome b561 content of 
800~900 nmoles, it was possible to purify about 0.60 mg of the recombinant human 101F6-
His8 protein with the cytochrome b561 content of 180 nmoles, with a purification fold of 56 
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from the stage of microsomes to the stage of the final desalting. Since the cytochrome b561 
content at the stage of microsomes would include a considerable amount of other b-type 
cytochromes, such as cytochrome bc1 complex, the actual yield of the recombinant 101F6-
His8 protein would be much better. Then, the purified 101F6-His8 protein was evaluated by 
SDS-PAGE, visible absorption spectroscopy, MALDI-TOF mass spectrometory, redox 
titration, heme content analysis, in comparison with those of classic chromaffin granule 
(CG) (i.e., chromaffine vesicle) cytochrome b561.  
SDS-PAGE analysis on the purified 101F6-His8 protein showed a single protein band with 
its estimated molecular weight around 26 kDa. Achievement of the highly purified sample 
by a single column chromatography step as in our present study might be possible by the 
better binding affinity of the 101F6-His8 protein towards Ni-NTA-Sepharose column, by the 
introduction of eight-histidine residue-tag at the C-terminus (Alisio & Mueckler, 2010). 
Occasionally we found a dimer (or trimer) form of the 101F6-His8 protein monomer upon 
the SDS-PAGE analysis. We found that such a formation of the dimer (or trimer) form was 
not due to a disulfide bond formation between the monomers and could be avoided 
without the heat treatment of the purified sample before the analysis. The great tendency 
to form aggregates of the 101F6-His8 protein during the purification steps is likely to be 
related to a spontaneous formation of the dimer (or trimer) and might be the intrinsic 
nature of the cytochrome b561 protein family more or less (Apps et al., 1984; Duong et al., 
1984; Liu et al., 2011). 
Visible absorption spectra of the purified 101F6-His8 protein were analyzed in the region 
from 700 to 340 nm. The purified 101F6-His8 protein exhibited typical spectra characteristics 
as a member of the cytochrome b561 family (Tsubaki et al., 1997). A strong Soret band at 414 
nm and weak Q bands between 500-600 nm were observed for the oxidized form. Addition 
of sodium dithionite produced the fully-reduced form with a Soret band at 427 nm and 
resolved Q bands at 529 (-band) and at 561 nm (-band) (Figure 1). For the heme content 
analysis, the purified 101F6-H8 protein was converted to a pyridine hemochrome by the 
addition of pyridine and NaOH according to the method of (Fuhrhop & Smith, 1975) as 
modified with (Berry & Trumpower, 1987). An extinction coefficient value for heme B 
pyridine hemochrome of 34.4 mM-1cm-1 at 557 nm (in the absolute spectrum) (Fuhrhop & 
Smith, 1975) was used. Protein concentration was determined by a modified Lowry method 
(Markwell et al., 1981) and by the Bradford method (Bradford, 1976). Bovine serum albumin 
was used as a standard in each method. Concentration of the standard solution was 
assessed spectrophotometrically using an extinction coefficient of 6.60 %-1cm-1 at 280 nm. 
The heme content of the purified 101F6-His8 protein was found to be 1.59 (±0.06) mole/mole 
protein, as calculated from the absolute spectrum at 557 nm of the pyridine hemochrome. 
This value was slightly less than the calculated value for bovine CG cytochrome b561 at 1.70 
mole heme/mole protein (Tsubaki et al., 1997). Nevertheless, the value supported the 
presence of two heme B groups per protein in the purified sample, like the classic CG 
cytochrome b561. This result was also consistent with the result of EPR analysis on the 
purified form of oxidized 101F6-His8 (Recuenco et al., unpublished), which showed the 
presence of two independent heme centers. 
Mass spectrometric analyses were conducted with a Voyager DE Pro mass spectrometer 
(Applied Biosystems, Foster City, California, USA). The estimated molecular mass of the 
intact 101F6-His8 was found as 25941.70 Da, very close to the theoretical value 
corresponding to 1-240 residue (25996.9 Da; average). In total of 240 amino acid residues of 
 
Tumor Suppressor Genes 
 
300 
the 101F6-His8 protein, we could identify most of the cleaved peptides with coverage of 
more than 99% and there was no post-translational modification occurred. These results 
confirmed the successful expression and purification of the intact 101F6-His8 protein. 
 
 
Purification steps 
Total 
protein 
(mg) 
Total 
cytochrome 
b561 content 
(nmol) 
Specific 
content 
(nmol/mg 
protein) 
Purification 
Fold 
Yield 
(%) 
Microsomes 165.75 861 5.20 1 100 
 
β-octyl glucoside-
solubilized 
 
109.20 
 
459 
 
4.20 
 
0.81 
 
53.3 
 
Ni-NTA 
chromatography/desal/ 
concentrate 
 
 
0.60 
 
 
176 
 
 
293.3 
 
 
56 
 
 
20.5 
Table 1. Purification of recombinant human 101F6-His8 protein (starting from a culture of 
250 mL-scale).  
 
 
Fig. 1. Visible absorption spectra of purified 101F6-H8 protein. Spectra were measured in 
oxidized (solid line), AsA (10 mM)–reduced (broken line), and dithionite-reduced (dashed 
broken line) states with cytochrome b561 content of 1.66 M in 50 mM potassium phosphate 
buffer (pH 7.0) 1.0% -octyl glucoside at room temperature. 
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The 101F6-His8 protein was found to be reducible by AsA very efficiently. Redox titration 
analysis showed that its redox behaviour could be simulated satisfactory by assuming the 
presence of two independent heme b prosthetic groups with their midpoint potentials at 
+89.5 and +13.1 mV, respectively, slightly lower than the corresponding values of bovine 
CG cytochrome b561 (Tsubaki et al., 2000; Takeuchi et al., 2001). Electron accepting activity 
from AsA to the oxidized 101F6-His8 protein and electron donating activity from the 
reduced 101F6-His8 protein to MDA radical were further analyzed by a stopped-flow and 
pulse-radiolysis techniques, respectively. The results showed that these two properties are 
distinct from bovine CG cytochrome b561: (a) very high electron accepting rate constant from 
ascorbate compared to other cytochrome b561 (Kobayashi et al., 1998); (b) absence of initial 
pH-dependency from AsA to the oxidized heme of 101F6-His8 protein (Takigami et al., 
2003). Details were described elsewhere (Recuenco et al., unpublished results). These 
properties may be directly related to the tumor suppressor activity of 101F6-His8 protein in 
human lung tissues. 
3.2 Protein crystallization screening 
Purified eight-histidine-tagged human 101F6 protein in 50 mM potassium phosphate 
buffer (pH 7.0) containing 1% β-octyl glucoside was freed from aggregates by 
centrifugation at 15,000 rpm for 5 minutes. The supernatant containing the solubilized 
protein was put in Amicon Ultra-4 centrifugal filter unit (UFC 801096; Nihon Millipore 
K.K., Tokyo, Japan) and centrifuged at 3,000 rpm to concentrate the protein sample. The 
concentrated sample was again centrifuged to remove aggregates and then filtered 
through a 0.22 μm syringe filter. A 0.3 mL sample with a concentration at least 150 μM of 
cytochrome b561 content was enough for screening approximately 1000 different 
conditions using a crystallization robot, Hydra II Plus One system (Matrix Technologies 
Corp., Thermo Fischer Scientific Inc., Hudson, New Hampshire, USA). Screening of the 
crystallization condition was performed by a sitting-drop vapor diffusion method on 96-
well Intelli-plates at room temperature. A ratio of 0.3 μL protein and 0.3 μL precipitant 
over 30 μL well solution was employed. Crystallization screening solutions such as, 
Classics Neo, Classics Neo II, JCSG+, Mb Class I, MPD, pH clear, pH clear II, AmSO4, PEG 
I, and PEG II Suite (Qiagen K. K., Tokyo, Japan), were used. After the deposition of the 
samples, plates were incubated at 20°C for about 14 days. 
Crystals with size of 0.020 mm were formed from the following precipitants: 
JCSG+ (20 % PEG3350, 0.2 M sodium thiocyanate), Classics Neo (1.0 M imidazole (pH 7.0), 
and Classics II (25 % PEG3350, 0.2 M ammonium acetate, 0.1 M bis-Tris (pH 5.5) (Figure 2). 
Diffraction data were first measured on an R-axis imaging plate (IP) area detector (Rigaku 
Corp., Tokyo, Japan) at the Protein Design Laboratory, Yokohama City University. The X-
ray diffraction data of the crystals were further collected at the Photon Factory in Tsukuba, 
Ibaraki, Japan (Beam line; PF-BL5A). The crystals from Classics II (25 % PEG3350 (w/v), 0.2 
M ammonium acetate, 0.1 M bis-Tris (pH 5.5) were able to produce an X-ray diffraction 
pattern with a maximum resolution at 8.4 Å (Figure 2B). Further, optimization of the 
conditions using 20 % PEG3350 (w/v), 0.2M ammonium acetate, 0.1 M bis-Tris (pH 5.5) and 
15 % PEG3350 (w/v), 0.2 M ammonium acetate, 0.1 M bis-Tris (pH 5.5) produced better 
crystals (Figure 3).  The crystals from 15 % PEG3350 (w/v), 0.2M ammonium acetate, 0.1M 
bis-Tris (pH 5.5) produced a diffraction pattern of spots with the highest resolution at 4 Å 
(Figure not shown).  
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Fig. 2. Screening of crystallization conditions for 101F6-His8 protein. (A-C) Crystals formed 
upon crystallization screening with a sitting-drop vapor diffusion method on 96-well plates. 
Conditions: Precipitant, 25% PEG3350, 0.2M Ammonium acetate, 0.1M bis-Tris (pH5.5) 
solution; Temperature 20 °C; Incubation time 10-14 days; Protein concentration, 150 μM in 
50 mM potassium buffer (pH 7.0) containing 1.0 % β-octyl glucoside. (D-F) Diffraction 
patterns of the 101F6-H8 crystals obtained from the conditions described above. Highest 
resolution at 8 Å was obtained at Tsukuba Photon Factory (Beam Line: PF-BL5A, Exposure 
time=20 sec). 
4. Discussion 
The candidate tumor suppressor protein 101F6 could be an important factor in cell 
proliferation and apoptosis. The reported induction of apoptosis in cultured cancer cells and 
inhibition of tumor growth in mouse models on forced expression of the 101F6 gene (Ji et al., 
2002; Ohtani et al., 2007) gave a promising outlook for cancer prevention and treatment. In 
the present study, the human 101F6 protein was expressed and purified successfully from 
the yeast Pichia pastoris cells. The purified 101F6-His8 protein was found to be reducible by 
AsA very efficiently and can donate electrons to MDA radical very rapidly. These new 
findings provide clues as to the possible role of the 101F6 protein in AsA-recycling that may 
be linked to processes that ultimately lead to apoptosis (Figure 3). Our view is basically 
consistent with the proposal by Ohtani et al., in which the exogenously-expressed 101F6 
protein in cancer cells enhanced intracellular uptake of AsA, leading to an accumulation of 
cytotoxic H2O2 and synergistic killing of tumor cells through caspase-independent apoptotic 
and autophagic pathways (Ohtani et al., 2007). Our present view, however, needs further 
clarification to explain the possible mechanism(s) to enhance the cellular uptake of AsA by 
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the introduction of the 101F6 protein into the ER membranes. Further, the proximate target 
of the 101F6 protein in the proposed AsA-signaling pathway must be clarified. Importantly, 
in our scheme in Figure 3, H2O2 was not included. Ohtani et al. observed a significant 
increase in the intracellular accumulation of H2O2 in non-small cell lung cancer (NSCLC) 
cells only in response to exogenous 101F6 and AsA (Ohtani et al., 2007). Therefore, it might 
be very important to clarify the molecular mechanism concealed in the 101F6 protein in 
facilitating the formation and accumulation of cytotoxic H2O2 by the increased concentration 
of cytosolic AsA. For these purposes, complete three-dimensional structural information 
about this hydrophobic membrane protein is highly necessary and it would be very helpful 
for the understanding of the mechanism of the putative tumor suppression function and, 
further, in the design of therapeutic agents for cancer.  
 
 
 
 
Fig. 3. Crystals formed from crystallization screening with a sitting-drop vapor diffusion 
method after optimization of precipitant composition. (A and B) 15% PEG3350 (w/v), 0.4M 
Ammonium acetate, 0.1M bis-Tris (pH6.0). Temperature 20°C; Incubation time, 10-14 days; 
Protein concentration, 150μM of 101F6-His8 protein in 50 mM potassium phosphate buffer 
(pH 7.0) containing 1.0 % β-octyl glucoside.  
A
B
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Fig. 4. Proposed topological model and function of the human tumor suppressor 101F6 
protein in human cells. The human 101F6 protein contains six transmembrane -helices and 
two b-type hemes. Alignment with other cytochromes b561 identified four histidine residues 
that might be the axial ligands of two hemes: His48 and His120 for the intravesicular heme; 
and His86 and His159 for the cytosolic side heme. The 101F6 protein may be located in the 
small vesicle or ER membranes. The 101F6 protein may function as an electron transfer 
protein inside the vesicles for AsA recycling. An electron donor donates an electron to the 
cytosolic heme of the 101F6 protein. The electron is then passed to the intravesicular heme 
via intramolecular electron transfer. MDA radical that might have been generated in some 
processes in the lumen accepts the electron from the intravesicular heme to re-generate AsA. 
AsA in the lumen of the vesicles is used as a cofactor to activate a certain target protein that 
may signal a caspase-independent pathway to induce apoptosis or autophagy. 
Purification and crystallization of membrane proteins are considered to be much more difficult 
than soluble proteins. This difficulty is mostly due to the presence of transmembrane domains, 
in which hydrophobic -helical domains were covered with detergent molecules, which was 
inevitably used for the solubilization of the proteins, forming a micelle structure. Such 
hydrophobic domains do not have specific interactions with other protein molecules, having a 
tendency to form non-specific aggregates during the protein purification, therefore, hampered 
the purification of membrane proteins into a homogenous state. Similar problems occur 
during the crystallization of a membrane protein. To obtain successful protein crystals of a 
membrane protein, we may have two strategies; one way is increasing a part of the 
hydrophilic domain to facilitate the specific interactions among the hydrophilic amino acid 
residues of the protein. Usually, a monoclonal body specific to such a hydrophilic domain 
would be used for such purpose. The other way is a choice of detergents. To find the best 
conditions for crystal growth with a suitable crystal group, one needs large amounts of pure 
protein sample and suitable detergents (Gutmann, 2007; Wetterholm et al., 2008). 
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We could obtain enough amounts of nearly homogeneous sample of human 101F6 protein 
in the form of eight-histidine-tagged fusion protein from the heterologous expression 
system of yeast Pichia pastoris cells. The protein samples were subjected to crystallization 
trials where initial screening was performed using a crystallization robot and commercially-
available protein crystallization precipitants containing varying proportions of different 
salts, polymers and organic solvents. This allowed the screening of about 1000 different 
conditions within a very short time and usage of a tiny amount of the protein sample.  
The β-octyl glucoside detergent used throughout in this study was a small micelle-forming 
detergent. Small micelle-forming detergents solubilize membrane proteins efficiently and 
leave hydrophilic parts of the protein being exposed to the water medium, allowing better 
interactions with other protein molecule(s) that are required for the formation of protein 
crystal lattice (Gutmann, 2007). However, if the hydrophobic regions are not well-covered 
with detergent molecules, aggregation of the membrane protein may occur. Large micelle-
forming detergents such as n-dodecyl-β-D-maltoside and polyoxyethylene dodecyl ether 
can be used to address this problem. But with the use of these detergents, only small 
portions of the protein may be actually available for the lattice formation with other protein 
molecules. Thus, the human 101F6 protein should be subjected to a detergent screening to 
obtain better diffracting crystals and resolve its X-ray structure. 
5. Conclusion 
Previous studies showed that forced expression of the 101F6 gene in cultured cancer cells 
and in animal cancer models could significantly inhibit tumor growth. These promising 
results encouraged our investigation on the properties and function of the 101F6 protein. 
The human 101F6 protein was successfully expressed as an octahistidine-tagged fusion 
protein in the methylotropic yeast Pichia pastoris and was purified in its functional form. 
Characterization of the protein revealed that it possesses similar absorption spectra and 
AsA-reducibility as the prototype bovine CG cytochrome b561. However, the results from 
kinetic studies on the reduction by AsA and the oxidation by MDA radical indicated 
different properties in the electron transfer mechanism. Most of the differences may be 
attributed to the low sequence homology of the 101F6 protein to the bovine CG cytochrome 
b561. Other previously studied members of the cytochrome b561 family are much more similar 
to each other because of their higher sequence homology. Present study showed that it was 
possible to produce high quality sample and good diffracting crystals of the octahistidine-
tagged 101F6 protein. An extensive screening for the best condition for crystallization 
should be done with the use of other detergents (such as n-dodecyl-β-D-maltoside), 
precipitants, and monoclonal antibodies. The detailed protein structure of the 101F6 protein 
through X-ray crystallography may be attained in the near future. 
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1. Introduction 
Lung cancer is the number one cause of cancer-related deaths worldwide. It claims 1.3 
million lives every year (www.who.int/mediacentre) (1). To understand the mechanism of 
lung carcinogenesis is one of the essential tasks for effective control of lung cancer. Lung 
cancer and other cancers have long been viewed as “genetic diseases” (2, 3). Particularly, 
tumor suppressor gene (TSG) deactivation plays a critical role in carcinogenesis. 
Historically, majority of the scientific evidence on tumor suppressor gene-related 
carcinogenesis describes the genetic defects occurring either in the TSGs themselves, such as 
mutations, or in their environment, such as activation of their inhibitors. Therapeutic 
applications of such knowledge against cancers have been attempted through reconstituting 
wild-type TSG products in target cells/tissues by genetic manipulation or biological or 
chemical molecules, thereby restoring the functions of TSGs and possibly slowing cancer 
progression. 
Ever since the 'two-hit' hypothesis (4) and the first proposal of a potential tumor suppressor 
gene being involved in the retinoblastomas formation (5), especially after the function of 
wild-type p53 gene was clearly described (6, 7), the therapeutic research effort has been 
shifted from optimizing the non-specific radiation and chemotherapy that mainly kill fast-
dividing cells to targeting the specific genetic changes. Restoring the function of TSGs has 
been considered as one of the most promising directions for cancer therapy.  
Directly transfecting TSGs into the cancer cells to restore the function of the TSGs and 
inhibit the tumor growth has become a promising direction to develop novel cancer therapy 
for the past two decades. Adenoviral and retroviral vectors have been used to deliver TSGs 
into human tumors by intratumoral or regional administration. The best example is the 
adenoviral carried wild-type p53 gene used to treat patients with non-small cell lung cancer 
(NSCLC) by direct intratumoral injection (8). Nonviral gene delivery methods such as 
cationic liposomes and cationic polymers were also developed for delivering TSGs because 
of their distinct advantage of lack of immunogenicity (9-11). Our lab has developed a unique 
cationic liposomal p53 and cationic polymers p53 to treat orthotopic human NSCLC model 
in mice with intratracheal or aerosol administration, which significantly enhanced the gene 
delivery efficiency to the airway epithelium and markedly reduced the systemic toxicity, the 
results showed a great therapeutic potential in the preclinical orthotopic human NSCLC 
xenografts in mice (12, 13). 
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However, the overall efficacy of these TSG therapies by direct gene transfection or delivery 
was limited. One of the important reasons is that most cases of “loss of function” found in 
tumor tissues are at the mature stage of the carcinogenesis process, at which moment the 
multiple irreversible genetic defects are established already, therefore, it is very difficult to 
reverse the carcinogenesis process by restoring or correcting the functions of one or a few 
TSGs. 
More recently, increasing evidence, particularly the “cancer stem cell” model suggests that 
epigenetic changes, which occur in normal stem or progenitor cells, are the earliest events in 
cancer initiation (14). Therefore, to catch the early cancer-specific epigenetic changes and 
reverse them logically becomes a better strategy than those focusing on the irreversible 
genetic defects.  
Multiple research groups have demonstrated that correcting the aberrant methylation in the 
promoter region of TSGs could inhibit cancer development. Among these studies, we have 
directly proved the concept in the orthotopic lung cancer models in mice. Briefly, we first 
proved that azacytidine (Aza), a demethylation agent, could effectively demethylate the 
hypermethylated promoter of RASSF1a gene (a TSG), at non-cytotoxic concentration range 
which was a thousand fold lower than its cytotoxic concentration. Then we used 
intratracheal injection of Aza at a non-cytotoxic dose to treat the airway inoculated NSCLC 
xenografts in mice, and we found that the demethylation treatment significantly prolonged 
the life of the tumor-bearing mice, and the locoregional therapy for localized lung cancer in 
the airway epithelium was significantly superior than the systemic (IV) treatment. Our 
results demonstrated that the model NSCLC could be inhibited if the TSGs were reactivated 
by the reversal of the hypermethylation in the promoter regions. In this chapter, we will also 
discuss the possible application, the advantages and limitation of the current epigenetic 
methods aimed to enhance cancer therapeutic efficacy by promoting TSGs. 
Restoring TSG functions through epigenetic manipulations will be a promising strategy for 
cancer therapy and prevention, which shifts the focus from treating cells with irreversible 
genetic lesions to targeting the reversible epigenetic changes. Further work in this field will 
complement our knowledge of TSG-expression control and enhance our understanding of 
the carcinogenesis process. This exciting new therapeutic strategy could potentially reduce 
cancer mortality when applied to populations of individuals at risk. 
In this chapter we will briefly summarize the studies describing the aberrant epigenetic 
alterations in lung cancer and the methods to control carcinogenesis with epigenetic 
manipulations, particularly, through controlling TSGs. We will also outline advances in the 
potential use of these epigenetic events for cancer diagnosis, prognosis and targeted 
epigenetic therapy, and present an experimental study of demethylation therapy at the 
preclinical level.  
2. Epigenetic changes and lung cancer 
Epigenetic changes usually are heritable changes in gene expression level without alteration 
of DNA sequence. Unlike genetic changes, epigenetic changes are reversible. The normal 
epigenetic process is important for gene expression and genome stability. When this normal 
process is disrupted, carcinogenesis may start. Therefore, epigenetic changes are considered 
a key player in the onset and progression of different type of cancers including lung cancer. 
The most frequently reported epigenetic phenomena are chromatin modifications including 
post-translational modifications of histones and chromatin modifying complexes, non-
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coding RNAs mediated regulations, and particularly DNA methylation. Epigenetic 
processes are finely tuned, undergo many regulations in response to the environment, and 
involve almost all the signaling pathways described in the literature. Epigenetics plays a 
crucial role in the control of nuclear architecture and gene activity and constitutes one of the 
bases of the biological diversity. In the first part of this chapter, we mainly focus on DNA 
methylation and its links to TSGs and lung cancer.  
2.1 DNA methylation and lung cancer 
DNA methylation is the most widely studied epigenetic modification restricted to the DNA 
motif called CpG dinucleotides, i.e. cytosine followed by guanine residues (15). Enriched in 
genomic regions known as “CpG islands,” these CpG dinucleotides are typically at least 200 
bp and up to several Kb in length with a high GC percentage, and are mainly found near or 
at the transcription start site within the promoter of about 40% of mammalian genes. CpG 
islands play a major role in the process of transcriptional regulation, and the ability of a 
gene to be or not to be transcribed is correlated with the unmethylated and methylated 
status of a CpG island, respectively, in the presence of the required co-regulators. 
Methylation is the only covalent modification of the DNA in mammalian cells and carries 
out normal physiological functions during embryonic development (16), genomic 
imprinting (17), and chromosome-X inactivation (18). However, frequent alterations in DNA 
methylation are observed in cancers such as hypermethylation of CpG islands at tumor 
suppressor gene (TSG) loci leading to the loss of their expression, genome-wide 
hypomethylation in the body of genes and in DNA repetitive sequences leading to genomic 
instability (16), and altered DNA methyltransferases (DNMTs) expression (17). 
DNA hypermethylation in the promoter region of TSGs is frequently found in human lung 
cancer tissues and cell lines. It was proved to be responsible for silencing the TSG and 
therefore promoting the initiation and development of the lung carcinogenesis. The best-
studied example is the case of p16INK4a (CDKN2A); its promoter hypermethylation 
prevents the negative control exerted by p16INK4a on RB phosphorylation, thereby 
promoting cell cycle progression. p16INK4a hypermethylation is considered as one of the 
earliest event in lung tumorigenesis and increases constantly with disease progression (19, 
20). An increasing number of other genes have been investigated for their methlyation status 
in lung cancer, including h-cadherin (CDH13) (21), 14-3-3σ (22), death associated protein 
kinase 1 (DAPK1) (23), ras association domain family 1 gene (RASSF1a) (24), caspase-8 (25), 
retinoic acid receptor β-2 (RAR-β), tissue inhibitor of metalloproteinase 3 (TIMP3), o6-
methylguanine DNA methyltransferase (MGMT), E-cadherin (ECAD), gluthatione s-
transferase p1 (GSTP1) (26), FHIT (27, 28), ASC/TMS1, HSRBC, TSLC1, DAL-1, and PTEN 
(29). Since these genes are involved in a broad range of biological processes, such as cancer 
cell cycle regulation, proliferation, apoptosis, cell adhesion, mobility, and DNA repair, 
promoter DNA hypermethylation may be a key event in lung carcinogenesis. Furthermore, 
genome-wide analyses have suggested that the presence of promoter DNA 
hypermethylation is probably more extensive than previously thought (30-33). For instance, 
Shames et al. recently identified 132 genes that are methylated with high penetrance in lung 
cancer cells (32). More strikingly, Brena et al. reported that 4.8% of all CpG island promoters 
might be aberrantly methylated, suggesting that the expression of about 1,400 genes might 
be disturbed in lung cancer (30).  
Due to the spontaneous hydrolytic deamination under physiological conditions, methylated 
cytosine can be considered as a potent endogenous mutagen for C to T mutations, therefore 
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DNA hypermethylation can actually predispose to mutational events (14). Although 
representing only 1% of the bases in the mammalian genome, methylated cytosine might be 
responsible for as much as 30% of all transition mutations found in human disease such as 
cancers (34, 35). 
The mechanism of the aberrant hypermethylation in the promoter region of TSGs in human 
non-small-cell lung cancer especially among smoker patients was described as the 
overexpression of DNA methyltranferases including DNMT1, DNMT3A and DNMT3B. 
Interestingly, polymorphisms that influence expression of the DNMT3B gene have been 
connected with increasing risk of lung cancer (36, 37). An adverse consequence of methylation 
of CpG sites appears to facilitate the binding for benzo[a]pyrene, a carcinogen, found in 
cigarette smoke, leading to the formation of major DNA damage hotspots in human lung 
cancer (38, 39). A well-illustrated example of this phenomenon is the occurrence of some 
hotspot mutations of the p53 tumor suppressor gene in lung tumors (40, 41).  
Clinical evidence also showed that TSG promoter methylation is associated with the 
smoking history of patients with lung cancer. In lung adenocarcinomas and squamous cell 
carcinomas, the frequency of p16, MGMT, RASSF1, MTHFR, and FHIT promoter 
methylation was significantly higher among smokers than never-smokers (42-45); but the 
promoter methylation of other genes such as RASSF2, TNFRSF10C, BHLHB5, and BOLL 
was higher in never-smoker lung cancer patients than those of smokers (46, 47), suggesting 
smoking may target specific genes for methylation. 
The roles of methylation in lung cancers for early detection, risk assessment, disease 
progression, and prognosis have also been studied. DNA methylation may serve as a 
marker for the early detection of lung cancer when found in the sputum of the patient (19, 
48). For example, p16INK4a and MGMT promoter methylation could predict the 
development of squamous cell carcinoma up to three years before clinical diagnosis (49, 50), 
and RASSF1A, APC, ESR1, ABCB1, MT1G, and HOXC9 genes were found more frequently 
methylated in stage I lung adenocarcinomas/squamous cell carcinomas than the non-
cancerous lesions (51), whereas the prevalence of hDAB2IP, H-cadherin, DAL-1, and FBN2 
methylation was associated significantly with advanced stage of lung cancer (52-54). 
Altogether, theses studies highlight promoter methylation as a promising epigenetic 
approach for early detection and prognosis of NSCLC.  
Demethylating drugs have great and promising clinical potential based on their ability to 
restore the expression of epigenetic silenced TSGs and inhibit tumor cell growth, while 
inducing manageable short-term side effects at the effective doses (55). The 5-aza-2′-
deoxycytidine demethylating agent has been reported to increase the survival of 
chemotherapy-naive NSCLC patients, up to 6 years in some cases (56), although the 
relatively high dose in the treatment could be suspected to contribute partially cytotoxic 
effect to the final therapeutic outcome. More therapeutic investigations are underway, 
aiming at combining the demethylating agents with histone deacetylase inhibitors and 
attempting to integrate epigenetic therapy with more standard therapy. 
2.2 Chromatin modifications and lung cancer 
Chromatin is formed by basic units called the nucleosome, which is assembled by wrapping 
approximately 147 bp of genomic DNA around a histone octamere containing two copies of 
each of the core histones H2A, H2B, H3 and H4. The core histones possess an amino-
terminal tail that protrudes outside of the nucleosome, which are subjected to a wide  
variety of post-translational covalent modifications such as acetylation, methylation, 
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phosphorylation and ubiquitinylation. Access to the chromatin is thus affected by these 
modifications and therefore influences almost all DNA-based processes. Consequently, the 
structure and integrity of the genome and normal patterns of gene expression are potentially 
affected by the global alterations of histone modification patterns. 
The protein complexes that regulate transcription by modifying histones or altering 
chromatin structure are mainly represented by Histones AcetylTransferases 
(HATs)/Histones Deacetylases (HDACs) and Histones methyltransferases 
(HMTs)/Histones Demethylases (DHMTs) complexes that determine the level of acetylation 
and methylation, respectively, of the amino-terminal domains of nucleosomal histones 
associated with them, and by ATP-dependent complexes such as SWI/SNF which use the 
energy of ATP hydrolysis to locally disrupt or alter the association of histones with DNA. 
Histone deacetylation mediated by HDACs works synergistically to alter the chromatin 
condensation status and represses transcription with DNMTs and a group of methylated 
DNA-binding proteins (57). In general, high HDAC activity is associated with condensed, 
transcriptionally inactive chromatin. 
Altered expression pattern of histone and chromatin modifying enzymes have been found 
in human tumors, and histone modifications may contribute to tumorigenesis (58, 59). A 
clinical study including 138 lung cancer patients demonstrated that changes in global levels 
of histone 3 lysine 4 dimethylation (H3K4diMe), histone 3 lysine 9 acetylation (H3K9Ac), 
and histone 2A lysine 5 acetylation (H2AK5Ac) are predictive of the clinical outcome of lung 
cancers. Seligson et al (58) discovered that lower cellular levels of H3K4diMe and H3K18Ac 
predict significantly poorer survival probabilities for lung cancer patients (60). It has been 
summarized that the status of acetylation and methylation of specific lysine residues 
contained within the tails of nucleosome core histones is crucial in regulating chromatin 
structure and gene expression (61, 62). 
In addition to this epigenetic function, certain HDACs also exhibit important cytoplasmatic 
function by controlling the acetylation status and function of numerous cytoplasmic 
proteins and transcription factors that may be important in carcinogenesis (63). Moreover, 
Sasaki et al (64) reported that expressions of HDAC1 correlated with the progression of lung 
carcinomas. Bartling et al (65) found HDAC3 upregulation in squamous lung cancers 
compared with non-tumor tissues in lung. Osada et al discovered that in a group of 72 lung 
cancer patients, the reduction of class II HDAC gene expression was clearly associated with 
poor prognosis (66). These results suggested that HDAC might be involved in lung cancer 
occurrence, progression, and prognosis and that inhibition of HDAC activity might be a 
possible target for lung cancer treatment.  
Increasing laboratory evidence has illustrated the therapeutic mechanisms of HDACi: e.g., 
HDAC inhibitor FK228 suppressed the PI3K/Akt (67) and Src/Raf/MEK/ERK1/2 (68) 
signaling pathways, resulting in the downregulation of the anti-apoptotic proteins Bcl-2 and 
Bcl-xL, upregulation of the pro-apoptotic protein Bax, and the induction of time-dependent 
apoptosis in both adenocarcinoma (69) and small cell carcinoma cells (69, 70). Coincident 
with inhibition of ERK1/2 and PI3K/AKT survival pathways, the HDAC inhibitor FK228 
enhanced JNK and p38MAPK signaling (68), whereas an SIRT1 inhibitor, Sirtinol, impaired 
activation of Ras/MAPK pathways in response to EGF and insulin-like growth factor-I (71). 
Furthermore, another HDAC inhibitor, trichostatin A, suppressed the levels of COX-2 
mRNA and protein expression, which were correlated with an inhibition in prostaglandin 
E2 synthesis in lung adenocarcinoma cells (69). Clearly, HDACi have a specific antitumor 
effect and thorough studies analyzing the full potential and mechanism of these drugs with 
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regards to optimal dose, schedule, patient selection and combination strategies would allow 
the development of molecules with more effective therapeutic effect. 
Recently, targeting HDAC activity using inhibitors of HDAC (HDACi) has become a novel 
and promising anticancer strategy, in particular in the treatment of advanced NSCLC where 
phase I and II trials have been completed (72). In addition, several HDACi have been shown 
to increase the cytotoxic effects of radiation in NSCLC by decreasing DNA repair efficiency 
and promoting cell death (73). HDACi also showed favorable results when used in 
combination with standard NSCLC chemotherapeutic agents and are likely to be a novel 
approach for the treatment of NSCLC because of an anti-growth activity against NSCLC 
cells (74, 75). Ongoing clinical trials are exploring the use of many new HDACi alone or as 
part of a combination with existing therapeutic modalities such as chemotherapy or 
radiotherapy (76).  
2.3 Micro-RNAs and lung cancer 
Micro-RNAs (miRNAs) are small non-coding RNAs with ~22 nucleotides in length (77, 78). 
miRNAs control a wide range of biological processes including apoptosis, development, 
proliferation and differentiation (78). High-throughput analyses have highlighted aberrant 
miRNA expression profiles in an increasing range of human cancer types (79-81) and all 
these studies suggested that cancer cells express altered miRNAs patterns consisting of both 
overexpression and downregulation. Therefore, miRNAs may function either as tumor 
suppressors or oncogenes and the genomic abnormalities found to influence their activity 
are the same as those described for protein-coding genes.  
To date, both laboratory and clinical studies demonstrate a deregulation of miRNA 
expression in lung cancer and highlight them as useful diagnostic, pronostic and therapeutic 
tools. A growing number of miRNAs has been found aberrantly expressed in lung cancer 
and our understanding of miRNA expression patterns and functions in normal and lung 
cancer cells is just starting to emerge. Such miRNAs as miR-21, miR-126, miR-31, miR-519c, 
Let-7a, miR-133B, miR-15a, miR-16, and miR-183 have been found to regulate lung cancer 
cell proliferation, migration and invasion by targeting specific molecules, including Crk, 
EGFL7, VEGF, LATS2, PPP2R2A, HIF-1α, NIRF, MCL-1, Bcl-2, cyclins D1, D2 and E1, and 
Ezrin (82-89). 
Growing evidence indicates that miRNA expression profiles confer important clues for 
clinical diagnosis and prognosis of human lung cancer. MicroRNA microarray analyses 
have identified profiles which could discriminate lung cancers from noncancerous lung 
tissues, as well as molecular signatures that differ according to tumor histology (80, 90). 
Interestingly, recent identification of Has-miR-205 has suggested it to be a highly specific 
marker for squamous carcinoma (91), therefore a clinical diagnostic assay based on miR-205 
expression levels could aid the differential diagnosis of NSCLCs. Since miRNAs are more 
stable than mRNA and more tissue specific than DNA, their measurement could provide a 
novel and promising non-invasive approach to discriminate between normal and cancer 
patient samples. Studies found that aberrant miRNA expression could be used as a marker 
for the diagnosis of NSCLC in sputum specimen (92) and miRNA expression in peripheral 
blood or in serum correlated well with its expression in the tumor sample (93). 
In terms of prognostic value, several miRNAs are reported to be associated with the clinical 
outcome of lung cancer. For instance, clinical study indicated that overexpression of mature 
miR-21 in the tissue and sputum samples could be an independent negative prognostic 
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factor for overall survival in NSCLC patients (94). Detection of miR-21 expression in sputum 
as a non-invasive approach for the diagnosis of lung cancer confers better sensitivity than 
sputum cytology (92). Clinical studies also showed reduced let-7 (81) and miR-34 (95) 
expression or enhanced miR-146b (96) and miR155 (80) expression with short survival or a 
high probability of relapse in patients with NSCLC. In patients with NSCLC, a five-miRNA 
signature including miR-221, let-7a, miR-137, miR-372, and miR-182 was identified and 
validated as an independent predictor of cancer relapse and survival (97). Remarkably, this 
signature is valuable even after patient stratification by stage or histology. In addition, 
expression levels of miR-486, miR-30d, miR-1, and miR-499 in serum could be used to 
predict survival for patients with NSCLC (98). Overexpression of miR-155 correlates with a 
poor prognosis when all clinical variables are considered together (80). Since miRNAs are 
upstream regulators of gene expression, they may be more powerful prognostic markers 
than their downstream target genes. For example, miR-146b alone was found to have a 
predictive accuracy for prognosis in ~78% of patients with lung squamous cell carcinoma 
(96), better than the overall predictive accuracy of 68% for a 50-gene signature (99). 
The potential for using miRNAs in lung cancer therapy is now being explored. Let-7 
overexpression confers radio-sensitivity to lung cancer cells (100). miR-128b LOH, a direct 
regulator of EGFR, correlates with clinical response and survival following gefitinib 
treatment (101). miR-221, miR-222 and miR-17-92 sensitize lung cancer cells to cytotoxic 
agents (102-104). Such results offer the experimental bases for the use of miRNAs as 
therapeutic targets. Further experiments are needed to uncover the emerging power of small 
non-coding RNAs to improve lung cancer therapeutics, and would have significant 
consequences for cancer patients in clinic. 
Accumulative scientific evidence suggests that cancer, particularly lung cancer, is not only a 
genetic disease (2, 3), but also an epigenetic disease. Laboratory and clinical studies clearly 
demonstrate that many aberrant epigenetic events occurring before the genetic changes are 
responsible for the cancer initiation and progression. It has been confirmed that disruption 
of the normal epigenetic processes promotes lung carcinogenesis and lung tumor growth 
through complicated mechanisms involving TSGs silencing and oncogene activation. 
Majority of these disruptions are found to be the consequence of exposure to environmental 
carcinogens, particularly from cigarette smoking causing heritable epigenetic changes. The 
management of aberrant epigenetic states as a way to target early lung cancer development 
or lung tumor progression is therefore a logical therapeutic approach. 
In the future, to develop new anti-tumor agents, such as DNMTi or HDACi, and the specific 
treatment strategies including tumor-targeted drug delivery system and specific 
administration routes, and to avoid the non-specific toxicity of anti-cancer drugs, will be of 
particular interest. Indeed, the side effects of these epigenetic compounds may have 
unscheduled consequences in terms of gene expression, in that they may display growth-
promoting effects on tumor cells. As more critical miRNAs are found and the expression of 
many of them reduced in lung cancer cells, targeting miRNA is becoming a promising 
strategy in terms of cancer treatment. Administration of synthetic oligonucleotides that 
mimic endogenous miRNAs might be used to treat specific tumor types if an effective 
delivery system can be developed. Moreover, targeting oncogenic miRNAs through 
administration of anti-sense oligonucleotides, called anti-miRNA oligonucleotides (AMO) is 
coming into focus, given that the use of antagomirs, which are AMOs conjugated with 
cholesterol, has emerged as an efficient approach to inhibit miRNA activity (105). Further 
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studies to uncover the potential usefulness of chromatin modifying drugs in restoring the 
loss of expression of tumor suppressor miRNAs are underway. There is no doubt that a 
more comprehensive dissection of the cellular and molecular pathways controlled by 
epigenetic processes will provide new insights into cancer related mechanisms and will 
highlight promising fields for the development of novel therapies to fight lung cancer. 
3. A preclinical study to use demethylating agent to treat orthotopic human 
lung cancer xenografts 
Lung cancer has remained as the number one cause of cancer-related deaths worldwide for 
decades (106). Traditional methods are mainly non-specific cytotoxic radiation therapy and 
chemotherapy; their non-specificity and therefore, life-threatening toxicity determined their 
limitation in the application. There is an urgent need to develop more sensitive diagnosis 
and more effective therapeutic methods to save lung cancer patients. About 90% of lung 
cancer cases are the end result of cumulative aberrant epigenetic changes and genetic 
damage to the respiratory epithelium chronically exposed to environmental, particularly 
tobacco carcinogens (107-109). One of the well accepted mechanisms of carcinogenesis in 
lung cancer is the aberrant methylation of CpG islands in the promoter regions of tumor 
suppressor genes (TSGs) leading to underexpression or absence of the proteins of those 
genes thus propagating tumorigenesis (110).  
It has also been proved that the promoter hypermethylation down regulated TSGs can be 
reversed by DNA-methyltransferase inhibitors (DMTI) like azacytidine (Aza), Aza-2’-
deoxycytidine, and Zebularine (11, 111, 112). These agents have been in clinical treatment 
for NSCLC patients by systemic administration with high doses and limited efficacy.  
Inhalation of carcinogens, mainly as a result of tobacco exposure, causes a field 
cancerization effect thereby placing the entire bronchial epithelium at risk of developing 
bronchogenic carcinoma. Any strategies that aim at decreasing the incidence of lung cancer 
or decreasing the incidence of a second primary in a patient with a history of lung cancer 
would have to have an effect on the entire bronchial epithelium. In the case of a 
pharmacologic agent, this would be possible and feasible by inhalation of aerosolized 
solution of the drug. DMTI agents like Aza have the potential to reexpress tumor suppressor 
genes, which might lead to reversal of premalignant changes, slow the carcinogenesis 
process, and eventually decrease the incidence of bronchogenic carcinoma (113). Systemic 
administration of these drugs has been explored in advanced NSCLC patients but not 
pursued because of significant systemic toxicity (114).  
In this part we present a study with two objectives: 1. To prove that whether reversing the 
hypermethylation in promoter region of the TSGs can make a positive contribution to the 
therapeutic outcome of lung cancer. 2. To prove whether the airway administration more 
effective than systemic administration to treat airway localized advanced bronchial 
premalignancy or endobronchial lung cancer. In this study, we used intratarcheal injection 
of Aza to treat the orthotopic lung cancer models in mice, the low dose (non-cytotoxic dose) 
we used mainly brought demethylating effect of Aza and avoided its cytotoxic effect. 
3.1 Experimental design and methods 
In order to prove whether demethylation on the hypermethylated promoters of TSGs will 
contribute therapeutic efficacy in the preclinical level, we tested the demethylation function 
of a typical demethylation agent azacytidine (Aza) in vitro and in vivo. Particularly, we 
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used intratracheal injection of Aza to treat orthotopic lung cancer xenografts in the efficacy 
study. The detailed experimental studies are presented below. 
We selected three different human non-small cell lung cancer cell lines for the in vitro and in 
vivo studies: a squamous cell carcinoma cell line H226, a bronchioalveolar carcinoma cell 
line H358, and a metastatic large cell carcinoma H460 from pleural effusion. All cell lines 
were purchased from American Type Culture Collection (ATCC, Manassas, VA) and 
cultured per ATCC’s protocols.  
3.1.1 In vitro studies  
In order to distinguish the cytotoxic effect and demethylation effect of Aza, we used MTT 
assay to determine the growth inhibition range of Aza and methylation-specific PCR with 
the samples treated by a set concentrations of Aza to detect the minimal concentration for 
the effective demethylation at the promoter region of TSGs. MTT assay used was literature 
method (115), briefly, ~5,000 cells in 0.135 µL RPMI 1640/well were seeded in 96-well plates. 
After 24 h of culture, Aza at various concentrations was added to the cells. Three days later, 
the cells were stained with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) and lysed. The absorbance of each well was measured in a microplate reader at 570 
nm. The percent growth inhibition of the cells was calculated as the absorbance of treated 
cells normalized to no treatment cells. 
We selected RASSF1a as the first candidate TSG to prove the concept. Because it was found 
silenced by promoter hypermethylation in 32.6% of NSCLC patients (116). The human 
NSCLC cells H226 were treated with Aza at 0.1, 1, and 10 ng/ml. On day 4 after the 
treatment, the cells were harvested. About 8 x 104 cells were used to detect the methylation 
status of the RASSF1a promoter using EZ DNA Methylation-Direct KitTM (Zymo Research 
Corp., Orange, CA, USA), according to the manufacturer’s instructions. The bisulfate-
converted DNA was then used as a template for methylation-specific PCR reactions using 
primers specific for either the modified methylated or modified unmethylated promoter 
sequences of the RASSF1a genes. The primers used have been described previously by 
others (117). The sequences are: methylated: 5’-GGG TTT TGC GAG AGC GCG-3’ (forward) 
and 5’-GCT AAC AAA CGC GAA CCG-3’(reverse); unmethylated: 5’-GGT TTT GTG AGA 
GTG TGT TTA G-3’(forward), and 5’-CAC TAA CAA ACA CAA ACC AAA C-3’(reverse). 
Briefly, PCR reactions contained 1-4 microliters of bisulfate-converted DNA, purified as 
above, 300 ng each of forward and reverse primers, 45 microliters of Platinum® PCR 
SuperMix (Invitrogen), and distilled water to a final reaction volume of 50 microliters. PCR 
amplification conditions were as described in the literature (117), unless otherwise noted. 
The PCR products were separated on 2% agarose gels containing ethidium bromide and 
were visualized under UV illumination.  
3.1.2 Animal studies  
The studies were begun from testing acute toxicity and finding the therapeutic dose. CD-1 
mice (Harlan) were used to evaluate and compare the acute toxicities of Aza by the 
intratracheal or intravenous routes. Two groups of mice (5-8 mice/group) were treated with 
90 mg/kg of Aza via intravenous injection (IV) or intratracheal injection (IT), respectively. 
The dose of 90 mg/kg is the maximum tolerated dose (MTD) of IV Aza in mice. The IV and 
IT injection methods were described previously (12, 118). Briefly, for the IT the mice were 
anesthesized with intraperitoneal injection of 30-50 mg/kg of Nembutal or isoflurane 
 
Tumor Suppressor Genes 
 
318 
inhalation, fixed on the small animal fixing board. The mouth of mouse was open with a 
forceps; the drug solution or cell suspension was carefully injected into the trachea through 
mouth via a 22-gage feeding needle attached to a 1 ml syringe. The injection volume did not 
exceed 100 µl/mouse. If necessary, a “tube” type of light inserting into the mouth can be 
used to help locate the trachea.  
For myelotoxicity assessment, blood (100 µl/mouse, 5 mice/group) was drawn from the tail 
vein before treatment (at day 0) and on days 4, 7, 14, and 28 after treatment. Red blood cells 
(RBC) were removed from the blood samples using RBC lysis buffer (eBioscience San Diego, 
CA) as per the manufacturer’s protocol. White blood cells (WBC) were collected and 
counted with a hematocytometer under a microscope. Blood samples from mice without 
treatment were used as controls. In the organ toxicity studies, groups of mice given IT of 
Lactated Ringer’s Solution or without treatment were used as vehicle and normal controls, 
respectively. Creatinine levels, and liver function tests were determined at Antech Diagnosis 
(Lake Success, NY). Organ pathological examination was performed at different time points. 
Briefly, 5 mice in each group were euthanized on day 4, 7, 14, and 28 days after 
administration of the drug. Blood was drawn from the caudal vena cava, and lungs, livers 
and kidneys were resected and fixed with 10% buffered Formalin. The fixed tissues were 
processed with standard procedure for H&E staining. The toxicity levels were determined 
by giving toxicity grade to each tissue sample. The grading based on the general pathology 
guidelines was 0 to 4, they reflect a percentage of damaged tissue of 0, <10 (mild), 10-30 
(moderate), 30-60 (severe), >60 (life threaten), respectively.  
To mimic human NSCLC, we developed a mouse model by intratracheal inoculation of 
human lung cancer cells in nude mice (12). Briefly, the nude mice (in this particular 
example, male and female NCRNU-M-F nude mice, 6-7 weeks old, purchased from Taconic 
Farms, Germantown, NY) were given tumor inoculation with 2~5 x 106 cells/mouse by IT 
described above. In this model, we found that the cancer cells initially attached on the 
airway epithelium of the mice and survived (from day 0 to 10), and then they formed micro 
nodules in the airway (from day 7 to 21), and finally the tumors invaded lung tissue (from 
day 14 to 35). The tumors mainly remain in the lung during the rest of lifetime of the mice, 
and the animal on average die on day 45 to 70 from the lung tumor burden (13). This model 
mimics the human NSCLCs that develop on the airway epithelium before they invade the 
lung parenchyma, and it is one of human lung cancer relevant models to evaluate lung 
cancer therapeutics by different administration routes, particularly by airway 
administration. 
In the antitumor efficacy test, we used a relative low dose of Aza with intratracheal injection 
to avoid the cytotoxic effect and emphasize the demethylation effect of Aza. Ten days after 
the intratracheal tumor inoculation, the nude mice were randomly divided into 3 groups of 
5 mice each in each test, and were treated with daily intravenous injection (IV) of Aza at 6.25 
mg/kg/day x 6 doses or intratracheal injection (IT) of Aza at 2.5 mg/kg/every other day x 3 
doses. The IT used the same method of the tumor inoculation described above. These 
optimal doses for the therapeutic study were determined in prior dose ranging studies. A 
group of mice without treatment was used as control. Survival was used as the major 
endpoint to evaluate efficacy.  
The same Aza formulation was used for the IT and IV treatment. It was made by dissolving 
azacytidine powder (Sigma, St Louis, MO) in Lactated Ringer’s Injection (Hospira, Inc., Lake 
Forest, IL) and passing the solution through 0.22 µm filter immediately prior to use. 
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3.1.3 Statistical analysis  
Differences among different groups were analyzed by two-side Log Rank Assay. A 
difference was considered statistically significant when p < 0.05.  
3.2 Results 
3.2.1 Growth inhibition and demethylation function of Aza in human NSCLC cell lines 
Aza has the both functions. In order to know whether Aza’s demethylation effect can 
function at a non-toxic concentration, we measured its cell growth inhibition and 
demethylation function in the selected human NSCLC cell lines. We found that Aza 
inhibited the growth of the NSCLC cells in a dose dependent manner as shown in Figure 1. 
The 50% inhibitory concentrations (IC50) of Aza were 0.6, 3.4, and 4.9 µg/ml in H226, H358, 
and H460 cells, respectively. In this study, Aza at a concentration below 0.6 µg/ml did not 
cause significant growth inhibition in all tested cell lines.  
 
 
Fig. 1. Growth inhibition of Aza on human NSCLC cell lines. H226, H358, and H460 cells 
were treated with (5-fold) increasing concentrations of Aza. The percentage of growth 
inhibition was measured with MTT Assay. The data for each cell line are mean ± standard 
deviation obtained from 3 independent experiments.  
The demethylation function of Aza were detect by a methylation-specific PCR method in the 
H226 NSCLC cell line at a very low concentration range (0.1 ~ 10 ng/ml). As shown in 
Figure 2, the unmethylated band (#5) of the promoter of RASSF1a gene was found in the 
H226 cells at the lowest concentration of 0.1 ng/ml, which is 6000-fold lower than the IC50 
of Aza in the same cell line. This indicates that when directly exposing lung cancer cells to 
Aza, Aza can function as effective demethylation agent at an extremely low concentration 
without causing any direct cytotoxicity.  
3.2.2 Intratracheal administration of Aza results in significantly reduced toxicity 
Myelosuppression is the dose-limiting toxicity of intravenously administered Aza when 
used clinically. In this study, we compared the myelotoxicity of IT and IV Aza at the same 
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dose, 90 mg/kg that is MTD when using IV administration. IT Aza produced significantly 
less myelotoxicity than IV Aza at the MTD of IV Aza. As shown in Figure 3, IV Aza 
significantly reduced the total WBC by > 68% on day 4 and 7 (p < 0.004) and >38% on day 14 
(p < 0.006), the WBC count recovered to about 90% of the normal level on day 28. While the 
only detectable WBC reduction in IT Aza treated mice was about 13% on day 7 (p < 0.01). 
The recovery was faster (on day 14) and complete (>97% of the normal level, p > 0.5) 
compared with IV Aza (Figure 3).  
 
 
Fig. 2. The demethylation function of Aza in the NSCLC cells. H226 human NSCLC cells  
(8 x 104 cells) were treated with Aza at 0.1, 1, and 10 ng/ml. The methylation status of the 
RASSF1a promoter was detected by methylation-specific PCR method using the EZ DNA 
Methylation-Direct Kit. The pair of bands from 1 to 3 are samples of water, methylated DNA 
control, and unmethylated DNA control; from 4 to 7 are samples of H226 cells treated with 
Aza at 0, 0.1, 1, and 10 ng/ml, respectively. The letters “U” and “M” represent 
unmethylated and methylated detection, respectively.  
 
Fig. 3. IT administration of Aza is 5-fold less myelosuppression compared to IV Aza. Aza 
was administered IT (round dots) or IV (triangle dots) at a dose of 90 mg/kg. Control mice 
were not given any treatment (square dots). Blood was drawn on day 0, 4, 7, 14, and 28 after 
treatment. WBC was counted after removal of red blood cells. The data of each group (5-8 
mice each) are mean ± standard deviation.  
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To know whether the IT Aza will cause the locoregional toxicity or systemic toxicity in other 
organs, an organ toxicity study in a scope of acute toxicity of IT Aza were performed and 
the IV Aza was used as comparison. At the MTD, the results of serum liver function  
tests and serum creatinine measurements were normal for all mice and there were no 
differences among the groups of IT Aza, IV Aza, and no treatment (data not shown). On 
histopathological evaluation, no liver or kidney toxicities were identified in any treatment 
group (data not shown). By lung histological evaluation, moderate pulmonary toxicity was 
observed in all 5 animals in the IT Aza group on day 7 but not at the other time points. Of 
note is that the IT dose used in these experiments is 12-fold higher dose than the optimized 
total dose used in the therapeutic experiments. The lung toxicity was described as moderate 
pneumonitis, characterized by type II pneumocyte hypertrophy, neutrophilic infiltration, 
and lymphohistiocytic inflammation (Figure 4, photograph 2). As stated, no pulmonary  
 
 
Fig. 4. IT Aza at the therapeutic dose does not produce pulmonary toxicity. ICR mice were 
intratracheally injected with 90 mg/kg of Aza, 2.5 mg/kg qod x 3 of Aza, or the equal 
volume of vehicle (Lactated Ringer’s Injection). The lungs of mice were resected on day 4, 7, 
and 14 after injection. Standard H & E staining of lung tissues was used to assess pulmonary 
toxicity. Photographs 1 to 6 are the lungs from mice receiving 90 mg/kg of IT Aza (1~3) or 
the same volume of IT vehicle (4~6). Photograph 7 is the lung from mice receiving the 
therapeutic dose of IT Aza (2.5 mg/kg, qod x 3) on day 7 post the final injection. Photograph 
8 is the lung from untreated mice.  
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toxicity was observed in animals treated with IT Aza on days 4 or 14. At the optimal 
therapeutic dose (2.5 mg/kg, qod x 3), IT Aza did not cause lung toxicity (Figure 4, 
photograph 7) and any other toxicity (data not shown). The pulmonary toxicity grades are 
listed in Table 1. These results indicate that the pulmonary toxicity caused by IT Aza at 
supratherapeutic doses (the MTD of IV Aza) is moderate (photograph 2) and reversible 
within 2 weeks (photograph 3). IT Aza at the therapeutic dose, IT vehicle, and IV Aza (data 
not shown) did not cause detectable pulmonary toxicity.  
 
Day 4 7 14 28 
IT Aza (90 mg/kg) 0* 2* 0* 0 
IT Aza (2.5 mg/kg x 3) 0 0* 0 0 
IT Vehicle 0* 0* 0* 0 
IV Aza (90 mg/kg) 0 0 0 0 
No Treatment 0 0* 0 0 
 * histopathological photographs are shown in Figure 3. 
Table 1. Toxicity grade of lungs of the mice treated with IT Aza 
3.2.3 Intratracheal administration of Aza significantly prolonged the survival of mice 
bearing orthotopic human NSCLC xenografts 
To evaluate the efficacy of IT Aza in clinically relevant NSCLC models, we inoculated the 
human NSCLC cell lines H266, H358, and H460 into the lungs of nude mice via the trachea. 
These models mimic closely orthotopic human NSCLC. In mice, small mucosal tumor 
nodules are evident at 1-3 weeks after the inoculation of tumor cells. In the absence of any 
intervention, the mice succumb to the tumor in 6-10 weeks. The survival curve in these 
models closely correlates with the tumor burden (13), and can be utilized as an endpoint for 
the evaluation of treatment efficacy.  
Treatments were initiated on day 10 post tumor inoculation. The survival observed in 
mice treated with IT Aza was compared to that in mice treated with IV Aza and untreated 
tumor-bearing mice. Animals in each treatment group were given multiple injections; 
these doses and schedules were optimized in a preliminary study (data not shown). The 
total dose was 7.5 mg/kg for IT Aza (2.5 mg/kg, qod x 3) and 37.5 mg/kg for IV Aza (6.25 
mg/kg, qd x 6). Both dose levels are significantly lower than the corresponding MTD’s. 
Results are shown in Figure 5. IV Aza had limited efficacy against three lung cancer 
models at the optimal therapeutic dose: the median survival increased by 10% in H226 
model (72 vs. 67), , and 22% in the H358 model (73 vs. 60 days, p > 0.05) and 60% in the 
H460 model (80 vs. 50 days, p < 0.01), whereas IT Aza demonstrated significantly 
increased efficacy: the median survival increased by 107% (139 vs. 67), 63%, (98 vs. 60 
days, p < 0.006), and 142% (121 vs. 50 days, p < 0.002) in the H226, H358, and H460 model, 
respectively. The increased lifespan (%ILS) (119) of IT Aza treated mice bearing H226, 
H358, or H460 lung tumors was 3.2- to 8.6-fold higher than that of IV Aza treated mice 
(96.2% vs. 11.2%; 75.8% vs. 21.5%; 131.3% vs. 40.7%). The efficacy of each treatment is 
summarized in Table 2. 
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Fig. 5. Intratracheal administration of low dose Aza significantly prolongs survival of mice 
bearing orthotopic human NSCLC xenografts. Mice intratracheally inoculated with H226 
(left), H358 (middle), or H460 (right) human NSCLC cell lines were treated with IT Aza 
(thick line) or IV Aza (dash line) on day 10 at a dose of 2.5 mg/kg qod x 3 for IT and 6.25 
mg/kg daily x 6 for IV. The control was a group of untreated mice (thin line).  
 
  No treatment IV IT IT vs. V P value 
H226 
Median Survival 
(Range) 67 (50~84) 72 (55~101) 139 (89~178) 1.93 0.016 
%ILS 0 11.2 96.2 8.59 
H358 
 
Median Survival 
(Range) 60 (46~75) 73 (54~93) 98 (75~146) 1.34 0.018 
%ILS 0 21.5 75.8 3.52 
H460 
Median Survival 
(Range) 50 (42~75) 80 (58~100) 121 (75~183) 1.51 0.005 
%ILS 0 40.7 131.3 3.23 
Table 2. Efficacy summary 
3.3 Discussion 
Azacytidine (Aza) is approved by the Food and Drug Administration for the treatment of 
myelodysplastic syndromes (11), a preleukemic condition, and has potential for the 
treatment of other cancers and premalignant conditions as a result of a cytotoxic effect, a 
DNA demethylating effect, or both. As a cytotoxic agent in proliferating cells, Aza can 
disrupt RNA metabolism, DNA synthesis, and protein synthesis. Particularly, Aza is 
incorporated into DNA and inhibits DNA methyltransferases and causes hypomethylation 
of replicating DNA (120, 121) which can result in re-expression of tumor suppressor genes 
silenced by hypermethylation. From 1973 to 1977, there were at least 9 clinical studies in 
solid tumor patients with intravenous Aza, which included 78 lung cancer patients (122). 
The therapeutic efficacy observed was limited, possibly due to two major reasons: First, the 
studies were performed in advanced lung cancer patients where reversal of 
hypermethylation per se may not be sufficient to have a therapeutic impact; second, all the 
studies were done using systemic administration or a sub-optimal dose schedule, which 
limits the use of these agents as a result of systemic toxicity. The studies presented here 
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were designed to provide the foundation for the potential use of a regional demethylation 
strategy for malignant or premalignant conditions of the bronchial epithelium in which 
DNA hypermethylation plays an important role. We used Aza as a model compound and 
tested its toxicity and antitumor efficacy by direct delivery in the respiratory airways via the 
trachea in models of endobronchial human NSCLC. Our studies demonstrate that IT Aza 
produced a 5-fold reduced myelosuppression (as assessed by WBC nadir) than IV Aza at a 
dose equivalent to the IV MTD and 3-fold higher antitumor efficacy (as assessed by %ILS) at 
a dose 5-fold lower than that of IV Aza, the end-result being a 75-fold increased therapeutic 
index. These results justify continuing exploring regional demethylating therapy for the 
treatment of malignant or premalignant conditions of the lungs that are easily accessible 
through the airways, including advanced premalignancy, bronchioalveolar carcinoma, and 
small parenchymal metastatic disease. 
Lung cancers develop in the epithelium in direct contact with the airways because 
carcinogens reach the lungs through inhalation. Bronchial premalignancy, carcinoma in situ, 
small primary or metastatic tumors, and some cases of BAC are theoretically more accessible 
via the endobronchial space than through the bloodstream. Aerosol approaches to the 
treatment or prevention of these conditions are therefore a more logical therapeutic strategy 
than systemic treatment. However, in the present studies we used intratracheal 
administration rather than aerosol administration because the purpose was proof of concept 
and administration of drugs by aerosolization to mice is inefficient. The major difference 
between these two types of drug administration (IT vs. aerosol) would be a higher 
distribution of the drug to the alveolar space with aerosol administration. We are currently 
conducting studies to validate the results presented here using the clinically available 
formulation of Aza administered by aerosolization to mice.  
Our toxicity studies demonstrate, as expected, that Aza given IT results in a 5-fold reduced 
myelosuppression, which is the dose-limiting toxicity of IV Aza. Most importantly, IT Aza 
at 90 mg/kg only caused moderate pulmonary inflammation on day 7 after IT 
administration. It was encouraging to see that there was no evidence of lung inflammation 
on day 14 post IT Aza, even when the dose used for IT was as high as the maximum 
tolerated dose using the IV route. In the efficacy experiments, the optimal total IT dose used 
was 12 fold lower, a dose did not cause any pulmonary toxicity. To confirm this, we are 
currently performing more refined lung toxicity studies in the context of our current 
therapeutic experiments using aerosolized administration.  
In the efficacy experiments, the efficacy (%ILS) of IT Aza at a 5-fold lower dose was 3.2- to 
8.6-fold superior to that of IV Aza in mice with endobronchial H226, H358, or H460 tumors. 
These results indicate that the regional administration route into the airways is more 
efficient than the intravenous route for the treatment of endobronchial tumors. The main 
therapeutic potential of airway-administered Aza is secondary prevention of NSCLC due to 
the field cancerization effect of inhaled carcinogens via tobacco smoke. The proposed 
mechanism would be hypomethylation of CpG islands of the promoter regions of tumor 
suppressor genes thereby inhibiting development of dysplasia and progression of dysplasia 
to cancer. In these studies, we used a mouse model of endobronchial tumors but not 
dysplasia. We are currently developing an animal model of lung premalignancy in mice by 
exposing them to tobacco carcinogens directly into the upper airways. We plan to test the 
ability of aerosolized Aza in reversing tumor suppressor gene hypermethylation in this 
model.  
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In these studies, the efficacy endpoint was survival secondary to antitumor effect in models 
of malignancy. In the anticipated clinical scenario, the intermediate efficacy endpoint would 
be changes in hypermethylation patterns or effective gene reexpression. In this study, the 
optimal therapeutic dose was 12-fold lower than the maximum tolerated dose (MTD). This 
finding suggests that this strategy may have a large therapeutic window and that the risk of 
acute or chronic side effects might be very low if these agents were used at optimal doses 
rather than MTD. Therefore, determining optimal doses based on pharmacodynamic 
assessments in patients enrolled in clinical studies with this new therapeutic strategy are 
essential to minimize the potential side effects. Particularly, the potential carcinogenicity of 
this approach could become an important limitation if benefit was demonstrated but 
required chronic administration of unnecessarily high doses of these agents. Therefore, in 
the context of our initial Phase I clinical study of inhaled Aza we intend to monitor 
methylation patterns as well as gene reexpression in the target tissue pre and post-therapy 
to establish an optimal dose based on target effects rather than a maximum tolerated dose.  
In vitro, we have proved that Aza can effectively demethylate the hypermethylation in the 
promoter of tumor suppressor gene at a non-toxic concentration. In vivo, we found that IT 
Aza are effective against experimental lung cancer by prolonging the life of the mice bearing 
orthotopic lung tumors without causing any detectable systemic or locoregional toxicity. 
Here the functions of both the epigenetic effect and the locoregional administration played 
an important role. We believe that the lung-specific epigenetic treatment with Aza has great 
potential to reduce the tumor burden by reversing the hypermethylation in the promoters of 
the tumor suppressor genes and therefore reactivating the silenced genes. This is an 
important project to be further studied.  
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